VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 20 (1-22 septiembre/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

The race to find a cure for disease X – before it arrives

Sep 2. At the height of the pandemic, the Bangkok's Hospital for Tropical Diseases, was heaving with locals anxiously awaiting Covid test results. Now there are just a handful of people – and they already know they're infected.

Having tested positive for SARS-CoV-2, these volunteers are taking part in a trial with an ambitious objective: to identify antivirals that could help fight the next pandemic.

It's the latest phase of a trial launched in 2021, which aimed to evaluate different treatments for Covid.

Regulatory delays meant the study began later than hoped, and many of the initial results came too late to inform policy. But instead of dismantling the trial apparatus, scientists have now expanded the study to hone in on other threats – including 'disease x', an as-yet-unknown pandemic pathogen.

"There's now this very clear mission – the challenge to have medical countermeasures ready… within 100 days of a public health emergency declaration," said Dr Stije Leopold, head of antiviral clinical research at the Mahidol Oxford Tropical Medicine Research Unit (Moru) in Thailand.

"But if we only start innovating at the point the clock starts ticking, we're never going to make it," he told the Telegraph. "So in our trials, we focus on pandemic preparedness efforts, to evaluate different antiviral drugs in peacetime."

The study is split into three sections, each looking at a different disease – 'Platcov' for Sars-Cov-2, 'Ad Astra' for flu, and 'Arsynal-FC' for RSV.

Overall, 16 existing treatments are currently being analysed – some already approved, some repurposed, some in new combinations – and more than 3,200 patients have been enrolled in Thailand, Brazil, Laos, Nepal and Pakistan.

Dr Leopold said influenza was deemed a priority, as there's little data directly comparing existing treatments, or looking at the impact of taking existing drugs in combination – for instance pairing either oseltamivir, baloxavir or favipiravir.

At the same time, there's a high likelihood the virus could evolve into something new, especially as H5N1 is now rampant in US cattle. Southeast Asia is also a hotspot for bird flu spillover, with 15 cases in people infected in Cambodia alone in 2025.

Meanwhile the study enrolled its first RSV patients earlier this year. There are currently no routine antiviral treatments approved against the disease, but the burden is growing worldwide – especially among the elderly. The Arsynal-FC branch of the trial is testing whether the Covid drug molnupiravir could also be used for RSV.

As well as proving useful for existing viruses, the data gained could help scientists prioritise which treatments should be trialled if a new but similar threat emerges.

“As we saw with Covid-19, pre-existing knowledge on other similar viruses is a key element to a rapid response to outbreaks,”said Dr Natsuko Imai, research lead at Wellcome, the British foundation which funds Moru.

“The evidence gained from these trials on which drugs can treat which infections gives us a head start for developing treatments for new emerging threats,” she told the Telegraph.

Overall, the trial design is similar to the UK’s Recovery trial, in that it uses a randomised, ‘‘adaptive platform’. This is scientific jargon for ‘flexible’ – different treatments are evaluated at the same time, allowing for direct comparisons, with drugs added or dropped as results emerge.

But unlike Recovery, which assessed treatments based on hospitalisation and mortality rates, the Moru-led trial tracks virus clearance. Researchers are not analysing how sick a person becomes, but how many days it takes an antiviral to rid the pathogen from their system.

“This means we’re focused on healthy adults, and don’t need to enrol as many patients to get clear results,” said Dr Podjanee Jittamala, a researcher at Moru and doctor at the Hospital for Tropical Diseases, and principal investigator of the Thai-arm of the study.

“But it means we also have to enrol patients into the trial very early in their infection. Then we ask the participants to come back here every day for five days to have swabs taken, and we analyse for viral load,” she said, standing in the sparse testing area.

The drawback is that further trials would be needed for regulators to approve repurposed drugs or new combinations, as data on disease severity, hospitalisations and mortality is required.

“Typically regulators need clinical outcomes,” said Prof Peter Horby, director of the Pandemic Sciences Institute at the University of Oxford and architect of the Recovery trial.

“But I think this is a great addition to our arsenal, in terms of getting the evidence we need to triage and take forward drugs,” Prof Horby, who is not involved in the Moru-led trial, added.

Trials like these are relatively rare. Within the flagship 100 day “moonshot mission”, which aims to develop medical countermeasures within 100 days of a pandemic pathogen, much of the focus is instead trained on vaccines.

Prof Horby said this is partly because it’s harder – while there are now well-established vaccine platforms, it’s a challenge to create broadly applicable antivirals.

Plus few are deemed a profitable investment by many pharmaceutical companies, and there is no equivalent of the Coalition for Epidemic Preparedness Innovations for treatments. This initiative, founded in 2016, funds vaccine research for pandemic threats.

“Cepi was established and got health financing to take forward vaccines that otherwise weren’t commercially viable,” Prof Horby told the Telegraph. “There isn’t that for therapeutics.”

He added that there have been some attempts to organise work in this area – for instance the Therapeutic Coalition, set up by the International Pandemic Preparedness Secretariat, held its first scientific advisory meeting last month.

But this is not a funding mechanism – and the lack of early stage drug development is reflected in the fact that pandemic preparedness trials are not testing any brand new treatments.

“We’ve got these fantastic clinical evaluation platforms now, the dynamic ones on viral load [like at Moru], and big clinical end point trials like Recovery,” said Prof Horby, who is not involved in the Moru-led trial.

“But we haven’t got any exciting drugs to put in them, so it’s earlier clinical development that really needs investment. That’s not a reflection on the trials, but the pipelines.”

Fuente: The Telegraph. Disponible en https://n9.cl/j5stzr

ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT

Sep 3. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a company whose stock has surged over 168% in the past year according to InvestingPro data, announced Wednesday it has rebranded as MindWalk and will change its Nasdaq ticker symbol to HYFT, unifying its subsidiaries BioStrand and Talem under a single corporate identity.

The company described the move as reflecting its evolution into what it calls a "Bio-Native AI platform business" that combines artificial intelligence, multi-omics data, and laboratory research for drug discovery and development. With a market capitalization of $89 million and a healthy current ratio of 2.08, the company maintains strong liquidity to support its transformation.

"Today is an evolutionary step forward," said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk, in a press release statement.

The rebranding comes alongside a business model shift from specialized laboratory services to an integrated platform approach. The company plans to offer data-as-a-service (DaaS) and software-as-a-service (SaaS) products while enhancing asset generation and pursuing larger partnerships.

At the center of MindWalk’s operations is its LensAI platform powered by HYFT technology, which the company says integrates biological data across various formats into a structured system to accelerate drug discovery.

The new ticker symbol HYFT replaces IPA on the Nasdaq exchange, highlighting the foundational role of the company’s HYFT technology in its artificial intelligence capabilities.

MindWalk describes its technology as enabling rapid epitope mapping, molecular design, vaccine exploration, and biologics analytics to develop drug candidates more efficiently.

The company, formerly known as ImmunoPrecise Antibodies, will now operate as MindWalk Holdings Corp., consolidating all its previous subsidiaries under the new brand. According to InvestingPro analysis, analyst price targets range from $3 to $5, suggesting potential upside, though the company currently operates with moderate debt levels and faces near-term profitability challenges. For deeper insights into MindWalk’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, ImmunoPrecise Antibodies Ltd. reported a record quarterly revenue of $7 million for Q4 2025, marking its highest earnings to date. The company also saw an improvement in its gross margin, which increased to 64% from 48% in the previous year. These financial results come amidst strategic advancements, including the progression of its universal dengue vaccine candidate to the manufacturing phase. The vaccine is now set for pre-clinical testing to evaluate its ability to generate monoclonal antibody responses against the virus.

Additionally, ImmunoPrecise Antibodies has completed the sale of its Netherlands-based subsidiary to AVS Bio for $12 million, resulting in net proceeds of $11.7 million. This transaction is part of the company's ongoing efforts to streamline its operations. Despite these positive developments, the company's stock experienced a decline. However, the focus remains on the company's strategic initiatives and financial growth.

Fuente: Investing.com. Disponible en https://n9.cl/mj44f

Biotech to 'Shift to U.K. and China' After U.S. 'Own Goal' on mRNA Cuts

Sep 5. The U.K. and China will be the biggest beneficiaries of the U.S. health secretary's "own goal" of pulling funding for mRNA vaccines, according to experts.

Robert F. Kennedy Jr., a controversial member of Donald Trump's cabinet who claims he wants to "make America healthy again," is scrapping $500 million in funding for the technology—which was used to combat COVID-19.

Paul Hunter, professor of medicine at the University of East Anglia, said other countries with active biotechnology industries will benefit, but the decision will still delay the development of new vaccines worldwide.

"Progress will continue but not as quickly as otherwise. Lives will be lost that could have been saved had there been a vaccine," he told Times Higher Education.

The U.S. Department of Health and Human Services said 22 projects by major pharmaceutical companies, including Pfizer and Moderna, will be affected. The projects were working on vaccines against bird flu and other viruses.

"It will certainly make the U.S. poorer for not having a biotechnology industry that is not as competitive as it could be," added Hunter. "The U.S. will certainly lose out to China and Europe, and when its researchers move overseas, it may not be easy to get them to return later."

He said the migration of talent to the U.K. is already under way—with his department recently shortlisting a research assistant who had been working in the U.S.

Kennedy said mRNA technology "poses more risks than benefits" for respiratory viruses and announced a shift toward "safer, broader vaccine platforms that remain effective even as viruses mutate."

"I would certainly say it's an own goal for the U.S. and something they are likely to regret," said Robin Shattock, professor of mucosal infection and immunity at Imperial College London.

Shattock said innovation would continue at pace in the U.K., mainland Europe and Asia. While China pushes ahead with RNA technologies, the U.S. appears to be looking to shift to older technology used by Chinese companies.

"This current retrograde step by the U.S. will allow others to catch up and likely pull ahead in the context of

vaccines," he added. "It will only take another pandemic for them to rapidly see their mistake."

Charles Bangham, professor emeritus of immunology also at Imperial, said the cuts to U.S. aid and higher education funding have already been seriously damaging for research, but this latest "antiscience" decision will be harmful to both manufacturing and health.

"The disinvestment in mRNA vaccine development and production is, in my view, a serious error."

"It is a blow to the U.S.' own interests—they're shooting themselves in the foot."

In the absence of any strong evidence that COVID-19 vaccines caused adverse reactions, Bangham said it was hard to rationalize why the U.S. was acting so decisively on "the basis of a few anecdotes."

"It's more than a lack of competency. I think it's active and explicit, and often voiced, opposition and denigration and disavowal of the value of scientific evidence, which I think is extremely damaging."

Along with the U.K., Europe and China, there are now "huge opportunities" for research development in Southeast Asia, he added.

Fuente: Inside Higher Ed. Disponible en https://n9.cl/mcjbx

Vacunas, ciencia y salud pública: sin lugar para el negacionismo

5 sep. La reciente decisión del Estado de Florida, Estado Unidos, de eliminar la obligatoriedad de la vacunación expone a toda su población a riesgos innecesarios y al resto del mundo a la reemergencia de enfermedades prevenibles. No se trata de un hecho aislado: es parte de una corriente negacionista, terraplanista y anticiencia que crece a escala global y que, de no ser enfrentada con decisión política y sanitaria, puede poner en peligro décadas de avances en salud pública.

Las vacunas son una de las herramientas más seguras, efectivas y costo-eficientes que tiene la humanidad para prevenir enfermedades. No hay intervención sanitaria que haya salvado más vidas en la historia, con excepción del acceso al agua potable. En Argentina, la Ley 27.491 —sancionada en 2018— establece que la vacunación es un bien social y una política pública preventiva de interés nacional. Eso significa que el Estado tiene la obligación de garantizar la disponibilidad, el acceso oportuno y la obligatoriedad de su aplicación.

La evidencia es contundente: cada caída en la cobertura de vacunación se traduce en brotes, internaciones y muertes evitables. En las Américas, la Organización Panamericana de la Salud registró entre enero y junio de 2025 más de 7.000 casos de sarampión en nueve países, con trece fallecidos, lo que representa un incremento de 29 veces respecto de 2024. La coqueluche (tos continua), por su parte, pasó de 4.139 casos en 2023 a más de 43.000 en 2024. Estos números no son abstracciones: son la prueba concreta de lo que ocurre cuando la vacunación pierde prioridad.

En este país, entre 2009 y 2019 las coberturas del Calendario Nacional de Vacunación cayeron en promedio diez puntos porcentuales. Ninguna vacuna superó el 90 por ciento en 2019, y la pandemia de COVID-19 profundizó esta tendencia: en 2020 ninguna vacuna alcanzó el 80 por ciento. Esto abrió la puerta a la reemergencia de enfermedades que creíamos controladas.

En la Provincia de Buenos Aires la situación fue similar: caída sostenida hasta 2020 y una recuperación parcial desde 2021, sin volver a los niveles previos. Según los registros nominales y digitales, en 2024 las coberturas de la vacuna quíntuple en lactantes fueron de 75 por ciento a los 2 meses, 73 a los 4 meses, 69 por ciento a los 6 meses y apenas 61 por ciento al refuerzo de los 18 meses. Para la triple viral, clave para prevenir sarampión, la cobertura en el ingreso escolar fue del 55 por ciento en 2024. Estos números muestran con crudeza el riesgo que enfrentamos si no redoblamos esfuerzos.

En este escenario epidemiológico sensible, resulta peligroso dar espacio a discursos negacionistas y anticiencia. Porque cada vez que alguien desalienta la vacunación, aunque sea desde la ignorancia, erosiona la confianza social en la política sanitaria y pone en riesgo a la comunidad entera. La vacunación no es una decisión individual: es un acto colectivo de cuidado. La falta de cobertura no solo afecta a quien no se vacuna, sino también a quienes no pueden hacerlo por motivos médicos y dependen de la inmunidad comunitaria.

La vacunación no es solo un procedimiento médico, es una política de salud pública que encarna la idea de comunidad. Cada dosis aplicada es un acto de solidaridad que protege tanto a quien la recibe como a quienes lo rodean. En un tiempo en que los discursos anticiencia intentan sembrar dudas, es imprescindible reafirmar que el cuidado colectivo y la prevención son conquistas sociales que no podemos dar por sentadas. Defender la vacunación es defender la vida, la justicia social y el derecho a una salud digna para todos y todas.

Es decir, las vacunas son la demostración más clara de que la ciencia y la salud pública transforman la vida de los pueblos. Frente a la irresponsabilidad de quienes difunden el negacionismo y relativizan la evidencia, debemos decir con firmeza que la salud no se discute.

Fuente: Página12. Disponible en https://n9.cl/43s0w

Sanofi's New RSV Vaccine Study: A Potential Game-Changer in Immunization

Sep 7. Sanofi has launched a Phase 1 clinical study titled 'A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age.' The study aims to assess the safety and immune response of various lipid nanoparticle (LNP) formulations of mRNA vaccines targeting the respiratory syncytial virus (RSV) in healthy adults aged 18 to 49. This research is significant as it explores innovative vaccine technologies that could enhance protection against RSV.

The study tests multiple formulations of RSV vaccines, each administered as a single intramuscular injection. These formulations are designed to provoke an immune response against RSV, potentially offering new preventive measures against this common respiratory virus.

This interventional study is randomized and follows a parallel assignment model. It employs triple masking, meaning that participants, care providers, and investigators are blinded to the treatment allocations. The primary goal is prevention, focusing on evaluating the vaccines' safety and immunogenicity.

The study began on July 8, 2025, with the latest update submitted on August 13, 2025. These dates mark the

recruitment phase and the ongoing progress of the study, which is crucial for tracking its development and future outcomes.

Sanofi's ongoing study could influence its stock performance positively, as successful results may enhance its position in the competitive vaccine market. Investors should monitor this study's progress, considering the potential impact on Sanofi's market share and the broader industry dynamics.

The study is currently recruiting, with further details available on the ClinicalTrials portal.

Fuente: TIP RANKS. Disponible en https://n9.cl/6ypqs

GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada

Sep 9. GSK announced today that Arexvy (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) will be offered through select provincially funded programs to help prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) among eligible Canadian adults.

The inclusion of Arexvy follows the March 2025 update from the National Advisory Committee on Immunization (NACI), which recommends RSV vaccination for all adults aged 75 and older, as well as those aged 60 and above residing in nursing homes or other chronic care facilities. Adults aged 50 to 74 are advised to consider vaccination in consultation with their healthcare provider.

Anthony Quinn, President, Canadian Association of Retired Persons: "As Canada's population ages, it's essential that older adults have timely and equitable access to vaccines that can help protect them from serious respiratory illnesses like RSV. As we head into the fall and winter months - and the risk of respiratory virus infections increases - vaccination against RSV can reduce hospitalizations and safeguard the health and independence of seniors across the country."

Alison Pozzobon, Vice President of Communications, Government Affairs and Market Access, GSK, said: "We are proud to have Arexvy included in publicly funded immunization programs, enabling broader access to an important vaccine for older Canadians who are among those at increased risk for severe RSV disease. As more provinces prioritize RSV prevention, GSK is committed to collaborating with public health partners across the country to continue to expand access to Arexvy and help ensure that vulnerable Canadians can be protected against the virus and its complications.

Adults aged 50 and older who are not eligible for vaccination against RSV as part of a publicly funded program can access Arexvy at pharmacies across Canada. In most cases a prescription from one's primary care provider is required.

About Arexvy

Arexvy is currently approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk for RSV disease. Arexvy was the first authorized RSV vaccine in Canada for older adults.

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant.

The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus.

About RSV in adults

RSV is a common contagious virus affecting the lungs and breathing passages. Adults can be at increased risk for RSV disease due to comorbidities, immune compromised status, or advanced age.ii RSV can exacerbate conditions, including COPD, asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalization, and death.iii In Canada, it is estimated that more than 23,000 adults are hospitalized with RSV annually.iv Unfortunately, RSV can act as a tipping point, potentially leading to serious long-term health consequences. Approximately 1 in 9 patients hospitalized with RSV do not survive.

Fuente: BioSpace. Disponible en https://n9.cl/k2tni

Vacuna antineumocócica de Merck se muestra prometedora en niños y adolescentes de riesgo

Sep 11. La vacuna antineumocócica de Merck provocó respuestas inmunitarias en niños y adolescentes con mayor riesgo de enfermedad grave en un estudio de fase avanzada, informó el jueves la farmacéutica.

La empresa estaba probando la inyección, Capvaxive, frente a su vacuna más antigua, Pneumovax 23, en niños mayores de dos años y adolescentes menores de 18, que han completado un régimen de vacunación antineumocócica pediátrica primaria, y tienen una o más enfermedades crónicas que los ponen en mayor riesgo.

Capvaxive ya está aprobado para adultos en Estados Unidos, la Unión Europea y Japón, entre otros lugares.

La inyección generó respuestas inmunitarias contra 21 cepas de la bacteria responsable de las infecciones neumocócicas, que pueden causar enfermedades graves como neumonía, meningitis y sepsis.

En el estudio, que contó con 882 participantes, Capvaxive demostró ser no inferior a Pneumovax 23 frente a las 12 cepas bacterianas comunes a ambas vacunas y superior frente a las nueve exclusivas de Capvaxive, a los 30 días de la vacunación, según Merck.

La proporción de pacientes con efectos secundarios relacionados con el tratamiento fue comparable en ambas vacunas, según el fabricante.

Merck también ofrece otras dos vacunas antineumocócicas: Vaxneuvance, para personas a partir de seis semanas de edad, y Pneumovax 23, para adultos mayores de 50 años y niños mayores de dos años.

La vacuna Prevnar 20 de Pfizer, que protege contra 20 cepas de la bacteria, está aprobada para personas mayores de seis semanas.

La enfermedad neumocócica se propaga por contacto directo con secreciones respiratorias como la saliva o la mucosidad. Los niños menores de cinco años y los adultos mayores de 65 corren un mayor riesgo de contraer la enfermedad.

Fuente: LA NACIÓN. Disponible en https://n9.cl/65wqq

China plans to add HPV vaccine to national immunization program, expanding coverage for females

Sep 11. China is planning to roll out human papillomavirus (HPV) vaccination services for females of eligible age and incorporate the vaccine into its national immunization program this year, the National Health Commission (NHC) announced on Thursday.

Under China's Vaccine Management Law, the country implements a national immunization program that provides residents with selected vaccines free of charge.

In recent years, a growing number of local governments have begun providing free domestic HPV vaccinations to girls -- mainly adolescents aged 9 to 14.

Calls to add HPV vaccines to China's national immunization program have increased in recent years, driven by the wider availability of affordable domestic vaccines and the mounting burden of cervical cancer.

China currently has both domestic and imported HPV vaccines on the market. The country's first homegrown nine-valent HPV vaccine, rolled out in June, was administered for the first time this Tuesday.

HPV is the primary cause of cervical cancer and a major threat to women's health. Statistics show that globally, approximately 700,000 cancer cases each year are associated with HPV, including an estimated 530,000 cases of cervical cancer.

Health experts believe vaccination remains the most effective and affordable way to prevent infection and lower the risk of cervical cancer and related diseases. Notably, data show that vaccination is up to 94 percent effective in preventing HPV infection.

In 2020, the World Health Organization (WHO) launched a global strategy to accelerate the elimination of cervical cancer, aiming for 90 percent of girls to be fully vaccinated against HPV by the age of 15 by 2030.

In alignment with this WHO strategy, China's NHC launched a cervical cancer elimination action plan for the 2022-2030 period, urging the expansion of HPV vaccination coverage nationwide.

Fuente: The State Council The People´s Republic of China. Disponible en https://n9.cl/vjpea

PCV21 Effective in Children, Adolescents at Increased Pneumococcal Disease Risk

Sep 13. Investigators at the 6th European Society of Clinical Microbiology and Infectious Diseases Conference on Vaccines in Lisbon, Portugal, have unveiled positive results from the phase 3 STRIDE-13 clinical trial (NCT06177912), in which the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive; Merck) administered to high-risk children and adolescents aged 2 to less than 18 years who had previously completed a pneumococcal vaccine series demonstrated robust immune responses and noninferiority to the pneumococcal 23-valent polysaccharide vaccine (PPSV23), according to a news release from Merck.

PCV21 was specifically designed to target serotypes causing most of the invasive pneumococcal disease (IPD) cases in adults, according to Paula Annunziato, senior vice president of infectious diseases and vaccines at Merck Research Laboratories. It is indicated for the prevention of invasive disease and

pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years and older. Although the STRIDE family of trials has affirmed PCV21's effectiveness in adults, its potential in children had remained unknown until now.

"While [PCV21] was designed to specifically cover the serotypes that cause the majority of IPD cases in adults, findings from STRIDE-13 underscore its added potential to help protect children and adolescents who are at an increased risk," Annunziato said in the news release.

Results of STRIDE-13 Show Immunogenicity in Younger Individuals

In STRIDE-13, a phase 3, randomized, double-blind, active comparator-controlled clinical trial, investigators evaluated the immunogenicity, safety, and tolerability of PCV21 compared with PPSV23 specifically in young patients with increased pneumococcal disease risk. A series of medical conditions can put patients at heightened risk for IPD, including diabetes, chronic liver disease, chronic lung disease, chronic heart disease, or chronic kidney disease. In total, 882 participants with these conditions were randomly assigned 3:2 to receive either a single dose of PCV21 or PPSV23 following completion of a primary pediatric pneumococcal vaccine regimen. The pediatric regimen included either pneumococcal 7-valent conjugate vaccine, pneumococcal 10-valent conjugate vaccine, or pneumococcal 13-valent conjugate vaccine.

Thirty days post vaccination, the immunogenicity of PCV21 serotypes was assessed through the measurement of serotype-specific opsonophagocytic activity (OPAs) geometric mean titers (GMTs). Simultaneously, safety was evaluated, measured as a proportion of individuals with adverse events (AEs).

The investigators found that PCV21 was immunogenic for all 21 serotypes included in the vaccine at the 30-day follow-up. Furthermore, immune responses elicited by the vaccine were noninferior to PPSV23 for each of their shared 12 serotypes, as determined by prespecific statistical criteria. For the 9 serotypes included in PCV21 but not PPSV23, PCV21 demonstrated superiority, as determined by serotype-specific OPA GMTs at 30 days.

Regarding safety, there was a generally comparable proportion of participants with solicited, systemic AEs and vaccine-related AEs; however, solicited injection-site AEs were observed more frequently in patients receiving PCV21 (72.3%) compared with PPSV23 (58.2%).

These new data signify the effectiveness of PCV21 in children and adolescents, highlighting its potential in this population. Previous studies have investigated PCV21 among infants and toddlers being coadministered other common pediatric vaccines, but these studies have included healthy individuals, while STRIDE-13 features patients who are at high risk for severe pneumococcal disease. The positive results could lead to future recommendations from regulatory bodies allowing younger individuals to receive PCV21.

"Children and adolescents living with chronic medical conditions are at increased risk of pneumococcal disease, and offering them additional protection is essential," Rotem Lapidot, chief of pediatric infectious diseases at Rambam Health Care Campus and STRIDE-13 investigator, said in the news release. "Results from STRIDE-13 demonstrate the potential of [PCV21] to deliver protection for these vulnerable populations, who may benefit from additional pneumococcal disease coverage by including serotypes not contained in other approved pneumococcal infant regimens."

Fuente: Pharmacy Times. Disponible en https://n9.cl/dv9gx

Navigating the Post-Pandemic Landscape: How ARPA Funding Shapes Biotech and Pharma Strategies

Sep 13. The U.S. biotech and pharmaceutical sectors have long operated in a landscape shaped by public health policy and government funding. However, the absence of recent, publicly documented federal programs or policy shifts targeting vaccine-related research post-2020 raises critical questions about how industry players are adapting to a post-pandemic environment. While initiatives like Operation Warp Speed and ARPA-H (Advanced Research Projects Agency for Health) dominated headlines in 2020–2021, the current climate appears to lack comparable large-scale interventions. This vacuum has forced companies to recalibrate their strategies, relying on indirect signals from broader economic and public health investments—most notably the American Rescue Plan Act (ARPA)—to navigate uncertainty.

The ARPA Effect: Indirect Catalysts for Sector Resilience

The American Rescue Plan Act (ARPA), enacted in March 2021, allocated $350 billion to state and local governments, with explicit mandates to address pandemic-related economic and public health challenges. While not a direct investment in vaccine research, ARPA's emphasis on infrastructure, emergency services, and workforce support has created a ripple effect for biotech and pharma firms. For instance, Aroostook County in Maine used its ARPA allocation to upgrade emergency communications systems and provide stipends for essential workers. Such investments indirectly bolster public health infrastructure, which is critical for vaccine distribution and community trust—key factors for pharmaceutical companies reliant on real-world adoption of their products.

Data from the U.S. Department of Treasury underscores the flexibility of ARPA funds, allowing states to prioritize projects that align with long-term public health goals. Department of Treasury. This adaptability suggests that biotech firms may benefit from a more resilient healthcare ecosystem, even if they are not direct recipients of federal grants. For example, improved broadband access and water infrastructure funded through ARPA could enhance telehealth capabilities and clinical trial logistics, both of which are vital for drug development pipelines.

Strategic Sector Positioning: Innovation Amid Policy Ambiguity

In the absence of targeted federal programs, biotech and pharma companies have adopted a dual strategy: diversifying R&D portfolios while deepening partnerships with state-level actors. According to a report by Bloomberg, firms like Moderna and Pfizer have increasingly focused on mRNA platforms beyond vaccines, such as oncology and rare diseases, to hedge against regulatory and market risks. This pivot reflects a recognition that post-pandemic government priorities may shift away from infectious disease preparedness toward chronic care and aging populations—a trend reinforced by demographic data from the CDC.

At the same time, companies are leveraging ARPA-funded infrastructure to optimize supply chains and manufacturing. For example, regional hubs supported by ARPA grants for workforce training and logistics could reduce reliance on centralized production facilities, mitigating bottlenecks in drug distribution. This decentralization aligns with broader industry trends toward localized manufacturing, as highlighted in a 2024 analysis by Reuters.

Risks and Opportunities in a Policy Vacuum

The lack of recent federal action on vaccine research introduces both risks and opportunities. On one hand, the absence of programs like Operation Warp Speed may stifle innovation in pandemic preparedness, leaving gaps in rapid-response capabilities. On the other, it compels companies to innovate independently, potentially accelerating breakthroughs in areas like AI-driven drug discovery or decentralized clinical trials.

However, this environment also heightens regulatory and financial volatility. Without clear policy signals, firms face challenges in forecasting demand for vaccines or securing long-term partnerships with government agencies. For instance, the delayed rollout of ARPA-H—a Biden administration initiative aimed at high-risk, high-reward health research—has left many companies in limbo, according to a 2025 industry survey.

Adapting to a New Normal

The biotech and pharma sectors are navigating a complex post-pandemic landscape defined by indirect government support and strategic innovation. While the absence of recent federal vaccine-focused programs creates uncertainty, the ARPA-driven emphasis on public health infrastructure offers a foundation for long-term resilience. Investors should monitor how companies leverage these indirect benefits—such as improved logistics and workforce stability—while remaining vigilant about the risks of a policy vacuum. As the sector evolves, the ability to adapt to both direct and indirect policy shifts will determine which firms thrive in the next phase of the industry's transformation.

Fuente: AInvest. Disponible en https://n9.cl/u0r3z

Sask. university researchers aim to develop new vaccines with quantum computing

Sep 15. A University of Saskatchewan lab is hoping to stop the next pandemic before it begins with the help of some very large and powerful computers.

Quantum computing is still an emerging technology, but U of S researchers say they don't want to wait for the devices to be fully finished before putting them to practical use.

The hope is that the powerful computers, which can handle much more complex problems than regular computers, can be used to speed up vaccine development.

"You can use these quantum computers to access very special information about the immune system," said Steven Rayan, the director of the Centre for Quantum Topology and Its Applications (quanTA) at the U of S.

"We're already on the path of putting these to use in a way that will be good for society," Rayan said.

Two research centres at the university are partnering to do the work: quanTA, which specializes in computing and mathematics, and the Vaccine and Infectious Disease Organization (VIDO).

The hope is that scientists will be able to go from identifying "a pathogen of concern" or "infectious agent" to having a viable vaccine discovered through quantum computing in "less than 100 days," Rayan said.

This is possible, said VIDO's principal investigator Gordon Broderick, because the computers will allow scientists to create "a digital twin" of a virus or bacterial agent.

He said the computer version would allow scientists to quickly run through multiple "what if" scenarios, far more quickly than replicating them in a lab.

"What if I protected you with this agent? What if I designed the vaccine in this way?" Broderick said.

Using a computer to digitally try those scenarios would mean only the best ideas would be tested in the lab using vials, cell cultures and animals, he said.

Still an emerging technology

Rayan said "there are limits to ordinary computers," which are just a collection of off-on switches, zeros and ones, and are not built to handle the complexities of the human immune system.

"But quantum computers are a little bit more like nature itself," Rayan said.

They're designed to mimic nature at a really small, quantum level and can be deployed to simulate natural processes, he said.

Like in the early days of computing, current quantum computers are room-sized and scientists are still finalizing the design, he said.

The university is partnering with IBM to remotely access quantum computers in Quebec, through the Quebec agency, la Plateforme d'Innovation Numérique et Quantique.

A federal department, Prairies Economic Development Canada, pays for the University of Saskatchewan's access to the IBM computers.

Both researchers say the work offers exciting opportunities for students, who are able to log time on the computers — something most institutions aren't able to offer yet.

Three years later: What has COVID-19 taught us and are we ready for the next big threat?

Sask. vaccine manufacturing facility the first of its kind in Canada

"A lot of quantum computing is really just being treated in a theoretical way at the moment," Rayan said, adding that many are waiting for the technology to be perfected before thinking about how to use it.

"We're not really willing to wait."

Fuente: CBC News. Disponible en https://n9.cl/ybj7a

BIDMC Investigators Pave the Way for Next-Generation TB Vaccine

Sep 15. Tuberculosis or TB, an airborne bacterial respiratory infection, is one of humanity's oldest foes and is today the world's leading cause of death from infectious disease, claiming more than 1.2 million lives each year. The single available vaccine protects young children from severe cases of TB but does little to prevent the spread of disease in adolescents and adults.

Now, scientists at Beth Israel Deaconess Medical Center (BIDMC) in Harvard Medical School, Boston Massachusetts, have created a new TB vaccine candidate with newly identified antigens and delivered by mRNA technology, the same approach that allowed the rapid development of safe and effective vaccines against COVID-19. As the team reported in Cell, the next-generation TB vaccine concept is planned for clinical testing in adults and could result in an important advance in TB prevention that could benefit all age groups.

"We systematically evaluated multiple potential TB vaccine antigens to develop a novel TB vaccine

candidate," said corresponding author Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at BIDMC, whose work contributed to the development of Johnson & Johnson's COVID-19 vaccine. "We used the mRNA platform that is flexible, scalable, and can combine multiple antigens into one shot."

TB lacks an obvious target for vaccine design. Using a dataset of immune responses in humans exposed to TB, Barouch and colleagues developed a screening pipeline to test which antigens elicited responses from human immune cells, then ranked them by strength. The process revealed a multitude of TB antigens for potential use in a vaccine. Selecting the top contenders in each of several categories, Barouch and colleagues designed a vaccine concept that combined three TB antigens—called a trivalent vaccine—and tested it in an animal model.

"Choosing which antigens to target is a significant challenge in TB vaccine development," said lead author Samuel J. Vidal, MD, PhD, a staff scientist in the Barouch Laboratory at CVVR. "The three antigens we chose have not previously been evaluated in clinical trials. Our trivalent mRNA vaccine concept improved upon the century-old BCG shot in animal models—it reduced infection rates, reduced bacterial spread, and lowered bacterial levels in the lungs."

The trivalent vaccine antigens also triggered immune responses in humans exposed to TB, suggesting that the approach could work in people. The vaccine concept is now planned to move into Phase 1 clinical trials, the first step in testing its safety and effectiveness in humans, offering a potential path toward better protection against one of the world's most devious infectious diseases.

"Taken together, our findings open the door to a new vaccine candidate for TB," said Barouch, who is also is also a professor of medicine at Harvard Medical School and a member of the Ragon Institute of MGH, MIT and Harvard. "We're excited to be moving this novel TB vaccine candidate toward clinical trials."

Coauthors included Ninaad Lasrado, Lisa H. Tostanoski, Jayeshbhai Chaudhari, Esther R. Mbiwan, Ganad D. Neka, Ellis A. Strutton, Alejandro A. Espinosa Perez, Daniel Sellers, Julia Barrett, Michelle Lifton, Erica N. Borducchi, and Malika Aid of BIDMC; Shoko Wakabayashi of Harvard T.H. Chan School of Public Health; Behnaz Eshaghi, Ana Jaklenec, and Robert Langer of Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Wenjun Li of University of Massachusetts Lowell; and Thomas J. Scriba of University of Cape Town.

Fuente: BIDMC. Disponible en https://n9.cl/i8rrsu

Abierta la puerta para que la vacuna antimeningitis MenACYW TT pueda administrarse a los 6 meses de vida

17 sep. El Grupo IHP ha participado en el ensayo clínico MET58 con resultados favorables para la protección frente a la meningitis en lactantes. La investigación, publicada en la revista 'Infectious Diseases and Therapy', analiza por primera vez la posibilidad de administrar la vacuna MenACYW TT (MenQuadfi®) comercializada con indicación desde los 12 meses de edad, y compararla con la ya comercializada MCV4 TT (Nimenrix®), que tiene indicación desde las 6 semanas de vida, junto a las vacunas habituales (hexavalente, neumococo y triple vírica).

Más del 95% de los bebés han alcanzado niveles protectores tras la dosis de recuerdo, con una eficacia igual o superior frente a los serotipos C, W e Y, y con una respuesta suficiente frente al A.

En representación del grupo pediátrico andaluz, el Dr. Ignacio Salamanca, coordinador de la Unidad de Investigación, ha formado parte del equipo investigador que ha llevado a cabo este ensayo en su fase III en 1.660 bebés de entre seis semanas y 18 meses, repartidos en 33 centros de siete países europeos.

Dr. Ignacio Salamanca
Fuente: Grupo IHP

Hasta ahora, la protección tenía indicación a partir de los 12 meses

El experto de Grupo IHP afirma que, hasta ahora, la protección frente a los serotipos A, C, W y Y con el suero vacunal de estudio "tenía indicación a partir de los 12 meses, con lo que dejaba desprotegido al lactante menor de un año de edad; este estudio demuestra que se podría empezar a los 42 días de vida con esta vacuna sin comprometer la respuesta de ella y de otras vacunas al coadministrar".

El resultado ha sido un éxito: más del 95% de los bebés han alcanzado niveles protectores tras la dosis de recuerdo, y el nuevo preparado ha mostrado una eficacia igual o superior a la pauta ya existente frente a los serotipos C, W e Y, con una respuesta suficiente frente al A.

El perfil de seguridad, similar al de la vacuna comparada

Además, no se han detectado interferencias con los demás sueros del calendario de vacunación infantil. Asimismo, el especialista de Grupo IHP subraya que el perfil de seguridad es similar al de la vacuna comparada, con reacciones leves como fiebre, irritabilidad o dolor en la zona de inyección, y sin aparición de efectos adversos nuevos.

El Dr. Salamanca sostiene que "estos datos allanan el camino para poder contar con otra vacuna tetravalente en un grupo tan vulnerable como es el de los lactantes menores de 6 semanas. Debemos recordar que los lactantes son el grupo con mayor riesgo de enfermedad meningocócica invasora, con tasas cuatro veces superiores al resto de la población, y que la observación en Europa de picos de casos por W e Y en la última década ha reforzado la necesidad de ampliar la prevención en estas edades".

Fuente: FÁRMACO SALUD. Disponible en https://n9.cl/ng6kyv

Vacunación del adulto: dos décadas de progreso y desafíos pendientes

17 sep. La décima edición del Neumoforo, celebrado en la Universidad Rey Juan Carlos, se inauguró con una advertencia clara: la resistencia a los antibióticos constituye ya una «pandemia silenciosa» que amenaza con poner en jaque a la medicina moderna. Además, en el primer día de la jornada se han destacado los hitos conseguidos a lo largo de las últimas dos décadas en la vacunación.

Tras la bienvenida por parte de Ángel Gil de Miguel, profesor de Medicina Preventiva y Salud Pública en la Universidad Rey Juan Carlos, el encargado de abrir el encuentro fue Fernando González Romo, especialista del Servicio de Microbiología Clínica del Hospital Clínico San

Carlos, quien defendió el papel de las vacunas como herramienta clave para frenar la expansión de las resistencias antimicrobianas (RAM).

"Los antibióticos han salvado millones de vidas y han permitido desarrollar la cirugía moderna, los trasplantes o la quimioterapia. Pero hoy asistimos a un escenario en el que su eficacia peligra", advirtió González Romo, recordando que ya en 1945 Alexander Fleming alertó sobre el riesgo del «uso irreflexivo» de la penicilina.

Una amenaza creciente

El especialista subrayó que, aunque el problema tiene múltiples causas, las cifras hablan por sí solas: en 2019, la resistencia a los antimicrobianos estuvo asociada a casi cinco millones de muertes en el mundo y, de no revertirse la tendencia, podrían alcanzarse los 10 millones anuales en 2050. «El impacto no será solo sanitario, también económico y social. Se calcula una caída del PIB mundial de entre el 1,1 y el 3,8%, además de millones de personas empujadas a la pobreza extrema», explicó.

Este desafío ha sido reconocido por la OMS y la ONU, que ya en 2016 celebraron una asamblea monográfica sobre el tema. Años después, sin embargo, «seguimos con muchos planes sobre el papel y pocos en marcha», señaló González Romo, en referencia a los programas nacionales puestos en marcha en 178 países, incluidos los de España.

Vacunas como parte de la solución

Si bien los planes iniciales contra la RAM se centraban en promover un uso más racional de los antibióticos, González Romo destacó que la actualización del plan español en 2017 ya incluyó un apartado específico sobre inmunización. La razón es clara: las vacunas no solo previenen infecciones, también reducen la necesidad de prescribir antibióticos y, por tanto, frenan la aparición de resistencias.

«Vacunar no solo protege al individuo, también al colectivo. Evita que la bacteria colonice, circule y transfiera genes de resistencia. Además, preserva la microbiota y reduce la presencia de antibióticos en el medioambiente», explicó.

En esta línea, la OMS recogió esta estrategia en su plan de acción de 2021, con tres ejes principales: aumentar el uso de vacunas existentes, acelerar el desarrollo de nuevas y avanzar en la medición de su impacto frente a la resistencia.

Los datos avalan este enfoque. En el caso del neumococo, la introducción de las vacunas conjugadas ha reducido de forma drástica las infecciones por cepas resistentes en países como Estados Unidos, España o Israel. Algo similar ocurrió con *Haemophilus influenzae* tipo b, cuyas resistencias prácticamente desaparecieron tras la generalización de la vacuna.

El experto citó también ejemplos de gran relevancia internacional, como la fiebre tifoidea, donde la introducción de una vacuna conjugada de bajo coste está frenando resistencias en países con alta incidencia, o la tuberculosis, con proyectos en marcha que podrían cambiar radicalmente la evolución de la enfermedad más letal de origen bacteriano. Incluso en infecciones de origen vírico como la gripe o el virus respiratorio sincitial (VRS), la vacunación ha demostrado un impacto indirecto en la reducción de tratamientos antibióticos.

Veinte años de vacunación del adulto: avances y retos pendientes

Tras la conferencia inaugural, se continuó con la primera mesa de debate dedicada a repasar dos décadas de vacunación en la población adulta. El periodista Oriol Güell, encargado de moderar la sesión, arrancó con una reflexión que situó el valor de las inmunizaciones en perspectiva: «Mientras estamos aquí reunidos hablando de vacunas, ahí fuera están haciendo su trabajo. En estos minutos se han salvado muchas vidas y

se han evitado cuadros tan graves como el herpes zóster, que tanto impacta en la vida de los pacientes».

Sin embargo, y pese a los progresos alcanzados, la mesa coincidió en que la vacunación del adulto sigue lejos de alcanzar la notoriedad y las coberturas de la vacunación infantil. Factores como la menor percepción del riesgo, la escasa conciencia social de los beneficios, la complejidad logística para identificar grupos de riesgo o incluso la desigualdad territorial entre comunidades autónomas explican parte de esta brecha.

Para profundizar en estos desafíos, el panel reunió a algunas de las principales voces del ámbito de la salud pública y la vacunología: Marta Molina, subdirectora general de Prevención y Promoción de la Salud de la Comunidad de Madrid; Ángel Gil de Miguel, profesor de Medicina Preventiva y Salud Pública en la Universidad Rey Juan Carlos; María Garcés Sánchez, pediatra y subdirectora general en la Conselleria de Sanidad de la Comunitat Valenciana; José Antonio Forcada Segarra, presidente de la Asociación Nacional de Enfermería y Vacunas (ANENVAC); y Jaime Pérez Martín, presidente de la Asociación Española de Vacunología (AEV).

El debate permitió hacer memoria de los principales hitos en estas dos décadas de vacunación del adulto. Jaime Pérez Martín recordó la importancia del documento de consenso publicado en 2018, que supuso un antes y un después en la definición de grupos de riesgo y en la armonización de criterios. «Era absurdo que cada comunidad autónoma trabajara de forma individual», señaló. «Ese documento fue contundente y muy bien recibido por los profesionales, pero ahora el reto es que llegue a todos los sanitarios, no solo a los que trabajamos en vacunas».

En esa misma línea, José Antonio Forcada defendió la necesidad de avanzar hacia un «calendario para toda la vida». Según explicó, «las vacunas no son cosa de niños, son para toda la vida, desde la mujer embarazada hasta las últimas etapas de la existencia». A su juicio, la pandemia de COVID-19 supuso un punto de inflexión para que la población adulta tomara conciencia de que también necesitaba protegerse.

María Garcés Sánchez destacó la aportación de las vacunas conjugadas y el desarrollo de fórmulas con adyuvantes para combatir la inmunosenescencia: «Han sido hitos comparables a los anticuerpos monoclonales. Estas innovaciones han permitido respuestas inmunes más sólidas en el adulto, reduciendo

complicaciones graves como la neumonía asociada a la gripe».

Por su parte, Ángel Gil de Miguel recordó que ya en 2005 algunas comunidades empezaron a dar pasos con calendarios específicos para adultos. «La inclusión de la vacunación en la embarazada ha sido otro avance fundamental. Hoy vacunamos frente a gripe, tosferina o COVID con coberturas excelentes, algo impensable hace apenas dos décadas».

La perspectiva institucional llegó de la mano de Marta Molina que insistió en que el gran salto cultural pasa por decisiones contundentes: «El hito de elaborar un calendario a lo largo de la vida es clave. Lo vemos en los datos: las vacunas con indicación poblacional alcanzan siempre mejores coberturas que aquellas limitadas a grupos de riesgo».

Superar barreras y cambiar la cultura social

En la siguiente parte del coloquio, los expertos señalaron los obstáculos que aún frenan la vacunación del adulto. Entre ellos, la falta de un calendario único en España, la dificultad para definir y registrar a los grupos de riesgo o la escasa sensibilización de algunos profesionales sanitarios. «El problema es que muchos compañeros que no trabajan en vacunación no incluyen todavía las inmunizaciones en sus protocolos de atención», lamentó Molina.

Forcada reforzó esta idea desde la práctica enfermera: «Las vacunas deberían estar integradas en los cuidados de enfermería, no solo en primaria, también en todas las especialidades. Aún hoy hay pacientes que solo acceden a ellas si lo piden por iniciativa propia».

Por otro lado, los ponentes coincidieron también en la relevancia de la comunicación. Para Jaime Pérez, «hay que transmitir mensajes positivos y tangibles, como que la vacuna de la gripe evita 100.000 hospitalizaciones al año en Reino Unido. Pero también debemos explicar con claridad qué riesgos asume quien no se vacuna».

De esta mesa se extrae un mensaje claro: la vacunación del adulto necesita planificación, coordinación y un cambio cultural profundo. Como resumió Gil de Miguel, el objetivo no es solo reducir hospitalizaciones y muertes, sino también mejorar la calidad de vida de una población cada vez más longeva y activa.

De la vacuna antigripal al herpes zóster

Por último, los expertos destacaron vacunas concretas para ilustrar los avances y retos de la vacunación adulta. Jaime Pérez destacó la vacuna neumocócica, recordando la transición de la polisacárida (PPSV23) a las vacunas conjugadas, necesarias para mantener la protección en la población adulta. Por su parte, José Antonio Forcada subrayó la vacuna antigripal, con mejoras recientes que protegen especialmente a personas mayores y de riesgo, reduciendo hospitalizaciones y complicaciones. María Garcés resaltó la vacuna frente al herpes zóster, clave para prevenir reactivaciones del virus varicela-zóster en adultos, mientras que Marta Molina abordó la vacunación frente al virus respiratorio sincitial (VRS) en adultos.

Finalmente, en conjunto, los expertos coincidieron en que la innovación, la investigación y la educación sanitaria son fundamentales para consolidar la vacunación del adulto, mejorar coberturas y normalizar el calendario vacunal a lo largo de toda la vida.

Fuente: Gaceta Médica. Disponible en https://n9.cl/83nl8

What Will Vaccines of the Future Look Like?

Sep 18. When COVID-19 swept the globe, hospitals filled and supply chains broke down. Canada waited months for doses to arrive from abroad, exposing how unprepared we were.

Now scientists are rethinking what vaccines could be—faster to make, easier to deliver and designed to meet the next global threat head-on.

We asked Peter Pelka, a professor in the Department of Microbiology at UM: What will vaccines of the future look like?



Made in 100 days

Traditionally, vaccines took years to develop, which is far too slow for viruses that can spread worldwide in weeks. COVID-19 proved it doesn't have to be that way, with vaccines created in the U.S. at record speed, yet Canada couldn't produce them at all.

Pelka wants to change that. His team is working to develop a flexible platform that could turn an emerging virus threat into a vaccine in as little as 100 days.

"The objective is to develop a platform so that no matter what pathogen comes around, whether it is a pandemic virus or a disease with pandemic potential, we can have it in vaccine form within about 100 days," Pelka says. "It would be ready to deploy in a similar way to the seasonal flu shot, using a platform that is safe and well understood."

The difference this time? Investment and scale.

Backed by a $57-million federal commitment, UM is building the Prairie Biologics Accelerator at its Fort Garry campus and the PRAIRIE One Health Emerging Respiratory Disease Centre at its Bannatyne campus. These facilities will anchor a Prairie-wide biomanufacturing hub that links UM with researchers at the Universities of Alberta, Calgary and Saskatchewan, creating the capacity to design, test and manufacture vaccines right here at home.

"COVID-19 exposed the fact that we had no capacity to manufacture a vaccine in-house," Pelka says. "It was immediately recognized that we couldn't prioritize our own citizens. We don't want to be in that position again."

Needle-free delivery

The vaccines most people know come in a syringe. But Pelka believes the future will look different. His team is working on vaccines that can be taken orally or through a simple nasal spray.

"Delivery by oral route and nasal is not something new. Polio vaccine, for example, is still given this way," Pelka says. "What excites me about this is that it will reduce barriers, it will reduce the cost, and I think it will increase uptake of the vaccine."

One of the biggest barriers is access. Some communities don't have a doctor, nurse or pharmacist to give injections, and some people are reluctant to get injections at all. Needle-free vaccines, which could be used at

home, remove those obstacles.

Also, Pelka says the needle-free vaccines could be stored for weeks or months without special equipment. This makes them easier to distribute and use in communities with limited health-care access.

And by targeting the nose and mouth—the same places where many pathogens enter the body—these vaccines may also provide stronger protection at the site of infection.

Smarter design

One of the biggest hurdles in vaccine development is the sheer amount of data generated in animal studies. Hundreds of different immune responses can be measured, but only a few actually predict whether a vaccine will work.

Pelka and his colleagues are using artificial intelligence to cut through that noise. By training algorithms on large datasets, they can identify which signals matter most—and ignore the rest.

“That way, the next time we develop a vaccine, we don’t need to repeat every test,” Pelka says. “We can focus on the predictors that really matter and not waste time or money on the rest.”

In practice, this means moving from trial and error to targeted design, shaving weeks or months off the development timeline. For Pelka, it’s a key step toward reaching the goal of a 100-day vaccine.

Building jobs, building innovation

The benefits of the Prairie Biologics Accelerator and PRAIRIE One Health Emerging Respiratory Disease Centre will extend beyond health security. Construction will generate jobs immediately, while the long-term payoff will come in research and biomanufacturing careers. Once operational, these state-of-the-art facilities will help attract top talent and create opportunities for the next generation of health-care innovators, Pelka says. Together, they add a new dimension to Manitoba’s health-care system and economy, positioning the province at the centre of vaccine innovation.

Fuente: UM The Magazine. Disponible en https://n9.cl/7xp40

Building a global AI platform for pandemic preparedness

Sep 18. Artificial Intelligence, or AI, is transforming the way in which science can help secure the world and its people against disease outbreaks.

For CEPI and its partners, that means rapidly accelerating and exponentially improving how scientists can design and deliver new vaccines against novel or re-emerging infectious disease threats. Our aim, described in CEPI’s 100 Days Mission, is for the world to be able to do that within 100 days of a new pathogen being identified as having the potential to cause a pandemic.

To advance this mission we plan to collaborate on the development of a revolutionary new artificial intelligence platform called the Pandemic Preparedness Engine.

This end-to-end digital research and development system is designed to integrate multiple vast and disparate datasets—from genomic surveillance, epidemiological models and viral phylogenetics to vaccine design toolkits, preclinical and clinical pipelines, safety monitoring and regulatory submissions—into a single, secure platform.

By applying advanced generative AI techniques, the Pandemic Preparedness Engine will be able to scan this wealth of global data, identify whether a pathogen has pandemic potential and propose antigens and designs for potential vaccine candidates in minutes, hours and days rather than in months.

Initially, the AI platform will be trained on data from hundreds of studies across high-risk viral families. These will include the coronaviruses—the family that spawned the SARS epidemic, multiple MERS outbreaks and then the COVID-19 pandemic, all of them deadly—as well as the filoviruses such as Ebola and Marburg, and the arenaviruses such as Lassa fever.

The computational pipeline's data will also cover lesser-known but equally high-risk pathogens such as Nipah virus, Rift Valley fever and Crimean-Congo haemorrhagic fever. And the system will continuously update its knowledge base as new research emerges, making it an evolving scientific resource.

Researchers seeking rapid answers when a new disease outbreak emerges will be able to interrogate the Pandemic Preparedness Engine directly, asking detailed and complex questions and getting the very best evidence-based answers in minutes. They could, for example, model how a novel virus might be likely to spread in different environments, or identify the most promising vaccine targets, or simulate manufacturing processes to find the fastest route to large-scale vaccine production.

CEPI is mindful of how AI-powered vaccine development has the potential to widen the gap between nations by concentrating technology and expertise in a few countries. This could lead to a significant gap in access to these state-of-the-art AI tools for developing life-saving vaccines, with many nations being left behind.

To mitigate this, CEPI is working with governments and institutions to establish a global network of high-performance computing hubs known as AI factories to enable access to the Pandemic Preparedness Engine for researchers and CEPI partners in regions around the world. The aim is to bridge the technology gap between countries, ensuring that pandemic preparedness is a globally shared effort that delivers mutual benefit for all.

Of course, security is a central pillar of this digital platform's design and architecture. CEPI and its partners are building capabilities for the responsible use of these AI tools, while enabling accelerated vaccine development.

The AI platform's architecture will incorporate multiple layers of biosecurity, from rigorous vetting of researchers and training data to secure computing infrastructure and controlled data transfer protocols. An embedded and autonomous "biosecurity agent" will monitor activity in real time, serving as a guardrail against potential misuse of the AI models.

It's CEPI's hope that the Pandemic Preparedness Engine will harness the transformative advantages of AI in building robust and equitable global health security—translating AI from a promising tool for health into a real frontline defence capability against future pandemic threats.

Fuente: CEPI. Disponible en https://n9.cl/q6c4fy

Post-Pandemic Healthcare Reallocation: Vaccine Demand Shifts and Biotech Innovation in 2025

Sep 19. The post-pandemic healthcare sector is undergoing a seismic reallocation of resources, driven by evolving vaccine demand and rapid biotech innovation. Central to this transformation is the U.S. Centers for Disease Control and Prevention's (CDC) 2025 booster strategy, which has redefined vaccination priorities and created both challenges and opportunities for adaptive vaccine platforms. As the market shifts toward high-risk populations and next-generation technologies, investors must navigate a landscape shaped by regulatory uncertainty, technological agility, and financial recalibration.

The CDC's 2025 Strategy: A Paradigm Shift in Vaccine Prioritization

The CDC's 2025 guidelines mark a departure from universal vaccination mandates, emphasizing annual updated vaccines for adults aged 18 and older while narrowing focus to high-risk groups—those over 65, immunocompromised individuals, and people with chronic conditions. This strategy mirrors seasonal flu shot models, with updated vaccines targeting circulating variants like the JN.1 Omicron lineage. Notably, the CDC now recommends a second booster dose six months after the initial one for high-risk populations, reflecting concerns about waning antibody levels and the need to sustain T-cell immunity.

However, the policy landscape has grown contentious. The reconstituted Advisory Committee on Immunization Practices (ACIP), under Robert F. Kennedy Jr., has introduced regulatory uncertainty by halting $500 million in mRNA vaccine projects and favoring whole-virus vaccines. Critics argue this undermines pandemic preparedness, as mRNA platforms are uniquely adaptable to viral mutations. Meanwhile, the FDA's decision to restrict future vaccine approvals to high-risk populations—based on immunogenicity data rather than randomized trials—has further narrowed market access.

Market Dynamics: Adaptive Platforms and Regional Opportunities

The adaptive vaccine platforms market is expanding, driven by mRNA and viral vector technologies. The global mRNA vaccines market, valued at $10.4 billion in 2025, is projected to grow at a 11.86% CAGR, reaching $18.28 billion by 2030. Innovations such as self-amplifying mRNA, lipid nanoparticle encapsulation, and needle-free delivery systems are reducing production costs and logistical barriers, particularly in low- and middle-income countries.

Regionally, North America remains a leader due to robust R&D funding and healthcare infrastructure, while the Asia-Pacific region is emerging as a growth engine, fueled by government incentives and high population density. Europe's market is fragmented but gaining momentum, with the Middle East and Africa showing untapped potential as regulatory frameworks evolve.

Financial Projections: Key Players in a Shifting Landscape

The financial health of major players reflects the sector's volatility. Moderna, which reported a $825 million net loss in Q2 2025, has slashed its revenue forecast to $1.5–2.5 billion and announced $1.5 billion in cost cuts.

Despite these challenges, the company is pivoting toward respiratory vaccines and next-gen COVID shots (e.g., mNEXSPIKE) to offset declining demand for its Spikevax product.

BioNTech faces similar headwinds, with first-quarter 2025 revenues at €182.8 million and full-year guidance of €1.7–2.2 billion. The firm is maintaining aggressive R&D spending (€2.6–2.8 billion) to advance oncology

programs and variant-adapted vaccines. Collaborations, such as its joint influenza-COVID-19 vaccine project with Pfizer, signal a strategic focus on combination therapies.

Pfizer's Comirnaty vaccine revenue is projected at $1.8 billion for 2025, down from earlier estimates, as policy barriers and hesitancy dampen uptake. However, the company's international contracts with BioNTech provide stability through 2026, and its emphasis on high-risk populations aligns with the CDC's new framework.

Historical performance suggests that even when these firms miss earnings expectations, their stocks may exhibit resilience. For example, Moderna's four earnings misses since 2022 showed a muted short-term impact but a positive drift of +7–9% versus a −4% benchmark by day 30. BioNTech demonstrated stronger post-miss performance, with cumulative abnormal returns reaching +10% versus a −0.4% benchmark by day 11 and day 27, with win rates ≥75%. These patterns highlight the potential for long-term recovery despite short-term volatility, reinforcing the importance of strategic patience in this sector.

Investment Opportunities: Navigating Uncertainty

For investors, the post-2025 landscape offers both risks and rewards. Adaptive platforms like mRNA remain critical, but success hinges on navigating regulatory shifts and supply chain challenges. Key opportunities include:

1. Agile Manufacturing: Modular production facilities and single-use bioprocessing systems enable rapid scale-up during outbreaks.
2. Geographic Diversification: Asia-Pacific and Latin America present high-growth markets for affordable, thermostable vaccines.
3. Strategic Partnerships: Collaborations between biotechs and governments (e.g., HHS's pandemic preparedness contracts) mitigate R&D risks.

A Sector in Transition

The post-pandemic healthcare sector is at an inflection point. While the CDC's 2025 strategy has narrowed vaccine demand to high-risk populations, it has also accelerated innovation in adaptive platforms. For companies like Moderna, BioNTech and Pfizer, the path forward requires balancing cost-cutting with R&D investments in next-gen technologies. Investors who prioritize flexibility—betting on mRNA advancements, regional expansion, and regulatory agility—will be best positioned to capitalize on this evolving landscape.

- ***CDC's 2025 vaccine strategy prioritizes high-risk groups, shifting from universal mandates and boosting T-cell immunity through dual boosters.***
- ***mRNA vaccine market grows at 11.86% CAGR to $18.28B by 2030, driven by innovations in delivery systems and cost reductions for low-income regions.***
- ***Moderna and BioNTech cut costs amid declining demand, pivoting to respiratory vaccines and oncology R&D while navigating regulatory uncertainties.***
- ***Asia-Pacific and North America lead vaccine expansion, with strategic partnerships and modular manufacturing addressing supply chain and regulatory challenges.***

Fuente: AInvest. Disponible en https://n9.cl/6nb7p

WHO to accelerate action on health agenda at UNGA High-Level Week

Sep 22. The World Health Organization (WHO) will play an important role at the United Nations General Assembly (UNGA) High-level Week, from 22 to 30 September 2025, where global leaders will gather to accelerate progress on the 2030 Sustainable Development Goals (SDGs).

Health will be a central theme, with Heads of State and governments meeting on 25 September 2025 to set a new vision for the prevention and control of noncommunicable diseases (NCDs) and the promotion of mental health and well-being towards 2030 and beyond through a new, ambitious political declaration.

The declaration will reaffirm the global commitment to reduce premature mortality from NCDs by one third by 2030 and to expand access to mental health services. It will also outline a 5-year action plan featuring priority, evidence-based and cost-effective interventions to reduce the burden of NCDs, strengthen mental health systems and advance universal health coverage.

NCDs are a major health issue both globally and regionally. They account for 74% of global deaths, while mental health conditions affect nearly 1 billion people worldwide. In the Eastern Mediterranean Region, NCDs claim 2.8 million lives annually, and mental health challenges persist. Both NCD and mental health conditions are compounded by conflict, displacement and chronic under-investment.

WHO Regional Director for the Eastern Mediterranean Dr Hanan Balkhy will represent the Region at UNGA alongside a technical delegation. “The WHO is committed to supporting countries in achieving the SDGs and reducing premature mortality from NCDs,” said Dr Balkhy. “At the regional level, we are also committed to reducing the burden of NCDs and mental health conditions. We call on global leaders to invest in health systems that deliver essential services to all people, everywhere.”

Dr Balkhy’s participation will focus on:

- showcasing regional progress and challenges in eradicating polio and hepatitis and addressing NCDs and mental health;
- linking global commitments to regional realities; and
- strengthening donor visibility and reinforcing partnerships with regional and international stakeholders.

Other key health events at UNGA

Health will feature prominently across several other high-impact events during UNGA. The High-Level Week’s agenda includes the “100 Days Mission” of the Coalition for Epidemic Preparedness Innovations (CEPI) on harnessing artificial intelligence (AI) to prevent future pandemics, and the Concordia Summit roundtable on the healing power of social connection. The week will also see the launch of WHO’s Mental Health Atlas 2024 and the World Mental Health Today report.

Discussions will explore the intersection of climate change and health, the future of digital health systems and the role of AI in emergency preparedness. A high-level roundtable on health taxes, hosted by Bloomberg, will bring together Heads of State to discuss fiscal strategies for healthier societies. A dedicated side event on childhood cancer will spotlight global efforts to improve care and outcomes for children with cancer.

On 23 September, as part of the 80th United Nations General Assembly, a high-level side event titled “Revolutionizing Care for Noncommunicable Diseases: Expanding Access through Primary Health Care” will be held. Co-organized by the Governments of Saudi Arabia and Mexico, in collaboration with the WHO Regional Office for the Eastern Mediterranean and Pan American Health Organization, the event will spotlight how primary health care can transform NCD management, reduce economic burdens and improve well-being. Ministers of health, global leaders and partners will share successful strategies and initiatives to advance equitable, people-centered care.

Another side event, “Unity in Wellness: Advancing Peace through Global Health”, will spotlight the Global Health and Peace Initiative (GHPI), a WHO initiative co-led by Oman and Switzerland. GHPI aims to strengthen the link between health and peace, showing how improvements in one can drive progress in the other.

Fuente: Eastern Mediterranean Region EMRO WHO. Disponible en https://n9.cl/7imwxl

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/09/01"[Date - Publication] : "2025/09/22"[Date - Publication])) 974 records

Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control.
Peng K, Zhao X, Li H, Fu YX, Liang Y.J Exp Med. 2025 Sep 1;222(9):e20241454. doi: 10.1084/jem.20241454. Epub 2025 Jun 6.PMID: 40479650

Pneumococcal Vaccine.
Koslap-Petraco M.Nurs Clin North Am. 2025 Sep;60(3):399-410. doi: 10.1016/j.cnur.2024.10.003. Epub 2025 May 22.PMID: 40716801

Epic science.
DuBois JL.Trends Biochem Sci. 2025 Sep;50(9):735-737. doi: 10.1016/j.tibs.2025.06.014. Epub 2025 Jul 22.PMID: 40695679

Functions and therapeutic applications of pseudouridylation.
Luo N, Huang Q, Zhang M, Yi C.Nat Rev Mol Cell Biol. 2025 Sep;26(9):691-705. doi: 10.1038/s41580-025-00852-1. Epub 2025 May 20.PMID: 40394244

Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study.
Pérez Marc G, Vizzotti C, Fell DB, Di Nunzio L, Olszevicki S, Mankiewicz SW, Braem V, Rearte R, Atwell JE, Bianchi A, Fuentes N, Zadoff R, Vecchio G, Gabriela Abalos M, Fan R, Del Carmen Morales G, Gessner BD, Jodar L, Libster R, Rearte A; BERNI study working group.Lancet Infect Dis. 2025 Sep;25(9):1044-1054. doi: 10.1016/S1473-3099(25)00156-2. Epub 2025 May 5.PMID: 40339585

Assessing the Efficacy and Immunogenicity of Anticaries Vaccine-A Systematic Review and Meta-Analysis.
Kumar G, Dash P, Nanda SB, Fareed M, Karobari MI.Immun Inflamm Dis. 2025 Sep;13(9):e70253. doi: 10.1002/iid3.70253.PMID: 40911429

Pediatric Infectious Skin Conditions.
Boll JN Jr, Boahene A, Goettel C.Prim Care. 2025 Sep;52(3):437-469. doi: 10.1016/j.pop.2025.04.004. Epub 2025 Jul 4.PMID: 40835284

Vaccination in pregnancy to protect the newborn.
Male V, Jones CE.Nat Rev Immunol. 2025 Sep;25(9):649-661. doi: 10.1038/s41577-025-01162-5. Epub 2025 Apr 23.PMID: 40269273

CD38-Targeting Peptide Vaccine Ameliorates Aging-Associated Phenotypes in Mice.
Yu S, Li Z, Tang Y, Chen Y, Ma Y, Du K, Zong Z, Feng K, Wei Y, Chen L, Deng H.Aging Cell. 2025 Sep;24(9):e70147. doi: 10.1111/acel.70147. Epub 2025 Jun 25.PMID: 40557469

Vaccine hesitancy for allergist-immunologists.

Moser CA.Ann Allergy Asthma Immunol. 2025 Sep;135(3):245-246. doi: 10.1016/j.anai.2025.06.009. Epub 2025 Jun 9.PMID: 40499649

What is the future of Mpox outbreak?
Makokha GN, Abuduwaili M, Chayama K, Hijikata M.Virology. 2025 Sep;610:110618. doi: 10.1016/j.virol.2025.110618. Epub 2025 Jun 27.PMID: 40609174

Mansonella perstans - the forgotten filaria.
Ritter M, Hsu HY, Lenz B, Kien CA, Gandjui NVT, Hübner MP, Hoerauf A, Wanji S.Trends Parasitol. 2025 Sep 3:S1471-4922(25)00225-9. doi: 10.1016/j.pt.2025.08.003. Online ahead of print.PMID: 40908246

Influence of structural modifications in synthetic vectors of lipid adjuvants on mRNA vaccine delivery.
Chilumula S, Hanchate P, Patri SV, Marepally S.Biomater Sci. 2025 Sep 9;13(18):4952-4969. doi: 10.1039/d5bm00839e.PMID: 40792498

Targeting Intratumoral Bacteria for Cancer Treatment.
Shi J, Liang J, Li Y, Zhang Z, Sun J, He Z, Luo C, Qu X, Che X, Zhang S.Small. 2025 Sep;21(35):e2505651. doi: 10.1002/smll.202505651. Epub 2025 Jul 11.PMID: 40643027

Dengue and severe dengue.
Kalimuddin S, Chia PY, Low JG, Ooi EE.Clin Microbiol Rev. 2025 Sep 5:e0024424. doi: 10.1128/cmr.00244-24. Online ahead of print.PMID: 40910631

Therapeutic B-cell depletion: Mechanisms, clinical applications, and implications for secondary immunodeficiency.
Elmoursi A, Barmettler S.J Allergy Clin Immunol. 2025 Sep;156(3):597-603. doi: 10.1016/j.jaci.2024.11.026. Epub 2024 Nov 28.PMID: 39613109

Anti-vaccine antibodies against measles, rubella, parotitis and hepatitis B in children with inflammatory bowel disease and healthy controls.
Makarova E, Goleva O, Gabrusskaya T, Ulanova N, Volkova N, Shilova E, Tolkmit M, Revnova M, Kharit S, Kostik M.World J Clin Pediatr. 2025 Sep 9;14(3):104704. doi: 10.5409/wjcp.v14.i3.104704. eCollection 2025 Sep 9.PMID: 40881079

Mitigating atherosclerosis: Integrating vaccines with gene targets.
Haraj A, Bakhshandeh M, Shokri N, Shariat Rad P, Alyan A, Chegini Z, Nazari MA, Taji SPS, Najafi M.Am Heart J Plus. 2025 Aug 6;57:100588. doi: 10.1016/j.ahjo.2025.100588. eCollection 2025 Sep.PMID: 40823653

Biomaterials nanoplatform-based tumor vaccines for immunotherapy.
Li Z, Zhang H, Gong Q, Luo K.Bioact Mater. 2025 Jun 30;51:924-961. doi: 10.1016/j.bioactmat.2025.06.038. eCollection 2025 Sep.PMID: 40678264

Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China.

Liu L, Zhang Q, Shu Y, Wang L, Shuai Z, Chu M, Zhang Z, Zhang R.Pharmacoecon Open. 2025 Sep 9. doi: 10.1007/s41669-025-00604-z. Online ahead of print.PMID: 40924360

Mpox Awareness and Vaccine Acceptability among Transgender Women and Men who have Sex with Men in India: Predictors and Implications for Outbreak Preparedness.
Chakrapani V, Sebastian A, Jyrwa JLR, Kaur J, Nelson R, Shunmugam M, Periasamy M, Patel VV.Sex Transm Dis. 2025 Sep 9. doi: 10.1097/OLQ.0000000000002242. Online ahead of print.PMID: 40924172

A recombinant adenovirus-vectored PEDV vaccine co-expressing S1 and N proteins enhances mucosal immunity and confers protection in piglets.
Luo Y, Yan S, Shi Y, Zhang M, Zhang L, Zheng S, Ni J, Liu P.Vet Microbiol. 2025 Sep;308:110633. doi: 10.1016/j.vetmic.2025.110633. Epub 2025 Jul 8.PMID: 40651152

Herpes Zoster Vaccine and Rheumatoid Arthritis.
Lai SW.J Rheumatol. 2025 Sep 1;52(9):958. doi: 10.3899/jrheum.2025-0272.PMID: 40592553

Immunoinformatics-guided vaccine design: A review with case study on Marburg virus.
Rao DF, Patel SK, Pandya HA.Biochem Biophys Res Commun. 2025 Sep 2;782:152572. doi: 10.1016/j.bbrc.2025.152572. Online ahead of print.PMID: 40907270

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model.
Wu Y, Sun G, Ren W, Gui Y, Wang C, Ye X, Chen Y, Pang X, Zhang Q, Wang ZJ, Wu Y.J Nanobiotechnology. 2025 Sep 2;23(1):602. doi: 10.1186/s12951-025-03681-8.PMID: 40898321

Molecular organization of the New World arenavirus spike glycoprotein complex.
Mann CJ, Yang P, Olal D, Fan X, Smith KN, Clark LE, Krammer F, Bian Y, Abraham J.Nat Microbiol. 2025 Sep;10(9):2207-2220. doi: 10.1038/s41564-025-02085-6. Epub 2025 Aug 8.PMID: 40781447

Trust, Information and Vaccine Aonfidence in Crisis Settings: A Scoping Review.
Dwyer H, Enria L, Palmer J, Ayub S, Beckmann N.Public Health Chall. 2025 Jun 26;4(3):e70073. doi: 10.1002/puh2.70073. eCollection 2025 Sep.PMID: 40584000

Exploration of the social determinants of diarrhoea, rotavirus vaccine uptake, and vaccine 'fatigue' in Ethiopia, Kenya, and Malawi.
Phiri MM, Osman R, Weldegebriel S, Sabola S, Ongadi B, Beavis C, Mwendera C, Nyirenda D; on behalf The GHRG-G.I. Consortium.PLoS One. 2025 Sep 9;20(9):e0319691. doi: 10.1371/journal.pone.0319691. eCollection 2025.PMID: 40924732

Vaccine Hesitancy and Its Epistemic Antecedents: A Meta-Analysis.
Andrews EA, Walter N, Ophir Y, Walter D, Robbins CL.Health Commun. 2025 Sep;40(10):1934-1945. doi: 10.1080/10410236.2024.2431165. Epub 2024 Nov 25.PMID: 39582463

Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.

Zhou S, Liang Y, Hao Y, Wang Q, Xu Y, Su T, Cheng F, Zhu G.Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102623. doi: 10.1016/j.omtn.2025.102623. eCollection 2025 Sep 9.PMID: 40704024

PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins.
Zhang C, Hou J, Li Z, Shen Q, Bai H, Chen L, Shen J, Wang P, Su Y, Li J, Zhang Q, Liu C, Xi X, Qi F, Chen Y, Xie X, Ye AY, Liu X, Plebani R, Church G, Si L.Nat Chem Biol. 2025 Sep;21(9):1330-1340. doi: 10.1038/s41589-024-01813-z. Epub 2025 Jan 15.PMID: 39814992

COVID-19 Vaccination in Canadian Dental Schools.
Turquete I, Madathil S, Allison PJ.J Public Health Dent. 2025 Sep;85(3):244-251. doi: 10.1111/jphd.12670. Epub 2025 Mar 21.PMID: 40118795

Gender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity.
Svarça L, Bojadzieva S, Rashiti P, Rashiti-Bytyçi A, Kabashi D.Allergol Immunopathol (Madr). 2025 Sep 1;53(5):5-11. doi: 10.15586/aei.v53i5.1369. eCollection 2025.PMID: 40923415

Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
Xie N, Shen G, Huang C, Zhu H.Chin Med J (Engl). 2025 Sep 5;138(17):2057-2090. doi: 10.1097/CM9.0000000000003708. Epub 2025 Aug 4.PMID: 40757404

H5N1 virus invades the mammary glands of dairy cattle through 'mouth-to-teat' transmission.
Shi J, Kong H, Cui P, Deng G, Zeng X, Jiang Y, He X, Zhang X, Chen L, Zhuang Y, Wang Y, Ma J, Li J, Zhang Y, Wang C, He C, Yang J, Li J, Liu W, Yang J, Mao S, Liu J, Chen P, Tian G, Li C, Guan Y, Bu Z, Chen H.Natl Sci Rev. 2025 Jul 1;12(9):nwaf262. doi: 10.1093/nsr/nwaf262. eCollection 2025 Sep.PMID: 40809875

Applications of DNA-based nanostructures in immunotherapy.
Li D, Liu H, Li X, Yang C, Zhu H, Wang H, Liu J, Ding B.Adv Drug Deliv Rev. 2025 Sep;224:115660. doi: 10.1016/j.addr.2025.115660. Epub 2025 Jul 30.PMID: 40749946

HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study Results.
Marks KM, Kang M, Umbleja T, Cox A, Vigil KJ, Avihingsanon A, Sugandhavesa P, Katsidzira L, Kosgei J, Perazzo H, Price J, Caruso S, Knowles K, Alston-Smith BL, Rathod P, Sherman KE; ACTG 5379 (BEe-HIVe) Study Team.JAMA. 2025 Sep 9;334(10):910-912. doi: 10.1001/jama.2025.9894.PMID: 40601334

Deep learning in next-generation vaccine development for infectious diseases.
Bhattacharya M, Lo YH, Chatterjee S, Das A, Wen ZH, Chakraborty C.Mol Ther Nucleic Acids. 2025 Jun 4;36(3):102586. doi: 10.1016/j.omtn.2025.102586. eCollection 2025 Sep 9.PMID: 40641804

Persistent IP-10/CXCL10 dysregulation following mild Omicron breakthrough infection: Immune network signatures across COVID-19 waves and implications for mRNA vaccine outcomes.

Vacharathit V, Pluempreecha M, Manopwisedjaroen S, Srisaowakarn C, Srichatrapimuk S, Sritipsukho P, Sritipsukho N, Thitithanyanont A.Clin Immunol. 2025 Sep;278:110507. doi: 10.1016/j.clim.2025.110507. Epub 2025 Apr 28.PMID: 40306350

SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.
Semancik CS, Fantin R, Butt J, Abdelnour A, Loria V, Porras C, Aparicio A, Jackson SS, Wong-McClure R, Ocampo R, Morera M, Zúñiga M, Calderón A, Cortés B, Castro R, Binder M, Waterboer T, Prevots DR, Herrero R, Hildesheim A; RESPIRA Study Group.PLoS One. 2025 Sep 3;20(9):e0331212. doi: 10.1371/journal.pone.0331212. eCollection 2025.PMID: 40901824

Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.
Williams TC, Marlow R, Cunningham S, Drysdale SB, Groves HE, Hunt S, Iskander D, Liu X, Lyttle MD, Mpamhanga CD, O'Hagan S, Waterfield T, Roland D; PERUKI & BronchStart Collaboration.Lancet Child Adolesc Health. 2025 Sep;9(9):655-662. doi: 10.1016/S2352-4642(25)00155-5. Epub 2025 Jul 18.PMID: 40690922

Combating vaccine hesitancy: The case of HPV vaccination.
Diaz L, Villarreal DM, Marquez K, Scartascini C.Soc Sci Med. 2025 Sep;381:118081. doi: 10.1016/j.socscimed.2025.118081. Epub 2025 Jun 13.PMID: 40532497

A bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.
Zhao Y, Zhao Z, Cheng C, Tian M, Zhang Q, Jin M.Vaccine. 2025 Sep 8;64:127685. doi: 10.1016/j.vaccine.2025.127685. Online ahead of print.PMID: 40925163

Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus.
Chatterjee R, Kommaraju SY, Mettingal Ramakrishnan S, Ravikumar KL, Aggarwal A.Lupus Sci Med. 2025 Sep 8;12(2):e001551. doi: 10.1136/lupus-2025-001551.PMID: 40921623

COVID-19 Vaccine Booster Uptake and Effectiveness Among Persons With Systemic Autoimmune and Rheumatic Diseases.
Ziemba YC, Elkin EP, Kazemian E, Wilson BM, Siddiqui H, Schleicher CB, Hsiao CA, Zidar DA, Kushi LH, Figueiredo JC, Skarbinski J, Crawford JM.J Rheumatol. 2025 Sep 1:jrheum.2025-0535. doi: 10.3899/jrheum.2025-0535. Online ahead of print.PMID: 40750311

mRNA vaccines: Emerging opportunities for herpesvirus prevention and therapeutic intervention.
Cai W, Cai M, Wu M, Gao X.Int J Biol Macromol. 2025 Sep;321(Pt 1):146204. doi: 10.1016/j.ijbiomac.2025.146204. Epub 2025 Jul 21.PMID: 40701471

Tick and host microbiotas: immunomodulators in tick-borne diseases?
Boulanger N.Trends Parasitol. 2025 Sep;41(9):796-805. doi: 10.1016/j.pt.2025.07.009. Epub 2025 Aug 7.PMID: 40780971

Measles Matters: A Clinical Overview and Update.
Otto-Ryan A, Kwong J.Nurs Clin North Am. 2025 Sep;60(3):421-429. doi: 10.1016/j.cnur.2025.04.001. Epub 2025 May 22.PMID: 40716803

Neoantigen-targeting vaccine treats melanoma.
Crunkhorn S.Nat Rev Drug Discov. 2025 Sep;24(9):665. doi: 10.1038/d41573-025-00128-5.PMID: 40721868

RAE1-armoured DC vaccine boosts NKG2D-CAR-T cells elicited anti-solid tumour treatment.
Duan Y, Zhan W, Yao J, Zhang L, Ge Y, Zhou Y, Gao Y, Guo D, Du B, Wang L, Ji Y, Jiang W.Pharmacol Res. 2025 Sep;219:107867. doi: 10.1016/j.phrs.2025.107867. Epub 2025 Jul 17.PMID: 40683483

FIGO position statement on the effectiveness and safety of the HPV vaccine.
Marshall A, Pareja R, Ruzindana K, Bhatla N, Wilailak S; FIGO Committee on Women's Cancer.Int J Gynaecol Obstet. 2025 Sep 3. doi: 10.1002/ijgo.70506. Online ahead of print.PMID: 40900298

Viroporins: emerging viral infection mechanisms and therapeutic targets.
Qu Y, Li J, Deng H, Wang Y, Li L-F, Xia B, Li Y, Qiu H-J, Li S.J Virol. 2025 Sep 2:e0103825. doi: 10.1128/jvi.01038-25. Online ahead of print.PMID: 40891825

STING-adjuvanted outer membrane vesicle nanoparticle vaccine against Pseudomonas aeruginosa.
Bjånes E, Krishnan N, Koh T, Ngo AT, Cole J, Olson J, Cornax I, Chen CH, Chavarria N, Dahesh S, Hannah SM, Stream A, Zhang JA, Besançon H, Sun D, Yendluri S, Morrill S, Zhou J, Mohapatra A, Fang RH, Nizet V.JCI Insight. 2025 Jul 24;10(17):e188105. doi: 10.1172/jci.insight.188105. eCollection 2025 Sep 9.PMID: 40705476

COVID-19 Vaccine Hesitancy and Uptake Among California Workers in 2020-2022.
Garvey K, Vergara X.Am J Ind Med. 2025 Sep;68(9):740-760. doi: 10.1002/ajim.23743. Epub 2025 Jun 18.PMID: 40533877

Impact of Rotavac Vaccine on Hospital-Based Disease Prevalence and Strain Diversity in India: A Systematic Review and Meta-Analysis.
Saikia K, Ahmed R, Das B, Paul S, Ray SK, Chandra Deka R, Borah PP, Saharia N, Namsa ND.Rev Med Virol. 2025 Sep;35(5):e70066. doi: 10.1002/rmv.70066.PMID: 40776477

Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine.
Wu M, Zhang W, Song H, Hu Y, Li W.Nanomedicine (Lond). 2025 Sep;20(17):2275-2289. doi: 10.1080/17435889.2025.2540775. Epub 2025 Jul 29.PMID: 40728220

An intranasally- and intramuscularly-deliverable nanostructured lipid carrier-replicon RNA vaccine drives protective systemic and mucosal immunity.
McClary WD, Brandt DS, Jennewein MF, Singh J, Beaver S, Ykema MR, Press C, Melief E, Bakken J, Fusco P, Lo E, Battisti P, Cross N, Kasal DN, Hartwig AT, Casper C, Bowen RA, Gerhardt A, Voigt EA.J Control Release. 2025 Sep 10;385:114054. doi: 10.1016/j.jconrel.2025.114054. Epub 2025 Jul 20.PMID: 40695376

A trivalent enteric coronaviruses inactivated vaccine provides effective protection against PEDV, TGEV, and PDCoV.

Fan L, Yi X, Zhong C, Yang C, Niu Z, Xue X, Wang W, Guo R, Ma J, Zha Y, Shu J, Li J, Li B.Vet Microbiol. 2025 Sep;308:110630. doi: 10.1016/j.vetmic.2025.110630. Epub 2025 Jul 4.PMID: 40633274

Targeting the zinc metalloprotease gp63 of Leishmania for vaccine design and new drug discovery using immunoinformatics, molecular docking and molecular dynamics simulation studies.
Ali MT, Rahman T, Palit P, Uddin MI, Seidel V.Exp Parasitol. 2025 Sep 2;277:109009. doi: 10.1016/j.exppara.2025.109009. Online ahead of print.PMID: 40907690

Pre-Vaccination Immunotypes and Immune Entropy Are Indicators of Multiple Vaccine Responsiveness.
Cevirgel A, van der Heiden M, Shetty SA, Viljanen M, Vos M, Bijvank E, van Sleen Y, Imhof C, Rolwes JAJ, Samson LD, Beckers L, Rots N, van Beek J, Buisman AM, van Baarle D.Aging Cell. 2025 Sep;24(9):e70151. doi: 10.1111/acel.70151. Epub 2025 Jul 24.PMID: 40703047

Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study.
Kupa LVK, Medeiros-Ribeiro AC, Aikawa NE, Pasoto SG, Borba EF, Assad APL, Saad CGS, Yuki EFN, Seguro LPC, Andrade D, Shinjo SK, Sampaio-Barros PD, Shimabuco AY, Moraes JCB, Sampaio VS, Giardini HAM, Silva CAA, Bonfá E.J Clin Rheumatol. 2025 Sep 1;31(6):e104-e111. doi: 10.1097/RHU.0000000000002216. Epub 2025 Mar 4.PMID: 40036115

Maladaptive trained immunity in viral infections.
Sviridov D, Netea MG, Bukrinsky MI.J Clin Invest. 2025 Sep 2;135(17):e192469. doi: 10.1172/JCI192469. eCollection 2025 Sep 2.PMID: 40892509

Drug and vaccine-associated pemphigoid in patients aged 50 years and older: a pharmacovigilance study.
Tran TS, Le DV, Nguyen TM, Lehman JS, Wetter DA, Nguyen GH.J Am Acad Dermatol. 2025 Sep 1:S0190-9622(25)02719-7. doi: 10.1016/j.jaad.2025.08.083. Online ahead of print.PMID: 40902666

Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.
Hrabal I, Aliabadi E, Weber S, Ssebyatika GL, Krey T, Holicki CM, Schmid L, Dinkelborg K, Schröder C, Fast C, Behrendt P, Groschup MH, Eiden M.Liver Int. 2025 Sep;45(9):e70246. doi: 10.1111/liv.70246.PMID: 40747926

The Search for a Respiratory Syncytial Virus Vaccine.
Wright PF.NEJM Evid. 2025 Sep;4(9):EVIDe2500194. doi: 10.1056/EVIDe2500194. Epub 2025 Aug 26.PMID: 40856553

Platelets and platelet-leukocyte interactions in infectious diseases.
de Paula MML, Oliveira RTR, Hottz ED.Curr Opin Hematol. 2025 Sep 1;32(5):261-269. doi: 10.1097/MOH.0000000000000878. Epub 2025 Jul 14.PMID: 40667838

A combined designed CSP and Pfs48/45 infection and transmission blocking vaccine for malaria.

Gupta R, Dickey TH, Salinas ND, Patel PN, Ma R, Shi D, Singleton M, Ouahes T, Pham TP, Miura K, Long CA, Lambert LE, Tolia NH.NPJ Vaccines. 2025 Sep 2;10(1):208. doi: 10.1038/s41541-025-01262-2.PMID: 40897705

Bottom-up development of lipid-based synthetic cells for practical applications.
Yandrapalli N.Trends Biotechnol. 2025 Sep;43(9):2150-2169. doi: 10.1016/j.tibtech.2025.03.009. Epub 2025 Apr 21.PMID: 40263003

Genomic characteristics and pathogenicity of three newly isolated NADC34-like PRRSV strains in China and evaluation of one strain for inactivated vaccine candidate.
Yang H, Song W, Li Z, Zhu Z, Wu W, Peng C, Xie R, Hua L, Chen H, Wu B, Peng Z.Virology. 2025 Sep;610:110605. doi: 10.1016/j.virol.2025.110605. Epub 2025 Jun 11.PMID: 40513364

Immunogenicity and innate immunity to high-dose and repeated vaccination of modified mRNA versus unmodified mRNA.
Engstrand O, Joas G, Miranda MC, Yan X, Lenart K, Cerveira RA, Reinhardt A, Loré K.Mol Ther Nucleic Acids. 2025 Jun 9;36(3):102588. doi: 10.1016/j.omtn.2025.102588. eCollection 2025 Sep 9.PMID: 40612710

A new frontier in oncology: Understanding the landscape of cancer vaccines.
Suvvari TK, Killi K, Veggalam S, Kandi V.J Oncol Pharm Pract. 2025 Sep 8:10781552251375363. doi: 10.1177/10781552251375363. Online ahead of print.PMID: 40920359

Barriers and strategies to enhance HPV vaccine uptake in adolescents living with HIV and their guardians in Lilongwe, Malawi.
Masamba Makanani C, Nyondo-Mipando AL, Jumbe V.Sci Rep. 2025 Sep 1;15(1):32230. doi: 10.1038/s41598-025-03145-x.PMID: 40890168

Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.
Garling A, Auvray F, Epardaud M, Oswald É, Branchu P.J Extracell Vesicles. 2025 Sep;14(9):e70150. doi: 10.1002/jev2.70150.PMID: 40919883

Literature review: Current trends and future prospects of digital vaccine supply chain support technology.
Ran W, Li Z, Xue Y, He D.Hum Vaccin Immunother. 2025 Dec;21(1):2553454. doi: 10.1080/21645515.2025.2553454. Epub 2025 Sep 3.PMID: 40899752

[Translated article] New Prevention Measures in Venereology: Evidence Review on the DoxiPrEP/PEP Antibiotic and the 4CMenB Vaccine.
Català A, Riera J, Fuertes de Vega I.Actas Dermosifiliogr. 2025 Sep;116(8):T849-T862. doi: 10.1016/j.ad.2025.06.014. Epub 2025 Jun 24.PMID: 40570953

Host innate immune antagonism and immune evasion strategies of porcine reproductive and respiratory syndrome virus.
He Z, Yan J, Liu M, Liao J, Li F, Guo C.Int J Biol Macromol. 2025 Sep;322(Pt 1):146756. doi: 10.1016/j.ijbiomac.2025.146756. Epub 2025 Aug 10.PMID: 40796041

Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers.
Idoko OT, Vargas SL, Bueso A, Rivera D, Edward H, Simon M, Banooni P, Berger S, Janicot S, Vercasson C, Pallardy S, Nteene R, Adhikarla H, Gerchman E, Gasparotto M, Gallichan S, Rivas E, Buchholz UJ, Collins PL, Sesay S, Gurunathan S, De Bruijn I, Dhingra MS.NEJM Evid. 2025 Sep;4(9):EVIDoa2500026. doi: 10.1056/EVIDoa2500026. Epub 2025 Aug 26.PMID: 40856556

Unmet needs in vaccine development.
Heller J, Holt T, Kaplow L, Mmopi M, Rowland E, Sabow A.Nat Rev Drug Discov. 2025 Sep;24(9):660-661. doi: 10.1038/d41573-025-00100-3.PMID: 40640570

PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
Akutagawa K, Miki S, Yamada E, Sakamoto N, Miyazaki T, Sugii N, Zaboronok A, Matsuda M, Ishikawa E.J Neurooncol. 2025 Sep;174(3):709-719. doi: 10.1007/s11060-025-05102-0. Epub 2025 Jun 12.PMID: 40504311

Prospects for therapeutic T-cell vaccine strategies for HIV cure.
Mothe B, Brander C.Curr Opin HIV AIDS. 2025 Sep 1;20(5):463-471. doi: 10.1097/COH.0000000000000965. Epub 2025 Jul 9.PMID: 40638102
Cite

A Systematic Review of Discrete Choice Experiments on Preferences for COVID-19 Vaccinations.
Hinzpeter EL, Kairies-Schwarz N, Beaudart C, Douxfils J, Nayak D, Hiligsmann M.Patient. 2025 Sep;18(5):461-480. doi: 10.1007/s40271-025-00753-7. Epub 2025 Jul 10.PMID: 40638063

Antigen-dependent interplay of formulation, systemic innate responses, and antibody responses to multi-component replicon RNA vaccination.
Kimura T, Reed SJ, Warner NL, Fredericks MN, Lewis TB, Lafferty A, Hodge E, Simpson A, Hinkley T, Khandhar AP, Fuller DH, Erasmus JH.Mol Ther Nucleic Acids. 2025 Jun 9;36(3):102595. doi: 10.1016/j.omtn.2025.102595. eCollection 2025 Sep 9.PMID: 40606648

Serotype replacement and mobile genetic elements in *Streptococcus pneumoniae*: a systematic review.
Sunmonu GT, Lo SW, Sheppard AE, Ogunniyi AD.Microb Genom. 2025 Sep;11(9). doi: 10.1099/mgen.0.001497.PMID: 40924620

Re: A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma.
Zhang H, Liu Y, Lin A, Luo P, Wang L, Jiang A.Eur Urol. 2025 Sep;88(3):313-314. doi: 10.1016/j.eururo.2025.02.017. Epub 2025 Mar 7.PMID: 40057402

Lyme borreliosis vaccine VLA15 tested safe and immunogenic in children and adolescents.
Hajdusek O, Perner J.Lancet Infect Dis. 2025 Sep;25(9):951-952. doi: 10.1016/S1473-3099(25)00160-4. Epub 2025 Apr 25.PMID: 40294610

Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine.

Subramani C, Meyer M, Hyde MA, Comeaux ME, Hao H, Crowe JE Jr, Popov VL, Thaker H, Himansu S, Carfi A, Bukreyev A.J Clin Invest. 2025 Jul 3;135(17):e194586. doi: 10.1172/JCI194586. eCollection 2025 Sep 2.PMID: 40608418

Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV.
Maziec K, Baliga-Gil A, Kierzek E.Mol Ther Nucleic Acids. 2025 May 20;36(3):102572. doi: 10.1016/j.omtn.2025.102572. eCollection 2025 Sep 9.PMID: 40529300

Codon Usage Evolution in Viruses: Implications for Survival and Pathogenicity.
Kaleem S, Dahal U, Devi S, Kour B, Kour S.J Mol Evol. 2025 Sep 4. doi: 10.1007/s00239-025-10263-7. Online ahead of print.PMID: 40906273

mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models.
Limeres MJ, Gambaro R, Svensson M, Fraude-El Ghazi S, Pretsch L, Frank D, Islan GA, Berti IR, Bros M, Tam YK, Muramatsu H, Pardi N, Gehring S, Cacicedo ML.Mol Ther. 2025 Sep 3;33(9):4156-4174. doi: 10.1016/j.ymthe.2025.06.027. Epub 2025 Jun 14.PMID: 40518670

Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
Zhao Z, Ma X, Milligan P, Cheung YB.Vaccine. 2025 Sep 2;63:127673. doi: 10.1016/j.vaccine.2025.127673. Online ahead of print.PMID: 40902335

Mucus-penetrating nanomotor system strengthens mucosal immune response to in situ bacterial vaccine against severe bacterial pneumonia.
Song T, Li N, Zuo Q, Huang L, Liu Z, Guo Z.Biomaterials. 2025 Sep;320:123236. doi: 10.1016/j.biomaterials.2025.123236. Epub 2025 Mar 3.PMID: 40054375

Using Social Media to Combat Influenza Vaccine Misinformation and Improve Uptake: A Social Media Campaign and Repeated Cross-sectional Survey Analysis.
Steier JB.Mayo Clin Proc Digit Health. 2025 May 23;3(3):100229. doi: 10.1016/j.mcpdig.2025.100229. eCollection 2025 Sep.PMID: 40607109

Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey.
Micheletto C, Lorenzini G, De Grazia S, Di Marco F, Di Matteo R, Faverio P, Gramegna A, Vicentini M, Blasi F.Hum Vaccin Immunother. 2025 Dec;21(1):2552557. doi: 10.1080/21645515.2025.2552557. Epub 2025 Sep 3.PMID: 40899479

Progress in brucellosis immune regulation inflammatory mechanisms and diagnostic advances.
Lu P, Luo B, Wang Q, Wang L, Chen M, Jia J, Yang M, Pan J, Liu J, Li Z.Eur J Med Res. 2025 Sep 1;30(1):830. doi: 10.1186/s40001-025-03068-3.PMID: 40890848

Recent Developments of RNA Vaccines and Therapeutics: Reagents, Formulations, and Characterization.
Tomeh MA, Smith RK, Watkinson A.Mol Pharm. 2025 Sep 1;22(9):5257-5282. doi: 10.1021/acs.molpharmaceut.5c00670. Epub 2025 Aug 11.PMID: 40788115

Screen first, vaccinate later: Enhancing tuberculosis vaccination safety through newborn immunodeficiency screening.
Nosan G, Cerkvenik Škafar A.Vaccine. 2025 Sep 3;64:127679. doi: 10.1016/j.vaccine.2025.127679. Online ahead of print.PMID: 40907067

Factors Influencing Parental Decisions on Respiratory Syncytial Virus Immunoprophylaxis.
Shedlock KE, Hicks SD, Gardner RE, Kaye LD, Lipsett BJ, Schaefer EW, Paul IM, Fogel BN.J Pediatr Clin Pract. 2025 Jun 6;17:200153. doi: 10.1016/j.jpedcp.2025.200153. eCollection 2025 Sep.PMID: 40636557

Global dengue epidemic worsens with record 14 million cases and 9000 deaths reported in 2024.
Haider N, Hasan MN, Onyango J, Billah M, Khan S, Papakonstantinou D, Paudyal P, Asaduzzaman M.Int J Infect Dis. 2025 Sep;158:107940. doi: 10.1016/j.ijid.2025.107940. Epub 2025 May 29.PMID: 40449873

Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases.
Gurung S, Perocheau D, Ghosh R, Hart SL, Baruteau J.J Inherit Metab Dis. 2025 Sep;48(5):e70078. doi: 10.1002/jimd.70078.PMID: 40826824

Vaccine Effects on In-hospital COVID-19 Outcomes.
Gonçalves BP, Olliaro PL, Horby P, Cowling BJ.Epidemiology. 2025 Sep 1;36(5):646-649. doi: 10.1097/EDE.0000000000001877. Epub 2025 Jun 17.PMID: 40525720

The Vaccine Trust Framework: mixed-method development of a tool for understanding and quantifying trust in health systems and vaccines.
Bowen DH, Casciola L, Aimade W, Lindeburg E, Muhula SO, Osur J, Rakhshani NS, Fayomi SA, Johnson T, Holme M, Vangsgaard C; ReD Trust Group.Lancet Glob Health. 2025 Sep;13(9):e1553-e1563. doi: 10.1016/S2214-109X(25)00245-1.PMID: 40845881

Mpox outbreak response: Regulatory and public health perspectives from India and the world.
Tiwari R, Gulati P, Raghuvanshi RS.J Infect Public Health. 2025 Sep;18(9):102839. doi: 10.1016/j.jiph.2025.102839. Epub 2025 May 23.PMID: 40483795

Multi-engineered T cell vaccine boosting TCR-T cell therapy enhances anti-tumor function and eradicates heterogeneous solid tumors.
Che X, Zheng S, Sun Y, Wang X, Zhang P, Cao J, Bai Y.Mol Ther. 2025 Sep 3;33(9):4529-4551. doi: 10.1016/j.ymthe.2025.05.036. Epub 2025 May 30.PMID: 40450522

Vaccination strategies for transplantation in Japan (solid organ transplantation and hematopoietic stem cell transplantation).
Tanaka T, Kakiuchi S, Fujita A, Tashiro M, Izumikawa K.J Infect Chemother. 2025 Sep;31(9):102772. doi: 10.1016/j.jiac.2025.102772. Epub 2025 Jul 10.PMID: 40651571

Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence.
Zhou SH, Lei YJ, Wen Y, Ding D, Luo MQ, Cui HY, Guo J.J Control Release. 2025 Sep 10;385:113979. doi: 10.1016/j.jconrel.2025.113979. Epub 2025 Jun 24.PMID: 40570966

A vaccine emergency-when to overrule parental refusal of vaccination at birth for prevention of vertical transmission of hepatitis B virus?
Basu Roy R, Paulus S, Kelly DF, Brrang H, Taylor A, Tudor-Williams G, Nastouli E, Banerjee A, Horne M, Parker EPK, ElSharkawy A, Mandal S, Ramsay ME, Pollard AJ, Savulescu J, Wilkinson D.Arch Dis Child. 2025 Sep 8:archdischild-2025-328641. doi: 10.1136/archdischild-2025-328641. Online ahead of print.PMID: 40921482

Probiotics integrated to cancer vaccines and their potential for cancer management.
Khan AA, Chaudhary AA, Singh H, Baig MS.Microb Pathog. 2025 Sep;206:107742. doi: 10.1016/j.micpath.2025.107742. Epub 2025 May 27.PMID: 40441392

Strategies for the Prevention and Management of Respiratory Infections in Patients at High Risk in the UAE: A Cross-Disciplinary Position Paper.
Shehab A, Al Dhanhani H, Alhammadi O, Hassan MB, Farghaly M, Hassoun A, Mahboub B, Tahlak M, Abutayeh RF, Haridy H, Hassanien A, Joury J, Al-Shamsi HO.Pulm Ther. 2025 Sep;11(3):405-421. doi: 10.1007/s41030-025-00304-3. Epub 2025 Jul 19.PMID: 40684072

Phase 2 randomized controlled trial of seasonal influenza vaccine shows Advax() delta inulin adjuvant accelerates the humoral anti-influenza response.
Li L, Honda-Okubo Y, Khanna V, Sajkov D, Petrovsky N.Immunol Cell Biol. 2025 Sep;103(8):794-808. doi: 10.1111/imcb.70050. Epub 2025 Jul 25.PMID: 40709978

Risk Perceptions Regarding Tuberculosis Among Hispanic Adults - United States, 2020-2022.
Caruso E, Mangan JM, Maiuri A, Bouwkamp B, DeLuca N.Am J Health Promot. 2025 Sep 4:8901171251376650. doi: 10.1177/08901171251376650. Online ahead of print.PMID: 40906515

COVID-19 and COVID-19 Vaccine-Related Skin Ulcerations in the Lower Extremities: A Case Report and Literature Review.
Beaineh P, El-Bsat A, Hafez B, Bizri AR, Kibbi AG, Merashli M, Haddad F.Int J Low Extrem Wounds. 2025 Sep;24(3):723-727. doi: 10.1177/15347346241275785. Epub 2024 Oct 29.PMID: 39471824

Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7/8 adjuvant for robust protection against heterologous pandemic and endemic viruses.
Yoo YJ, Kim S, Wickramasinghe A, Kim J, Song J, Kim YI, Gil J, Noh YW, Lee MH, Oh SS, Lee MM, Seong Y, Lee JS, Choi YK, Lim YT.Cell Mol Immunol. 2025 Sep;22(9):1045-1060. doi: 10.1038/s41423-025-01306-6. Epub 2025 Jun 25.PMID: 40562869

Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity.
Zhang G, Tu J, Zhang Y, He J, Peng G, Fan Q, Zhang Y, Zhang M, Tan H, Xu Y, Cheng J.Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102620. doi: 10.1016/j.omtn.2025.102620. eCollection 2025 Sep 9.PMID: 40704028

AlphaFold 3: an unprecedent opportunity for fundamental research and drug development.
Fang Z, Ran H, Zhang Y, Chen C, Lin P, Zhang X, Wu M.Precis Clin Med. 2025 Jul 1;8(3):pbaf015. doi: 10.1093/pcmedi/pbaf015. eCollection 2025 Sep.PMID: 40799364

The persuasiveness of vaccine focused social media posts to parents of adolescents.
Imburgia TM, Fontenot HB, Glauberman GHR, Liebermann E, Kornides ML, Lim E, Matsunaga M, Zimet GD.Prev Med Rep. 2025 Aug 5;57:103194. doi: 10.1016/j.pmedr.2025.103194. eCollection 2025 Sep.PMID: 40821924

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study.
Giles ML, Tabora C, Baccarini C, Barrientos L, Vargas JC, Montellano ME, Nguyen P, Deshmukh S, Neville M, Hohenboken M, van Boxmeer J, Jin H, Bugarini R, Liu X, Walson JL, Verhoeven C, Smolenov I.EClinicalMedicine. 2025 Aug 20;87:103428. doi: 10.1016/j.eclinm.2025.103428. eCollection 2025 Sep.PMID: 40896462

Advances in molecular diagnostics of Neisseria gonorrhoeae.
Yu CY, Lim XR, Van Phan T, Mat Isa N, Yean CY, Chan KG, Ang GY.J Microbiol Methods. 2025 Sep;236:107197. doi: 10.1016/j.mimet.2025.107197. Epub 2025 Jul 15.PMID: 40675222

Construction and biological characteristics analysis of a gene-deleted recombinant virus strain of LSDV-ORF151.
Li J, Ke Q, Huang W, Ren S, Li M, Yao K, Ma X, Sun Y, Yin X.Virology. 2025 Sep;610:110623. doi: 10.1016/j.virol.2025.110623. Epub 2025 Jul 8.PMID: 40651150

Reverse vaccinology and immunoinformatics approaches for multi-epitope vaccine design against Klebsiella pneumoniae reveal a novel vaccine target protein.
Elfadil MM, Samhoon SOA, Saadaldin MM, Ibrahim SAE, Mohamed AAM, Suliman OH, Mohamed O, Damiri N, Firdaus-Raih M, Mohamed SB, M Ali Q.J Genet Eng Biotechnol. 2025 Sep;23(3):100510. doi: 10.1016/j.jgeb.2025.100510. Epub 2025 May 23.PMID: 40854630

Immunogenicity and safety of 'Comvigen', a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.
Jantarabenjakul W, Nantanee R, Puthanakit T, Gatechompol S, Avihingsanon A, Punrin S, Tantawichien T, Nitayaphan S, Thitithanyanont A, Buranapraditkun S, Jongkaewwattana A, Ketloy C, Prompetchara E, Lawpoolsri S, Wijagkanalan W, Alameh MG, Hong L, Samija M, Weissman D, Ruxrungtham K; ChulaVac006 Study Team.Lancet Reg Health Southeast Asia. 2025 Aug 15;40:100650. doi: 10.1016/j.lansea.2025.100650. eCollection 2025 Sep.PMID: 40895389

Immunoinformatics-Driven Design of a Multi-Epitope Vaccine Targeting Simian Virus VP1 Major Capsid Protein for Oncogenic Viral Infection Prevention.
Akbar R, Fatima S, Rahman SU, Malik A, Akhtar S, Siddiqi NJ, Aiman S, Huang K.Rev Med Virol. 2025 Sep;35(5):e70065. doi: 10.1002/rmv.70065.PMID: 40781525

Pneumococcal surface proteins as targets for next-generation vaccines: Addressing the challenges of serotype variation.
Gopalakrishnan S, Jayapal P, John J.Diagn Microbiol Infect Dis. 2025 Sep;113(1):116870. doi: 10.1016/j.diagmicrobio.2025.116870. Epub 2025 Apr 28.PMID: 40347702

The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins.
Kumar S, Jain S, Wali B, Zarnitsyna VI, Joshi D, Ellis ML, Lai L, Malik AA, McPherson TO, Godbole S, Patel A, Linderman S, Solis D, Sahoo MK, Bechnak K, Paredes I, Tanios R, Kazzi B, Dib SM, Litvack MB, Wimalasena ST, Hicks H, Tamin A, Bowen NE, Atherton L, Paden C, Harcourt JL, Wentworth DE, Ciric C, West RH, Rostad CA, Teng IT, Wang D, Ortlund EA, Menachery VD, Edupuganti S, Kwong PD, Rouphael N, Pinsky BA, Douek DC, Moreno A, Wrammert J, Suthar MS.Sci Transl Med. 2025 Sep 3;17(814):eadu8067. doi: 10.1126/scitranslmed.adu8067. Epub 2025 Sep 3.PMID: 40901926

Essential role of CD56^{dim}NKG2C^{+} NK cells trained by SARS-CoV-2 vaccines in protecting against COVID-19.
Zheng H, Chen Y, Li J, Zhang Y, Li H, Zhao X, He Z, Liao Y, Zhang Z, Shi H, Yang F, Hu Y, Li Y, Li J, Zhao Y, Zhang X, Yang J, Li Q, Liu L.Mol Ther. 2025 Sep 3;33(9):4488-4508. doi: 10.1016/j.ymthe.2025.05.031. Epub 2025 May 30.PMID: 40450518

HPV Vaccination in Morocco: Quiet Progress or Public Health Failure?
Hiba B, Zinab A.J Cancer Educ. 2025 Sep 4. doi: 10.1007/s13187-025-02729-5. Online ahead of print.PMID: 40903596

Plant-based edible vaccines: Can cholera be the case study in Africa?
Siamalube B, Ehinmitan E, Kachenga L, Runo S, Ngotho M, Onguso J.J Genet Eng Biotechnol. 2025 Sep;23(3):100527. doi: 10.1016/j.jgeb.2025.100527. Epub 2025 Jun 23.PMID: 40854646

Looped Audiovisual Health Education Talk Reduces Vaccine Clinic Wait Time in Nigeria.
Oluwafemi RO, Ajayi B, Mendonca EA, Biondich P, Ekhaguere OA.Child Care Health Dev. 2025 Sep;51(5):e70152. doi: 10.1111/cch.70152.PMID: 40761007

The life-and-death struggle between the complement system and pathogens: Mechanisms of elimination, evasion tactics, and translational potential.
Lian S, Liu J, Yang Y, Zhu G, Xia P.Virulence. 2025 Dec;16(1):2553781. doi: 10.1080/21505594.2025.2553781. Epub 2025 Sep 4.PMID: 40905313

COVID-19 Vaccine Hesitancy, Self-Reported Adverse Events, and Determinants Among Ethiopian Healthcare Professionals During COVID-19 Pandemic.
Abiye AA, Endale S, Negash Z, Hussen SU, Gebregeorgise DT, Tamiru MT, Beyene DA, Amde HS, Negash AY.Public Health Chall. 2025 Jul 25;4(3):e70078. doi: 10.1002/puh2.70078. eCollection 2025 Sep.PMID: 40718149

Anticipated protection overcomes vaccine hesitancy and mistrust among women enrolled in the DC MACS/WIHS Combined Cohort Study.
Spence AB, Visconti A, Goparaju L, Wingood G, Krier S, Friedman MR, Kassaye S.J Acquir Immune Defic Syndr. 2025 Sep 3. doi: 10.1097/QAI.0000000000003757. Online ahead of print.PMID: 40900131

Nanoparticles as an Alternative Strategy to Control Foot and Mouth Disease Virus in Bovines.

Abbas RZ, Ambrose S, Khan AMA, Mobashar M, Mohamed K.Biol Trace Elem Res. 2025 Sep;203(9):4590-4606. doi: 10.1007/s12011-025-04533-0. Epub 2025 Feb 7.PMID: 39918774

Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study.
Top KA, Bettinger JA, Embree JE, Jadavji T, Purewal R, Sauvé L, Papenburg J, Deeks SL, Wilson SE, Dahdah N, Sadarangani M, Halperin SA, Kakkar F, Morris SK; IMPACT Investigators.J Pediatr. 2025 Sep;284:114642. doi: 10.1016/j.jpeds.2025.114642. Epub 2025 May 13.PMID: 40373954

A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets.
Wang WC, Sayedahmed EE, Alhashimi M, Elkashif A, Gairola V, Murala MST, Sambhara S, Mittal SK.Mol Ther Nucleic Acids. 2025 Jun 9;36(3):102594. doi: 10.1016/j.omtn.2025.102594. eCollection 2025 Sep 9.PMID: 40635672

Adopting the estimand framework in prophylactic vaccine trials.
Beckers F, Karkada N, Yang Y, Scott J, Huang L, Klinglmüller F, Fay MP, Englert S, Spiessens B, Van Dromme I, Shekar T, Zhou H, Deng Q, Casula D, Janes H, Moulton LH.Vaccine. 2025 Sep 3;64:127645. doi: 10.1016/j.vaccine.2025.127645. Online ahead of print.PMID: 40907068

A Comprehensive Lateral Flow Strip Assay for On-Site mRNA Vaccine Quality Control in Decentralized Manufacturing.
Luo D, Zhang Z, Guo J, Zhang J, Huang A, Cao Q, Zheng J, Yuan Y, Wang D, Cao Y.Adv Sci (Weinh). 2025 Sep 3:e02387. doi: 10.1002/advs.202502387. Online ahead of print.PMID: 40899607

Development of a mouse model for *Klebsiella pneumoniae*-associated neonatal sepsis.
Miller JC, Choi M, Zhao Z, Mushrush EM, Legesse TB, Cross AS, Baliban SM, Tennant SM.Microbiol Spectr. 2025 Sep 2;13(9):e0069725. doi: 10.1128/spectrum.00697-25. Epub 2025 Aug 1.PMID: 40748073

Thermostable unit solid dose formulations for subcutaneous administration of DNA vaccines.
Garcia-Valtanen P, Yeow AEL, Mekonnen ZA, Whelan DM, Santos R, Al-Delfi Z, Rodrigues S, Gavan P, Howard K, Masavuli MG, Grubor-Bauk B.Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102628. doi: 10.1016/j.omtn.2025.102628. eCollection 2025 Sep 9.PMID: 40896582

Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.
Sahoo D, Rodriguez E, Nguyen K, Chintapula U.ACS Appl Bio Mater. 2025 Sep 1. doi: 10.1021/acsabm.5c00959. Online ahead of print.PMID: 40888536

Boot camp translation: A novel method to increase human papillomavirus (HPV) vaccination uptake.
O'Leary ST, Skenadore A, Mosley BS, Severson R, Rice JD, Simpson MJ, Brewer SE.Vaccine. 2025 Sep 2;63:127683. doi: 10.1016/j.vaccine.2025.127683. Online ahead of print.PMID: 40902333

Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.

Boga DJ, Robinson M, Tirupathi M, Juste RS, Lazarus K, Etienne K, Wright M, Reid R, Shahid N, Nelson CM, Koru-Sengul T, Safren SA, Ironson G, Rodriguez A, Wright I, Feaster D, Dale SK.Vaccine. 2025 Sep 5;64:127649. doi: 10.1016/j.vaccine.2025.127649. Online ahead of print.PMID: 40913818

Protective effects of inactivated SPIV vaccine in sea perch (Lateolabrax japonicas) by intraperitoneal injection and immersion immunization.
Liu M, Chen H, Zeng Z, Mu G, Zhang D, Huang Y, Huang X, Qin Q.Fish Shellfish Immunol. 2025 Sep 4;167:110700. doi: 10.1016/j.fsi.2025.110700. Online ahead of print.PMID: 40914507

Immune Response to COVID-19 Vaccination in Children With Cancer.
Body A, Lal L, Downie P, Anazodo A, O'Brien T, Padhye B, Fuentes-Bolanos N, Srihari S, Stephanie Ahern E, Haber M, Smith C, Lineburg K, Turville S, Naing Z, Rawlinson W, Buttery J, Raina MacIntyre C, Milch V, Segelov E.Pediatrics. 2025 Sep 1;156(3):e2024070209. doi: 10.1542/peds.2024-070209.PMID: 40774663

Investigating barriers and facilitators to Fall 2023 COVID-19 vaccine uptake in public health students.
Nagajothi N, Dou P, Felter E, Lazarus A, Hoffman B.J Am Coll Health. 2025 Sep 3:1-10. doi: 10.1080/07448481.2025.2552828. Online ahead of print.PMID: 40902030

Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent vaccine against diverse variants.
Wang S, Sun H, Wang Y, Wang Z, Yuan L, Guo H, Gao J, Lan M, Wu Y, Shang H, Chen X, Chen Z, Hu J, Tang Z, Wen G, Ying D, Liu C, Jiang Y, Su J, Lin M, Wu T, Li S, Zhang T, Zhang J, Guan Y, Xia N, Yuan Q, Zheng Q, Zhang Y, Zheng Z.Proc Natl Acad Sci U S A. 2025 Sep 2;122(35):e2503254122. doi: 10.1073/pnas.2503254122. Epub 2025 Aug 25.PMID: 40854137

Educational determinants of immunization coverage among internally displaced persons (IDPs) in Mogadishu: a cross-sectional study.
Abdi YH, Abdullahi YB, Abdi MS, Bashir SG, Ahmed NI.Arch Public Health. 2025 Sep 1;83(1):222. doi: 10.1186/s13690-025-01707-z.PMID: 40890758

The promise and practicality of measuring vaccine trust in LMICs to inform intervention design and implementation.
Kaufman J, Danchin M.Lancet Glob Health. 2025 Sep;13(9):e1496-e1497. doi: 10.1016/S2214-109X(25)00298-0.PMID: 40845871

An alphavirus vaccine development utilizing RNA replication-defective strategy.
Zhang Z, Huang J, Li Z, Deng C, Zhang H, Zhang B, Zhang Y.Mol Ther. 2025 Sep 2:S1525-0016(25)00725-7. doi: 10.1016/j.ymthe.2025.08.051. Online ahead of print.PMID: 40898615

Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults 65 years of age" [Vaccine 62 (2025) 127456].
Kishino H, Inoue S, Matsuoka O, Yagi M, Igarashi R, Oshima N, Sawata M, Platt HL.Vaccine. 2025 Sep 6;64:127688. doi: 10.1016/j.vaccine.2025.127688. Online ahead of print.PMID: 40916264

Awareness and uptake of herpes zoster vaccine among patients with diabetes mellitus in the Aseer Region, Saudi Arabia: A cross-sectional study.
Alamri A, Althaqafi A, Salawati R, Asiri R, Aldugman M, Al Saleh M, AlAsmari B, AlBraik M, Ghazy RM.Medicine (Baltimore). 2025 Sep 5;104(36):e44356. doi: 10.1097/MD.0000000000044356.PMID: 40922237

Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy and safety.
Peters NE, Shields AM, Hambleton S, Richter AG.Clin Exp Immunol. 2025 Sep 2:uxaf059. doi: 10.1093/cei/uxaf059. Online ahead of print.PMID: 40916471

Vaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.
Noble C, Gualtieri R, Mattiello V, Cimasoni L, Blanchard-Rohner G.Pediatr Infect Dis J. 2025 Sep 1. doi: 10.1097/INF.0000000000004947. Online ahead of print.PMID: 40924709

Addressing male HPV vaccination in China: A narrative review of challenges and opportunities.
Wong LP, Chen X, Huang Z, Zimet G, Zhao Q, Lin Y, Hu Z.Hum Vaccin Immunother. 2025 Dec;21(1):2552061. doi: 10.1080/21645515.2025.2552061. Epub 2025 Sep 3.PMID: 40903877

Evaluation of synthetic mRNA with selected UTR sequences and alternative poly(A) tail, *in vitro* and *in vivo*.
Medjmedj A, Genon H, Hezili D, Loth AN, Clemençon R, Guimpied C, Mollet L, Bigot A, Wien F, Hamacek J, Chapat C, Perche F.Mol Ther Nucleic Acids. 2025 Jul 30;36(3):102648. doi: 10.1016/j.omtn.2025.102648. eCollection 2025 Sep 9.PMID: 40822034

Acute Posterior Multifocal Placoid Pigment Epitheliopathy-Like Panuveitis Following Mpox Vaccination.
Lu LM, Samalia PD, Niederer RL.Ocul Immunol Inflamm. 2025 Sep 4:1-5. doi: 10.1080/09273948.2025.2551802. Online ahead of print.PMID: 40906575

Influenza vaccination hesitancy and decision between parental and grandparental caregivers of preschoolers: a comparative study.
Zhou Y, Wang H, Chu L, Chen K, Xu Y, Fu C.Vaccine. 2025 Sep 3;64:127696. doi: 10.1016/j.vaccine.2025.127696. Online ahead of print.PMID: 40907066

Association between live herpes-zoster vaccine and stroke risk: A population-based nested case-control study.
Yahav A, Ryan D, Naftali J, Arbel A, Najjar R, Stein N, Barnett O, Auriel E, Saliba W.Int J Stroke. 2025 Sep 6:17474930251380184. doi: 10.1177/17474930251380184. Online ahead of print.PMID: 40913529

Alternative therapeutic approaches for combating multi-drug-resistant bacteria: Reverse vaccinology against Enterobacter cloacae.
Soares GG, Damas MSF, Laprega PM, Shilling RE, Rangel EOR, Cerdeira LT, Homem MRP, Pitondo-Silva A, Costa-Fuentes ASD, Pranchevicius MDS.J Genet Eng Biotechnol. 2025 Sep;23(3):100519. doi: 10.1016/j.jgeb.2025.100519. Epub 2025 Jun 17.PMID: 40854638

Viral interference during coinfection and sequential infection of enterovirus A71 and coxsackievirus A16.

Chang HY, Ong KC, Jasni K, Abdullah S, Ong YJ, Sam IC, Chan YF.Virology. 2025 Sep;610:110610. doi: 10.1016/j.virol.2025.110610. Epub 2025 Jun 21.PMID: 40570759

Understanding measles infection and how to improve uptake of the MMR vaccine.
Jones R, Youlden H, McDermott C, Perry M, Norwood J.Nurs Child Young People. 2025 Sep 9. doi: 10.7748/ncyp.2025.e1562. Online ahead of print.PMID: 40926461

Biomimetic mineralization material RMCP enhanced immunogenicity of subunit vaccine against Clostridium perfringens infection in mice.
Jia S, Zhou X, Fang L, Jiang Z, De X, Liu R, Wang F, Ge J.Int J Biol Macromol. 2025 Sep;324(Pt 2):147314. doi: 10.1016/j.ijbiomac.2025.147314. Epub 2025 Sep 1.PMID: 40902765

Comparative performance of serum and plasma samples in SARS-CoV-2 serology and neutralization assays.
Chentoufi HA, Galipeau Y, Arnold C, Dewar-Darch D, Dyks A, Cooper C, Langlois MA.J Virol Methods. 2025 Sep;337:115186. doi: 10.1016/j.jviromet.2025.115186. Epub 2025 May 13.PMID: 40374015

COVID-19 vaccine-associated reactive axillary lymph nodes on FDG PET/CT: a systematic review and meta-analysis.
Adin ME, Nguyen D, Shin C, Pucar D.Nucl Med Commun. 2025 Sep 3. doi: 10.1097/MNM.0000000000002041. Online ahead of print.PMID: 40900040

Serological differentiation between naturally acquired mpox and MVA-BN-vaccine induced antibody responses using ratios of MPXV and VACV antigen pairs in the MSD immunoassay.
Pettke A, Keszei M, Christ W, Mayola Danés N, Gredmark-Russ S, Söderholm S, Filén F, Storgärd E, Westergren V, Yman V, Aarum J, Klingström J, Johansen K, Ekström AM, Sondén K.Microbiol Spectr. 2025 Sep 2;13(9):e0018225. doi: 10.1128/spectrum.00182-25. Epub 2025 Aug 8.PMID: 40778847

Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population.
García FÁ, Martinón-Torres F, Pineda V, López-Ibáñez de Aldecoa A, Gálvez P, Ta A, Perdrizet J.Expert Rev Pharmacoecon Outcomes Res. 2025 Sep;25(7):1101-1113. doi: 10.1080/14737167.2025.2521445. Epub 2025 Jun 24.PMID: 40539970

Assessment of Obstetric Providers' Practice Surrounding Vaccine Counseling and Administration for Non-Birthing Partners.
Griffin LB, Passarelli N, Whelan A, Russo M, Zitek E, Hardy E, Clark MA, Lewkowitz AK.R I Med J (2013). 2025 Sep 2;108(9):36-41.PMID: 40854029

Design and immunological evaluation of a multi-epitope vaccine candidate against Toxoplasma gondii incorporating MIC13, GRA1, and SAG1 antigens in BALB/c mice.
Hosseininejad Z, Daryani A, Fasihi-Ramandi M, Asgarian-Omran H, Nayeri T, Dodangeh S, Amouei A, Javidnia J, Mayahi S, Sarvi S, Aghayan SA.Food Waterborne Parasitol. 2025 Jun 2;40:e00269. doi: 10.1016/j.fawpar.2025.e00269. eCollection 2025 Sep.PMID: 40546389

Computational identification of membrane proteins for vaccine design against drug-resistant Moraxella catarrhalis.

Arshad F, Pervaiz R, Sarfraz A, Ejaz H, Alotaibi A, Ullah R, Nishan U, Ali A, Khan MU, Shah M.Mol Genet Genomics. 2025 Sep 6;300(1):92. doi: 10.1007/s00438-025-02288-w.PMID: 40913648

Transplacental transfer of maternal SARS-CoV-2 antibodies in dichorionic and monochorionic twin pregnancies.
Stolarczuk JE, Sosa M, Pike M, Baranoff A, Lekander A, Cho H, Goecker EA, Greninger AL, Eckert LO, Englund JA, Kachikis A.PLoS One. 2025 Sep 2;20(9):e0328137. doi: 10.1371/journal.pone.0328137. eCollection 2025.PMID: 40892764

Correlation between the immune response to COVID-19 vaccines and the constitutions of traditional Chinese medicine.
Chen P, Yen HR, Lee HJ, Wu MY, Park K, Song YC.Hum Vaccin Immunother. 2025 Dec;21(1):2553371. doi: 10.1080/21645515.2025.2553371. Epub 2025 Sep 5.PMID: 40910738

A combination of multiple LC-MS approaches for the comprehensive characterization of recombinant herpes zoster vaccine.
Long Z, Wei C, Zhu X, Luo X, Li X, Zhao S.J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Sep 1;1263:124712. doi: 10.1016/j.jchromb.2025.124712. Epub 2025 Jun 26.PMID: 40602088

Spatial disparities in perfluoroalkyl and polyfluoroalkyl substances exposure and immunosuppressive effects on vaccine induced antibody levels in Guangzhou children.
Mou Z, Zhu P, Deng F, Xu Y, Qin P, Peng R, Li J, Tan L.Environ Pollut. 2025 Sep 3;385:127066. doi: 10.1016/j.envpol.2025.127066. Online ahead of print.PMID: 40912534

Assessment of hepatitis C virus permissiveness in iteratively genetically humanized mice.
Schwoerer MP, Carver S, Cafiero TR, Joyce B, Berggren KA, Suzuki S, Heller B, O'Connell AK, Gertje HP, Crossland NA, Posfai E, Ploss A.J Virol. 2025 Sep 3:e0079325. doi: 10.1128/jvi.00793-25. Online ahead of print.PMID: 40899815

Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis.
Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, Yamashita T, Kuroda A, Nomura S, Akita H, Itaka K, Kodama T, Kakimi K.Gastric Cancer. 2025 Sep;28(5):825-836. doi: 10.1007/s10120-025-01640-8. Epub 2025 Jul 31.PMID: 40738981

Engineered Immunoagonist Non-Coding RNA (incRNA) Activates Dual TLR Pathways for Cancer Immunotherapy.
Forster J 3rd, Fish A, Malhotra M, Pinjari A, Debnath M, Kulkarni A.Adv Healthc Mater. 2025 Sep 4:e03771. doi: 10.1002/adhm.202503771. Online ahead of print.PMID: 40906496

Perceptions on vaccines, vaccine communication and information needs of healthcare professionals involved in older adult vaccination: A cross-country interview study.
Wennekes MD, De Haan F, Eilers R, Caputo A, Nicoli F, Nagy D, Stein ML, Gagneux-Brunon A, Gavioli R, Vokó Z, Timen A; VITAL Consortium.PLOS Glob Public Health. 2025 Sep 2;5(9):e0004928. doi: 10.1371/journal.pgph.0004928. eCollection 2025.PMID: 40892730

Purification of O-antigen for polysaccharide vaccine development against Salmonella paratyphi.
Kowlakuntla ER, T C V.Prep Biochem Biotechnol. 2025 Sep 2:1-9. doi: 10.1080/10826068.2025.2555304. Online ahead of print.PMID: 40891258

Examining the hesitations of pregnant women towards COVID-19 vaccines during the pandemic: A mixed methods approach.
Aksoy SD, Yalçın SU, Odabaş RK.Midwifery. 2025 Sep;148:104469. doi: 10.1016/j.midw.2025.104469. Epub 2025 May 23.PMID: 40449311

Call for Increased Community Education Regarding Common HPV-Associated Cancers Within the Urban Safety-Net Hospital Population.
Rai I, Karkala E, Borgaonkar R, Seide J, Mokhtar R, Pierre-Joseph N.J Cancer Educ. 2025 Sep 1. doi: 10.1007/s13187-025-02722-y. Online ahead of print.PMID: 40888851

Vision Crisis-Bilateral Outer Retinitis Due to Mumps Virus.
Sriram R, Sethu S, Ghosh A, Shetty R, Rizvi S, Dave N, Fernandes RS, Bagchi A, Kawali A, Mishra SB, Mahendradas P.Ocul Immunol Inflamm. 2025 Sep;33(7):1436-1443. doi: 10.1080/09273948.2024.2382925. Epub 2024 Aug 8.PMID: 39116409

Equine influenza antigen-based particle vaccine protects mice against homologous and heterosubtypic viral challenges.
Siddoway AC, Van Zanten A, Verhoeven D, Wannemuehler MJ, Mallapragada SK, Narasimhan B.Acta Biomater. 2025 Sep 1;203:578-590. doi: 10.1016/j.actbio.2025.07.042. Epub 2025 Jul 22.PMID: 40706783

Improving vaccine communication to the often-overlooked young adult population: A qualitative study of 20-29 year olds in British Columbia, Canada.
Dhutt GS, Bettinger JA, Greyson D.Hum Vaccin Immunother. 2025 Dec;21(1):2552565. doi: 10.1080/21645515.2025.2552565. Epub 2025 Sep 7.PMID: 40916424

Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan.
Tabynov K, Kuanyshbek A, Zharmambet K, Yelchibayeva L, Karibayev T, Berdikulov M, Zhumadilova Z, Tabynov K.Virology. 2025 Sep;610:110601. doi: 10.1016/j.virol.2025.110601. Epub 2025 Jun 6.PMID: 40516487

Characterization and immunogenicity analysis of glutathi- one S-transferase from Otodectes cynotis.
Wang H, Tan M, Gui Y, Wu X, Guo M, He R.Mol Biochem Parasitol. 2025 Sep;263:111688. doi: 10.1016/j.molbiopara.2025.111688. Epub 2025 Jul 3.PMID: 40617329

Targeting Streptococcus pyogenes atpF protein for multi-epitope vaccine development: a genomics-driven immunoinformatics strategy.
Agarwal M, Handique S, Rajkhowa S, Das A, Panda D, Al-Hussain SA, Zaki MEA.J Genet Eng Biotechnol. 2025 Sep;23(3):100546. doi: 10.1016/j.jgeb.2025.100546. Epub 2025 Aug 5.PMID: 40854665

An immunoinformatics approach in designing high-coverage mRNA multi-epitope vaccine against multivariant SARS-CoV-2.
Giri-Rachman EA, Kurnianti AMF, Rizarullah, Setyadi AH, Artarini A, Tan MI, Riani C, Natalia D, Aditama R, Nugrahapraja H.J Genet Eng Biotechnol. 2025 Sep;23(3):100524. doi: 10.1016/j.jgeb.2025.100524. Epub 2025 Jun 21.PMID: 40854643

Oncolytic Hydrogel Enhances Immune Checkpoint Blockade by Generating In Situ Vaccine, Remodeling Tumor Physical and Metabolic Barriers.
Yang Z, Liu K, Li H, Li Y, Sun Q, Shang W, Wang M, Yang Y, Liu H, Yin D, Shen W.ACS Nano. 2025 Sep 8. doi: 10.1021/acsnano.5c09729. Online ahead of print.PMID: 40919615

COVID-19 vaccine-induced systemic lupus erythematosus: The underlying immunological and genetic mechanisms.
Wang P, Jin S, Li X, Zhu H, Hu F, Li Z.Lupus. 2025 Sep;34(10):1061-1066. doi: 10.1177/09612033251357627. Epub 2025 Jul 17.PMID: 40674605

A BtpB-Deleted Brucella Vaccine Strain Provides Dual Advantages: Enhanced Protection and Diagnostic Differentiation Capability in Mice.
Xu Z, Deng X, Gao H, Wang Y, Zhang H, Xu Y, He H, Wu A, Zhang Y, Yi J, Wang Z, Chen C, Ma Z.Microb Biotechnol. 2025 Sep;18(9):e70223. doi: 10.1111/1751-7915.70223.PMID: 40926333

Acclimation of suspension LMH cell line for high-efficient inactivated FAdV-4 vaccine production.
Zhang H, Liao M, Gao X, Xue X, Cao H.Poult Sci. 2025 Sep;104(9):105424. doi: 10.1016/j.psj.2025.105424. Epub 2025 Jun 11.PMID: 40527128

Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
Daigle D, Morales G, Hayford K, Haridy H, Abalos MG, Taysi BN, Fletcher MA.Vaccine. 2025 Sep 1;63:127669. doi: 10.1016/j.vaccine.2025.127669. Online ahead of print.PMID: 40896892

Delta inulin alone or combined with CpG oligonucleotide enhances antibody-dependent influenza vaccine protection in mice and nonhuman primate newborns.
Sakala IG, Honda-Okubo Y, Petrovsky N.Immunol Cell Biol. 2025 Sep;103(8):758-774. doi: 10.1111/imcb.70045. Epub 2025 Jun 29.PMID: 40582987

Towards precision epitopes based vaccine against Enterococcus faecalis by integrating vaccinomics, reverse vaccinology and biophysics approaches.
Ullah A, Azam S, Ahmad S, Khan I, Alammari DM, Abassi SW, Wei DQ, Alshabrmi FM, Aljasir MA, Alatawi EA.Biochem Biophys Rep. 2025 Jun 10;43:102082. doi: 10.1016/j.bbrep.2025.102082. eCollection 2025 Sep.PMID: 40546343

Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study.
Jin S, Asakura TR, Murayama H, Niyukuri D, Saila-Ngita D, Lim JT, Endo A, Dickens BL.PLoS Med. 2025 Sep 5;22(9):e1004726. doi: 10.1371/journal.pmed.1004726. eCollection 2025 Sep.PMID: 40911605

A systematic review of the efficacy of cancer vaccines in advanced breast cancer.

Charalampopoulou A, Filippatos C, Malandrakis P, Zagouri F, Gavriatopoulou M, Ntanasis-Stathopoulos I.Breast Cancer. 2025 Sep;32(5):892-904. doi: 10.1007/s12282-025-01751-1. Epub 2025 Aug 5.PMID: 40762664

Predictive modeling and explainable AI in addressing disparities in adolescent vaccination uptake: Insights from the US national immunization survey-Teen.
Mathkor DM, Sufyan M, Haque S.Comput Biol Med. 2025 Sep;196(Pt C):110953. doi: 10.1016/j.compbiomed.2025.110953. Epub 2025 Aug 17.PMID: 40825257

Factors influencing HPV vaccine initiation and intentions among Central American immigrant fathers in the United States: An exploratory cross-sectional study.
Hernandez Nieto A, Delgado D, Moreno VA, Lucero D, Rodriguez-Cruz N, Le Q, Lindsay AC.Vaccine. 2025 Sep 1;63:127672. doi: 10.1016/j.vaccine.2025.127672. Online ahead of print.PMID: 40896893

Influenza virus-like particles presenting *Toxoplasma gondii* dense granule protein 7 protect mice from lethal ME49 challenge.
Mao J, Kang HJ, Heo SI, Quan FS.Nanomedicine (Lond). 2025 Sep;20(18):2309-2320. doi: 10.1080/17435889.2025.2546769. Epub 2025 Aug 13.PMID: 40799047

Impact of measles vaccination on clinical characteristics and outcomes in children in Ramadi, Iraq.
Mawlood SK, Al-Ani MM, Al-Ani RM, Alshibib A.World J Clin Pediatr. 2025 Sep 9;14(3):107253. doi: 10.5409/wjcp.v14.i3.107253. eCollection 2025 Sep 9.PMID: 40881081

Evaluation of Mycoplasma mycoides subsp. mycoides antigens capable of stimulating host IRG-47 release identifies Mmm604, Mmm605, and Mmm606 as potential subunit vaccine antigens.
Liu T, Zhao H, Wu Q, Wei Y, Xin J, Pan Q.Infect Immun. 2025 Sep 9:e0018625. doi: 10.1128/iai.00186-25. Online ahead of print.PMID: 40924390

Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria.
Limon G, Tchakarova SR, Ludi A, Alexandrov T, Christova I, Petkova P, Maze E, Thomas K, Baker N, England M, Browning C, Wilsden G, Belij-Rammerstorfer S, Lambe T, Jolles A, Carroll M, Hewson R, Gubbins S, Charleston B, Lyons NA.Emerg Infect Dis. 2025 Sep;31(9):1738-1746. doi: 10.3201/eid3109.241952. Epub 2025 Aug 5.PMID: 40764710

Adjuvant combination enhances immune response of equine influenza virus vaccine in horses.
Dong-Ha L, Eun-Bee L, Jong-Pil S, Eun-Ju K.Equine Vet J. 2025 Sep 2. doi: 10.1111/evj.70090. Online ahead of print.PMID: 40898646

Salivary oxytocin and anxiety in older adults during the COVID-19 pandemic: A cross-sectional study.
Kunitake Y, Imamura Y, Kunitake H, Ohishi-Fukuchi J, Tateishi H, Matsushima J, Murakawa-Hirachi T, Kojima R, Shiraishi T, Orihashi R, Mizoguchi Y.Psychoneuroendocrinology. 2025 Sep;179:107502. doi: 10.1016/j.psyneuen.2025.107502. Epub 2025 Jun 4.PMID: 40499278

Exploring Antiviral Strategies to Combat African Swine Fever.

Urbano AC, Melo B, Ferreira F.FEMS Microbiol Rev. 2025 Sep 8:fuaf044. doi: 10.1093/femsre/fuaf044. Online ahead of print.PMID: 40920441

The guinea pig as a relevant preclinical model in the rat race for a vaccine against congenital cytomegalovirus infection.
Choi KY, McGregor A.Virology. 2025 Sep;610:110560. doi: 10.1016/j.virol.2025.110560. Epub 2025 May 6.PMID: 40413831

LitAutoScreener: Development and Validation of an Automated Literature Screening Tool in Evidence-Based Medicine Driven by Large Language Models.
Tao Y, Li X, Yisha Z, Yang S, Zhan S, Sun F.Health Data Sci. 2025 Sep 2;5:0322. doi: 10.34133/hds.0322. eCollection 2025.PMID: 40904687

Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
Smith JB, Heiland L, Arnold LD, Simpson MC, Massa ST.Oral Oncol. 2025 Sep;168:107540. doi: 10.1016/j.oraloncology.2025.107540. Epub 2025 Jul 23.PMID: 40706192

Adults aged 65 years and older in South Africa have a responsibility to vaccinate against influenza.
Sarangarajan R, Ewuoso C.Dev World Bioeth. 2025 Sep;25(3):228-238. doi: 10.1111/dewb.12470. Epub 2024 Nov 18.PMID: 39555899

The Chrono-Vax trial protocol: The effect of the time of day of influenza vaccination on immune responses in adults aged 60-85 years.
Vink K, Brouwers TMJ, Beckers L, Smit D, Vos M, Guichelaar T, Bonten TN, Kervezee L, van Baarle D, Wallinga J.Contemp Clin Trials. 2025 Sep;156:108040. doi: 10.1016/j.cct.2025.108040. Epub 2025 Jul 31.PMID: 40752819

Recent progress in chitosan-based nanoparticles for drug delivery: a review on modifications and therapeutic potential.
Bal K, Küçükertuğrul Çelik S, Şentürk S, Kaplan Ö, Eker EB, Gök MK.J Drug Target. 2025 Sep;33(8):1366-1393. doi: 10.1080/1061186X.2025.2502956. Epub 2025 May 14.PMID: 40336193

Design of a Multi-Epitope Vaccine using beta-barrel Outer Membrane Proteins Identified in Chlamydia trachomatis.
Panda A, Kapoor J, Hareramadas B, Naqvi I, Ganta S, Chhabra R, Kumar S, Bandyopadhyay A.J Membr Biol. 2025 Sep 4. doi: 10.1007/s00232-025-00360-5. Online ahead of print.PMID: 40906223

Erratum for "Association Between Introduction of the 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) and Pneumonia Incidence and Mortality Among General Older Population in Japan: A Community-based Study."J Epidemiol 35(5) (2025) 237-244.
Sugiyama A, Kataoka M, Tokumo K, Abe K, Imada H, Sun B, Akuffo GA, Akita T, Fukuma S, Hattori N, Tanaka J.J Epidemiol. 2025 Sep 6. doi: 10.2188/jea.JE20250341. Online ahead of print.PMID: 40915898

Comprehensive insights into Japanese encephalitis virus: From molecular characterization to advanced detection and vaccine strategies.

Chugh P, Soni S, Ghanghas N, Kumar S, Mohan H.Antiviral Res. 2025 Sep 2:106268. doi: 10.1016/j.antiviral.2025.106268. Online ahead of print.PMID: 40907709

Co-loaded simvastatin-ginsenoside Rh2 liposomes enhance cellular immune responses as vaccine adjuvants.
Huang Y, Nie Q, Chen Z, Gong W, Cao W, Wang X, Liu Y, Meng Z.Biochem Biophys Rep. 2025 Jul 15;43:102159. doi: 10.1016/j.bbrep.2025.102159. eCollection 2025 Sep.PMID: 40697522

Global Burden of Human Metapneumovirus: Bridging Gaps in Prevention, Diagnostics and Treatment.
Adepoju VA, Adnani QES, Jamil S, Mohammadnezhad M, Abdulrahim A.Public Health Chall. 2025 Aug 1;4(3):e70094. doi: 10.1002/puh2.70094. eCollection 2025 Sep.PMID: 40756454

Factors Contributing to Pneumococcal, COVID-19, and Influenza Vaccine Uptake Among People Living With HIV in Belgium: A Retrospective Study.
Destordeur LC, Lopez Delhoulle V, Papadopoulos I, Maes N, Fombellida K, El Moussaoui M, Darcis G.Open Forum Infect Dis. 2025 Sep 3;12(9):ofaf513. doi: 10.1093/ofid/ofaf513. eCollection 2025 Sep.PMID: 40908973

Liver-Targeted Tolerogenic Vaccines: A Nano-Membrane Coupled Approach for Autoimmune Disease Therapies.
Chen X, Xie Z, Wu R, He X, Qin M, Wang H, Bai S, Chen Z, He C, Ou Y, Zhao Y, Xie M, Zhang Y, Du G, Sun X.Adv Mater. 2025 Sep;37(35):e2507743. doi: 10.1002/adma.202507743. Epub 2025 Jun 16.PMID: 40519000

Challenging 21-day quarantine guidelines for mumps in Beijing: Data-driven recommendations for a high-coverage MMR vaccination era (2019-2024).
Zhao Y, Cao Y, Liu F, Li Y, Sun Y, Li Z, Li C, Wang F, Ma J, Zhang J, Jia B.Hum Vaccin Immunother. 2025 Dec;21(1):2555087. doi: 10.1080/21645515.2025.2555087. Epub 2025 Sep 5.PMID: 40910792

Computational design of a multi-epitope mRNA vaccine against orthopoxviruses: A path toward comprehensive poxvirus protection.
Maghsoodi N, Nezafat N, Ramezani A.Comput Biol Med. 2025 Sep;196(Pt A):110764. doi: 10.1016/j.compbiomed.2025.110764. Epub 2025 Jul 14.PMID: 40664127

Explanatory spatial modeling of COVID-19 vaccine coverage in Thailand: policy implications for equitable distribution.
Sornlorm K, Muntaphan S.BMC Public Health. 2025 Sep 2;25(1):3028. doi: 10.1186/s12889-025-24217-7.PMID: 40898147

The effect of disease transmission on time-aggregated treatment efficacy estimates: a critical analysis of factors influencing the RTS,S and R21 malaria vaccine phase 3 trials.
Macià D, Pons-Salort M, Moncunill G, Dobaño C.Lancet Infect Dis. 2025 Sep;25(9):e516-e526. doi: 10.1016/S1473-3099(25)00090-8. Epub 2025 Apr 23.PMID: 40286802

Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development.

Rijal P, Wei L, Paesen GC, Stuart DI, Haworth M, Huang KA, Bowden TA, Townsend ARM.Elife. 2025 Sep 9;14:RP105317. doi: 10.7554/eLife.105317.PMID: 40924000

Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine.
Yin W, Chang C, Zhu Y, Ma F, Wang H, Lu Y, Tang B, Deng B.Virology. 2025 Sep;610:110616. doi: 10.1016/j.virol.2025.110616. Epub 2025 Jun 28.PMID: 40602261

Complete Regression of Anogenital Warts Following Intralesional Measles-Mumps-Rubella (MMR) Vaccine: A Case of Two.
Achdiat PA, Dwigunasari PR, Suwarsa O, Tsaqilah L, Maharani RH.Clin Cosmet Investig Dermatol. 2025 Sep 1;18:2119-2125. doi: 10.2147/CCID.S543393. eCollection 2025.PMID: 40917495

The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada.
Fust K, Kohli M, Cartier S, Joshi K, Van de Velde N, Beck E, Blake M.J Med Econ. 2025 Dec;28(1):1440-1450. doi: 10.1080/13696998.2025.2549630. Epub 2025 Sep 3.PMID: 40827738

Intracranial hemorrhage due to late-onset vitamin K deficiency bleeding.
Mallenahalli S, Rogers BD.Am J Emerg Med. 2025 Sep;95:287.e5-287.e7. doi: 10.1016/j.ajem.2025.07.006. Epub 2025 Jul 3.PMID: 40617743

Physician Practices, Attitudes, and Challenges Related to Pediatric COVID-19 Vaccination in the United States.
Kang Y, Zhang F, Vogt TM.J Pediatr Clin Pract. 2025 Jun 27;17:200160. doi: 10.1016/j.jpedcp.2025.200160. eCollection 2025 Sep.PMID: 40727315

Corrigendum to "Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains" [Vaccine 59 (2025) 127270].
Hasan Z, Masood KI, Qaiser S, Kanji A, Mwendwa F, Alenquer M, Iqbal J, Ferreira F, Wassan Y, Balouch S, Hussain S, Begum K, Feroz K, Muhammad S, Sadiqa A, Akhtar M, Habib A, Ahmed SMA, Mian AA, Hussain R, Amorim MJ, Bhutta ZA.Vaccine. 2025 Sep 1;63:127686. doi: 10.1016/j.vaccine.2025.127686. Online ahead of print.PMID: 40896891

Mapping Neuroinflammation With Diffusion-Weighted Magnetic Resonance Imaging: A Randomized Crossover Study.
Plank JR, Morgan CA, Dell'Acqua F, Sundram F, Hoeh NR, Muthukumaraswamy S, Lin JC.Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Sep;10(9):944-953. doi: 10.1016/j.bpsc.2025.05.002. Epub 2025 May 14.PMID: 40379248

NIR light-driven transformable liquid metal-based nanovaccines restrain postoperative colorectal cancer recurrence.
Dai Z, Liu F, Liu M, Song Y, Zhang H, Zhou C, Liu W, Li X, Wang G, Wang L, Wang Z.Bioact Mater. 2025 Jun 25;51:774-786. doi: 10.1016/j.bioactmat.2025.06.037. eCollection 2025 Sep.PMID: 40809081

Insights Into Kaposi Sarcoma-Associated Herpesvirus-Specific Humoral Responses.

Yalcin D, Eymard ED, Kiran K, Kibanga W, Liu Z, Wood C, Tso FY.J Med Virol. 2025 Sep;97(9):e70597. doi: 10.1002/jmv.70597.PMID: 40916576

Engineering a recombinant VP2-Based neutralizing epitope vaccine candidate against canine parvovirus: a preliminary immunogenicity assessment.
Wu Q, Jin Y, Cao W, Ren Z, Li X, Li Z, Han J, Shi C, Gao R, Yan M, Zhu S, Guan W, Shen X, Bai L, Ren G.Vet Res Commun. 2025 Sep 5;49(5):298. doi: 10.1007/s11259-025-10877-8.PMID: 40911252

Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial.
Hindson J.Nat Rev Gastroenterol Hepatol. 2025 Sep 8. doi: 10.1038/s41575-025-01123-2. Online ahead of print.PMID: 40926033

Influence of Pre-Vaccination HPV Status on Vaccine Effectiveness Among Chinese Women: A Multicenter Cross-Sectional Study.
Li L, Wu H, Chen Y, Shen Z, Fu K, Qiu M, Liu Y, Shen Y, Lu Y, Wen X, Yang S, Zou K, Zhang H, Gesang Y, Huang H, Zhao C, Sun P, Wu L, Zhang Y.Cancer Rep (Hoboken). 2025 Sep;8(9):e70294. doi: 10.1002/cnr2.70294.PMID: 40877214

Influenza and COVID-19 Multicomponent Vaccine in Adults-Reply.
Rudman Spergel AK, Callendret B, Kostanyan L.JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12225. Online ahead of print.PMID: 40920411

Effects of TcFLA-1BP and TcGP72 Deletion on the Infectivity and Survival of Trypanosoma cruzi in Cell Cultures.
Souza-Melo N, de Souza GH, de Souza W.Cell Biol Int. 2025 Sep 3. doi: 10.1002/cbin.70076. Online ahead of print.PMID: 40899868

Improving vaccine communication to the often-overlooked young adult population: A qualitative study of 20-29 year olds in British Columbia, Canada.
Dhutt GS, Bettinger JA, Greyson D.Hum Vaccin Immunother. 2025 Dec;21(1):2552565. doi: 10.1080/21645515.2025.2552565. Epub 2025 Sep 7.PMID: 40916424

Human papillomavirus vaccination coverage, intentions, and associated factors among university students in Ho Chi Minh City: A cross-sectional, online survey.
Nguyen NT, Nguyen NT, Le MH, Vu MK, Nguyen HC, Do LT.J Obstet Gynaecol Res. 2025 Sep;51(9):e70057. doi: 10.1111/jog.70057.PMID: 40891073

Comparative analysis of codon usage bias and host adaptation across avian metapneumovirus genotypes.
Shi S, Gao J, Gai M, Pan Y, Cao J, Peng T, Liu Y, Yang K.Poult Sci. 2025 Sep;104(9):105428. doi: 10.1016/j.psj.2025.105428. Epub 2025 Jun 11.PMID: 40541102

Comfort or hesitancy: A cross-sectional study of modifiable factors associated with co-vaccination behavior among United States and Canadian adults.
Frith E, Deedat S, Blazek ES, Bucher A.Prev Med Rep. 2025 Aug 6;57:103199. doi: 10.1016/j.pmedr.2025.103199. eCollection 2025 Sep.PMID: 40838177

Genomic Characterization of Lumpy Skin Disease Virus in Sardinia, Italy 2025.
Marcacci M, Di Donato G, Pinoni C, Di Lollo V, Ancora M, Valleriani F, Ciarrocchi E, Di Sabatino D, Bucciacchio A, Di Pasquale A, Cammà C, Puggioni G, Cappai S, Dei Giudici S, Muroni G, Brundu D, Morelli D.Vet Ital. 2025 Sep 2;61(3). doi: 10.12834/VetIt.3827.35876.1.PMID: 40904029

Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk.
Amure MT, Madathil SA, Laprise C, Rousseau MC, Nicolau BF.Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70124. Online ahead of print.PMID: 40924021

Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy.
Yin Q, Li J, Zhang J, Leng J, Zhang K, Gao X, Wang F, Yue Q, Ma C, Xu H, Liu X, Zhang H, Liu K.Nano Lett. 2025 Sep 10;25(36):13629-13638. doi: 10.1021/acs.nanolett.5c03459. Epub 2025 Aug 26.PMID: 40859665

Large language models for analyzing open text in global health surveys: why children are not accessing vaccine services in the Democratic Republic of the Congo.
Burstein R, Mafuta E, Proctor JL.Int Health. 2025 Sep 3;17(5):843-852. doi: 10.1093/inthealth/ihaf015.PMID: 40052518

Sinopharm COVID-19 Vaccination during Pregnancy Triggers Thyroid Stimulating Hormone Levels in Newborns.
Vatanparast A, Daghigh F, Akbari H.Am J Perinatol. 2025 Sep;42(12):1647-1653. doi: 10.1055/a-2526-5326. Epub 2025 Mar 6.PMID: 40049595

MiR-2779-x, a key microRNA that is related to the tumorigenicity of the MDCK cell line.
Yang D, Huang L, Shi J, Liu Z, Wang J, Ma Z, Abudureyimu A, Qiao Z, Chen J.Biochim Biophys Acta Gen Subj. 2025 Sep;1869(10):130843. doi: 10.1016/j.bbagen.2025.130843. Epub 2025 Jul 18.PMID: 40685024

A Safe and Broad-spectrum SARS-CoV-2 mRNA Vaccine with a New Delivery System for In-situ Expression.
Yu W, Chen X, Chen Q, Chen P, Liu N, Li Y, Tan X, Zhang Q, Rao Y, Guo M, Huang Z, Wang X, Zhang Z, Xiang W, Zhang Y, Liu Q, Yin H, Zhou L, Chen Y, Lan K.Virol Sin. 2025 Sep 4:S1995-820X(25)00127-0. doi: 10.1016/j.virs.2025.09.001. Online ahead of print.PMID: 40914292

Protective effects of inactivated SPIV vaccine in sea perch (Lateolabrax japonicas) by intraperitoneal injection and immersion immunization.
Liu M, Chen H, Zeng Z, Mu G, Zhang D, Huang Y, Huang X, Qin Q.Fish Shellfish Immunol. 2025 Sep 4;167:110700. doi: 10.1016/j.fsi.2025.110700. Online ahead of print.PMID: 40914507

Cytokines, chemokines, and immune cells involved in oral immunity towards the dental cariogenic bacterium Streptococcus mutans: Therapeutic interventions and vaccination.
Kazerooni MT, Hemmati S.Biomed Pharmacother. 2025 Sep;190:118394. doi: 10.1016/j.biopha.2025.118394. Epub 2025 Aug 1.PMID: 40752424

PHLA-SiNet: A novel peptide-HLA binding prediction model using heterogeneous Siamese neural networks.
Nazarloo M, Saadat M, Zare-Mirakabad F.Comput Biol Med. 2025 Sep 1;197(Pt A):111017. doi: 10.1016/j.compbiomed.2025.111017. Online ahead of print.PMID: 40896909

High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease.
Hegde Y, Lazarus SK, Farraye FA, Hollnagel F, Hayney MS, Caldera F.J Clin Gastroenterol. 2025 Sep 1;59(8):773-779. doi: 10.1097/MCG.0000000000002098.PMID: 40424081

Effectiveness of a Structured Educational Intervention on Parents' Knowledge, Perception, and Acceptance Towards Human Papillomavirus Vaccine.
Dhakal RD, Poudel S, Sigdel P, Regmi S.Public Health Chall. 2025 Jul 4;4(3):e70076. doi: 10.1002/puh2.70076. eCollection 2025 Sep.PMID: 40626200

Cholera epidemiology analysis through the experience of the 1973 Naples epidemic.
Maurizio B, Erika DZ, Cristina P, Mariano M, Davide O.Open Med (Wars). 2025 Sep 4;20(1):20241029. doi: 10.1515/med-2024-1029. eCollection 2025.PMID: 40918162

Strategic approaches for global cervical cancer elimination: An update review and call for national action.
Wilailak S, Kengsakul M, Kehoe S.Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1(Suppl 1):120-128. doi: 10.1002/ijgo.70276.PMID: 40908769

Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.
Hanumunthadu B, Demissie T, Greenland M, Skidmore P, Tanha K, Crocker-Buque T, Owino N, Sciré AS, Crispino C, De Simone D, Benincasa M, Aruta MG, Rossi O, Colucci AM, Berlanda Scorza F, Arora AK, Liu X, Clutterbuck EA, Godfrey L, Canals R, Ramasamy MN; Vacc-iNTS Consortium.EBioMedicine. 2025 Sep 3;119:105903. doi: 10.1016/j.ebiom.2025.105903. Online ahead of print.PMID: 40907249

Developing and Implementing an Intervention to Increase Immunization Coverage Among Frontline Long-Term Care Staff.
Sobczyk EA, Schultz EM, Shen AK, Casey DM, Roney HL, Bumpas SA, Eber LB, Fiebelkorn AP.J Am Med Dir Assoc. 2025 Sep;26(9):105761. doi: 10.1016/j.jamda.2025.105761. Epub 2025 Jul 24.PMID: 40651498

Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
Balam S, Kane F, Traore B, Konate D, Diallo FA, Dolo H, Somboro AM, Kodio O, Togo ACG, Diarra B, Incandela NC, Diallo F, Traore A, Kante S, Guindo MDA, Kouriba B, Coulibaly YI, Faye O, Doumbia S, Diakite M.Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680. Online ahead of print.PMID: 40897596

Emergence of a piliated and multidrug-resistant *Streptococcus pneumoniae* serotype 35B-ST156 clone in Japan.
Miyazaki H, Nakano S, Shibuya R, Chang B, Miyazaki Y, Matsumoto T, Akeda Y.Microbiol Spectr. 2025 Sep 2;13(9):e0063225. doi: 10.1128/spectrum.00632-25. Epub 2025 Aug 5.PMID: 40762490

A Synergistic 3D-Printed Collar Transforms Radiofrequency Ablation Into Potent Thermal Immunotherapy for Lung Cancer.
Chen W, Wu Y, Luo J, Wei W, Hu Q, Xu Y, Zheng X, Sun Z, Yang L, Ding J, Xu L, Han S, Cai W, Wang K.Adv Mater. 2025 Sep 1:e02375. doi: 10.1002/adma.202502375. Online ahead of print.PMID: 40891114

Novel Chimeric CTLA-4 B-cell Epitope Peptide Vaccines Demonstrate Effective Antitumor Immunity with/without PD1/PDL1 Blockade in Multiple Syngeneic Murine Models of Breast and Colorectal Cancers.
Guo L, Overholser J, Naylon S, Roche S, Ede N, Kaumaya PTP.Mol Cancer Ther. 2025 Sep 2;24(9):1362-1377. doi: 10.1158/1535-7163.MCT-24-0908.PMID: 40325996

Hepatitis C virus modified (S)E2(F442NYT)-mRNA-LNP candidate vaccine promotes helper CXCR5(+)T cells.
Haga Y, Babu E P, Swiderska-Syn M, Reagan EK, Weissman D, Ray R.J Virol. 2025 Sep 5:e0135525. doi: 10.1128/jvi.01355-25. Online ahead of print.PMID: 40910688

Expression and characterization of recombinant epsilon toxin variants of Clostridium perfringens type D in Pichiapastoris.
Manfredi MJ, Larsen AE, Mortola EC, Sguazza GH.Protein Expr Purif. 2025 Sep;233:106739. doi: 10.1016/j.pep.2025.106739. Epub 2025 May 16.PMID: 40383408

Cultural context and pandemic preparedness: Reassessing the Global Health Security Index's predictive power during COVID-19.
Kim H, Kim T, Ten GK.Soc Sci Med. 2025 Sep;381:118239. doi: 10.1016/j.socscimed.2025.118239. Epub 2025 Jun 6.PMID: 40499233

Antibody and B-Cell Responses to PHH-1V81 XBB.1.16-Adapted SARS-CoV-2 Booster Vaccination Are Associated With Variant Neutralization.
Torres C, Jiménez A, Deulofeu M, Prenafeta A, Dobaño C, Moncunill G, Ferrer L, Molinos-Albert LM.J Med Virol. 2025 Sep;97(9):e70583. doi: 10.1002/jmv.70583.PMID: 40878548

Strengthening New Vaccine Introduction in Low- and Middle-Income Countries: Establishing Hospital-Based Sentinel Surveillance for Vaccine Safety Monitoring.
Shaum A, Blau E, Longley A, Huang WT, Gidudu J.Am J Trop Med Hyg. 2025 Sep 4:tpmd250363. doi: 10.4269/ajtmh.25-0363. Online ahead of print.PMID: 40907498

Enteric (typhoid and paratyphoid) fever.
Kuehn R, Rahden P, Hussain HS, Karkey A, Qamar FN, Rupali P, Parry CM.Lancet. 2025 Sep 3:S0140-6736(25)01335-2. doi: 10.1016/S0140-6736(25)01335-2. Online ahead of print.PMID: 40914181

COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of Protection.
Yeola A, Houston S, Aggarwal A, Gamage R, Maltby VE, Fabis-Pedrini MJ, Le-Kavanagh L, Merheb V, Nguyen K, Lee FXZ, Walters S, Taha M, O'Connell A, Jokubaitis VG, Roldan A, Monif M, Butzkueven H, Sampangi S, Rath L, Fazzolari K, Hardy TA, Beadnall HN, Barnett MH, Kermode AG, Dwyer C, Kalincik T, Broadley SA, Turville SG, Reddel SW, Ramanathan S, Lechner-Scott J, Van Der Walt A, Brilot F.Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200443. doi: 10.1212/NXI.0000000000200443. Epub 2025 Jul 22.PMID: 40694731

Relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against clinical outcomes according to history of atrial fibrillation: a pre-specified analysis of the DANFLU-1 randomized trial.

Espersen C, Johansen ND, Modin D, Janstrup KH, Loiacono MM, Harris RC, Biering-Sørensen T.Eur Heart J Open. 2025 Aug 21;5(5):oeaf102. doi: 10.1093/ehjopen/oeaf102. eCollection 2025 Sep.PMID: 40927272

Live vaccine development through targeted protein degradation.
Zhang Q, Si L.Nat Rev Immunol. 2025 Sep;25(9):633. doi: 10.1038/s41577-025-01212-y.PMID: 40707692

Human papillomavirus (HPV) vaccination in women with conisation.
Kapp P, Schmucker C, Siemens W, Brugger T, Gorenflo L, Röbl-Mathieu M, Grummich K, Thörel E, Askar M, Brotons M, Andersen PH, Konopnicki D, Lynch J, Ruta S, Saare L, Swennen B, Tachezy R, Takla A, Učakar V, Vänskä S, Zavadska D, Adel Ali K, Olsson K, Harder T, Meerpohl JJ.Cochrane Database Syst Rev. 2025 Sep 8;9(9):CD016121. doi: 10.1002/14651858.CD016121.PMID: 40919695

Atorvastatin-Loaded Mineralized Vaccine Reprograms Endosomal Trafficking to Amplify STING-Driven Cancer Immunotherapy.
Yang Y, Long W, Pei X, Li S, Fu B, Zhai H, Zhang X, Wan Y, Peng Y, Cai T.Angew Chem Int Ed Engl. 2025 Sep 8;64(37):e202503749. doi: 10.1002/anie.202503749. Epub 2025 Jul 23.PMID: 40696965

Using positive imagination to reduce negativity in information processing and hesitant attitudes towards childhood COVID-19 vaccinations in parents: A randomized controlled trial.
Yuan J, Dong M, Lam WWT, Liao Q.Br J Health Psychol. 2025 Sep;30(3):e12808. doi: 10.1111/bjhp.12808.PMID: 40462413

Rational design of a multi epitope vaccine against Salmonella typhi via subtractive proteomics, reverse vaccinology and molecular modeling.
Albutti A.Sci Rep. 2025 Sep 1;15(1):32057. doi: 10.1038/s41598-025-15254-8.PMID: 40890251

A robust comprehensive immunoinformatics approach for designing a potential multi-epitope based vaccine against a reiterated monkeypox virus.
Raj KH, Hossain E, Zahin H, Noman AA, Saba AA, Sayem M, Yasmin T, Nabi AHMN.Biochem Biophys Rep. 2025 Jun 12;43:102075. doi: 10.1016/j.bbrep.2025.102075. eCollection 2025 Sep.PMID: 40583904

Safety and efficacy of high-dose versus standard-dose influenza vaccines in hematopoietic stem cell transplant recipients: A meta-analysis of randomized controlled trials.
Vidya AP, Wijaya NJ, Gathmir DZP, Kornel NAK, Farhan M, Sianipar IR.Transpl Immunol. 2025 Sep;92:102270. doi: 10.1016/j.trim.2025.102270. Epub 2025 Jul 29.PMID: 40744300

Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar.
Albahari D, Abdallah O, Alqam SMI, Mohammed MFH, Ahmed MAS, Wadoo O.Explor Res Clin Soc Pharm. 2025 May 18;19:100614. doi: 10.1016/j.rcsop.2025.100614. eCollection 2025 Sep.PMID: 40502459

Development of a novel multi-epitope vaccine against triple-negative breast cancer targeting A-kinase anchoring protein 3 using bioinformatics.
Nafiah Z, Ujiantari NSO, Rattyananda BS, Utami ST, Alwi RS, Hermawan A.Comput Biol Med. 2025 Sep;196(Pt B):110757. doi: 10.1016/j.compbiomed.2025.110757. Epub 2025 Jul 18.PMID: 40683100

What Are the Infection Prevention Behaviors of Kidney Transplant Recipients and the Factors Related to These?
Sarıgöl Ordin Y, Karakılçık B.J Clin Nurs. 2025 Sep;34(9):3650-3659. doi: 10.1111/jocn.17522. Epub 2024 Nov 5.PMID: 39497642

Development of a VirB12 gene-deleted Brucella abortus A19 strain as a vaccine candidate for differentiating infected from vaccinated animals in cattle and establishment of a differentiating ELISA assay.
Ye F, Ma X, Liu L, Gu W, Zhong Q, Yi X, Liu Y.Am J Vet Res. 2025 Jul 10;86(9):ajvr.25.01.0028. doi: 10.2460/ajvr.25.01.0028. Print 2025 Sep 1.PMID: 40645225

Development and Evaluation of Dual Microneedle Array Patch for Sequential Intradermal Delivery of Adjuvant and Antigen.
Lee YL, Cha HR, Lee DE, Ryu M, Chung HW, Park S, Choi JA, Baek SK, Lee JM, Park JH.Pharm Res. 2025 Sep 4. doi: 10.1007/s11095-025-03914-3. Online ahead of print.PMID: 40908359

Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.
Simba H, McCormack V, Bilaba J, Mmbaga BT, Kini L, Mshana JA, Masenga JE, Gliksohn A, Massah B, Freeland H, Roberts E, Gheit T.Br J Cancer. 2025 Sep;133(5):599-603. doi: 10.1038/s41416-025-03107-0. Epub 2025 Jul 4.PMID: 40615714

Transient increased risk of shingles post Shingrix vaccination: Self-controlled case series analysis.
Shetty AN, Hennessy D, Kattan GS, Ojaimi S, Clothier HJ, Buttery JP.Clin Infect Dis. 2025 Sep 9:ciaf473. doi: 10.1093/cid/ciaf473. Online ahead of print.PMID: 40924159

Examining the relationship between COVID-19 vaccines and recall rates in breast screening.
Squillace L, Pizzi L, Chiereghin A, Bazzani C, Saguatti G, Tafà A, Roti L, Mezzetti F.Ann Ig. 2025 Sep-Oct;37(5):666-675. doi: 10.7416/ai.2025.2699. Epub 2025 Apr 10.PMID: 40223494

mRNA-LNP vaccine encoding the Plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice.
Limsalakpetch A, Kum-Arb U, Yongvanitchit K, Im-Erbsin R, Ubalee R, Waters N, Vesely BA, Muramatsu H, Weissman D, Tam YK, Yoshida S, Adams J, Yadava A, Pardi N, Pichyangkul S.Mol Ther Nucleic Acids. 2025 Jul 30;36(3):102645. doi: 10.1016/j.omtn.2025.102645. eCollection 2025 Sep 9.PMID: 40832631

Microneedle-Delivered Multivalent MPXV DNA Vaccines Induce Promising Immunity Profiles and Cross-Protection in Mice.
Wang Y, Cheng X, Huang B, Tan R, Fan F, Zhao L, Wang W, Ye F, Deng Y, Gao X, Wang B, Tan W.Immunology. 2025 Sep 2. doi: 10.1111/imm.70030. Online ahead of print.PMID: 40897344

Self-assembled nanoparticle vaccine comprised of multiple epitopes provides robust protective immunity against reoviruses in fish model.
Xu FF, Zhao Z, Deng ZY, Tang JL, Zhu B.Cell Commun Signal. 2025 Sep 2;23(1):389. doi: 10.1186/s12964-025-02411-9.PMID: 40898220

The Effectiveness of Postal Mail and Text Message-Based Childhood and Adolescent Immunization Recall in Minnesota.

Jiter NJ, Campbell T, Kuramoto SK, Favero R, Kidrowski H.J Public Health Manag Pract. 2025 Sep-Oct 01;31(5):859-869. doi: 10.1097/PHH.0000000000002180. Epub 2025 Jul 17.PMID: 40627857

Recent advances on the syntheses of oligosaccharides and the corresponding glycoconjugates towards development of vaccine candidates against invasive Neisseria meningitidis strains.
Basu N, Mukherjee MM, Ghosh R.Carbohydr Res. 2025 Sep;555:109545. doi: 10.1016/j.carres.2025.109545. Epub 2025 May 29.PMID: 40472439

Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibit *Shigella flexneri* invasion.
Moon Y-E, An T, Park P-G, Hong K-J.Microbiol Spectr. 2025 Sep 2:e0099325. doi: 10.1128/spectrum.00993-25. Online ahead of print.PMID: 40891984

Assessing immunization coverage in Southern togo: implications for perennial malaria chemoprevention delivery.
Arikawa S, Tchankoni MK, Gbeasor-Komlanvi F, Atekpe SP, Atcha-Oubou T, Figueroa-Romero A, Orne-Gliemann J, Menendez C, Gonzalez R, Briand V, Ekouevi D.BMC Public Health. 2025 Sep 2;25(1):3035. doi: 10.1186/s12889-025-24191-0.PMID: 40898090

Next-generation multi-epitope subunit vaccine design: A computational approach utilizing two stable proteins to combat Human Metapneumovirus (HMPV).
Mahmud Supto MS, Hasan Shanto MR, Tanoy NM, Anam Fahim MF, Hasan M, Mia MM, Ahmed S.Comput Biol Med. 2025 Sep;196(Pt C):110935. doi: 10.1016/j.compbiomed.2025.110935. Epub 2025 Aug 18.PMID: 40829349

Community engagement: the missing piece in solving the puzzle of XDR-typhoid spread in Pakistan.
Madiha, Shahzadi A, Ashiq Z.J Public Health Policy. 2025 Sep;46(3):645-652. doi: 10.1057/s41271-025-00568-8. Epub 2025 May 8.PMID: 40341792

The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.
Firuzpour F, Barancheshmeh M, Ziarani FF, Karami L, Aram C.Biochem Biophys Rep. 2025 Jul 4;43:102135. doi: 10.1016/j.bbrep.2025.102135. eCollection 2025 Sep.PMID: 40688509

The isolation and immunoprotective efficacy of outer membrane vesicles of Dichelobacter nodosus.
He X, Shi Y, Liu J, Fu S, Wang B, Li B, Sang Y, Jiang K, Sun D, Guo D.Vet Microbiol. 2025 Sep;308:110632. doi: 10.1016/j.vetmic.2025.110632. Epub 2025 Jul 7.PMID: 40639038

Designing a multi-epitope vaccine against the midgut-specific fibrinogen-related protein 1(FREP1) of Anopheles stephensi to enhance protection against the malaria parasite: a step beyond traditional vaccine development approaches.
Yadav M, Dahiya N, Singh H, Kataria D, Janjoter S, Sehrawat N.Biotechnol Lett. 2025 Sep 3;47(5):93. doi: 10.1007/s10529-025-03632-1.PMID: 40900278

Immunology of RNA-based vaccines: the critical interplay between inflammation and expression.
Tregoning JS, Wang Z, Sridhar S, Shattock RJ, DeRosa F.Mol Ther. 2025 Sep 8:S1525-0016(25)00739-7. doi: 10.1016/j.ymthe.2025.09.011. Online ahead of print.PMID: 40926412

Parental vaccine hesitancy among mothers in Georgia: the role of trust in science, government, and religion.
Chakhunashvili K, Soni P, Chakhunashvili DG.J Public Health (Oxf). 2025 Sep 7:fdaf112. doi: 10.1093/pubmed/fdaf112. Online ahead of print.PMID: 40914958

Manganese oxide nanoparticle acts as a promising immune adjuvant via tuning ferroptosis signaling.
Liang X, Qi S, Fang L, Wu Y, Mao C, Jiang Y.J Control Release. 2025 Sep 10;385:114022. doi: 10.1016/j.jconrel.2025.114022. Epub 2025 Jul 9.PMID: 40645294

Construction of a multi-epitope vaccine against Helicobacter pylori fused with the CTLA-4 extracellular domain and expressed in BCG.
Ru Z, Yu M, Zhu Y, Ding J, Li J, Zhang M, Zhang Z, Zhang F.Gene. 2025 Sep 10;964:149634. doi: 10.1016/j.gene.2025.149634. Epub 2025 Jun 18.PMID: 40553902

Enhancing RNA Delivery: Practical insights into NeoLNP™ transfection reagent.
Chen X, Wu Y, Liu L, Wang W.Methods. 2025 Sep;241:59-66. doi: 10.1016/j.ymeth.2025.05.007. Epub 2025 May 21.PMID: 40409482

Was health skepticism accounted for in communication about the COVID-19 vaccine? A content analysis of federally-sponsored public service announcements about the vaccine to protect against COVID-19 in the United States.
Tait ME, Fowler EF, Gollust SE.Prev Med Rep. 2025 Aug 5;57:103193. doi: 10.1016/j.pmedr.2025.103193. eCollection 2025 Sep.PMID: 40821921

Midwives' Perceptions of Promoting Pregnancy Vaccines in Wales: Identifying Factors Influencing Vaccine Uptake Using the COM-B Framework.
Lloyd K, Jones S.Public Health Chall. 2025 Sep 7;4(3):e70114. doi: 10.1002/puh2.70114. eCollection 2025 Sep.PMID: 40923040

Powder-attached microneedles for the stable and effective transdermal delivery of clinically validated mRNA-LNP vaccine.
Kim JS, Kim NE, Choi JA, Choi IJ, Choi JE, Kang A, Kwon D, Lim M, Kim J, Baek SK, Song M, Song YJ, Park JH.Eur J Pharm Biopharm. 2025 Sep;214:114811. doi: 10.1016/j.ejpb.2025.114811. Epub 2025 Jul 19.PMID: 40692039

Pathogenicity of Aeromonas hydrophila Isolated From Diseased Largemouth Bass (Micropterus salmoides) and Development of an Inactivated Vaccine.
He G, Tang X, Zhou Q, Wu Z, Li Y.J Fish Dis. 2025 Sep 3:e70051. doi: 10.1111/jfd.70051. Online ahead of print.PMID: 40899581

Evaluation of immunoprotective effects of PlpE multi-epitope protein incorporated within the aluminum hydroxide-adjuvanted inactivated vaccine against Pasteurella multocida infection in chickens.
Xiang X, Sun Y, Zhang H, Wu X, Xia J, Han X, Huang Y, Cui M.Poult Sci. 2025 Sep;104(9):105426. doi: 10.1016/j.psj.2025.105426. Epub 2025 Jun 14.PMID: 40561824

Metabolite derived from green tea polyphenol increases and activates plasmacytoid dendritic cells.
Kumazoe M, Nakajima M, Kawamoto R, Fujimura Y, Tomioka R, Suzuki M, Tanaka Y, Tachibana H.J Nat Med. 2025 Sep;79(5):1057-1066. doi: 10.1007/s11418-025-01929-z. Epub 2025 Jul 5.PMID: 40617911

Isolation and Molecular Characterization of Three Staphylococcus pseudintermedius Strains from Dogs and Humans in Egypt.
Elaadli H, Badr Y, Raouf M, Kania SA, Elsakhawy OK, Altaib H, Abouelkhair MA.Curr Microbiol. 2025 Sep 6;82(10):493. doi: 10.1007/s00284-025-04477-7.PMID: 40913632

The modified mRNA vaccine protects immunocompromised AG129 mice from lethal challenge and multi-tissue infection by Zika virus.
Yan Y, Wang J, Yang H, Yang Y, Yuan L, Tang C, Zhou Y, Huang Q, Yu W, Liang X, Lin D, Li Y, Du X, Yuan Y, Peng R, Xu J, Guo Z, Xie W, Quan W, Chen H, Zhou J, Lu S, Peng X.Emerg Microbes Infect. 2025 Sep 3:2556729. doi: 10.1080/22221751.2025.2556729. Online ahead of print.PMID: 40899968

Performance evaluation of micro-foci reduction neutralization test for the detection of neutralizing antibodies in human samples against dengue viruses circulating in India.
Chelluboina S, Borkar S, Chandra Mishra A, Arankalle VA, Shrivastava S.Virology. 2025 Sep;610:110620. doi: 10.1016/j.virol.2025.110620. Epub 2025 Jul 1.PMID: 40616872

High Prevalence of Macrolide-resistant ptxP3-prn150 Bordetella pertussis in Jiangsu Province, China, 2024.
Qin S, Wang Z, Wu Y, Hu R, Cao L, Shan M, Tian Y, Guo H.Pediatr Infect Dis J. 2025 Sep 5. doi: 10.1097/INF.0000000000004963. Online ahead of print.PMID: 40924779

Safety, tolerability, immunogenicity, and plasmapheresis-based antibody collection in a phase 1b open label trial of two investigational monovalent chimpanzee adenoviral vectored filovirus vaccines, cAd3-Sudan and cAd3-Marburg, in healthy adults.
Vert-Wong E, Stevenson ME, Rustomjee R, Finch CL, Jakubik J, King TH.EBioMedicine. 2025 Sep 3;119:105889. doi: 10.1016/j.ebiom.2025.105889. Online ahead of print.PMID: 40907247

Attenuation of a local Mycobacterium avium subsp paratuberculosis virulent strain by homologous recombination.
Colombatti Olivieri MA, Moyano RD, Nagel A, Gravisaco MJ, Delgado FO, Alvarado Pinedo MF, Travería GE, Alonso MN.Res Vet Sci. 2025 Sep;193:105758. doi: 10.1016/j.rvsc.2025.105758. Epub 2025 Jun 13.PMID: 40554293

Fueling IgA-Dominated Humoral Immunity with an Intranasal Hybrid Tumor Vaccine to Opsonize and Strike Epithelial Breast Cancer.
Sun Q, Lu H, Yang W, Song Z, Chen C, Ruan X, Luo M, Li Y, Li H, Yang Z, Liu K, Shang W, Xu Y, Wu Q, Shen W, Yang Y, Yin D.Adv Mater. 2025 Sep;37(35):e2500631. doi: 10.1002/adma.202500631. Epub 2025 Jul 1.PMID: 40589412

An attenuated African swine fever virus with deletions of the *CD2v* and *A137R* genes offers complete protection against homologous challenge in pigs.

Peng G, Zhao X, Zou X, Zhang H, Zhao J, Zuo X, Tan S, Wu R, Guan X, Li S, Xu Y, Xia Y, Xu X, Xu L, Zhu Y, Liu J, Liu Y, Gao GF.J Virol. 2025 Sep 3:e0026225. doi: 10.1128/jvi.00262-25. Online ahead of print.PMID: 40899814

Enhanced Production of HCV E1E2 Subunit Vaccine Candidates via Protein-Protein Interaction Identification in Glycoengineered CHO Cells.
Wu MYM, Rocamora F, Robinson CM, Shin S, Maurya S, Toth EA, Fuerst TR, Lewis NE.Biotechnol J. 2025 Sep;20(9):e70112. doi: 10.1002/biot.70112.PMID: 40899434

Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden.
Nurminen ML, Lindemo P, Sundström A, Zethelius B, Larsson M, Attelind S, Pihlström N, Ljung R, Arthurson V.Clin Drug Investig. 2025 Sep;45(9):665-675. doi: 10.1007/s40261-025-01466-3. Epub 2025 Aug 12.PMID: 40796716

Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children.
Taur SR, Rampal R, Sathyanarayanan S, Nahdi FB, Wannaadisai W, Fletcher MA, Huang L.IJID Reg. 2025 Jul 16;16:100707. doi: 10.1016/j.ijregi.2025.100707. eCollection 2025 Sep.PMID: 40822643

Allergy to *Alternaria alternata*: Comprehensive review from the origin to the therapeutic approach.
Torres-Borrego J, Suárez-Pérez J, Aliaga-Mazas Y, Burgos AM, Nevot-Falcó S.Allergol Immunopathol (Madr). 2025 Sep 1;53(5):179-188. doi: 10.15586/aei.v53i5.1454. eCollection 2025.PMID: 40923435

Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder Cancer Model in hu-PBL-SCID Mice.
Wang B, Wu K, Cui Y, Han X, Xing T.Drug Dev Res. 2025 Sep;86(6):e70157. doi: 10.1002/ddr.70157.PMID: 40910989

Attenuated Salmonella Typhimurium expressing chimeric antigen from Leptospira as a recombinant vaccine candidate against leptospirosis.
Chagas DB, Santos FDS, de Oliveira NR, Noble EG, Maia MAC, Neto ACPS, Nogueira JD, Yim L, Moreno M, Chabalgoity JA, Bohn TLO, Dellagostin OA.Res Vet Sci. 2025 Sep;193:105802. doi: 10.1016/j.rvsc.2025.105802. Epub 2025 Jul 16.PMID: 40682928

HBV-encoded circRNA-5 promotes hepatocellular carcinoma progression by regulating the miR-9-3p/Hippo signaling axis.
Yang Y, Shen Y, Dang Y, Huang J, Su Y, Zhang J, Jiang X, Luo X, Wang J, Liu J.Microbiol Spectr. 2025 Sep 5:e0143925. doi: 10.1128/spectrum.01439-25. Online ahead of print.PMID: 40910771

Mass Spectrometry-Based Analysis of Surface Proteins in *Staphylococcus aureus* Clinical Strains: Identification of Promising k-mer Targets for Diagnostics.
Svetlicic E, Alarcon LA, Karlsson R, Jers C, Mijakovic I.J Proteome Res. 2025 Sep 5;24(9):4575-4585. doi: 10.1021/acs.jproteome.5c00321. Epub 2025 Aug 7.PMID: 40772958

Exploring mpox vaccination uptake and tolerability among people living with HIV: A study in an infectious disease unit in Italy.
Gaggioli S, Formica G, Petrini V, Krauss AR, Corsi P, Di Felice A, Fiorelli C, Mantengoli E, Malcontenti C, Francalanci E, Modi G, Trotta M, Kiros ST, Gazzarri E, Zocco N, Zammarchi L, Bartoloni A, Lagi F.Int J STD AIDS. 2025 Sep;36(10):816-821. doi: 10.1177/09564624251349888. Epub 2025 Jun 12.PMID: 40501423

Opposing impacts of DNA polyplex crosslinking on delivery efficiency and vaccine responses.
Uchida S.Mol Ther Nucleic Acids. 2025 Aug 8;36(3):102656. doi: 10.1016/j.omtn.2025.102656. eCollection 2025 Sep 9.PMID: 40822032

Prevalence and molecular characterization of parvoviruses in dogs and domestic cats in Guangxi, China: new emergence of CPV-2c in cats.
Sun F, Huang X, Li B, Zhou H, Long J, Qin Y, Ouyang K, Wei Z, Huang W, Chen Y.Top Companion Anim Med. 2025 Sep-Oct;68:101008. doi: 10.1016/j.tcam.2025.101008. Epub 2025 Aug 21.PMID: 40848913

The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Choi MG, Kim MH, Chun EM.Korean J Intern Med. 2025 Sep;40(5):801-812. doi: 10.3904/kjim.2025.056. Epub 2025 Aug 26.PMID: 40859806

Pay-It-Forward 23-Valent Pneumococcal Polysaccharide Vaccination Among Older Adults: Protocol for a Randomized Controlled Trial.
Qin J, Wei L, Tao C, He J, Wu D, Lin Z, Huang T, Qin S, Su Q, Gao Y, Chen S, Wang G, Tang X, Ye L, Liang H, Ning C, Tang W, Tucker JD, Liang B.JMIR Res Protoc. 2025 Sep 8;14:e70246. doi: 10.2196/70246.PMID: 40921060

Intestinal mucosal transcriptomic responses of Asian seabass (Lates calcarifer) vaccinated with an oral hydrogel-encapsulated multivalent Vibrio antigen following Vibrio spp. infection.
Kumwan B, Meachasompop P, Thompson KD, Thangsunan P, Buncharoen W, Thangsunan P, Srisapoome P, Uchuwittayakul A.Comp Biochem Physiol Part D Genomics Proteomics. 2025 Sep;55:101512. doi: 10.1016/j.cbd.2025.101512. Epub 2025 Apr 14.PMID: 40252617

Reduction in finisher pig death rate on a farm in Japan following use of a commercial killed vaccine against porcine reproductive and respiratory syndrome virus.
Yonezawa Y, Nakagami T, Tsutsumi N, Momma N, Taira O, Matsuyama R, Makita K.J Vet Med Sci. 2025 Sep 5;87(9):1060-1067. doi: 10.1292/jvms.24-0506. Epub 2025 Jul 18.PMID: 40691078

A heterologous prime-boost regimen using BCG and an mRNA encoding Ag85B heightens immune response in mice.
Pongma C, Keawvilai P, Pattarakankul T, Rotcheewaphan S, Alameh MG, Prompetchara E, Premchaiporn P, Chareanpat P, Yindeeyoungyeon W, Heyes J, Lam K, Ruxrungtham K, Palaga T.Biochem Biophys Res Commun. 2025 Sep 8;778:152408. doi: 10.1016/j.bbrc.2025.152408. Epub 2025 Jul 25.PMID: 40730090

Multidisciplinary perspective on a pharmacist-led vaccination clinic in a regional cancer care setting: A qualitative study.

Johnstone K, Cooper J, Smithson J, Glass B.Explor Res Clin Soc Pharm. 2025 Jul 5;19:100633. doi: 10.1016/j.rcsop.2025.100633. eCollection 2025 Sep.PMID: 40686850

Electronic Health Record Clinical Decision Support to Close the Human Papillomavirus Vaccination Gender Disparity in Children Aged 9 and 10 Years.
Stipelman CH, Ulibarri E, Wilson N, Olivas A, Sanders A, Trepman E, Kawamoto K.Clin Pediatr (Phila). 2025 Sep;64(8):1160-1168. doi: 10.1177/00099228251324017. Epub 2025 Mar 12.PMID: 40077902

Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.
Soppela S, González-Rodríguez M, Stone VM, Mustonen I, Jouppila NVV, Lampinen V, Haikarainen T, Flodström-Tullberg M, Junttila IS, Hankaniemi MM.J Biomed Sci. 2025 Sep 8;32(1):86. doi: 10.1186/s12929-025-01183-1.PMID: 40922007

Antibody responses to feline leukaemia vaccination: exploring the effect of sex, boosting schedule, site of administration and vaccine type.
Westman ME, Parr Y, Martin C, Wuestner E, Pan S, Norris JM, McDonald M, Dunbar D, Weir W, Hall E, Nakamura M, Atkin N, Hajjar R, Meggiolaro MN, Hughes D, Malik R, Hosie MJ.J Feline Med Surg. 2025 Sep;27(9):1098612X251353080. doi: 10.1177/1098612X251353080. Epub 2025 Sep 4.PMID: 40905267

MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.
Kosinska AD, Kächele M, Kerth HA, Mück-Häusl M, Ates Öz E, Gültan M, Hansen-Palmus L, Sacherl J, Ko C, Festag J, Lehmann MH, Mogler C, Steiger K, Knolle PA, Bauer T, Volz AK, Protzer U.Mol Ther Nucleic Acids. 2025 Jul 23;36(3):102641. doi: 10.1016/j.omtn.2025.102641. eCollection 2025 Sep 9.PMID: 40799509

Blood Storage in a Vaccine Carrier Eliminates the Need for Onsite Analysis of Major Hematological and Nutritional Biomarkers.
Jaafar LS, ZeinEddine RS, Chakhachiro Z, Obeid OA.J Appl Lab Med. 2025 Sep 3;10(5):1188-1199. doi: 10.1093/jalm/jfaf103.PMID: 40726361

Safety and Toxicological Evaluation of Subunit Keyhole Limpet Hemocyanin-Loaded Lipid-PLGA Hybrid Nanoparticles (sKLH-hNPs) as a Nanocarrier for an Opioid Use Disorder Vaccine.
Walter D, Ci Q, Hu H, DeHority R, Hinckley J, Bian Y, Serpa PBS, Southard T, Werre SR, Pravetoni M, Ehrich M, Zhang C.Int J Toxicol. 2025 Sep-Oct;44(5):395-406. doi: 10.1177/10915818251355948. Epub 2025 Jul 5.PMID: 40616372

High-quality genome assembly and annotation of live animal vaccine bacteria strains in South Korea.
Lee Y, Nah JJ, Ku HO, Jang I.BMC Genom Data. 2025 Sep 2;26(1):62. doi: 10.1186/s12863-025-01357-8.PMID: 40898044

Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective.
Wong J, Donegan K, Harrison K, Jan T, Cave A, Tregunno P.Drug Saf. 2025 Sep 3. doi: 10.1007/s40264-025-01579-w. Online ahead of print.PMID: 40900408

Cost-effectiveness analysis of seasonal influenza vaccination compared to no vaccination in the United Arab Emirates and Iraq.
Al Dallal S, Ghazi S, Jabbar F, Farghaly M, Fasseeh AN, Korra N, Shalaby A, H Ahmed Y, Arraj M, Elgouhari S, Abdelsamie S, Fahim W, Hamandi Z, Tahoun M, Abaza S, Kovács G.J Med Econ. 2025 Dec;28(1):1422-1439. doi: 10.1080/13696998.2025.2550115. Epub 2025 Sep 1.PMID: 40838717

Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025.
Jordan R, Archin NM, Cagno V, Feng JY, Guo H, Herrero LJ, Janeba Z, Meanwell NA, Moffat J, Neyts J, Rocha-Pereira J, Seley-Radtke KL, Sheahan TP, Spengler JR, Welch SR, Xie X, Zakaryan H, Schang LM, Durantel D.Antiviral Res. 2025 Sep;241:106222. doi: 10.1016/j.antiviral.2025.106222. Epub 2025 Jul 3.PMID: 40617260

COVID-19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022-2024: A Test-Negative Case-Control Study.
Kryeziu B, Cohuet S, Kalaveshi-Osmani A, Kaçaniku-Deva Z, Kaçaniku-Gunga P, Finci I, Sanchez MA, Humphreys J, Ramadani N, Haxhiu E, Danis K, Rose AMC, Humolli I, Katz MA.Influenza Other Respir Viruses. 2025 Sep;19(9):e70152. doi: 10.1111/irv.70152.PMID: 40922048

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada.
Speicher DJ, Rose J, McKernan K.Autoimmunity. 2025 Dec;58(1):2551517. doi: 10.1080/08916934.2025.2551517. Epub 2025 Sep 6.PMID: 40913499

Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024.
Stefanizzi P, Moscara L, Palmieri C, Martinelli A, Fontanelli S, Bellomo C, Spinelli G, Tafuri S.Virology. 2025 Sep;610:110613. doi: 10.1016/j.virol.2025.110613. Epub 2025 Jun 20.PMID: 40561867

Molecular characterization and antimicrobial resistance of *Streptococcus pneumoniae* isolated from adult patients with invasive pneumococcal disease in northern Japan, 2017-2023.
Kawaguchiya M, Aung MS, Urushibara N, Ohashi N, Kobayashi N, Kudo K, Ito M, Kobayashi N.IJID Reg. 2025 Jun 27;16:100693. doi: 10.1016/j.ijregi.2025.100693. eCollection 2025 Sep.PMID: 40698152

A consensus HA DNA vaccine targeting clade 2.3.4.4 H5Nx influenza viruses provides broad cross-clade protection in mice and ferrets.
Kim CU, Choi WS, Lee P, Jeong JH, Seo YB, Choi YW, Sohn MH, Choi SY, Jeong AY, Song MS, Kim DJ.Biomed Pharmacother. 2025 Sep 2;191:118485. doi: 10.1016/j.biopha.2025.118485. Online ahead of print.PMID: 40902412

Inhalable Nanovaccine Based on Bioengineered Bacteria-Derived Membrane Vesicles Against Lung Metastasis.
Miao Y, Zhang H, Wang C, Li P, Chen L, Kang Z, Xiao Z, Zhang Q, Wu Z, Yang Y, Chen Q.Adv Mater. 2025 Sep 4:e06174. doi: 10.1002/adma.202506174. Online ahead of print.PMID: 40904209

Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus.
Yeşiloğlu C, Altun B, Keskin O, Dizdar Ö, Kiraz S, Ünal S, Büyükaşık Y, Badur S.Expert Rev Vaccines. 2025 Dec;24(1):860-869. doi: 10.1080/14760584.2025.2550979. Epub 2025 Sep 3.PMID: 40878546

Recognizing a Few of the Vaccine Preventable Diseases.
Allen HD, Puri K, Zenel JA.Pediatr Rev. 2025 Sep 1;46(9):467-481. doi: 10.1542/pir.2025-006848.PMID: 40875261

Identification of conformational epitopes on VP1 of Senecavirus A by monoclonal antibodies and phage display.
Tian Z, Lv L, Chen S, An M, Li M, Yuan W, Li L.Vet Microbiol. 2025 Sep;308:110636. doi: 10.1016/j.vetmic.2025.110636. Epub 2025 Jul 11.PMID: 40663836

COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.
Martinez ES, Fuchs S, Szurmant H, Chen X, Comer A, Lee E, Hruby R, Giusti R, Loveless B, Sees JP, Crone P, Peek LJ, Pestano G, Xie B, Zammuto J, Hostoffer SR Jr, Sanchez J Jr.Virus Res. 2025 Sep;359:199607. doi: 10.1016/j.virusres.2025.199607. Epub 2025 Jul 14.PMID: 40669693

Impact of vaccination on the ecology of Escherichia coli in commercial Turkey production.
White LM, Weber BP, Mendoza KM, Flores-Figueroa C, Munoz-Aguayo J, Mattison KA, Miller EA, Johnson TJ.Poult Sci. 2025 Sep;104(9):105415. doi: 10.1016/j.psj.2025.105415. Epub 2025 Jun 9.PMID: 40516298

Oral delivery of recombinant outer membrane protein 23-based nanovaccine can minimize Aeromonas hydrophila infection in Oreochromis niloticus.
Harshitha M, DSouza DL, Rakshitha BT, Karunasagar I, Chakraborty A, Maiti B.Microb Pathog. 2025 Sep;206:107765. doi: 10.1016/j.micpath.2025.107765. Epub 2025 May 29.PMID: 40449764

Breaking Endosomal Barriers: Thiol-Mediated Uptake Lipid Nanoparticles for Efficient mRNA Vaccine Delivery.
Lian Z, Zheng L, Liu S, Zhang J, Zhou J, Wu J, Ouyang S, Li J, Yang H.J Am Chem Soc. 2025 Sep 3;147(35):31530-31540. doi: 10.1021/jacs.5c05367. Epub 2025 Jul 22.PMID: 40694665

Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged 50 years.
Kulkarni N, Averin A, Taur S, Huang L, Hariharan D, Atwood M, Gupta N.Expert Rev Pharmacoecon Outcomes Res. 2025 Sep;25(7):1087-1099. doi: 10.1080/14737167.2025.2508255. Epub 2025 Jun 4.PMID: 40462563

CLASV: Rapid Lassa virus lineage assignment with random forest.
Daodu RO, Awotoro E, Ulrich JU, Kühnert D.PLoS Negl Trop Dis. 2025 Sep 9;19(9):e0013512. doi: 10.1371/journal.pntd.0013512. Online ahead of print.PMID: 40924753

Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.

Zhong GH, Bi ZF, Chu K, Zhang L, Chen L, Zhu KX, Quan JL, Nie C, Chen Q, Qiu LX, Xu JB, Li JX, Zhang ML, Liu S, Nie LL, Li K, Su YY, Huang SJ, Zhang QF, Huang WJ, Pan HX, Wu T, Zhang J, Xia NS.Lancet Reg Health West Pac. 2025 Aug 27;62:101671. doi: 10.1016/j.lanwpc.2025.101671. eCollection 2025 Sep.PMID: 40919385

Outbreak of Neisseria meningitidis Conjunctivitis in Military Trainees - Texas, February-May 2025.
Ching SJ, Jung GO, Osuna A, Casey T, Xia H, Bostwick K, Patadia AH, Sweet LM, Gallardo-Huizar O, Gibbons TF, Marcus JE.MMWR Morb Mortal Wkly Rep. 2025 Sep 4;74(33):516-521. doi: 10.15585/mmwr.mm7433a1.PMID: 40906586

Safety of BNT162b2 mRNA COVID-19 Vaccine Batches: A Nationwide Cohort Study.
Hviid A, Svalgaard IB.Pharmacoepidemiol Drug Saf. 2025 Sep;34(9):e70207. doi: 10.1002/pds.70207.PMID: 40814857

A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic.
Mues KE, Zhou CK, Gerber JE, van Hunsel F, Klein NP, Izurieta HS, Chen RT.Vaccine. 2025 Sep 5;64:127691. doi: 10.1016/j.vaccine.2025.127691. Online ahead of print.PMID: 40913819

The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama.
Sáez-Llorens X, Lasalvia P, Jaramillo P, DeAntonio R.Expert Rev Pharmacoecon Outcomes Res. 2025 Sep;25(7):1073-1086. doi: 10.1080/14737167.2025.2514530. Epub 2025 Jun 4.PMID: 40458968

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged 18 Years in Singapore.
Zhang J, Vietri J, Averin A, Hariharan D, Atwood M, Huang L.Value Health Reg Issues. 2025 Sep;49:101136. doi: 10.1016/j.vhri.2025.101136. Epub 2025 May 23.PMID: 40412265

Nurses' attitudes about RSV vaccination for pregnant women and infants: Evidence from a cross-sectional survey.
Viskupič F, Wiltse DL, Stenvig TE.PLoS One. 2025 Sep 2;20(9):e0331326. doi: 10.1371/journal.pone.0331326. eCollection 2025.PMID: 40892804

The Return of MenW: Religious Mass Gatherings as Global Catalysts for Meningococcal Spread.
Al-Tawfiq JA, Memish ZA.J Epidemiol Glob Health. 2025 Sep 9;15(1):115. doi: 10.1007/s44197-025-00463-1.PMID: 40924251

Potential predictors of COVID-19 booster vaccine confidence among adult people: a cross-sectional analysis amid the Omicron surge in Southern Bangladesh.
Roy DN, Rashid M, Aktar A, Parvin MS, Islam ME.Vaccine. 2025 Sep 5;64:127693. doi: 10.1016/j.vaccine.2025.127693. Online ahead of print.PMID: 40913815

RISE: Two-Stage Rank-Based Identification of High-Dimensional Surrogate Markers Applied to Vaccinology.
Hughes A, Parast L, Thiébaut R, Hejblum BP.Stat Med. 2025 Sep;44(20-22):e70241. doi: 10.1002/sim.70241.PMID: 40911434

Study on the adjuvant activity and mechanism of action of a novel Monophosphoryl Lipid A.
Zhao L, Shi P, Zhang Y, Zhang M, Han N, Liu Z, Li S, Yin J, Zhai J.Mol Immunol. 2025 Sep 3;187:28-47. doi: 10.1016/j.molimm.2025.08.019. Online ahead of print.PMID: 40907461

Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?
Yaghi M, Dulai AS, Haddad NR, Murase EM, Murase JE.Int J Womens Dermatol. 2025 Sep 8;11(3):e220. doi: 10.1097/JW9.0000000000000220. eCollection 2025 Oct.PMID: 40927444

Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.
Mayerlen LI, Wong TAS, To A, Smith O, Chuang E, Donini O, Lehrer AT.Vaccine. 2025 Sep 2;64:127684. doi: 10.1016/j.vaccine.2025.127684. Online ahead of print.PMID: 40902221

Breed-specific humoral immune responses to lumpy skin disease vaccination and its associated factors in cattle.
Bok EY, Jung M, Kim UH, Lee HG, Do YJ, Son YB, Choi Y, Ha S.Vet Immunol Immunopathol. 2025 Sep;287:110983. doi: 10.1016/j.vetimm.2025.110983. Epub 2025 Aug 6.PMID: 40795755

Development of Receptor-Binding Domain (RBD)-Loaded PEG-PCL Nanoparticle Formulations Against SARS-CoV-2.
Ayçiçek Can S, Göksever S, Öz UC, Küçüktürkmen B, Abamor EŞ, İnan M, Bozkır A.Macromol Biosci. 2025 Sep 8:e00397. doi: 10.1002/mabi.202500397. Online ahead of print.PMID: 40920430

The role of the S1 gene in glandular stomach pathogenesis and tropism of infectious bronchitis virus H120 strain in poultry.
Dai Z, Teng Y, Song J, Xiao Z, Zhang J, Feng K, Shao G, Zhang X, Xie Q.Microbiol Spectr. 2025 Sep 2;13(9):e0000825. doi: 10.1128/spectrum.00008-25. Epub 2025 Aug 12.PMID: 40792512

Oral Immunization with Recombinant Saccharomyces cerevisiae expressing TM1 of Mycoplasma gallisepticum induces Unique Specific Antibodies and Protective Immunity.
Lu Z, Liu X, Zhang Y, Han Y, Ishfaq M, Lu B, Lu X.Microb Pathog. 2025 Sep 4:108012. doi: 10.1016/j.micpath.2025.108012. Online ahead of print.PMID: 40914327

The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants.
Feng S, Huang M, Quan Y, Sun L, Lin J, Zhang D, Wei X, Wang Z, Ma X, Wang S, Pan Q, Jia W, Wei D, Feng G, Xu M, Deng Z, Zhang Q.Virology. 2025 Sep;610:110612. doi: 10.1016/j.virol.2025.110612. Epub 2025 Jun 20.PMID: 40561863

ETEC biofilms are regulated by magnesium and lactate bioavailability.
Hollifield IE, Clement KL, Fernando KA, Blythe MD, Bitoun JP.Infect Immun. 2025 Sep 9;93(9):e0024325. doi: 10.1128/iai.00243-25. Epub 2025 Aug 11.PMID: 40788160

Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.

Chen X, Cheng ML, Huang XY, Sun MX, Li RT, Wu M, Li YY, Xu Q, Guan MY, Zhao H, Qin CF.EMBO Mol Med. 2025 Sep 8. doi: 10.1038/s44321-025-00304-5. Online ahead of print.PMID: 40926050

Rumor as ethical vernacular: Ebola and the womb in eastern Congo.
James M.Med Anthropol Q. 2025 Sep;39(3):e70015. doi: 10.1111/maq.70015. Epub 2025 Jul 22.PMID: 40692490

The Role of Family Communication Patterns within COVID-19 Vaccination Messaging.
Bruno CM, Waddell TF, Thomas SO.Health Commun. 2025 Sep 9:1-12. doi: 10.1080/10410236.2025.2555289. Online ahead of print.PMID: 40924065

hmLIGHT Enhances Vaccine Antitumor Effects by Facilitating T-cell Infiltration and Activation in the 4T1 Breast Cancer Model.
Dong L, Zhang S, Wuri Q, Qu X, Zhang K, Cai Z, Qiao Y, Feng M, Wang C, Wu H, Wu J, Kong W, Yu X, Zhang H.Mol Cancer Ther. 2025 Sep 2;24(9):1378-1388. doi: 10.1158/1535-7163.MCT-24-0333.PMID: 40066767

Impact of health promotion strategies on HPV vaccination uptake: A descriptive epidemiological study (2019-2024).
Štrbac M, Ukropina S, Nikolić N, Mašić K, Rajčević S, Čanković D, Vuleković V, Popov L, Ristić M.PLoS One. 2025 Sep 4;20(9):e0331592. doi: 10.1371/journal.pone.0331592. eCollection 2025.PMID: 40906650

Enzymatic divergence of GAPDH in Mycoplasma synoviae: Comparative insights from MS-H and TS4 strains.
Zare S, Marenda MS, Klose SM, Noormohammadi AH.Vet Microbiol. 2025 Sep;308:110653. doi: 10.1016/j.vetmic.2025.110653. Epub 2025 Jul 27.PMID: 40743594

Airway-applied mRNA vaccine needs tailored sequence design and high standard purification that removes devastating dsRNA contaminant.
Zhang J, Li C, Liu Y, Liao R, He D, Xu L, Chen T, Xiao Q, Luo M, Chen Y, Li Y, Zhu H, Rosenecker J, Ding X, Pei S, Guan S.Mol Ther. 2025 Sep 3;33(9):4193-4215. doi: 10.1016/j.ymthe.2025.05.024. Epub 2025 May 28.PMID: 40443030

The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response.
Mai F, Reisinger EC, Müller-Hilke B.Clin Immunol. 2025 Sep;278:110523. doi: 10.1016/j.clim.2025.110523. Epub 2025 May 15.PMID: 40381868

Association of COVID-19 vaccination with relapsed nephrotic syndrome and new onset nephrotic syndrome in children.
Mazza D, Ward E, Makeneni S, Zee J, Laskin B, Denburg M.Pediatr Nephrol. 2025 Sep;40(9):2855-2862. doi: 10.1007/s00467-025-06778-2. Epub 2025 Apr 22.PMID: 40261402

Signal peptides enhance immunogenicity and protection of recombinant Salmonella enterica serovar Choleraesuis vectors against Streptococcus suis.
Li YA, Feng Y, Ouyang H, Zhang Y, Shi H.Vet Microbiol. 2025 Sep;308:110650. doi: 10.1016/j.vetmic.2025.110650. Epub 2025 Jul 19.PMID: 40700978

Breaking From CDC, ACOG Continues Recommending COVID-19 Vaccine During Pregnancy.
Anderer S.JAMA. 2025 Sep 5. doi: 10.1001/jama.2025.16943. Online ahead of print.PMID: 40911303
386
Cite

The growing interests in Epstein-Barr virus: A bibliometric analysis of research trends, collaborations, and emerging hotspots.
Li L, Wu J, Cai J, Asghar MA, Xiao R, Wu J, Zhao Q, Zhang X.Infect Med (Beijing). 2025 Jun 22;4(3):100194. doi: 10.1016/j.imj.2025.100194. eCollection 2025 Sep.PMID: 40703323

Research on the detecting method for cracks on perforated embryo eggs based on acoustic responses.
Fang Y, Zhao M, Chen H, Zhao H, Fu D, Lin S, Wei Y.Poult Sci. 2025 Sep 2;104(11):105765. doi: 10.1016/j.psj.2025.105765. Online ahead of print.PMID: 40925149

Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis.
Bruess GES, Barry KK, Olsen GM, Foschi CM, Cook E, Liegl M, Pan AY, Lalor L.Pediatr Dermatol. 2025 Sep 2. doi: 10.1111/pde.70033. Online ahead of print.PMID: 40898756

Exploring the Cognitive, Affective, and Conative Factors of Bystander Intervention to Improve Protective Measures During Health Emergencies.
Ju I, Yel E, Song H.Health Commun. 2025 Sep;40(10):2099-2109. doi: 10.1080/10410236.2024.2442560. Epub 2024 Dec 20.PMID: 39704473

Mutations in feline infectious peritonitis virus nonstructural protein 14/16 methyltransferase attenuate the pathogenicity of the virus in cats.
Jiao Z, Li J, Wang P, Yan Y, Fang L, Chen Y, Hu X, Shi Y, Peng G.J Virol. 2025 Sep 9:e0083925. doi: 10.1128/jvi.00839-25. Online ahead of print.PMID: 40923786

Robust polyfunctional $CD8^+$ and $CD4^+$ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein.
Tscherne A, Kalodimou G, Jany S, Freudenstein A, Kumar S, Pilchová V, Friebis T, Maiwald G, Panhofer I, Sutter G, Volz A.J Gen Virol. 2025 Sep;106(9). doi: 10.1099/jgv.0.002142.PMID: 40889136

Diagnostic utility of multiplex PCR for direct detection and serotyping of group B streptococci from clinical specimens.
Ismail MBH, Nagaraj G, Ravikumar KL.J Microbiol Methods. 2025 Sep;236:107190. doi: 10.1016/j.mimet.2025.107190. Epub 2025 Jul 5.PMID: 40623472

Conserved and distinct expression of circular RNAs in commercially used Marek's disease vaccine viruses.
Ponsard C, Chasseur AS, Lombard P, Danneels B, Letellier C, Kheimar A, You Y, Denesvre C, Kaufer BB, Coupeau D, Muylkens B.J Gen Virol. 2025 Sep;106(9). doi: 10.1099/jgv.0.002146.PMID: 40911349

Barriers in the prevention and early detection of human papillomavirus in Latin America.

Santiago Sanabria L, Laverde Cardona VA, Pérez D YR, Abreu F, Cicerchia ML, Cajelli C, Inurreta Díaz MJ, Vásquez Medina MJ, Amador KA, Ruiz Carillo GR.Int J Gynaecol Obstet. 2025 Sep;170(3):1144-1152. doi: 10.1002/ijgo.70177. Epub 2025 Apr 22.PMID: 40261313

Influenza and COVID-19 Multicomponent Vaccine in Adults.
Liu Z, Zhang L, Jiang M.JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12222. Online ahead of print.PMID: 40920372

Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference.
Guo J, Wang T, Liu Z, Zeng W, Shen P, Sun Y, Zhan S, Xu Y.EClinicalMedicine. 2025 Aug 21;87:103449. doi: 10.1016/j.eclinm.2025.103449. eCollection 2025 Sep.PMID: 40896461

Flu Caused Highest Number of Pediatric Deaths Since 2009-2010.
Roush K.Am J Nurs. 2025 Sep 1;125(9):14. doi: 10.1097/AJN.0000000000000150a. Epub 2025 Aug 21.PMID: 40828822

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants.
Li Y, He J, Liu W, Qi R, Li J, Zhu F.Expert Rev Vaccines. 2025 Dec;24(1):840-848. doi: 10.1080/14760584.2025.2550984. Epub 2025 Sep 2.PMID: 40853047

Pepscan and bioinformatic strategies for identification of potential B-cell epitopes for a peptide-based vaccine for tick control.
Andrade-Silva V, Waldman J, Juliano MA, Tirloni L, da Silva Vaz I Jr.Mol Biochem Parasitol. 2025 Sep;263:111692. doi: 10.1016/j.molbiopara.2025.111692. Epub 2025 Aug 28.PMID: 40885405

Gene editing of a carcinogenic liver fluke tetraspanin impairs parasite surface biogenesis and extracellular vesicle uptake by human host cells.
Chaiyadet S, Ittiprasert W, Smout MJ, Khowawisetsut L, Ruangsuwast A, Brindley PJ, Loukas A, Laha T.J Infect Dis. 2025 Sep 4:jiaf466. doi: 10.1093/infdis/jiaf466. Online ahead of print.PMID: 40905941

Isolation and identification of Mycoplasma synoviae in Hebei, China, and evaluation of the immune protection efficacy of inactivated vaccines.
Wang Z, Chen L, Song L, Wei Z, Wang F, Li S, Yang Y, Han Z, Zhang Z, Wu T, Jia Q.Poult Sci. 2025 Sep;104(9):105479. doi: 10.1016/j.psj.2025.105479. Epub 2025 Jun 25.PMID: 40592287

Application of a Rationally Designed Mucosal Nanovaccine Platform in Bacterial Disease Prophylactics Using Fish as a Model Organism.

Diagnostic potential of recombinant Mycobacterium tuberculosis PcaA antigen and its enhancement of protective efficacy as a subunit vaccine booster following BCG priming.
Xu Y, Wang X, Zhong Q.J Microbiol Methods. 2025 Sep;236:107202. doi: 10.1016/j.mimet.2025.107202. Epub 2025 Jul 26.PMID: 40720996

Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newborns.

Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Weiner JA, Ackerman ME, Modlin JF, Sajjad OM, Arita M, Gast C, Mainou BA, Zaman K, Hoque M, Rana S, Bandyopadhyay AS, Wright PF.Clin Infect Dis. 2025 Sep 5:ciaf484. doi: 10.1093/cid/ciaf484. Online ahead of print.PMID: 40907970

Influenza and COVID-19 Multicomponent Vaccine in Adults.
Liu Z, Zhang L, Jiang M.JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12222. Online ahead of print.PMID: 40920372

Humoral Immune Response to Inactivated SARS-CoV-2 Vaccine in Populations With and Without Prior COVID-19 Infection: A Longitudinal Cohort Study.
Zhang S, Jiang X, Du C, Jia M, Huang Q, Tan H, Wang L.Viral Immunol. 2025 Sep 4. doi: 10.1177/08828245251370284. Online ahead of print.PMID: 40905942

Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type 1 Dendritic Cells for Cancer Immunotherapy Applications.
Balan S, O'Brien L, Peros A, Wang X, Leal Rojas I, McClain C, Radford KJ, Bhardwaj N.Cancer Immunol Res. 2025 Sep 2;13(9):1328-1341. doi: 10.1158/2326-6066.CIR-25-0034.PMID: 40600891

Leptospirosis seroprevalence in Canadian beef calves at or near fall weaning.
Pollock CM, Campbell JR, Windeyer MC, Rousseau M, Waldner CL.Can Vet J. 2025 Sep 1;66(9):955-960. eCollection 2025 Sep.PMID: 40927258

Influenza Vaccine Coverage Lower in Foreign-Born Middle Eastern and North African Children Compared to Other Groups: Results from the 2005-2018 National Health Interview Survey.
Dallo FJ, Brown K, Obembe A, Kindratt TB.J Racial Ethn Health Disparities. 2025 Sep 2. doi: 10.1007/s40615-025-02613-4. Online ahead of print.PMID: 40892164

Development of GFP-expressing infectious clones for PRRSV using TAR cloning for antiviral drug screening.
Zhang M, Qian B, Kunec D, Veit M.Npj Viruses. 2025 Sep 5;3(1):66. doi: 10.1038/s44298-025-00148-3.PMID: 40913022

Recombinant snakehead rhabdovirus-mediated expression of white spot syndrome virus (WSSV) VP28 confers protection against WSSV in Penaeus vannamei.
Choi MG, Hong SJ, Kim KH.Fish Shellfish Immunol. 2025 Sep;164:110439. doi: 10.1016/j.fsi.2025.110439. Epub 2025 May 23.PMID: 40414471

Effect of vibratory device on the time of administration of vaccines and on patient satisfaction measures.
Thompson A, Rodrigo ML, Roberts A, Waddell J, Carter R.J Child Health Care. 2025 Sep;29(3):618-625. doi: 10.1177/13674935241242156. Epub 2024 Mar 31.PMID: 38556616

Respiratory Syncytial Virus Vaccination Acceptance: The Importance of Asking "Why?".
Zeme M, Gaw SL.J Pediatr Clin Pract. 2025 Jul 7;17:200163. doi: 10.1016/j.jpedcp.2025.200163. eCollection 2025 Sep.PMID: 40703621

Characteristics of four natural poliovirus type 1 variants with six-nucleotide deletion (2,783-2,788 nt) in the VP1 region.
Lin J, Zhou L, Zhu C, Wei J, Lv B, Si Y, Zhu S, Ji T, Wang D, Yang Q, Xiao J, Yang L, Xiao K, Shao K, Zhang Y, Yan D.Microbiol Spectr. 2025 Sep 2;13(9):e0133425. doi: 10.1128/spectrum.01334-25. Epub 2025 Aug 8.PMID: 40778757

Social determinants of health and COVID-19 vaccination: An individual participant data meta-analysis of adult Latino participants.
De Anda S, Budd EL, Chaovalit P, Vu AH, Leve LD, DeGarmo DS.Prev Med. 2025 Sep;198:108335. doi: 10.1016/j.ypmed.2025.108335. Epub 2025 Jun 24.PMID: 40570937

Challenges of Vaccine-Induced Thrombotic Thrombocytopenia-Related Kidney Transplantation: Venous Graft Thrombosis in a Pediatric Recipient.
Droste M, Kubitza L, Wesche J, Jeruschke S, Berger M, Kaths M, Baba HA, Greinacher A, Pape L, Thiele T, Büscher AK.Am J Kidney Dis. 2025 Sep;86(3):408-412. doi: 10.1053/j.ajkd.2025.03.025. Epub 2025 Jun 5.PMID: 40482902

Immune Reconstitution and Need for Booster Vaccinations Among Non-Transplant Childhood Cancer Survivors: A Single-Center Experience.
Shin E, Han H, Nobleza KJ, Crews JD, Elizalde A, Cheek N, Voeller J.Cancer Rep (Hoboken). 2025 Sep;8(9):e70326. doi: 10.1002/cnr2.70326.PMID: 40887942

Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
Okoli GN, Murphy C, Mak L, Cheng SMS, Peiris M, Cowling BJ.Vaccine. 2025 Sep 2;63:127687. doi: 10.1016/j.vaccine.2025.127687. Online ahead of print.PMID: 40902334

Whole genome characterisation of DS-1-like G8P[4] rotavirus A strains circulating in South Africa between 2009 and 2021 reveals endemic sub-lineages and evidence of radical epitope changes.
Shange ND, Mogotsi MT, Ogunbayo AE, Page N, Sondlane H, Esona MD, Kumwenda B, Mhango C, Kawonga F, Matambo E, Mingle SNK, Dennis FE, Khuzwayo JC, Makoah NA, Donato CM, Nyaga MM.Infect Genet Evol. 2025 Sep 5;134:105818. doi: 10.1016/j.meegid.2025.105818. Online ahead of print.PMID: 40915595

Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina.
Isnardi CA, Pisoni C, Cosatti M, Roberts K, Virasoro BM, Kreimer J, Echeverría C, D'Angelo ME, Pereira D, Petkovic I, Tissera YS, Correa MÁ, Rodríguez Gil G, Quintana R, Cogo K, Alonso C, Kogan N, Toledo AL, Alfaro MA, Nieto R, García L, Rollano Perasso A, Debernardi ME, Troyano Z, Strusberg I, Pons-Estel GJ, Schneeberger EE.J Clin Rheumatol. 2025 Sep 1;31(6):e112-e118. doi: 10.1097/RHU.0000000000002251. Epub 2025 Jun 23.PMID: 40548899

Impact of Interventions to Improve Human Papillomavirus Vaccine Uptake on Other Vaccines Due: A Secondary Analysis of a Randomized Trial.

Jacobson RM, Herrin J, Jenkins G, Griffin JM, St Sauver JL, MacLaughlin KL, Zhu X, Finney Rutten LJ.Acad Pediatr. 2025 Sep-Oct;25(7):102870. doi: 10.1016/j.acap.2025.102870. Epub 2025 Jun 7.PMID: 40490190

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.
Thuluva S, Paradkar V, Gunneri S, Mogulla RR, Yerroju V, Dhar C, Ningaiah S, Panchakshari M, Gillurkar CS, Narang M, Kisan SS, Rao AV.Lancet Reg Health Southeast Asia. 2025 Jul 24;40:100642. doi: 10.1016/j.lansea.2025.100642. eCollection 2025 Sep.PMID: 40746973

Targeted Reprogramming of Tumor Cells by Digoxin-Loaded Immunogenic Nanoparticles Enhances Immunity Against Disseminated Tumor Cells.
Meng Y, Ba Q, Yao J, Wang J, Tian H, Kong Y, Fang M, Guo W, Gong W, Wang Y, Yang Y, Li Y, Yang M, Gao C.Adv Healthc Mater. 2025 Sep 4:e02881. doi: 10.1002/adhm.202502881. Online ahead of print.PMID: 40904220

Dengue disease severity in humans is augmented by waning Japanese encephalitis virus immunity.
Malhotra S, Gupta BP, Uranw S, Mantri CK, Rathore APS, St John AL.Sci Transl Med. 2025 Sep 3;17(814):eads9572. doi: 10.1126/scitranslmed.ads9572. Epub 2025 Sep 3.PMID: 40901927

The impact of a varicella vaccine introduction on the incidence of herpes zoster in Korean children, an ecological study.
Lee J.Infect Dis (Lond). 2025 Sep 3:1-8. doi: 10.1080/23744235.2025.2555896. Online ahead of print.PMID: 40899613

How did slovak students perceive the COVID-19 pandemic: Insights from one of the least vaccinated EU countries.
Korim V, Masaryk R, Lesičková M.J Health Psychol. 2025 Sep;30(10):2502-2515. doi: 10.1177/13591053241291477. Epub 2024 Oct 27.PMID: 39462181

Importance of BCG Vaccination at Birth in Pediatric Patients with Chronic Granulomatous Disease after Hematopoietic Stem Cell Transplantation in Developing Countries.
Hamidieh AA, Behfar M, Nejati N, Azar SS, Salmanifard MT, Malik R, Kashani H, Mohseni R, Jafari L.Immunol Lett. 2025 Sep 1:107083. doi: 10.1016/j.imlet.2025.107083. Online ahead of print.PMID: 40902675

Role of thioredoxin reductase (TrxB) in oxidative stress response of Francisella tularensis live vaccine strain.
Higgs M, Ma Z, Centone A, Bakshi CS, Malik M.J Bacteriol. 2025 Sep 3:e0017325. doi: 10.1128/jb.00173-25. Online ahead of print.PMID: 40899829

Effect of increased CpG and UpA dinucleotides in the West Nile virus genome on virus transmission by *Culex* mosquitoes and pathogenesis in a vertebrate host.
van Bree JWM, Visser I, Marshall EM, Willemsen WW, van de Waterbeemd C, Kenbeek D, Abma-Henkens MHC, Pijlman GP, van Oers MM, Rockx B, Fros JJ.J Virol. 2025 Sep 8:e0110225. doi: 10.1128/jvi.01102-25. Online ahead of print.PMID: 40919899

Exploration of hypothetical proteins and reverse vaccinology approach for novel multi-epitope vaccine design against multidrug-resistant clinical isolate Pseudomonas aeruginosa JJPA01.
Narthanareeswaran B, Narthanareeswaran M, Ranganathan S, Pandian CJ, Jeyakanthan J.Comput Biol Med. 2025 Sep 4;197(Pt A):111045. doi: 10.1016/j.compbiomed.2025.111045. Online ahead of print.PMID: 40912040

COVID-19 pandemic reclassification and implications for continuing uptake of COVID-19 vaccination: The case of Savannah Region, Ghana, 2023.
Adjei MR, Sarfo KA, Azornu CK, Kwarteng PG, Osei-Sarpong F, Baafi JV, Bafana NAA, Kubio C, Ohene SA, Grobusch MP.IJID Reg. 2025 Jun 27;16:100694. doi: 10.1016/j.ijregi.2025.100694. eCollection 2025 Sep.PMID: 40727032

miR-17-5p-PD-L1 pathway is a potential mechanism by which stress inhibits immune response to NDV vaccine in chickens.
Jiang Y, Han J, Tian Y, Zhang W, Zhang R, Xu X, Ma X, Man C.Poult Sci. 2025 Sep;104(9):105480. doi: 10.1016/j.psj.2025.105480. Epub 2025 Jun 25.PMID: 40592284

Cost-effectiveness and epidemiological impact of gender-neutral vaccination against human papillomavirus in economically developed metropolises of Beijing, Shanghai, and Guangzhou, China.
Fu X, Zhang Q, Wagner AL, Zhou W, Xia Y, Lu Y.Hum Vaccin Immunother. 2025 Dec;21(1):2557092. doi: 10.1080/21645515.2025.2557092. Epub 2025 Sep 9.PMID: 40923775

Self-reported dog vaccination practices in pet owners enrolled in the Dog Aging Project in the United States found most dogs were vaccinated according to veterinarians' recommendations.
Ekakoro JE, Ruple A; Dog Aging Project Consortium; Renter D, Cernicchiaro N.Am J Vet Res. 2025 Jul 2;86(9):1-12. doi: 10.2460/ajvr.25.01.0016. Print 2025 Sep 1.PMID: 40623437

Impurity profiling of PEGylated myristoyl diglyceride, DMG-PEG 2000, a functional excipient used in mRNA lipid nanoparticle formulations.
Sperber B, Gutmann M, Kehrein J, Lühmann T, Holzgrabe U, Meinel L.Eur J Pharm Biopharm. 2025 Sep;214:114762. doi: 10.1016/j.ejpb.2025.114762. Epub 2025 Jun 4.PMID: 40480444

Dengue virus infection reprograms baseline innate immune gene expression.
Ong EZ, Yee JX, Koh CW, Ooi JS, Tham CYL, Chan KR, Kareko BW, Lyski ZL, Tricou V, Dean H, Braun R, Kalimuddin S, Low JG, Messer WB, Sharma M, Ooi EE.Med. 2025 Sep 1:100841. doi: 10.1016/j.medj.2025.100841. Online ahead of print.PMID: 40925380

Efficacy of an optimal vaccination strategy for H120 and NNA vaccines against the novel HX strain of the IBV GVI-1 genotype.
Qin L, Yang F, Cai S, Zhou J, Sun Z, Zhao M, Jia X, Gao H, Zhang K.Vet Microbiol. 2025 Sep;308:110626. doi: 10.1016/j.vetmic.2025.110626. Epub 2025 Jul 5.PMID: 40633273

An attractive vaccine candidate based on AP205 VLPs fusing with a receptor-binding domain of a newly emerged porcine deltacoronavirus strain in China.
Chang X, Zhang Z, Chen Y, Zhang M, Fei F, Ma C, Wang Z, Xu F, Li L, Shan X, Li L, Sun P, Liu X.Vet Microbiol. 2025 Sep;308:110655. doi: 10.1016/j.vetmic.2025.110655. Epub 2025 Jul 27.PMID: 40729798

Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season.
Huang YT, Tsou TP, Kuo SH, Huang YT.Vaccine. 2025 Sep 5;64:127690. doi: 10.1016/j.vaccine.2025.127690. Online ahead of print.PMID: 40913816

Molecular Epidemiology of IBDV in Italy: Emergence of Northwestern European Reassortants (genotype A3B1) and Co-circulation with Local Strains.
Poletto F, Lizzi G, Legnardi M, Lupini C, Tucciarone CM, Franzo G, Giaccone V, Pedrazzoli S, Quaglia G, Graziosi G, Nardi M, Catelli E, Cecchinato M.Avian Pathol. 2025 Sep 9:1-19. doi: 10.1080/03079457.2025.2557881. Online ahead of print.PMID: 40923366

The role of the rural poultry sector in viral circulation and evolution: evaluation of infectious bronchitis virus and avian metapneumovirus dynamics in an Italian dealer farm.
Legnardi M, Poletto F, Sartore P, Franzo G, Tucciarone CM, Cecchinato M.Poult Sci. 2025 Sep;104(9):105420. doi: 10.1016/j.psj.2025.105420. Epub 2025 Jun 11.PMID: 40527127

Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.
Beyaert S, Loriot A, Magremanne M, Renwart W, Mahy P, Duprez T, Baldin P, Benidovskaya E, Huyghe N, Dahou H, Stroobant V, Gomard T, Machiels JP, Schmitz S.Eur Arch Otorhinolaryngol. 2025 Sep 3. doi: 10.1007/s00405-025-09655-8. Online ahead of print.PMID: 40900323

Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.
Moya Alvarez A, Arreguez ML, Uncos RE, Uncos DA, Pereyra WR, Ramos F, Lauthier JJ, Nina L, Mejía Montaño E, Hashiguchi Y, Korenaga M, Barroso PA, Marco JD.Med Microbiol Immunol. 2025 Sep 3;214(1):41. doi: 10.1007/s00430-025-00849-9.PMID: 40900277

Comparison of clinical characteristics of hospitalized pediatric patients with respiratory syncytial virus infections before and during/after the coronavirus disease 2019 pandemic in Japan -importance of universal prevention using maternal vaccination and nirsevimab.
Karahashi Y, Yamanaka T, Aizawa Y, Habuka R, Tsukano S, Saitoh A.J Infect Chemother. 2025 Sep;31(9):102779. doi: 10.1016/j.jiac.2025.102779. Epub 2025 Aug 6.PMID: 40774505

Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference.
Iwata K, Ikegaki S, Hyodo Y, Miyake H.Clin Transplant. 2025 Sep;39(9):e70307. doi: 10.1111/ctr.70307.PMID: 40901729

The role of vaccination and healthcare acquisition in respiratory failure during a COVID-19 outbreak in an acute hospital in Wales.
Hogg C, McKerr C, Craine N, Williams D, Perry M, Cottrell S.Infect Prev Pract. 2025 Jul 9;7(3):100474. doi: 10.1016/j.infpip.2025.100474. eCollection 2025 Sep.PMID: 40800205

A Safe and Versatile Minicell Platform Derived from *Lactiplantibacillus plantarum* for Biotechnological Applications.
Park J, Chang S, Kang H, Yi S, Jang lH, Lee KA, Kim D, Kim J.J Microbiol Biotechnol. 2025 Sep 5;35:e2507031. doi: 10.4014/jmb.2503.07031.PMID: 40915654

Development of *in vitro* and *in vivo* neutralization assays for New World alphaviruses based on the VSV pseudovirus system.
Liu Y, Chen C, Liao B, Geng X, Huang W, Nie J.Emerg Microbes Infect. 2025 Sep 1:2555721. doi: 10.1080/22221751.2025.2555721. Online ahead of print.PMID: 40890032

Effectiveness of Watching Cartoons in Reducing Pain in Children Receiving Vaccine Injection: A Randomized Controlled Trial.
Li F, Yu TT, Wang CM, Lu HY, Lu Y, Li LL.Public Health Nurs. 2025 Sep-Oct;42(5):1687-1693. doi: 10.1111/phn.70002. Epub 2025 Jul 1.PMID: 40590413

Recall interferon-gamma responses against Coccidioides are a surrogate marker for vaccine response in dogs.
Shubitz LF, Powell DA, Butkiewicz CD, Frelinger JA, Galgiani JN.Am J Vet Res. 2025 Jun 4;86(9):ajvr.25.04.0119. doi: 10.2460/ajvr.25.04.0119. Print 2025 Sep 1.PMID: 40466664

Development of a chemiluminescence enzyme immunoassay (CLEIA) for quantitating L1 protein in HPV vaccines.
Fei C, Yang H, Wang S, He W, Shen X, Zhang Y, Jiang Y, Yang L, Li X, Wu F, Wu Y, Liu Q.Anal Biochem. 2025 Sep;704:115889. doi: 10.1016/j.ab.2025.115889. Epub 2025 May 2.PMID: 40320155

Listeria monocytogenes adenosine auxotrophs are impaired for intracellular and extracellular growth but retain potent immunogenicity.
Feng Y, Lobanovska M, Vickery J, Castillo JG, Güereca L, Chang SK, DuPage M, Portnoy DA.Infect Immun. 2025 Sep 5:e0034325. doi: 10.1128/iai.00343-25. Online ahead of print.PMID: 40910949

Protecting the future of vaccine development amidst US funding withdrawal for mRNA vaccine research.
Petersen E, Ippolito G, Maeurer M, Ntoumi F, Nachega JB, Hui DS, Zumla A.Lancet Microbe. 2025 Sep 2:101226. doi: 10.1016/j.lanmic.2025.101226. Online ahead of print.PMID: 40912261

Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer.
Schmidinger M, Huebner-Resch I.Nat Rev Urol. 2025 Sep;22(9):567-568. doi: 10.1038/s41585-025-01018-6.PMID: 40148578

Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors.
Zhang Z, Li Y, Hong H, Wu Z.Chem Commun (Camb). 2025 Sep 2. doi: 10.1039/d5cc03243a. Online ahead of print.PMID: 40891269

Circulation of Measles Virus Genotype B3 in the Republic of the Congo Between 2023 and 2024: A Molecular Characterization Study.
Mavoungou YVT, Fritz M, Mayengue PI, Koukouikila FK, Louzolo IJ, Ngangoué LG, Lenguiya LH, Ahombo G, Butel C, Serrano L, Peeters M, Leroy EM, Niama FR.Health Sci Rep. 2025 Aug 26;8(9):e71201. doi: 10.1002/hsr2.71201. eCollection 2025 Sep.PMID: 40873887

mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies.
Debie Y, Verbruggen L, Peeters M, van Dam PA, Vandamme T.Int J Infect Dis. 2025 Sep;158:107939. doi: 10.1016/j.ijid.2025.107939. Epub 2025 May 23.PMID: 40414552

Ticking off Lyme disease: OspA mRNA vaccine halts infection in mouse model.
He W, Rasley A, Fischer NO, Kubicek-Sutherland JZ, Stromberg ZR.Mol Ther Nucleic Acids. 2025 Jul 31;36(3):102564. doi: 10.1016/j.omtn.2025.102564. eCollection 2025 Sep 9.PMID: 40791873

Formulation matters: LION nanoparticles improve RNA vaccine immunogenicity by containing systemic inflammation.
Subramani C, Barman TK.Mol Ther Nucleic Acids. 2025 Aug 11;36(3):102659. doi: 10.1016/j.omtn.2025.102659. eCollection 2025 Sep 9.PMID: 40832629

School Nurses' Experiences of the School-Based HPV Vaccination Program - A Decade Later.
Enskär I, Nevéus T, Enskär K, Källqvist C, Grandahl M.J Sch Nurs. 2025 Sep 8:10598405251374726. doi: 10.1177/10598405251374726. Online ahead of print.PMID: 40920344

Site-directed mutagenesis of transferrin binding protein B enhances immunogenicity and protective efficacy against Bibersteinia trehalosi.
Yan Z, Ma X, Long W, Yang R, Zhu J, Wei C, Yu X, Gan L, Guo J.Res Vet Sci. 2025 Sep;193:105812. doi: 10.1016/j.rvsc.2025.105812. Epub 2025 Jul 15.PMID: 40684649

Unmasking measles in pregnancy: A fatal rare case of maternal measles with posthumous diagnosis in a resource-constrained setting.
Lugata J, Mrosso O, Lyamuya T, Swai P, Mjema R, Kilonzo K, Mchome B, Batchu N.Radiol Case Rep. 2025 Jun 28;20(9):4749-4754. doi: 10.1016/j.radcr.2025.06.039. eCollection 2025 Sep.PMID: 40677882

Safer vaccine hope for RVF.
Gray A.Vet Rec. 2025 Sep 6;197(5):175. doi: 10.1002/vetr.5971.PMID: 40910654

RFK Jr demanded a vaccine study be retracted - the journal said no.
Fieldhouse R.Nature. 2025 Sep;645(8079):13-14. doi: 10.1038/d41586-025-02682-9.PMID: 40847188

Optimizing mucosal vaccination: Exploiting Lactobionic acid-modified chitosan for superior gene delivery systems.
Colaço M, Panão-Costa J, Cruz MT, de Almeida LP, Borges O.Int J Biol Macromol. 2025 Sep 5;327(Pt 2):147492. doi: 10.1016/j.ijbiomac.2025.147492. Online ahead of print.PMID: 40915467

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Olsen TA, Barnum KJ, Avigan D, Rosenblatt J.Best Pract Res Clin Haematol. 2025 Sep;38(3):101650. doi: 10.1016/j.beha.2025.101650. Epub 2025 Aug 20.PMID: 40915708

A Japanese encephalitis virus biological clone with an *E* gene point mutation exhibits *in vitro* and *in vivo* attenuation of neurovirulence.
Yu SP, Ong KC, Tan SH, Ishikawa T, Perera D, Hooi YT, Wong KT.J Gen Virol. 2025 Sep;106(9):002137. doi: 10.1099/jgv.0.002137.PMID: 40889137

An NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates.
Finn K, Chow J, Zhivaki D, Sengupta D, Concepcion H, Komoroski V, MacFarlane C, Coblentz PD, Chokshi M, Matissek S, Gosselin E, Alkekhia D, Nikiforov A, Lamberti N, Iheanyichukwu V, Kelly C, Arinze C, Cornforth A, Elloul S, Kagan JC.mBio. 2025 Sep 8:e0234325. doi: 10.1128/mbio.02343-25. Online ahead of print.PMID: 40919810

Public health response to immunodeficiency-related vaccine-derived poliovirus during a poliovirus outbreak in the Philippines: a case report.
Co KJA, Tarnate PSO, Castor MAR, Ong-Lim ALT.IJID Reg. 2025 Aug 7;16:100722. doi: 10.1016/j.ijregi.2025.100722. eCollection 2025 Sep.PMID: 40927059

Machine learning-based analysis of the impact of 5' untranslated region on protein expression.
Wang L, Liu S, Huang JX, Zhu H, Li S, Li Y, Chen S, Han J, Zhu Y, Wu J, Liao W, Zhang H, Zeng H, Li S, Zhao S, Wang B, Lin J, Zeng J.Nucleic Acids Res. 2025 Sep 5;53(17):gkaf861. doi: 10.1093/nar/gkaf861.PMID: 40923765

Author Correction: PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins.
Zhang C, Hou J, Li Z, Shen Q, Bai H, Chen L, Shen J, Wang P, Su Y, Li J, Zhang Q, Liu C, Xi X, Qi F, Chen Y, Xie X, Ye AY, Liu X, Plebani R, Church G, Si L.Nat Chem Biol. 2025 Sep;21(9):1467. doi: 10.1038/s41589-025-01956-7.PMID: 40506514

Science vs. Politics: Who Will Win the Vaccine Debate Remains to Be Seen.
Roush K.Am J Nurs. 2025 Sep 1;125(9):12-13. doi: 10.1097/AJN.0000000000000150. Epub 2025 Aug 21.PMID: 40828821

Florida moves to be the first US state to end vaccine mandates.
Tanne JH.BMJ. 2025 Sep 5;390:r1870. doi: 10.1136/bmj.r1870.PMID: 40912724

Understanding the landscape of cross-species transmission, epidemiology, phylogenetics, and antigenicity of HPAI strain A(H5N1) causing a recent outbreak in the USA.
Chakraborty C, Chen YP, Bhattacharya M, Das A, Wen ZH.J Genet Eng Biotechnol. 2025 Sep;23(3):100547. doi: 10.1016/j.jgeb.2025.100547. Epub 2025 Aug 16.PMID: 40854666

Correction: Immunoinformatic design of chimeric multiepitope vaccine for the prevention of human metapneumovirus (hMPV).
Ehsasatvatan M, Kohnehrouz BB, Salavatizadeh M.BMC Infect Dis. 2025 Sep 2;25(1):1093. doi: 10.1186/s12879-025-11493-2.PMID: 40898076

Porcine reproductive and respiratory syndrome virus type 1 and type 2 co-infection in a Japanese swine herd.
Taira O, Fujiwara A, Takai R, Tsutsumi N, Sugiura K.J Vet Med Sci. 2025 Sep 8. doi: 10.1292/jvms.25-0279. Online ahead of print.PMID: 40915927

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
Even C, Harrington KJ, Massarelli E, Laban S, Fayette J, Oliva M, Klein Hesselink M, Visscher S, Fury MG, Wiekmeijer AS, Licitra L, Melichar B, Devriese LA, Braña I, Jankowska P, Posner M, Glisson B, Kong A, Hooftman L, Melief CJM MD,, Ferrarotto R.J Immunother Cancer. 2025 Sep 8;13(9):e012555. doi: 10.1136/jitc-2025-012555.PMID: 40921630

Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus.
Sun N, Su Z, Yin C, Zheng X.Hum Vaccin Immunother. 2025 Dec;21(1):2557097. doi: 10.1080/21645515.2025.2557097. Epub 2025 Sep 9.PMID: 40926371

SARS-CoV-2 surveillance of wastewater in small rural communities identifies lack of vaccine coverage as influence of omicron outbreak.
Narum S, Stalder T, Ridenhour B, Coats ER.Water Res. 2025 Sep 1;283:123818. doi: 10.1016/j.watres.2025.123818. Epub 2025 May 12.PMID: 40381278

Resonance assignments of asymmetric tetrameric platelet factor 4 (PF4).
Ma Q, Huang J, Boulton S, Mak E, Akimoto M, Giraldo EL, Truong M, Daka M, Huynh A, Kwok S, Clare R, Nazy I, Lee W, Melacini G.Biomol NMR Assign. 2025 Sep 8. doi: 10.1007/s12104-025-10246-1. Online ahead of print.PMID: 40921952

Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons.
Irving SA, Groom HC, Belongia EA, Crane B, Daley MF, Jackson LA, Kenigsberg TA, Kuckler L, Tseng HF, Williams JTB, Zerbo O, Naleway AL.Vaccine. 2025 Sep 4;64:127667. doi: 10.1016/j.vaccine.2025.127667. Online ahead of print.PMID: 40912094

Effect of exchange of viral hemorrhagic septicemia virus (VHSV) G protein's signal peptide with piscidin signal peptide on virus replication and immunogenicity.
Bessaid M, Kim KH.Fish Shellfish Immunol. 2025 Sep;164:110455. doi: 10.1016/j.fsi.2025.110455. Epub 2025 May 26.PMID: 40436152

A holistic science-based approach to container closure integrity for parenteral products: Lessons learned from a vaccine requiring deep cold storage using a conventional vial system.
Edey M, Wilmer J, Duncan D, Rozentsvayg A, Mulhall S, Valley V.Eur J Pharm Biopharm. 2025 Sep;214:114791. doi: 10.1016/j.ejpb.2025.114791. Epub 2025 Jun 18.PMID: 40553913

Correction to "Closed-Loop" O(2)-Economizer Induced In Situ Therapeutic Vaccine against Hypoxic Tumors.
Zhao Y, Zhang M, Lv B, Xue G, Jiang H, Chen G, Ma Y, Sun Y, Cao J.ACS Nano. 2025 Sep 9;19(35):31930-31931. doi: 10.1021/acsnano.5c12988. Epub 2025 Aug 22.PMID: 40845364

Self-Assembled Nanoparticle Vaccines Elicit Robust Protective Immune Responses against Type O Foot-and-Mouth Disease Virus Infection.
Cao N, Li Y, Zhao Q, Yao M, Ren X, Tian L, Hu Z, Diao F, Li H, Lu Z, Rao G, Zhang H, Li K, Cao S, Li X, Qian P.ACS Nano. 2025 Sep 9. doi: 10.1021/acsnano.5c04881. Online ahead of print.PMID: 40926523

Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".
Oom AL, Wilson KK, Yonatan M, Rettig S, Youn HA, Tuen M, Shah Y, DuMont AL, Belli HM, Zucker JR, Rosen JB, Herati RS, Samanovic MI, Duerr R, Kottkamp AC, Mulligan MJ; NYC OSMI Study Group.J Virol. 2025 Sep 4:e0087225. doi: 10.1128/jvi.00872-25. Online ahead of print.PMID: 40905658

Correction to: PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
Akutagawa K, Miki S, Yamada E, Sakamoto N, Miyazaki T, Sugii N, Zaboronok A, Matsuda M, Ishikawa E.J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05203-w. Online ahead of print.PMID: 40924331

Conditional Effect of Need for Affect and Perceived Prior Knowledge in Processing HPV Messages.
Lee TK, Kim HK.J Health Commun. 2025 Sep 1:1-13. doi: 10.1080/10810730.2025.2552492. Online ahead of print.PMID: 40888308

Interferon-γ receptor signaling is critical for balanced immune activation and protection against influenza after vaccination.
Kim KH, Hwang HS, Lee Y, Jung YJ, Ko EJ, Song JM, Kang SM.Virology. 2025 Sep 1;612:110674. doi: 10.1016/j.virol.2025.110674. Online ahead of print.PMID: 40915090

Effect of the methotrexate discontinuation for 1 versus 2 weeks on vaccine response to seasonal influenza vaccine in rheumatoid arthritis: a noninferiority randomized controlled trial.
Park JK, Lee YJ, Kang EH, Shin K, Kim MJ, Ha YJ, Choi SR, Park JW, Kim MH, Kim JY, Jung JI, Choi Y, Winthrop KL, Lee EB.Arthritis Rheumatol. 2025 Sep;77(9):1276-1278. doi: 10.1002/art.42644. Epub 2023 Oct 5.PMID: 37410775

A Porcine Monoclonal Antibody Targeting a Conserved GP4 Epitope Protects against In Vivo Infection via the Induction of Broad-Spectrum PRRSV Neutralization.
Chen X, Zhao J, Ji P, Li X, Niu H, Jiao D, Zhang L, Zhu Q, Liu X, Hiscox JA, Stewart JP, Sun Y, Zhao Q.Adv Sci (Weinh). 2025 Sep 8:e08875. doi: 10.1002/advs.202508875. Online ahead of print.PMID: 40919718

Correction: Immunoinformatic evaluation for the development of a potent multi-epitope vaccine against bacterial vaginosis caused by Gardnerella vaginalis.
Motamedi H, Shoja S, Abbasi M.PLoS One. 2025 Sep 4;20(9):e0331745. doi: 10.1371/journal.pone.0331745. eCollection 2025.PMID: 40906687

Re: 'The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-2022 influenza season' by Bricout et al.

Braillon A.Clin Microbiol Infect. 2025 Sep;31(9):1609. doi: 10.1016/j.cmi.2025.01.022. Epub 2025 Jan 24.PMID: 39863072

Re: 'the relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France' by Bricout et al.
Donzelli A.Clin Microbiol Infect. 2025 Sep;31(9):1607-1608. doi: 10.1016/j.cmi.2024.12.030. Epub 2024 Dec 28.PMID: 39734019

Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein.
Pettersson JH, Tibbelin E, Heyman G, Aarum J, Karlsson Lindsjö O, Blom K, Sonden K, Klingström J.J Travel Med. 2025 Sep 6:taaf091. doi: 10.1093/jtm/taaf091. Online ahead of print.PMID: 40913469

NO-Driven Janus Nanomotor Enhances T-Cell Infiltration by Reconstructing Tumor-Associated Blood and Lymphatic Vessels.
Ma Q, Fu S, Xia Y, Gao S, Xia Z, Gu P, Yuan S, Liu J, Liang S, Li N, Yang Q, Mu W, Liu J, Liu X, Liu Y, Zhang N.Adv Sci (Weinh). 2025 Sep 8:e12090. doi: 10.1002/advs.202512090. Online ahead of print.PMID: 40917034

Fighting fire with fire: Prebunking with the use of a plausible meta-conspiracy framing.
Biddlestone M, Green R, Toribio-Flórez D, de Gourville D, Sutton RM, Douglas KM.Br J Psychol. 2025 Sep 8. doi: 10.1111/bjop.70023. Online ahead of print.PMID: 40916900

Long-term comparative effectiveness of BNT162b2 vaccine on SARS-CoV-2 infection in adolescents: A register-based real-world study from Denmark.
Bager MD, Andersen MP, Krogager ML, Schou M, Kragholm KH, Fosbøl EL, Køber L, Torp-Pedersen C.Public Health. 2025 Sep 6;248:105935. doi: 10.1016/j.puhe.2025.105935. Online ahead of print.PMID: 40915230

Recombinant Allergy Vaccine-Induced Transmission of Maternal Allergen-Specific Neutralizing IgG.
Pasikhov GB, Shilovskiy IP, Nikolskii AA, Yumashev KV, Kaganova MM, Gurskii DA, Popova MV, Strueva PA, Shershakova NN, Kovaleva EV, Onatsky NM, Kudlay DA, Valenta R, Khaitov MR.Allergy. 2025 Sep 5. doi: 10.1111/all.70042. Online ahead of print.PMID: 40913341

The Complex Issue of Trust of Israel's Jewish Religious Community in Health Care and Religious Institutions Involved in Addressing the COVID-19 Pandemic.
Spitz A, Siman-Tov M, Shapiro E.J Relig Health. 2025 Sep 9. doi: 10.1007/s10943-025-02436-x. Online ahead of print.PMID: 40924291

Epitope and HLA specificity of human TCRs against Plasmodium falciparum circumsporozoite protein.
van Dijk H, Wahl I, Kraker S, Robben PM, Dutta S, Wardemann H.J Exp Med. 2025 Sep 1;222(9):e20250044. doi: 10.1084/jem.20250044. Epub 2025 Jul 10.PMID: 40637713

Water Insecurity, Sociopolitical Instability, and Resurgence of Cholera in Haiti, 2022: An Outbreak Investigation.
Juin S, Michel E, Matias WR, Thermidor E, Franke MF, Evans MV, Denis H, Guillaume Y, Bouilly R, Mathurin W, Pierre K, Compere V, Rendel K, Amelus H, Andrecy L, Joseph GA, Boncy J, Lafontant D, Ivers LC.Am J Trop Med Hyg. 2025 Jul 1;113(3):689-693. doi: 10.4269/ajtmh.24-0755. Print 2025 Sep 3.PMID: 40602370

Myopericardial complications following COVID-19 disease and vaccination: a clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Imazio M, Basso C, Brucato A, Klingel K, Kuchynka P, Lazaros G, Merlo M, Sinagra G, Adler Y, Bucciarelli Ducci C, Cameli M, Castelletti S, Caforio AL, Crotti L, Dagna L, Frustaci A, Klein A, Kuusisto J, Lopez Sainz A, Marcolongo R, Pantazis A, Rigopoulos AG, Ristic A, Seferovic P, Sheppard M, Tschöpe C, Lüscher T.Eur Heart J. 2025 Sep 8;46(34):3328-3338. doi: 10.1093/eurheartj/ehaf222.PMID: 40390594

Nanomaterials Application for STING Pathway-Based Tumor Immunotherapy.
Zhao W, Tang X, Qin Y, Wang X, Zhong K, Gong N, Li T.Int J Nanomedicine. 2025 Sep 3;20:10771-10793. doi: 10.2147/IJN.S535460. eCollection 2025.PMID: 40927662

Avian reovirus in Italy: three episodes of abnormal losses in offspring of vaccinated broiler breeders.
Viel L, Cordioli B, Leardini S, Pastori A, Luisetto P, Luca Z, Garbuio M, Fusaro A, Terregino C, Zanardello C, Bortolami A.Vet Ital. 2025 Sep 10;61(3). doi: 10.12834/VetIt.3734.34668.2.PMID: 40926504

Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?
Platten M.Curr Opin Neurol. 2025 Sep 4. doi: 10.1097/WCO.0000000000001426. Online ahead of print.PMID: 40916936

Dissociable impacts of physical and psychological factors on side effects after COVID-19 vaccination in Japan: A within-subject repeated measures design.
Tsurumi K, Fujiwara H, Uwatoko T, Murai T.BMC Psychol. 2025 Sep 1;13(1):995. doi: 10.1186/s40359-025-03325-4.PMID: 40890884

Association Between Vaccination for Human Papillomavirus (HPV) and Autonomic Dysfunction and Menstrual Irregularities: A Self-Controlled Case Series Analysis.
Wastila L, Fu YH, Tung CC, Qato DM.Drugs Real World Outcomes. 2025 Sep;12(3):467-477. doi: 10.1007/s40801-025-00504-y. Epub 2025 Jun 16.PMID: 40524098

Representation of Pain and Injury in Children's Picture Books-A Content Analysis.
Mehar DE, Nichols S, Jordan A, Moseley GL, Noel M, Wallwork SB.Eur J Pain. 2025 Sep;29(8):e70102. doi: 10.1002/ejp.70102.PMID: 40801427

Candida auris adhesins, specifically Als3, a key target to understand and mitigate.
Lashine Y, Hamdy R, Dakalbab S, Lazreg IK, Al Dhaheri F, Chin SP, Hashim NM, Soliman SSM.Mycologia. 2025 Sep 4:1-16. doi: 10.1080/00275514.2025.2536345. Online ahead of print.PMID: 40906576

EgG1Y162 protein from Echinococcus granulosus modulates the immune functions of mouse splenic lymphocytes and regulates Th9 cells.

Chen X, Zhao H, Tuohetali A, Aizezi M, Song Y, Zhang X, Zhu J, Zhou T, Chen G, Lin R, Aimulajiang K.Int J Biol Macromol. 2025 Sep;322(Pt 1):146515. doi: 10.1016/j.ijbiomac.2025.146515. Epub 2025 Aug 11.PMID: 40769342

Acinetobacter baumannii as a Model for the Study and Application of Gram-Negative Outer Membrane Vesicles: A Systematic Review.
Cano-Castaño B, López-Siles M, Nonnoi F, Pérez A, Corral Lugo A, McConnell MJ.Microb Biotechnol. 2025 Sep;18(9):e70207. doi: 10.1111/1751-7915.70207.PMID: 40905513

A short peptide for efficient cellular mRNA delivery: A potential application for inducing an immune response.
Teko-Agbo CA, Josse E, Konate K, Deshayes S, de Santa Barbara P, Faure S, Boisguérin P, Vivès E.Mol Ther Nucleic Acids. 2025 Jul 29;36(3):102650. doi: 10.1016/j.omtn.2025.102650. eCollection 2025 Sep 9.PMID: 40832628

Carbon dots as a green alternative for preventing *Magnaporthe oryzae* infection in rice: Mechanisms of disease resistance.
Lei S, Liu W, Xing B, Wang J, Xu J, Wang C, Zhang C, Gao P, Wang J, Zhu L.Eco Environ Health. 2025 Jun 19;4(3):100167. doi: 10.1016/j.eehl.2025.100167. eCollection 2025 Sep.PMID: 40746397

Acidic pH-Triggered Membrane Fusion Enables Lyophilized Lipid Nanoparticles as Potent Cryoprotectants for Human Erythrocytes.
Li X, Wei Y, Li W, Xu R, Xu C, Luo B, Yang K, Yuan B.Adv Healthc Mater. 2025 Sep 3:e02455. doi: 10.1002/adhm.202502455. Online ahead of print.PMID: 40899629

Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria.
Limon G, Tchakarova SR, Ludi A, Alexandrov T, Christova I, Petkova P, Maze E, Thomas K, Baker N, England M, Browning C, Wilsden G, Belij-Rammerstorfer S, Lambe T, Jolles A, Carroll M, Hewson R, Gubbins S, Charleston B, Lyons NA.Emerg Infect Dis. 2025 Sep;31(9):1738-1746. doi: 10.3201/eid3109.241952. Epub 2025 Aug 5.PMID: 40764710

Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence.
Zhou SH, Lei YJ, Wen Y, Ding D, Luo MQ, Cui HY, Guo J.J Control Release. 2025 Sep 10;385:113979. doi: 10.1016/j.jconrel.2025.113979. Epub 2025 Jun 24.PMID: 40570966

Licoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies.
Faisal Ahmed S, Masudur Rahman Munna M, Hossain Ahmed M, Mostafizur Rahman M, Islam M, Bristy EM.J Genet Eng Biotechnol. 2025 Sep;23(3):100544. doi: 10.1016/j.jgeb.2025.100544. Epub 2025 Aug 5.PMID: 40854663

Chimeric hepatitis B core virus-like particles displaying the receptor-binding domain of porcine deltacoronavirus elicit protective immunity in piglets.
Liu Y, Bi Z, Cai X, Han X, Yao L.Vet Microbiol. 2025 Sep;308:110659. doi: 10.1016/j.vetmic.2025.110659. Epub 2025 Aug 5.PMID: 40780030

Dual-mode delivery of canine parvovirus type 2c VP2 protein in recombinant Lactobacillus plantarum: Surface display and intracellular expression systems.
Xu Z, He H, Wang D, Xiao M, Li J, Hou Y, Chen Y, Zu X, Hu J, Yang G, Jiang Y, Yang W, Huang H, Shi C, Zeng Y, Wang N, Cao X, Wang J, Wang C.Vet Microbiol. 2025 Sep;308:110651. doi: 10.1016/j.vetmic.2025.110651. Epub 2025 Jul 20.PMID: 40700977

The influence of protein corona on liposomal delivery systems: A comprehensive review.
Mojarad-Jabali S, Fatahi Y, Dinarvand R.Eur J Pharm Sci. 2025 Sep 1;212:107166. doi: 10.1016/j.ejps.2025.107166. Epub 2025 Jun 11.PMID: 40513682

Seroprevalence of Hepatitis A in Non-vaccinated Adolescents Aged 9 to 12 Years in New Delhi, India: A Cross-Sectional Study.
Agarwal A, Sajlan S, Chawla R, Mathur SB.Indian Pediatr. 2025 Sep;62(9):681-685. doi: 10.1007/s13312-025-00090-w. Epub 2025 Jun 3.PMID: 40459807

Recent advances in techniques used in the diagnosis of lumpy skin disease: a review.
Bhat BA, Alqahtani FM, Alhomrani M, Adil S, Alsanie WF, Alamri AS, Alkazmi LM.J Vet Diagn Invest. 2025 Sep 9:10406387251373081. doi: 10.1177/10406387251373081. Online ahead of print.PMID: 40926425

Exploring Sentiment, Values, and Misinformation Surrounding Vaccination Legislation on Twitter: A Case Study of California's Passage of SB277.
Martinez LS, Savage MW, Williams DM, Alvarado J, Cordon-Mulbry C, Dickerson D, Roquia R, Spitzberg BH, Peddecord M, Issa E, Tsou MH.Health Commun. 2025 Sep;40(10):1967-1982. doi: 10.1080/10410236.2024.2432066. Epub 2024 Dec 4.PMID: 39629695

Nonamyloid-beta active immunization for the treatment of Alzheimer's disease.
Triplett O, Varda N, Decourt B, Sabbagh MN.Expert Opin Investig Drugs. 2025 Sep 7:1-9. doi: 10.1080/13543784.2025.2551352. Online ahead of print.PMID: 40842219

Understanding the structure of measles virus and its implications for novel drug discovery.
Chen L, Kita S, Fukuhara H, Maenaka K.Expert Opin Drug Discov. 2025 Sep;20(9):1131-1140. doi: 10.1080/17460441.2025.2546888. Epub 2025 Aug 18.PMID: 40820583

Roman Catholic Religious Affiliation and Reactions to the Initial Stage of the COVID-19 Pandemic in Poland.
Nezlek JB, Cypryańska M.J Relig Health. 2025 Sep 7. doi: 10.1007/s10943-025-02443-y. Online ahead of print.PMID: 40914911

Analytical approach for identification and mechanistic insights into mRNA-lipid adduct formation.
Peronin S, Malburet C, Daher-Hassan C, Picard C, Willemin T, Costamagna F, Even L, Eynard T, Bensaid F, Fertier-Prizzon S, Francois-Heude M.Mol Ther Nucleic Acids. 2025 Aug 13;36(3):102684. doi: 10.1016/j.omtn.2025.102684. eCollection 2025 Sep 9.PMID: 40917898

Manipulation of macrophage signaling by *Leishmania* virulence factors.
Gurjar D, Bodhale N, Shukla D, Nayak D, Lenka N, Saha B.Virulence. 2025 Dec;16(1):2549802. doi: 10.1080/21505594.2025.2549802. Epub 2025 Sep 8.PMID: 40920481

Poliovirus surveillance in Mayotte, Indian Ocean, reveals encephalomyocarditis virus type 1 and a wide diversity of non-polio enteroviruses.
Tinard A, Joffret ML, Levert M, Wurtzer S, Bessaud M.Trans R Soc Trop Med Hyg. 2025 Sep 8:traf090. doi: 10.1093/trstmh/traf090. Online ahead of print.PMID: 40916768

April 2025 ACIP Meeting Update: Influenza, COVID-19, HPV, RSV and Other Immunizations.
Yonts AB, Gaviria-Agudelo C, Ratner AJ, O'Leary ST, Paulsen GC.Pediatrics. 2025 Sep 1;156(3):e2025072444. doi: 10.1542/peds.2025-072444.PMID: 40596750

Protein A-like peptide generation based on generalized diffusion model.
Zhou T, Zhang S, Song H, He Q, Fang C, Lin X.J Comput Aided Mol Des. 2025 Sep 4;39(1):76. doi: 10.1007/s10822-025-00653-w.PMID: 40906240

Screening and Characterization of B-Cell Epitopes of Porcine Respiratory Coronavirus Receptor Binding Domain Using Monoclonal Antibodies.
Wang A, Wang J, Zhou J, Chen Y, Liu H, Liang C, Zhu X, Liu E, Wu S, Qi Y, Zhang G.Microbiol Immunol. 2025 Sep;69(9):477-485. doi: 10.1111/1348-0421.70002. Epub 2025 Aug 3.PMID: 40753495

Beneficial infections of the enterovirus genus in patients with liver cancer.
Ma L, Hung MH, Rashidi Mehrabadi F, Wang L, Li Q, Forgues M, Wang KC, Budhu A, Candia J, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Ruchirawat M, Wang XW.Gut. 2025 Sep 8;74(10):1667-1679. doi: 10.1136/gutjnl-2024-334681.PMID: 40345802

Genomic analysis of the *Streptococcus pneumoniae* in Taiwan: a nationwide study from 2006 to 2022.
Cheng HR, Kuo SC, Lai JF, Wu HC, Chen FJ, Sytwu HK, Lo SW, Bentley SD, Huang YC.Microb Genom. 2025 Sep;11(9). doi: 10.1099/mgen.0.001498.PMID: 40924938

Editorial: Dormant Cancer Cells, Cancer Progression, and Post-Acute Sequelae of COVID-19 and Influenza.
Parums DV.Med Sci Monit. 2025 Sep 1;31:e951178. doi: 10.12659/MSM.951178.PMID: 40887959

Targeting of the cellular ATM rather than ATR kinase exhibits therapeutic potential during the lumpy skin disease virus infection in vivo and in vitro.
Ren S, Chen H, Wang S, Rehman ZU, Gao X, Yang X, Wang X, Yin X, Han J, Sun Y.Antiviral Res. 2025 Sep 6:106280. doi: 10.1016/j.antiviral.2025.106280. Online ahead of print.PMID: 40921270

Potential of MRNA vaccines for mpox prevention: current evidence and future directions.
Abdul-Rahman T, Faith OE, Ajetunmobi OA, Thaalibi HI, Ikele CG, Gautam G, Omotayo FO, Roy P, Adebayo AA, Mojeed MA, Kareem TT, Ali HI, Atieno RG, Ademeta EO, Garg N, Ashinze P, Scott GY.Ann Med Surg (Lond). 2025 Jul 10;87(9):5650-5660. doi: 10.1097/MS9.0000000000003558. eCollection 2025 Sep.PMID: 40901148

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis.
Fukami H, Oike Y.J Atheroscler Thromb. 2025 Sep 1;32(9):1071-1078. doi: 10.5551/jat.RV22038. Epub 2025 Jun 5.PMID: 40467521

Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches.
Naranjo-Gomez M, Pelegrin M.Curr Opin HIV AIDS. 2025 Sep 1;20(5):423-431. doi: 10.1097/COH.0000000000000960. Epub 2025 Jul 11.PMID: 40742781

Mapping novel linear B-cell epitopes target Hepatitis C virus envelope proteins E1 and E2 by monoclonal antibodies for increasing the sensitive detection sites.
Tian Y, Liu H, Chen Y, Ma Z, Zhou J, Tao S, Sun F, Li J, Liu E, Zhu X, Zhang G, Wang A.Int J Biol Macromol. 2025 Sep;321(Pt 4):146659. doi: 10.1016/j.ijbiomac.2025.146659. Epub 2025 Aug 6.PMID: 40780329

Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.
Sun Y, Shu X, Chen L, Shang W, Zhang Y, Xiao G, Zhang L.PLoS Pathog. 2025 Sep 8;21(9):e1013492. doi: 10.1371/journal.ppat.1013492. Online ahead of print.PMID: 40920846

Epidemiology, transmission dynamics, treatment strategies, and future perspectives on Oropouche virus.
Yoosuf BT, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R, Bushi G, Rani A, Sah S, Shabil M, Goh KW, Jena D.Diagn Microbiol Infect Dis. 2025 Sep;113(1):116882. doi: 10.1016/j.diagmicrobio.2025.116882. Epub 2025 May 1.PMID: 40367910

Navigating Social Influences: The Impact of Anticipated HPV Vaccination Stigma from Friends and Family on College Students' HPV Vaccination Intent.
Pierce JD, Xu YA, Hall NA, Anderson KS, Dawkins-Moultin L, Wong-Meli CCY, Cho D, Hopfer S, Ramondetta LM, Li Y, Lun D, Lu Q.Cancer Epidemiol Biomarkers Prev. 2025 Sep 2;34(9):1644-1655. doi: 10.1158/1055-9965.EPI-25-0032.PMID: 40643569

Rational synthesis, activity and mechanism insights of a new aminoquinoline salt against malaria parasites: in vitro and in vivo approaches.
de Oliveira BA, Raimundo FO, de Paula WT, Bezerra Bellei JC, Glanzmann N, Machado LF, da Fonseca AL, Freitas CS, da Costa Nunes IK, Neto AF, Rocha VN, Pereira HMG, Coelho EAF, de Pilla Varotti F, Scopel KKG, da Silva AD.Chem Biol Interact. 2025 Sep 5;418:111588. doi: 10.1016/j.cbi.2025.111588. Epub 2025 Jun 4.PMID: 40480411

Amplification-free CRISPR/Cas12a biosensor integrating AuNPs-mediated surface plasmon resonance for human papillomavirus detection and genotyping.
Deng Z, Mao X, Yang Y, Wu G, Meng H, Hou J, Yu XF, Zhou W, Mao G, Ma Y.Biosens Bioelectron. 2025 Sep 3;290:117960. doi: 10.1016/j.bios.2025.117960. Online ahead of print.PMID: 40914018

Molecular characterization and isolation of contemporary porcine sapoviruses from swine farms in the United States.
Aryal B, Petznick T, Takagi H, Oka T, Liu M, Li G, Li D, Wang Q.Vet Microbiol. 2025 Sep 2;310:110709. doi: 10.1016/j.vetmic.2025.110709. Online ahead of print.PMID: 40912028

Functional epitope mapping of porcine reproductive and respiratory syndrome virus nsp7α and nsp7β using monoclonal antibodies and development of a feasible ELISA.
Han S, Duan H, Yang N, Wang S, Gao F, Jiang Y, Tang C, Zhou Y, Tong G, Zhao K, Li L.Int J Biol Macromol. 2025 Sep;322(Pt 4):147104. doi: 10.1016/j.ijbiomac.2025.147104. Epub 2025 Aug 25.PMID: 40865809

Isolation and molecular characterization of Mycoplasma ovipneumoniae associated with respiratory infection in sheep and goats in South India.
Udhayavel S, Sukumar K, Senthilkumar K, Srinivasan P, Elango A.Braz J Microbiol. 2025 Sep;56(3):2087-2095. doi: 10.1007/s42770-025-01663-4. Epub 2025 Apr 26.PMID: 40287597

Host cell entry efficiency and neutralization sensitivity of the SARS-CoV-2 MC.10.1 variant.
Zhang L, Kempf A, Nehlmeier I, Chen N, Graichen L, Moldenhauer AS, Stankov MV, Happle C, Schulz SR, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M.Virology. 2025 Sep 1;612:110675. doi: 10.1016/j.virol.2025.110675. Online ahead of print.PMID: 40925177

Innovative Strategies to Reduce Exposure and Expression of the Major Cat Allergen Fel d 1.
Colosimo S, Indolfi C, Frattolillo V, Mondillo G, Perrotta A, Masino M, Decimo F, Miraglia Del Giudice M.Clin Transl Allergy. 2025 Sep;15(9):e70098. doi: 10.1002/clt2.70098.PMID: 40923153

Cell death pathways in response to *Mycobacterium tuberculosis* and other mycobacterial infections.
Faysal MA, Hanafy M, Zinniel DK, Tanni FY, Muthukrishnan E, Rathnaiah G, Barletta RG.Infect Immun. 2025 Sep 9:e0040125. doi: 10.1128/iai.00401-25. Online ahead of print.PMID: 40924403

Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Wagner L, Obersriebnig M, Kadlecek V, Hochreiter R, Ghadge SK, Larcher-Senn J, Hegele L, Maguire JD, Derhaschnig U, Jaramillo JC, Eder-Lingelbach S, Bézay N.Lancet Infect Dis. 2025 Sep;25(9):986-999. doi: 10.1016/S1473-3099(25)00092-1. Epub 2025 Apr 25.PMID: 40294611

Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health.
Brüssow H.Microb Biotechnol. 2025 Sep;18(9):e70225. doi: 10.1111/1751-7915.70225.PMID: 40898685

Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccination.
Knuutila A, Ahvenainen N, Barkoff AM, Mertsola J, van Gageldonk P, Buisman A, Valente Pinto M, Kelly D, He Q.Emerg Microbes Infect. 2025 Dec;14(1):2547720. doi: 10.1080/22221751.2025.2547720. Epub 2025 Sep 2.PMID: 40803045

SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
Lebedin M, Petrovsky N, Tabynov K, Tabynov K, Lebedin Y.Antiviral Res. 2025 Sep;241:106235. doi: 10.1016/j.antiviral.2025.106235. Epub 2025 Jul 9.PMID: 40645296

Efficacy of lumpy skin disease vaccines in cattle: a systematic review and meta-analysis.
Maneekesorn S, Koonyosying P, Muenthaisong A, Sangkakam K, Rittipornlertrak A, Nambooppha B, Apinda N, Sthitmatee N.Microb Pathog. 2025 Sep;206:107836. doi: 10.1016/j.micpath.2025.107836. Epub 2025 Jun 25.PMID: 40578710

First linear B-cell epitope identified on the nucleocapsid protein of bovine coronavirus.

Zhou Y, Zhang J, Wu H, Zhao S, Ren Y, Chen Q, Zhang Z, Liao X, Mo Y, Zhong Y, Zhang G.Virology. 2025 Sep;610:110581. doi: 10.1016/j.virol.2025.110581. Epub 2025 May 25.PMID: 40483734

Structural and Functional Characterization of the 28 kDa Structured Core of BmSA1, the Major Surface Antigen of Babesia Microti.
Mouhand A, Pissarra J, Barthe P, Roumestand C, Delbecq S.Proteins. 2025 Sep;93(9):1657-1671. doi: 10.1002/prot.26836. Epub 2025 May 9.PMID: 40345974

An archaeal protein nanoparticle platform for cancer cell-specific targeting and therapeutics.
Byun JH, Kim YR, Kim YS, Choi MJ, Ryu CJ, DasSarma P, DasSarma S, Kim JM.Int J Biol Macromol. 2025 Sep;322(Pt 4):146967. doi: 10.1016/j.ijbiomac.2025.146967. Epub 2025 Aug 18.PMID: 40834944

Low-grade persistent poliovirus infection in long-term polio survivors diagnosed with post-polio syndrome: diagnostic and clinical implications.
Toniolo A, Genoni A, Maccari G, Chumakov K, Basolo F, Bono G, Mauri M, Molteni F, Arrondini L, Bertolasi L, Monaco S.J Neurol. 2025 Sep 6;272(9):617. doi: 10.1007/s00415-025-13364-x.PMID: 40913634

Pathological and molecular findings associated with BRSV in cattle and buffaloes with pulmonary disease.
Kamdi B, Ingole R, Kudale A, Kumar A, Hajare S, Awandkar S, Kurkure N.Braz J Microbiol. 2025 Sep;56(3):2097-2109. doi: 10.1007/s42770-025-01676-z. Epub 2025 May 2.PMID: 40314915

A novel linear B-cell epitope on S2 protein of transmissible gastroenteritis virus identified using a monoclonal antibody.
Hou J, Hou R, Lu H, Yu Y, Zhao R, Shi Z, Lv Y, Liu J, Wang S, Yuan J, Shi C, Hu H.BMC Vet Res. 2025 Sep 1;21(1):533. doi: 10.1186/s12917-025-04968-6.PMID: 40890803

An in vivo combined induction strategy of whole cancer cell vaccines triggers systemic immunity to eradicate triple-negative breast cancer.
Lu Y, Dai Y, Qin Y, Jia X, Li X, Lu S, Liu X, Song Y, Deng Y.J Control Release. 2025 Sep 10;385:114045. doi: 10.1016/j.jconrel.2025.114045. Epub 2025 Jul 16.PMID: 40681021

Adult Patients with Celiac Disease Are Under-Vaccinated Against Pneumococcal Disease: A Quality Improvement Study.
Payne K, Jansson-Knodell C, Trommer E, Ford A, Weekley K, Gardinier D, Rubio-Tapia A.Dig Dis Sci. 2025 Sep 4. doi: 10.1007/s10620-025-09350-y. Online ahead of print.PMID: 40906340

Should Japanese athletes undergo booster vaccination for pertussis?
Hagiya H.IJID Reg. 2025 Jul 31;16:100718. doi: 10.1016/j.ijregi.2025.100718. eCollection 2025 Sep.PMID: 40893803

Injection site abscesses associated with commensal and environmental bacteria following intramuscular vaccination in horses.
Ryu SH, Forbes E, Kim BS, Park KT.Vet Anim Sci. 2025 Jul 25;29:100484. doi: 10.1016/j.vas.2025.100484. eCollection 2025 Sep.PMID: 40791848

Characteristics of Ongoing Clinical Trials for Cocaine Use Disorder Registered on Global Clinical Trial Databases.
Gushken F, Fidalgo TM, Tardelli VS.J Addict Med. 2025 Sep 8. doi: 10.1097/ADM.0000000000001580. Online ahead of print.PMID: 40919756

Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.
Zhao X, Liu B, William WN, Tsanov KM, Ho YJ, Barriga FM, Lim RJ, Trifas M, Khandekar A, Du Y, Lowe SW, Dubinett SM, Davoli T, Lippman SM.J Thorac Oncol. 2025 Sep;20(9):1177-1236. doi: 10.1016/j.jtho.2024.12.020. Epub 2024 Dec 24.PMID: 39725169

First trimester mRNA COVID-19 vaccination and risk of congenital malformation: a prospective observational Embryotox cohort study.
Kayser A, Lohse L, Padberg S, Keller-Stanislawski B, Oberle D, Beck E, Stegherr R, Beyersmann J, Dathe K.Clin Microbiol Infect. 2025 Sep;31(9):1571-1578. doi: 10.1016/j.cmi.2025.06.005. Epub 2025 Jun 7.PMID: 40490195

CD4⁺ tissue-resident memory T cells and their role in immunity.
Kirkby M, Veldhoen M.Immunol Cell Biol. 2025 Sep;103(8):809-819. doi: 10.1111/imcb.70052. Epub 2025 Jul 25.PMID: 40710024

Advancing continuous encapsulation and purification of mRNA vaccines and therapeutics.
Nourafkan E, Yang Z, Maamra M, Kis Z.Eur J Pharm Sci. 2025 Sep 1;212:107183. doi: 10.1016/j.ejps.2025.107183. Epub 2025 Jun 25.PMID: 40578454

Scalable Production of Recombinant Vesicular Stomatitis Virus Pseudoparticles Using HEK293 Suspension Cultures.
Zhang Z, Wloga E, Fulton BO, Coplan L, Bak H, Tustian AD.Biotechnol Bioeng. 2025 Sep;122(9):2353-2365. doi: 10.1002/bit.29042. Epub 2025 Jun 4.PMID: 40462709

Association between prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the incidence of infant and childhood respiratory infections: A systematic review.
Lyrou M, Karampas G, Metallinou D, Athanasiadou CR, Gourounti K, Jotautis V, Georgakopoulou VE, Spandidos DA, Sarantaki A.Med Int (Lond). 2025 Jun 24;5(5):51. doi: 10.3892/mi.2025.250. eCollection 2025 Sep-Oct.PMID: 40599152

Age-Dependent Risk of Bronchial Asthma Exacerbation in Respiratory Syncytial Virus Co-infection.
Arimura K, Kan-O K, Sato Y, Kikuchi K, Miura H, Sato A, Kondo M, Tagaya E.Lung. 2025 Sep 3;203(1):91. doi: 10.1007/s00408-025-00847-x.PMID: 40900370

A comparative analysis of clinical characteristics between primary and recurrent COVID-19 infections in China.
Chen Y, Su Q, Zhang D, Wei W, Zhang F, Li Q, Zhang J.Infect Med (Beijing). 2025 Jun 18;4(3):100187. doi: 10.1016/j.imj.2025.100187. eCollection 2025 Sep.PMID: 40688484

Responses of Kidney Transplant Recipients to Vaccination and Boosting.

Park WD, Nair SS, Wadei HM, Liang Y, Smith BH, Abdelrheem A, Schinstock CA, Isham CR, Kumanovics A, Ahmad N, Simonson RB, Ryser MF, Tapia-Cealle G, Badley AD, Stegall MD.Mayo Clin Proc. 2025 Sep;100(9):1506-1518. doi: 10.1016/j.mayocp.2025.03.017. Epub 2025 Jul 16.PMID: 40663029

Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era.
Yee ME, Abel L, Kalmus G, Patel A, Elmontser M, Bakshi N, Wang YF, Gonzalez MD, Adamkiewicz TV, Yildirim I, Lane PA.Pediatr Blood Cancer. 2025 Sep;72(9):e31881. doi: 10.1002/pbc.31881. Epub 2025 Jun 25.PMID: 40563215

Serological insights into MERS-CoV dynamics of antibody responses during acute and convalescent phases and their clinical relevance for diagnostics and immunity.
Shrwani KJ, Alharbi AM, Mahallawi WH, Asiri AY, Assiri AM, Algaissi A, Hashem AM, Alsafi R, Jubran MA, Gadour E, Alghamdi SA, Okmi EA, Dhayhi N, Asiri HA, Eisa ZM, Cunliffe N, Zhang Q.J Infect Public Health. 2025 Sep;18(9):102854. doi: 10.1016/j.jiph.2025.102854. Epub 2025 Jun 2.PMID: 40472481

An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment.
Li M, Zhang Y, Zong L, Zhang M, Wang S, Lei W, Qian W.Haematologica. 2025 Sep 1;110(9):2113-2128. doi: 10.3324/haematol.2024.286923. Epub 2025 Apr 10.PMID: 40207734

M1 Macrophage Extracellular Vesicles and TLR3 Agonist Nanoparticles Down-Regulate Immunosuppression and Metastasis via AKT/TAM in Triple-Negative Breast Cancer.
Souza SVP, Aguiar ACV, Albuquerque ECS, Eich C, Cruz LJ, Lara P, Jorquera-Cordero C, Gomes RF, Paula RCM, Freire RS, de AraújoJúnior AJRF.Mol Carcinog. 2025 Sep;64(9):1450-1461. doi: 10.1002/mc.70003. Epub 2025 Jun 24.PMID: 40553053

Prevalence, genomic features, and antibiotic sensitivities of Neisseria meningitidis isolates from patients with invasive meningococcal disease and healthy carriers in Zhejiang Province, 2015-2023.
Wang L, Deng X, Zhang Y, Yang Z, Wu Z, Yao W, Yao P, He H, Wu B.Diagn Microbiol Infect Dis. 2025 Sep;113(1):116843. doi: 10.1016/j.diagmicrobio.2025.116843. Epub 2025 Apr 10.PMID: 40311451

Insights into the phylogenetic profile and virulence-associated genes of multidrug-resistant uropathogenic *Escherichia coli* in North of Iran.
Sheikhi R, Darvishvand S, Shenagari M, Monfared A, Khosravi M, Sigarchi M, Ramezanzade E, Lebadi MK, Haghdar-Saheli Y, Aghajanzadeh P, Movassaghi A.IJID Reg. 2025 Jul 18;16:100711. doi: 10.1016/j.ijregi.2025.100711. eCollection 2025 Sep.PMID: 40893800

Gaps in immunization coverage at school entry and after two years of school attendance among immigrant and refugee children in Ontario, Canada.
Wilson SE, Chambers C, Wilton AS, Bai L, Crowcroft N, Deeks SL, Halperin SA, Kwong JC, Rashid M, Tu K, Wilson K, Guttmann A.PLoS One. 2025 Sep 9;20(9):e0330955. doi: 10.1371/journal.pone.0330955. eCollection 2025.PMID: 40924695

De Novo Immune Induction After COVID-19 Vaccination Under B-Cell Depletion Is Characterized by Robust T-Cellular Immunity in Patients With Inflammatory Central Nervous System Disease.

Fousse M, Klemis V, Bronder S, Urschel R, Hielscher F, Faßbender K, Sester U, Sester M, Schmidt T.Brain Behav. 2025 Sep;15(9):e70849. doi: 10.1002/brb3.70849.PMID: 40898724

Cervical cancer risk and high-risk HPV types distribution in Saudi Arabia: Trends from a national laboratory-based study.
Banjer HJ, Tayeb HH, Alzahrani KJ, Alsufiani SM, Alrowaihi JM.Saudi Med J. 2025 Sep;46(9):992-999. doi: 10.15537/smj.2025.46.9.20250266.PMID: 40897414

Disseminated gonococcal infection developing two days after initial eculizumab administration in a patient with neuromyelitis optica spectrum disorder: A case report and literature review.
Nishida Y, Ono D, Kawamura M, Kawamura T, Mimura K, Fukaura H, Ebata E, Koyama S, Ebihara Y, Oka H.J Infect Chemother. 2025 Sep;31(9):102782. doi: 10.1016/j.jiac.2025.102782. Epub 2025 Aug 6.PMID: 40780406

Glycoprofile Comparison of the SARS-CoV-2 Spike Proteins Expressed in CHO and HEK Cell Lines.
Wright HL, Evans C, Jackson PJ, James DC, Tee KL, Wong TS, Dickman MJ, Pandhal J.Mol Biotechnol. 2025 Sep;67(9):3737-3752. doi: 10.1007/s12033-024-01288-2. Epub 2024 Oct 1.PMID: 39352566

Systematic review of pro-equity strategies to improve vaccination among priority populations.
Tinessia A, Sabahelzain MM, King C, Khalatbari-Soltani S, Gunaratnam P, Dadari I, Lorenzo JC, Bhaumik S, Sheel M.Vaccine. 2025 Sep 8;64:127694. doi: 10.1016/j.vaccine.2025.127694. Online ahead of print.PMID: 40925162

Progress toward elimination mother-to-child transmission of HBV in Shandong Province, China: Coverage trend in hepatitis B vaccination and HBIG administration, 2017-2024.
Meng X, Zhang W, Yan B, Feng Y, Lu J, Zhang L.Hum Vaccin Immunother. 2025 Dec;21(1):2554029. doi: 10.1080/21645515.2025.2554029. Epub 2025 Sep 5.PMID: 40911468

SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis.
Mothae SA, Chiliza TE, Mvubu NE.Virology. 2025 Sep;610:110607. doi: 10.1016/j.virol.2025.110607. Epub 2025 Jun 12.PMID: 40544703

Investigating persistent measles dynamics associated with population immunity in Chad: a national secondary data model analysis from 2011 to 2025.
Paluku GK, Masresha BG, Mbaïlamen AD, Mbaihol T, El-Hafiz DM, Vincent T, Tamuzi JL, Katoto PD, Wiysonge CS, Anya BM.IJID Reg. 2025 Jun 15;16:100684. doi: 10.1016/j.ijregi.2025.100684. eCollection 2025 Sep.PMID: 40662127

Butyric and valeric glycerides alleviate sub-clinical necrotic enteritis effect on performance and gut health of broiler chickens.
Sumon SMR, Kumar A, Wu D, Gharib-Naseri K, Wu SB.Poult Sci. 2025 Sep;104(9):105441. doi: 10.1016/j.psj.2025.105441. Epub 2025 Jun 13.PMID: 40577949

The impact of age at initial HPV vaccination on cervical cancer screening participation in a nationally representative cohort of women in the United States.

Chirikova E, Dorismond V, Cortella AM, DeRouen MC, Sawaya GF.J Med Screen. 2025 Sep;32(3):126-132. doi: 10.1177/09691413251315879. Epub 2025 Jan 30.PMID: 39881610

A Disease Suppression Strategy in Action: The Impact of Non-Pharmaceutical interventions in the COVID-19 pandemic in Denmark.
Simonsen L, Pedersen RK, Andreasen V, Krause TG, Petersen E.Int J Infect Dis. 2025 Sep 2:108039. doi: 10.1016/j.ijid.2025.108039. Online ahead of print.PMID: 40907738

Evolving Strategies for Respiratory Syncytial Virus (RSV): A Review Article of Preventive Agents and Vaccines for RSV.
Howard N, Pudim E 3rd.Ann Pharmacother. 2025 Sep;59(9):850-861. doi: 10.1177/10600280241302085. Epub 2025 Jan 2.PMID: 39744803

Repeated introductions and widespread transmission of human metapneumovirus in Côte d'Ivoire.
Kadjo HA, Khan SM, Tamim S, Ar Gouilh M, Adagba M, Adjogoua E, Coulibaly D, Vabret A, Cherry JL, Nelson MI, Trovão NS.BMC Infect Dis. 2025 Sep 2;25(1):1092. doi: 10.1186/s12879-025-11512-2.PMID: 40898134

Prevalence and risk factors of hepatitis B virus infection in Zakho City, Kurdistan Region, Iraq; a population-based study.
Hussein NR, Naqid IA, Abozait HJ, Ibrahim NM, Jamal SA, Rashad BH, Waisi RA, Naji DA, Salih NS, Hassan IS, Ahmed PF, Khwasty NL, Haji MF, Issa AA, Abdulrazaq MT, Morad MMR, Saleem ZSM, Musa DH.IJID Reg. 2025 Jul 11;16:100703. doi: 10.1016/j.ijregi.2025.100703. eCollection 2025 Sep.PMID: 40756586

COVID-19 vaccination and use of antibiotics in COVID-19 patients: a systematic review and meta-analysis.
Politis M, Chatzichristodoulou I, Mouchtouri VA, Rachiotis G.Infect Prev Pract. 2025 Jun 3;7(3):100461. doi: 10.1016/j.infpip.2025.100461. eCollection 2025 Sep.PMID: 40922939

In vitro and *in vivo* evaluation of humanized monoclonal antibodies targeting pneumolysin.
Song L, Hu H, Huang J, Li H, Zhang Y, Ma N, Song Z.Microbiol Spectr. 2025 Sep 2;13(9):e0027725. doi: 10.1128/spectrum.00277-25. Epub 2025 Jul 25.PMID: 40709930

In vitro and *in vivo* evaluation of humanized monoclonal antibodies targeting pneumolysin.
Song L, Hu H, Huang J, Li H, Zhang Y, Ma N, Song Z.Microbiol Spectr. 2025 Sep 2;13(9):e0027725. doi: 10.1128/spectrum.00277-25. Epub 2025 Jul 25.PMID: 40709930

Decreased $CD4^+$ T cell counts drive aberrant B cell repertoire alterations in people living with HIV.
Huang L, Zhang X, Shi Y, Liang R, Chen Q, Yang J, Zhang X, Fang A, Zhang Q, Ding C, Wu J, Wu J, Gao Y.Antiviral Res. 2025 Sep;241:106236. doi: 10.1016/j.antiviral.2025.106236. Epub 2025 Jul 8.PMID: 40639686

The hypercoagulable state in COVID-19 and implications for free flap surgery in the lower limb: A retrospective multi-centre study.
Stark D, Hendrickson S, Dejsupa C, Lenguerrand E, Jeevaratnam J, Chaplin G, Giblin V, Wallace D, Kolaityte V, Wheble G.J Plast Reconstr Aesthet Surg. 2025 Sep;108:162-167. doi: 10.1016/j.bjps.2025.06.017. Epub 2025 Jun 24.PMID: 40617765

H1N1pdm09 returns: a comparative study in Anhui, China.
Yang S-T, Hu M-H, Fang W-X, Diao H-M, Musonye HA, Huang J-X, Xia Y-D, Yu J-L, Gong L, Hou S, Li D-X, Luo W-R, Zhou X, Luo X-W, Wu J-B, Pan H-F, He J.Microbiol Spectr. 2025 Sep 8:e0221824. doi: 10.1128/spectrum.02218-24. Online ahead of print.PMID: 40919781

Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods.
Cleary DW, Anderson R, Jones J, Gladstone RA, Osman KL, Devine VT, Morris DE, Lister AJJ, Gomer S, Hocknell RE, Dineen EJ, Jefferies JM, Campling J, Lahuerta M, Hayford K, Southern J, Gessner BD, Lo SW, Bentley SD, Faust SN, Clarke SC.Pneumonia (Nathan). 2025 Sep 5;17(1):20. doi: 10.1186/s41479-025-00174-y.PMID: 40908474

Long-term survival of *Babesia microti* and *Borrelia burgdorferi* in C3H/HeJ mice and their effect on Lyme arthritis and babesiosis manifestations.
Rocha SC, Moustafa MAM, Velásquez CV, Azuama OC, Zafar K, Meyer C, Araujo M, Taylor K, Parveen N.Microbiol Spectr. 2025 Sep 2;13(9):e0025225. doi: 10.1128/spectrum.00252-25. Epub 2025 Aug 12.PMID: 40793757

Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.
Nyombayire J, Ingabire R, Mazzei A, Sharkey T, Umuhoza C, Mukamuyango J, Allen S, Tichacek A, Parker R, Wall KM, Katwere M, Keshinro B, Gaddah A, Wang Y, Forcheh CA, McLean C, Oriol-Mathieu V, Luhn K, Robinson C, Karita E.Nat Med. 2025 Sep 8. doi: 10.1038/s41591-025-03932-z. Online ahead of print.PMID: 40921806

Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study.
Kim J, Lee K, Oh J, Lee H, Chang JI, Park TY, Yon DK, Oh HC.Korean J Intern Med. 2025 Sep;40(5):747-758. doi: 10.3904/kjim.2025.171. Epub 2025 Aug 29.PMID: 40916338

The impact of human papillomavirus (HPV) vaccination on the risk of adverse obstetric outcomes: a data linkage study.
Xu X, Cruickshank ME, Woolner AMF.Eur J Obstet Gynecol Reprod Biol. 2025 Sep 1;314:114678. doi: 10.1016/j.ejogrb.2025.114678. Online ahead of print.PMID: 40914008

Factors associated with mortality in immunocompromised children with varicella.
Putri AK, Widjajanto PH, Arguni E.BMC Pediatr. 2025 Sep 1;25(1):671. doi: 10.1186/s12887-025-06024-6.PMID: 40887615

Effects of bacteriophage supplementation on performance, gut health and blood biochemistry in broilers challenged with necrotic enteritis.
Muneeb M, Khan EU, Saima, Suleman M, Awais MM, Ahmad S.Res Vet Sci. 2025 Sep;193:105809. doi: 10.1016/j.rvsc.2025.105809. Epub 2025 Jul 13.PMID: 40680360

Cholera outbreak associated with drinking contaminated lake shore water, Namayingo District, Uganda, July-August 2023.
Rek J, Orit D, Waako S, Kwesiga B, Migisha R, Bulage L, Ario AR.BMC Public Health. 2025 Sep 2;25(1):3019. doi: 10.1186/s12889-025-23295-x.PMID: 40898167

"That's our culture…": Understanding cervical cancer stigma through Caribbean voices.
Thomas-Purcell K, Sealy DA, Purcell D, Richards C, Bailey A, Song G, Ashing K.J Cancer Policy. 2025 Sep;45:100609. doi: 10.1016/j.jcpo.2025.100609. Epub 2025 Jun 23.PMID: 40562279

Wzy 3D structural models correlate with inter-repeat unit glycosidic bond configuration in pneumococcal capsule polysaccharides.
Ganaie FA, Oliver MB, Saad JS, Glanville DG, Ulijasz AT, Nahm MH.Microbiol Spectr. 2025 Sep 3:e0032825. doi: 10.1128/spectrum.00328-25. Online ahead of print.PMID: 40899850

Screening and eradication of *Helicobacter pylori* for gastric cancer prevention: Taipei Global Consensus II.
Liou JM, Malfertheiner P, Hong TC, Cheng HC, Sugano K, Shah S, Sheu BS, Chen MJ, Chiang TH, Chen YC, Yamaoka Y, Wong SH, Chen CC, Lee YY, Quach DT, Wu DC, Hsu PI, Wu CY, Wu JY, Luo JC, Chang WL, Lu H, Suzuki H, Jung HY, Mahachai V, Vilaichone RK, Mégraud F, Lin JT, Yeoh KG, Leung WK, El-Omar EM, Lee YC, Wu MS; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM).Gut. 2025 Sep 5:gutjnl-2025-336027. doi: 10.1136/gutjnl-2025-336027. Online ahead of print.PMID: 40912906

Patterns of healthcare visits and vaccination among adolescents and young adults 16-23-years-old: a retrospective US claims database analysis.
Herrera-Restrepo O, Multani JK, Zhou Z, Paltanwale Q, Olaiya T, Coutinho AD, Shah RB, Chen CC.Curr Med Res Opin. 2025 Sep 4:1-18. doi: 10.1080/03007995.2025.2556983. Online ahead of print.PMID: 40905656

Detection and natural history of HPV infection of oral cavity and tonsils - a systematic literature review.
Maltseva M, Klasen C, Wuerdemann N, Hannich M, Klussmann JP, Wieland U.BMC Cancer. 2025 Sep 1;25(1):1405. doi: 10.1186/s12885-025-14547-5.PMID: 40890626

Limiting viral replication in hematopoietic cells delays Rift Valley fever virus disease progression in C57BL/6 mice.
Xu L, Paine AC, Barbeau DJ, Klimstra W, McElroy AK.J Virol. 2025 Sep 8:e0126125. doi: 10.1128/jvi.01261-25. Online ahead of print.PMID: 40920082

Incidence of Giant Cell Arteritis Following Herpes Zoster Ophthalmicus: A Multicenter Retrospective Cohort Study.
Nitzan I, Shemesh N, Kubovsky S, Shalmov T, Levy J, Amer R.Am J Ophthalmol. 2025 Sep;277:213-220. doi: 10.1016/j.ajo.2025.05.019. Epub 2025 May 23.PMID: 40414592

Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint Inhibitors.
Laurent L, Abbar B, Bihan K, Dumas E, Jochum F, Lebrun-Vignes B, Spano JP, Salem JE, Hamy AS, Reyal F, Gougis P.Clin Pharmacol Ther. 2025 Sep;118(3):593-599. doi: 10.1002/cpt.3721. Epub 2025 Jun 16.PMID: 40521636

Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.
Joseph R, Marais G, Iranzadeh I, Alisoltani A, Hardie D, Davies M-A, Heekes A, Chetty N, Timmerman V, Hsiao N-Y, Williamson C.J Virol. 2025 Sep 5:e0078025. doi: 10.1128/jvi.00780-25. Online ahead of print.PMID: 40910685

Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis.
Parellada CI, Reyes LF, Urrego-Reyes J, Webster JL, Pungartnik PC, Dos Santos AC, Rojas M, de la Hoz F.BMC Public Health. 2025 Sep 1;25(1):2990. doi: 10.1186/s12889-025-23631-1.PMID: 40890701

Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseases.
Baran J, Kuryk Ł, Garofalo M, Prygiel M, Zasada A, Szczepińska T, Staniszewska A, Kala D, Majewski P, Charkiewicz R, Staniszewska M.Immunol Res. 2025 Sep 3;73(1):126. doi: 10.1007/s12026-025-09681-y.PMID: 40900356

Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Bramante CT, Stewart TG, Boulware DR, McCarthy MW, Gao Y, Rothman RL, Mourad A, Thicklin F, Cohen JB, Garcia Del Sol IT, Ruiz-Unger J, Shah NS, Mehta M, Cardona OQ, Scott J, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, Collins S, Dunsmore SE, Adam SJ, Lindsell CJ, Hernandez AF, Naggie S; Accelerating COVID-19 Therapeutic Interventions and Vaccines–6 Study Group and Investigators.JAMA Intern Med. 2025 Sep 1;185(9):1092-1101. doi: 10.1001/jamainternmed.2025.2570.PMID: 40658388

A decentralized point of service triple prevention and treatment model for hepatitis B, C and HIV in people who inject drugs in South Africa.
Saayman E, Hechter VB, Sishwili NS, Sonderup MW.Int J Drug Policy. 2025 Sep;143:104894. doi: 10.1016/j.drugpo.2025.104894. Epub 2025 Jun 26.PMID: 40578045

[Evaluation of changes in serum measles antibody levels in children with tumors before and after chemotherapy and the necessity of revaccination with measles-containing vaccines].
Xu YY, Ji C, Shen HP, Che XR, Zhang XC, Du J, Zhang XP, Wang J, Gu WW, Liu Y.Zhonghua Yi Xue Za Zhi. 2025 Sep 9;105(34):2993-3001. doi: 10.3760/cma.j.cn112137-20250403-00819.PMID: 40904308

The Role of Adverse Event Follow-Up in Advancing the Knowledge of Medicines and Vaccines Safety: A Scoping Review.
Kara V, Van Hunsel F, Bate A, van Puijenbroek E.Drug Saf. 2025 Sep;48(9):977-991. doi: 10.1007/s40264-025-01553-6. Epub 2025 May 20.PMID: 40392520

The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.
Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, Boccia S, Castillo-Polo JA, Magrini E, Garcia-Vello P, Wool E, Gigante V, Duffy E, Cassini A, Huttner B, Pardo PR, Naghavi M, Mirzayev F, Zignol

M, Cameron A, Tacconelli E; WHO Bacterial Priority Pathogens List Advisory Group.Lancet Infect Dis. 2025 Sep;25(9):1033-1043. doi: 10.1016/S1473-3099(25)00118-5. Epub 2025 Apr 14.PMID: 40245910

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Blass E, Keskin DB, Tu CR, Forman C, Vanasse A, Sax HE, Shim B, Chea V, Kim N, Carulli I, Southard J, Lyu H, Lu W, Rickles-Young M, Afeyan AB, Olive O, Mehndiratta A, Greenslade H, Shetty K, Baginska J, Gomez Diaz I, Nau A, Pfaff KL, Gans A, Ranasinghe S, Buchbinder EI, Sussman TA, Insco ML, Yoon CH, Rodig SJ, Shukla SA, Li S, Aster JC, Braun DA, Cibulskis C, Hacohen N, Neuberg DS, Giobbie-Hurder A, Livak KJ, Fritsch EF, Oliveira G, Simon JM, Wu CJ, Ott PA.Cell. 2025 Sep 18;188(19):5125-5141.e27. doi: 10.1016/j.cell.2025.06.019. Epub 2025 Jul 10.PMID: 40645179

From dengue to chikungunya: Guangdong as a sentinel for arboviral threats in East Asia.
Feng Y, Chang F, Yang Y, Lu H.Biosci Trends. 2025 Sep 17;19(4):368-373. doi: 10.5582/bst.2025.01228. Epub 2025 Aug 2.PMID: 40754456

Clinical progress note: Rubella.
Gailani AE, Dehority W, Katz SE.J Hosp Med. 2025 Sep 12. doi: 10.1002/jhm.70169. Online ahead of print.PMID: 40938300

Immunogenicity of neoantigens: From CAR-T cell to various vaccines.
Davodabadi F, Arabpour J, Goleij P, Mohammadi E, Taheri M, Sethi G, Dua K, Sarhadi M.Int J Pharm. 2025 Sep 15;682:125924. doi: 10.1016/j.ijpharm.2025.125924. Epub 2025 Jul 5.PMID: 40623606

Unscientific vaccine policy endangers vulnerable patients.
The Lancet Rheumatology.Lancet Rheumatol. 2025 Sep 12:S2665-9913(25)00262-0. doi: 10.1016/S2665-9913(25)00262-0. Online ahead of print.PMID: 40953576

Enteric (typhoid and paratyphoid) fever.
Kuehn R, Rahden P, Hussain HS, Karkey A, Qamar FN, Rupali P, Parry CM.Lancet. 2025 Sep 20;406(10509):1283-1294. doi: 10.1016/S0140-6736(25)01335-2. Epub 2025 Sep 3.PMID: 40914181

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
Pelzl RJ, Benintende G, Gsottberger F, Scholz JK, Ruebner M, Yao H, Wendland K, Rejeski K, Altmann H, Petkovic S, Mellenthin L, Kübel S, Schmiedeberg M, Klein P, Petrera A, Baur R, Eckstein S, Hoepffner-Grundy S, Röllig C, Subklewe M, Huebner H, Schett G, Mackensen A, Laurenti L, Graw F, Völkl S, Nganou-Makamdop K, Müller F.Blood. 2025 Sep 11;146(11):1300-1313. doi: 10.1182/blood.2024027877.PMID: 40359478

Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12 years after pneumococcal vaccine introduction.
Bizuayehu HY, Kebede Y, Deressa M, Solomon E, Marami D, Karani A, Gardiner E, Dessie Y, Scott JAG, Gallagher KE.Vaccine. 2025 Sep 17;64:127762. doi: 10.1016/j.vaccine.2025.127762. Online ahead of print.PMID: 40966977

Immunological Aspects of Mucosal Vaccine-Based Bacterial-like Particles (BLPs) - An updated review.

Phuong Nguyen TD, Thuan Cu P, Laohasatian T, Doan TD.Microb Pathog. 2025 Sep 19:108055. doi: 10.1016/j.micpath.2025.108055. Online ahead of print.PMID: 40976473

Nonscientific mindsets and the gap between past vaccine behaviors and future intentions.
Sulik J, Krick C, Gümüşlü ZB, Navajas J, Deroy O.Health Psychol. 2025 Sep 18. doi: 10.1037/hea0001560. Online ahead of print.PMID: 40965936

Mapping the cancer vaccine landscape.
Hu F, Li H, Lv W, Li M, Gale RP, Huang X, Liang Y.J Immunother Cancer. 2025 Sep 12;13(9):e012505. doi: 10.1136/jitc-2025-012505.PMID: 40940135

Transforming drug and vaccine delivery for equitable access in global health.
Yang X, Zhang L, Staykov K, Wu Z, Jaklenec A.Biochem Biophys Res Commun. 2025 Sep 12;779:152415. doi: 10.1016/j.bbrc.2025.152415. Epub 2025 Aug 5.PMID: 40773922

Integrative mapping of preexisting influenza immune landscapes predicts vaccine response.
Hao S, Tomic I, Lindsey BB, Jagne YJ, Hoschler K, Meijer A, Carreño Quiroz JM, Meade P, Sano K, Peno C, Costa-Martins AG, Bogaert D, Kampmann B, Nakaya H, Krammer F, de Silva TI, Tomic A.J Clin Invest. 2025 Jul 15;135(18):e189300. doi: 10.1172/JCI189300. eCollection 2025 Sep 16.PMID: 40663396

Biologic drug development for treatment and prevention of sexually transmitted infections.
Gill DS, Ram S, Rice PA.Clin Microbiol Rev. 2025 Sep 11;38(3):e0010724. doi: 10.1128/cmr.00107-24. Epub 2025 May 29.PMID: 40439402

Recent advances in vaccine adjuvants: from lab to clinic.
Vardikar A, Prajapati MK, Gholap AD, Rojekar S, Keshari R, Jain H, Rajput A.Int J Pharm. 2025 Sep 18:126180. doi: 10.1016/j.ijpharm.2025.126180. Online ahead of print.PMID: 40975446

New drugs approved by European medicines agency during 2024.
Hu R, Liu D, Sun X, Yu Z.Eur J Med Chem. 2025 Sep 15;294:117761. doi: 10.1016/j.ejmech.2025.117761. Epub 2025 May 19.PMID: 40409054

Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024-2025.
Clercq A, Blanquart F, Vieillefond V, Visseaux B, Chakra CNA, Nunes MC, Jacques A, Haim-Boukobza S, Wehrle V, Deleglise G, Duret T, Bernard-Stoecklin S, Bercoff DP, Lina B, Rameix-Welti MA, Josset L, Enouf V; RELAB study group; Bal A.Emerg Microbes Infect. 2025 Sep 15:2562045. doi: 10.1080/22221751.2025.2562045. Online ahead of print.PMID: 40955037

Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity.
Kelly JD, Hoggatt KJ, Lo NC, Leonard S, Boscardin WJ, Kim HS, Lum EN, Austin CC, Byers AL, Tien PC, Austin PC, Bravata DM, Keyhani S.Clin Infect Dis. 2025 Sep 16;81(2):222-230. doi: 10.1093/cid/ciaf124.PMID: 40084406

Targets of protective immunity and opportunities in hepatitis C virus vaccine development.

Park SB, Zimmer-Harwood P, Liang TJ.Nat Rev Immunol. 2025 Sep 12. doi: 10.1038/s41577-025-01215-9. Online ahead of print.PMID: 40940609

Formulation, sterilization, and clinical evaluation of microneedles for vaccine and biologic delivery: A review.
Sanjanwala D, Shinde A, Patravale V.Int J Pharm. 2025 Sep 15;682:125874. doi: 10.1016/j.ijpharm.2025.125874. Epub 2025 Jun 20.PMID: 40544976

Determinants of COVID-19 vaccine hesitancy among healthcare personnel in a secondary-level health facility in Ghana.
Kumi GA, Gohoho M, Aku FY.PLOS Glob Public Health. 2025 Sep 18;5(9):e0004980. doi: 10.1371/journal.pgph.0004980. eCollection 2025.PMID: 40966242

WRIB poster award winners 2025.
Haile S, Jiang T, Kenney C, Pham J, Revaitis N, Wei W.Bioanalysis. 2025 Sep 18:1-5. doi: 10.1080/17576180.2025.2557143. Online ahead of print.PMID: 40964921

Vaccination Update and Specific Concerns for RA.
Urquiaga M, Winthrop KL, Curtis JR.Curr Rheumatol Rep. 2025 Sep 17;27(1):37. doi: 10.1007/s11926-025-01197-6.PMID: 40960573

Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.
Polishchuk V, Kostinov M, Ryzhov A, Dagil Y, Khrapunova I, Zhestkov A, Tarabrin E, Karchevskaya N, Vlasenko A, Kostinova A, Poddubikov A, Solovieva I, Khamidulina A, Prutskova E, Mekhantseva I.PLoS One. 2025 Sep 18;20(9):e0332346. doi: 10.1371/journal.pone.0332346. eCollection 2025.PMID: 40966213

Piercing the future of vaccination: the revolutionary role of microneedle-based systems in healthcare advancements.
Koçer AT, Durasi E, Kuscu E, Amasya H, Maden H, Ay HF, Calik H, Memis H, Çoksu İ, Surgit N, Gündüz O, Arayıcı PP, Cakir R, Ozturk RY, Yuka SA, Bedir T, Chifiriuc MC, Marinaș IC, Narayan R, Üstündağ CB.Vaccine. 2025 Sep 17;63:127612. doi: 10.1016/j.vaccine.2025.127612. Epub 2025 Aug 19.PMID: 40834549

Micronutrient and protein-energy supplementation enhance vaccine responses in undernourished children: Evidence from a systematic review.
Ngoie Mwamba G, Kabamba Nzaji M, Luboya Numbi O, Ali Mapatano M, Lusamba Dikassa PS.F1000Res. 2025 Sep 11;14:507. doi: 10.12688/f1000research.164227.4. eCollection 2025.PMID: 40787612

Reflections on the Optimal Use of eDiaries for Data Collection in Vaccine Clinical Trials.
Nukala U, Cho S, Suresh Sahu A, Zhou J, Steele WR, Whitaker BI, Ezzeldin H.J Med Internet Res. 2025 Sep 19;27:e66971. doi: 10.2196/66971.PMID: 40971572

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.
Chan MXJ, Khoo YK, Stona AC, Joarder T, de Alwis R, Vogel S, Lim JCW, Tan-Koi WC.Vaccine. 2025 Sep 17;63:127607. doi: 10.1016/j.vaccine.2025.127607. Epub 2025 Aug 21.PMID: 40845795

Immune Correlates and Vaccine Immunobridging: Statistical Innovations, Challenges, and Opportunities.
Carone M, Wolock CJ, Olivas-Martinez A, Rotnitzky A, Gilbert PB.J Infect Dis. 2025 Sep 16:jiaf451. doi: 10.1093/infdis/jiaf451. Online ahead of print.PMID: 40971983

A Molecular View of Lipid Nanoparticles: Insights into their Morphology and Structural Plasticity.
Porte S, V V, Sengupta D.Small. 2025 Sep 12:e05404. doi: 10.1002/smll.202505404. Online ahead of print.PMID: 40937586

Mosquito-based transmission-blocking vaccine candidates for malaria: progress, challenges, and innovations.
Dahiya N, Yadav M, Kataria D, Janjoter S, Sehrawat N.Mol Biol Rep. 2025 Sep 16;52(1):908. doi: 10.1007/s11033-025-10963-9.PMID: 40956368

Mucosal COVID-19 vaccines in clinical development.
Tscherne A, Sun W, Liu STH, Krammer F.Vaccine. 2025 Sep 17;63:127602. doi: 10.1016/j.vaccine.2025.127602. Epub 2025 Aug 22.PMID: 40848675

Engineering chimeric PCSK9 for a vaccine against atherosclerosis.
Malenšek Š, Lainšček D, Esih H, Orehek S, Fink T, Urbanc AG, Blinc A, Jerala R.Mol Ther Methods Clin Dev. 2025 Jul 12;33(3):101535. doi: 10.1016/j.omtm.2025.101535. eCollection 2025 Sep 11.PMID: 40821854

COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
Kitamura N, Tomo Y, Okuyama M, Ueda K, Matsuoka H, Morino S, Miyahara R, Yoneoka D, Takanashi S, Suzuki M.Vaccine. 2025 Sep 17;63:127656. doi: 10.1016/j.vaccine.2025.127656. Epub 2025 Aug 27.PMID: 40876144

mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.
Pati SS, Dhal S, Pattnaik R, Tripathy S, Kumar S.Curr Med Sci. 2025 Sep 15. doi: 10.1007/s11596-025-00112-5. Online ahead of print.PMID: 40952557

Post-vaccination SARS-CoV-2 infections among healthcare workers in a tertiary hospital in Ghana.
Marfoh K, Samba A, Okyere E, Fattah AZ, Darko DNA, Odoom PN, Ashaley MD.PLoS One. 2025 Sep 17;20(9):e0331971. doi: 10.1371/journal.pone.0331971. eCollection 2025.PMID: 40961054

Epstein-Barr Virus and spontaneous lymphoblastoid cell lines: establishment, molecular characteristics, immune modulation, and therapeutic insight.
Adeniran AA, Giovannoni G, Baker D, James LK.Clin Exp Immunol. 2025 Sep 15:uxaf061. doi: 10.1093/cei/uxaf061. Online ahead of print.PMID: 40971810

Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics.
Khosravi F, Rahmani P, Jahanban Esfahlan R.Biomed Pharmacother. 2025 Sep 15;191:118551. doi: 10.1016/j.biopha.2025.118551. Online ahead of print.PMID: 40957245

Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.

Cao M, Li Y, Song X, Lu Z, Zhai H, Qiu H-J, Sun Y.J Virol. 2025 Sep 12:e0099725. doi: 10.1128/jvi.00997-25. Online ahead of print.PMID: 40938098

Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines.
Vidal SJ, Lasrado N, Tostanoski LH, Chaudhari J, Mbiwan ER, Neka GD, Strutton EA, Espinosa Perez AA, Sellers D, Barrett J, Lifton M, Wakabayashi S, Eshaghi B, Borducchi EN, Aid M, Li W, Scriba TJ, Jaklenec A, Langer R, Barouch DH.Cell. 2025 Sep 15:S0092-8674(25)00982-1. doi: 10.1016/j.cell.2025.08.027. Online ahead of print.PMID: 40957415

CCHFV-M based DNA vaccine is highly immunogenic in multiple species and protects against challenge in cynomolgus macaques.
Suschak JJ, Fitzpatrick CJ, Shoemaker CJ, Shamblin JD, White LE, Cline CR, Douglas CE, Delp KL, Burt TLA, Lewis KD, Ravulapalli S, Coyne S, Ledesma-Feliciano C, Wilson G, Norris SLW, Scruggs JL, Davis I, Ricks KM, Stefan CP, Olshner SP, Zeng X, Golden JW, Hooper JW, Garrison AR.Antiviral Res. 2025 Sep 12:106282. doi: 10.1016/j.antiviral.2025.106282. Online ahead of print.PMID: 40947064

Needle-Free Transdermal Patch for Influenza Vaccination.
Tanaka K, Masaki H, Minamihata K, Wakabayashi R, Kawaguchi Y, Kamiya N, Goto M.ACS Appl Bio Mater. 2025 Sep 15;8(9):8391-8397. doi: 10.1021/acsabm.5c01361. Epub 2025 Aug 21.PMID: 40839797

Chikungunya's global rebound and Asia's growing vulnerability: Implications for integrated vector control and pandemic preparedness.
Ni J, Li Z, Hu X, Zhou H, Gong Z.Biosci Trends. 2025 Sep 17;19(4):404-409. doi: 10.5582/bst.2025.01239. Epub 2025 Aug 8.PMID: 40790814

Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.
Hure A, Peel R, D'Este C, Abhayaratna WP, Tonkin A, Hopper I, Thrift AG, Levi C, Sturm J, Durrheim D, Hung J, Briffa T, Chew DP, Ren S, McEvoy M, Hansbro P, Newby D, Szwec S, Chiu S, Attia J.JAMA Cardiol. 2025 Sep 17:e253043. doi: 10.1001/jamacardio.2025.3043. Online ahead of print.PMID: 40960793

Precision vaccine design targeting the prefusion state of viral glycoproteins: advances in structural vaccinology.
Kumar R, Maji S, Tiwari S, Misra J, Gupta J, Kumar N, Gupta R, Jha NK.Biochem Pharmacol. 2025 Sep 17;242(Pt 2):117349. doi: 10.1016/j.bcp.2025.117349. Online ahead of print.PMID: 40972736

Understanding vaccine willingness in post-COVID America: Key determinants and demographic differences.
Yang Y, Jin SW, Lee S, Lartey S, Pichon L, Levy M.Vaccine. 2025 Sep 12;64:127740. doi: 10.1016/j.vaccine.2025.127740. Online ahead of print.PMID: 40945178

Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR.
Tanaka Y, Hamano S, Ishii-Watabe A, Saito Y, Kikura-Hanajiri R.Mol Ther Methods Clin Dev. 2025 Aug 5;33(3):101549. doi: 10.1016/j.omtm.2025.101549. eCollection 2025 Sep 11.PMID: 40893162

Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.

Zhao Z, Ma X, Milligan P, Cheung YB.Vaccine. 2025 Sep 17;63:127673. doi: 10.1016/j.vaccine.2025.127673. Epub 2025 Sep 2.PMID: 40902335

Overcoming Immune Evasion in Staphylococcus aureus: Strategies for Rational Vaccine Design.
Shinwari K, Vieira B, Ciaparin I, Hakansson AP, Darrieux M, Converso TR.ACS Infect Dis. 2025 Sep 12. doi: 10.1021/acsinfecdis.5c00569. Online ahead of print.PMID: 40939045

Global variations in immunisation strategies against pertussis in infancy.
Murphy S, Kelly A, Kelly DF.Expert Rev Vaccines. 2025 Sep 17. doi: 10.1080/14760584.2025.2562197. Online ahead of print.PMID: 40958710

Stakeholder readiness in the evolving adult vaccine market.
Jenkins MP, Hill A, Forte AF, Welch VL, True JM, Jones CH.iScience. 2025 Aug 16;28(9):113385. doi: 10.1016/j.isci.2025.113385. eCollection 2025 Sep 19.PMID: 40949102

Redefining preclinical testing: human-relevant alternatives beyond animal models.
Jang J, Yang W, Yang H, Lee NK, Park JG, Kim W, Cha B, Yoon SJ, Noh JY, Lee J.BMB Rep. 2025 Sep 16:6516. Online ahead of print.PMID: 40962329

Vaccination among splenectomy patients: can unavailability or ignorance justify failure in administration?
Sandal S, Parija PP, Sudhanshu A, Kumar N, Mani A.Trop Doct. 2025 Sep 16:494755251379545. doi: 10.1177/00494755251379545. Online ahead of print.PMID: 40956972

Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers.
Wang Y, Cao F, Huang M, Teng Q, Guan Y, Pang J.FASEB J. 2025 Sep 15;39(17):e70989. doi: 10.1096/fj.202501308RR.PMID: 40880198

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.
Pial RH, Capeding MR, Tadesse BT, Excler JL, Song KR, Park EL, Park IY, Yang JS, Kim S, Lee EY, Eluru JR, Kwon SY, Jo SK, Ryu JH, Park HK, Shin JH, Yang SY, Kim DR, Song M, Wartel TA, Kim HS, Saluja T, Sahastrabuddhe S.Vaccine. 2025 Sep 16;64:127751. doi: 10.1016/j.vaccine.2025.127751. Online ahead of print.PMID: 40961798

Opportunities for machine learning to predict cross-neutralization in FMDV serotype O.
Makau DN, Arzt J, VanderWaal K.PLoS Comput Biol. 2025 Sep 17;21(9):e1013491. doi: 10.1371/journal.pcbi.1013491. Online ahead of print.PMID: 40961118

Examining the role of influence and trust in information sources on the COVID-19 vaccine decision-making process for pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan: A mixed methods study.
Schue JL, Fesshaye B, Miller ES, Singh P, Karron RA, Jessani S, Asim M, Okwaro F, Badzi CD, Amoah EM, Souza RT, Costa ML, Temmerman M, Torpey K, Cecatti JG, Saleem S, Belayneh G, Brizuela V, Gottlieb SL, Limaye RJ.Vaccine. 2025 Sep 12:127721. doi: 10.1016/j.vaccine.2025.127721. Online ahead of print.PMID: 40946063

Long-term effects of influenza and Bacille Calmette-Guérin vaccination on systemic inflammation.
Debisarun PA, Röring RJ, Bulut Ö, Ten Doesschate T, van der Vaart TW, Kumar V, Lemmers H, Dijkstra H, Janssen AB, Veerman K, Ter Heine R, van Crevel R, Ten Oever J, Joosten LA, Bonten MJ, van Werkhoven CH, van de Wijgert JH, Netea MG.Clin Transl Immunology. 2025 Sep 11;14(9):e70047. doi: 10.1002/cti2.70047. eCollection 2025.PMID: 40949320

Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
Daigle D, Morales G, Hayford K, Haridy H, Abalos MG, Taysi BN, Fletcher MA.Vaccine. 2025 Sep 17;63:127669. doi: 10.1016/j.vaccine.2025.127669. Epub 2025 Sep 1.PMID: 40896892

Trained immunity modulators: A new frontier in immunoregulation and disease intervention.
Chen J, Wang C, Chen S, Cai H, Wang M, Chang J, Cai X, Yang J, Cao P.J Adv Res. 2025 Sep 18:S2090-1232(25)00734-9. doi: 10.1016/j.jare.2025.09.029. Online ahead of print.PMID: 40975126

Functional Amyloids as Multifunctional Platforms for Targeted Drug Delivery and Immunotherapy.
McVay B, Wolfe D, Ramamoorthy A.Langmuir. 2025 Sep 17. doi: 10.1021/acs.langmuir.5c03238. Online ahead of print.PMID: 40959969

Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors.
Abel M, Warner AB, Karzai F, Madan RA.Immunotargets Ther. 2025 Sep 13;14:1041-1052. doi: 10.2147/ITT.S549873. eCollection 2025.PMID: 40970252

The public health and economic impact of the Greek pediatric national immunization program.
Gountas I, Talbird SE, Carrico J, Cook C, Skroumpelos A, Boutselakou E, Trimis G, Michos A, Pavlopoulou I, Bencina G, Sabale U.Expert Rev Vaccines. 2025 Sep 21. doi: 10.1080/14760584.2025.2564170. Online ahead of print.PMID: 40976961

Safety and immunogenicity of COVAC-2, a Sepivac SWE adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
Hamonic G, Pastural E, Arora S, Lew J, Cai Y, Scruten E, Buchanan R, ElSherif M, Ye L, Courant T, Ventura RA, Collin N, Daugan M, Gagnon L, Hodgson P, van Drunen Little-van den Hurk S, Falzarano D, Sanche S, Halperin SA, Langley JM, Gerdts V, Racine T.Vaccine. 2025 Sep 15;64:127748. doi: 10.1016/j.vaccine.2025.127748. Online ahead of print.PMID: 40957309

Effect of CRISPR-Cas9 mediated knockout of IRF3 gene in BHK-21 cells on immune gene expression and foot-and-mouth disease virus replication.
Das LJ, Venkatesan G, Krishnaswamy N, Shekhawat I, Vijayapillai U, Priyanka M, Dechamma HJ.Microb Pathog. 2025 Sep 12;208:108022. doi: 10.1016/j.micpath.2025.108022. Online ahead of print.PMID: 40947068

Enterobactin: A key player in bacterial iron acquisition and virulence and its implications for vaccine development and antimicrobial strategies.
Amiri M, Golchin M, Jamshidian Mojaver M, Farzin H, Hajizade A.Virulence. 2025 Dec;16(1):2563018. doi: 10.1080/21505594.2025.2563018. Epub 2025 Sep 19.PMID: 40966180

Development and immunological insights into recombinant/subunit vaccines against avian coccidiosis.
Iqbal S, Tanveer S, Allaie IM, Jan Y, Tramboo S, Maqbool N.J Microbiol Methods. 2025 Sep 11;238:107255. doi: 10.1016/j.mimet.2025.107255. Online ahead of print.PMID: 40945794

Human papillomavirus (HPV) awareness, knowledge, and vaccine uptake among Cape Verdean immigrant parents in the United States: A community-based, cross-sectional study.
Antunes CV, Pires AG, Barros O, DePina A, Le Q, Lindsay AC.Hum Vaccin Immunother. 2025 Dec;21(1):2561410. doi: 10.1080/21645515.2025.2561410. Epub 2025 Sep 16.PMID: 40957578

Poliomyelitis: The paradigm of an eliminated disease: Sequelae and challenges to eradication.
Tuells J, Antonio Hurtado-Sánchez J.Rev Esp Anestesiol Reanim (Engl Ed). 2025 Sep 15:500484. doi: 10.1016/j.redare.2025.500484. Online ahead of print.PMID: 40962176

A New Threat on the Rise: Oropouche Viral Infection.
Agarwal S, Gupta V, Gupta A, Singh B, Jain R.Ann Afr Med. 2025 Sep 15. doi: 10.4103/aam.aam_199_25. Online ahead of print.PMID: 40952812

The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence.
Patel C, Wang X, Giles M, Burns P, Nguyen T, Macartney K, Williams PCM.Vaccine. 2025 Sep 17;63:127659. doi: 10.1016/j.vaccine.2025.127659. Epub 2025 Aug 25.PMID: 40857937

Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multi-center, randomized, double-blind, placebo-controlled, phase 3 clinical trial.
Wang S, Jin P, Quan Y, Lv H, Hongxing-Pan, Hu X, Liang Q, Chen Y, Wei M, Lu Q, Wang Y, Liang Z, Fu J, Xu N, Chen Z.Clin Microbiol Infect. 2025 Sep 15:S1198-743X(25)00459-8. doi: 10.1016/j.cmi.2025.09.009. Online ahead of print.PMID: 40962113

Development of a broad-spectrum multiepitope vaccine against dabie bandavirus through immunoinformatic approaches.
Naveed M, Asim M, Aziz T, Saqi MM, Rehman HM, Al-Megrin WAI, Shami A, Alwethaynani MS, Fallatah D, Al-Joufi FA, Khan AA.Int Immunopharmacol. 2025 Sep 16;166:115492. doi: 10.1016/j.intimp.2025.115492. Online ahead of print.PMID: 40961753

Bridging innovation and policy: comparative pathways of national vaccine development in low- and middle-income countries.
Marandi V.Osong Public Health Res Perspect. 2025 Sep 17. doi: 10.24171/j.phrp.2025.0208. Online ahead of print.PMID: 40957855

Use of Cannabis and Odds Ratio for Oropharyngeal and Oral Cancer-A Cohort Study.
Katz J, Gao H, Spritzer S, Garcia IA.J Oral Pathol Med. 2025 Sep 11. doi: 10.1111/jop.70055. Online ahead of print.PMID: 40935384

Evaluation of immunogenicity of mumps vaccine strains in cotton rat (Sigmodon hispidus) model.
Ito T, Yamaji Y, Sawada A, Nakayama T.Vaccine. 2025 Sep 17;63:127640. doi: 10.1016/j.vaccine.2025.127640. Epub 2025 Aug 21.PMID: 40845792

Supporting dialogue amongst multicultural communities: Exploring the role of vaccine champions.
Karras J, Harrison M, Danchin M, Kaufman J, Leask J, Petrakis D, Gore E, Seale H.Vaccine. 2025 Sep 17;63:127629. doi: 10.1016/j.vaccine.2025.127629. Epub 2025 Aug 19.PMID: 40834550

Efficacy of influenza vaccines and its relationship with immunological surrogate endpoints: a systematic review and meta-analysis of RCT.
Ge H, Cao H, Lv J, Li X, Lee A, Zou J, Jiang M, Xiao L, Gan Y, Shen M, Feng D.Clin Microbiol Infect. 2025 Sep 11:S1198-743X(25)00455-0. doi: 10.1016/j.cmi.2025.09.005. Online ahead of print.PMID: 40945718

Erythrocyte invasion in malaria: from molecular mechanisms to rational vaccines.
Alam N, Farrell B, Jamwal A, Higgins MK.Nat Rev Microbiol. 2025 Sep 15. doi: 10.1038/s41579-025-01235-1. Online ahead of print.PMID: 40954307

Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024).
Cai H, Jia B, Song Z, Wang L, Zhao S.Vaccine. 2025 Sep 17;63:127628. doi: 10.1016/j.vaccine.2025.127628. Epub 2025 Aug 19.PMID: 40834551

Effect of 5 % lactose and 0.1 % polysorbate 80 buffer on protein-based multivalent ETEC vaccine candidate MecVax stabilization and immunogenicity.
Edao B, Upadhyay I, Zhang W.Vaccine. 2025 Sep 17;63:127634. doi: 10.1016/j.vaccine.2025.127634. Epub 2025 Aug 21.PMID: 40845793

Research on molecular epidemiology of aviadenovirus in Turkish commercial poultry flocks.
Sahindokuyucu I, Yilmaz Cagirgan O, Kilic H, Cagirgan AA, Yazici Z.Br Poult Sci. 2025 Sep 17:1-11. doi: 10.1080/00071668.2025.2558993. Online ahead of print.PMID: 40960490

Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.
Sahoo D, Rodriguez E, Nguyen K, Chintapula U.ACS Appl Bio Mater. 2025 Sep 15;8(9):7513-7534. doi: 10.1021/acsabm.5c00959. Epub 2025 Sep 1.PMID: 40888536

Boot camp translation: A novel method to increase human papillomavirus (HPV) vaccination uptake.
O'Leary ST, Skenadore A, Mosley BS, Severson R, Rice JD, Simpson MJ, Brewer SE.Vaccine. 2025 Sep 17;63:127683. doi: 10.1016/j.vaccine.2025.127683. Epub 2025 Sep 2.PMID: 40902333

Circular RNA lipid nanoparticle vaccine against SARS-CoV-2.
Swingle KL, Hamilton AG, Han X, Liao KC, Safford HC, Thatte AS, Geisler HC, Xu J, Saw TY, Wan Y, Mitchell MJ.Proc Natl Acad Sci U S A. 2025 Sep 23;122(38):e2505718122. doi: 10.1073/pnas.2505718122. Epub 2025 Sep 15.PMID: 40953267

Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy.
James A, P S V, G S M, Sastri KT, A R A, Gowda CU, V B.Crit Rev Oncol Hematol. 2025 Sep 12;216:104938. doi: 10.1016/j.critrevonc.2025.104938. Online ahead of print.PMID: 40946878

A multidimensional analysis and future perspectives of cellular cancer vaccines.
Li X, Song R, Zhu J, He J, Liu X.Biochem Biophys Res Commun. 2025 Sep 16;780:152380. doi: 10.1016/j.bbrc.2025.152380. Epub 2025 Jul 30.PMID: 40816050

Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.
Schnyder Ghamloush S, Fanning S, Essink B, Eder F, Snape MD, Stoszek SK, Guo R, Dhar R, Righi V, Morsy L, Kapoor A, El Asmar L, Shaw CA.Hum Vaccin Immunother. 2025 Dec;21(1):2557676. doi: 10.1080/21645515.2025.2557676. Epub 2025 Sep 15.PMID: 40953212

Arboviral Diseases in a Changing World: Evolutionary Dynamics, Host-Vector Interactions, and Novel Control Strategies.
Abbasi E.Vector Borne Zoonotic Dis. 2025 Sep 16. doi: 10.1177/15303667251376450. Online ahead of print.PMID: 40955762

Clinical progress note: Hepatitis A virus.
McCluskey JM 3rd, Bockrath RA, Jhaveri R.J Hosp Med. 2025 Sep 11. doi: 10.1002/jhm.70171. Online ahead of print.PMID: 40932297

Insights into hepatitis B vaccination decision-making: Exploring vaccine preferences, health disparities, and practice patterns among patients and healthcare providers.
Scherkoske M, Moran J, Barnett M, Lewin C, Campbell S, Novy P.Hum Vaccin Immunother. 2025 Dec;21(1):2555698. doi: 10.1080/21645515.2025.2555698. Epub 2025 Sep 18.PMID: 40964698

Main-chain disulfide-linked cationic polycarbonates for local mRNA delivery.
Gong X, Yang Y, Wang Z, Zhang Q, Liu Y.Int J Pharm. 2025 Sep 14;684:126179. doi: 10.1016/j.ijpharm.2025.126179. Online ahead of print.PMID: 40957542

Factors influencing HPV vaccine initiation and intentions among Central American immigrant fathers in the United States: An exploratory cross-sectional study.
Hernandez Nieto A, Delgado D, Moreno VA, Lucero D, Rodriguez-Cruz N, Le Q, Lindsay AC.Vaccine. 2025 Sep 17;63:127672. doi: 10.1016/j.vaccine.2025.127672. Epub 2025 Sep 1.PMID: 40896893

Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic.
Manaquin R, Desmoulin A, Luong Nguyen LB, Kornblum D, Deparis X, Ferdynus C, Bertolotti A, Verger P, D'Ortenzio E, Pasquet A, Eldin C, Gérardin P, Mosnier E.Vaccine. 2025 Sep 13;64:127720. doi: 10.1016/j.vaccine.2025.127720. Online ahead of print.PMID: 40946352

Predicting influenza vaccine-elicited antibody responses with practical point systems.
Shen Y, Sung MH, Ge Y, Chen Y, Carlock MA, Hanley HB, Jiang S, Handel A, Ross TM.Vaccine. 2025 Sep 16;64:127737. doi: 10.1016/j.vaccine.2025.127737. Online ahead of print.PMID: 40961797

Safety and immunogenicity of rVSVdeltaG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults (EbolaCov): protocol for a phase IV, single-centre, single-blinded, randomised controlled trial.

Gokani K, Taylor A, Packham A, Musabyimana JP, Shema H, Mutabaruka A, Roche S, Takwoingi Y, Umuhoza C, Nyombayire J, Muvunyi C, Green C.BMJ Open. 2025 Sep 21;15(9):e102898. doi: 10.1136/bmjopen-2025-102898.PMID: 40976661

Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
Luong Nguyen LB, Magloire L, François A, Billard D, Priou F, Arrondeau J, Linassier C, Ben Ghezala I, Gross-Goupil M, Charles J, Dohollou N, Vanhems P, Cracowski C, Leroi AM, Lainé F, Galtier F, Barthelemy K, Priet S, Gharib M, Chalouni M, Barquin A, Loubet P, de Lamballerie X, Launay O, Wittkop L, Blay JY, Spano JP; ANRS0001S COV-POPART cohort study group.Vaccine. 2025 Sep 17;63:127633. doi: 10.1016/j.vaccine.2025.127633. Epub 2025 Aug 22.PMID: 40848673

Prolonged Monkeypox Virus Infections, California, USA, May 2022-August 2024.
Schildhauer S, Saadeh K, Snyder RE, Tang EC, Chapman E, Sykes DA, Peters P, Jacobson K, Watson J, Johnson KA.Emerg Infect Dis. 2025 Sep 11;31(10). doi: 10.3201/eid3110.250507. Online ahead of print.PMID: 40936180

New Doc on the Block: Scoping Review of AI Systems Delivering Motivational Interviewing for Health Behavior Change.
Karve Z, Calpey J, Machado C, Knecht M, Mejia MC.J Med Internet Res. 2025 Sep 16;27:e78417. doi: 10.2196/78417.PMID: 40957014

Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.
van Beek LF, He X, Koks MS, van der Gaast-de Jongh CE, Roukens AHE, Visser LG, Diavatopoulos DA, de Graaf H, de Jonge MI.Vaccine. 2025 Sep 15;64:127749. doi: 10.1016/j.vaccine.2025.127749. Online ahead of print.PMID: 40957304

Political vaccine hesitancy: not new but growing problem.
MacDonald NE, Dubé È, Graham JE.Vaccine. 2025 Sep 17;63:127643. doi: 10.1016/j.vaccine.2025.127643. Epub 2025 Aug 22.PMID: 40848674

Revisiting hepatitis B vaccination in children with transfusion-dependent thalassemia.
Wirahmadi A, Rahmartani LD, Wahidiyat PA.Ann Hematol. 2025 Sep 16. doi: 10.1007/s00277-025-06476-x. Online ahead of print.PMID: 40956435

Willingness to pay for herpes zoster vaccination in urban China.
Wang Y, Wang M, Xia Y, Zhu D, Shi Z, He P.Hum Vaccin Immunother. 2025 Dec;21(1):2559510. doi: 10.1080/21645515.2025.2559510. Epub 2025 Sep 15.PMID: 40954560

High-dose influenza vaccine for elderly: a closer look into the real-world data.
Colombo L, Elisabeth Steinberg A, Hadigal S.Curr Med Res Opin. 2025 Sep 18:1-9. doi: 10.1080/03007995.2025.2559871. Online ahead of print.PMID: 40955150

Immunoinformatics design of multi-epitope vaccine candidates against "ESKAPE" pathogens as nosocomial infection.

Khalaj A, Moghri SAHMH.Comput Biol Med. 2025 Sep 15;197(Pt B):111100. doi: 10.1016/j.compbiomed.2025.111100. Online ahead of print.PMID: 40957351

Validation and psychometric evaluation of the Arabic Adult Vaccine Hesitancy Scale.
Nour R, Powell L, Alnakhi WK, Mamdouh H, Sleibi R, Hussain HY, Al Suwaidi H, Zary N.Hum Vaccin Immunother. 2025 Dec;21(1):2560152. doi: 10.1080/21645515.2025.2560152. Epub 2025 Sep 18.PMID: 40966173

WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever- key considerations and research gaps.
Ibarz Pavon AB, Clemens J, Craviotto A, Crump JA, Garrett DO, Gordon MA, John J, Keddy KH, Laurens MB, Liu X, Marks F, Pollard AJ, Saha S, Wilder-Smith A.Gates Open Res. 2025 Sep 15;9:71. doi: 10.12688/gatesopenres.16364.1. eCollection 2025.PMID: 40964609

Nosocomial outbreak of multidrug-resistant Streptococcus pneumoniae serotype 15A (non-vaccine serotype) in a community hospital.
Takahashi J, Yajima T, Kawaguchiya M, Hashimoto N, Furuya M, Kobayashi N, Sato N, Hata F.J Infect Chemother. 2025 Sep 18:102811. doi: 10.1016/j.jiac.2025.102811. Online ahead of print.PMID: 40975130

Preparation and Evaluation of Sodium Alginate Nanoparticles Containing Recombinant Diphtheria Toxoid (CRM197) and their Immunogenicity in Mice.
Aghamiri S, Noofeli M, Goudarzi HR, Saffarian P, Najafabadi ZS.Curr Pharm Des. 2025 Sep 18. doi: 10.2174/0113816128402345250905072744. Online ahead of print.PMID: 40976900

Managing allergy-related COVID-19 vaccine hesitancy: A multi-methods analysis of practitioner notes and referral outcomes.
Clarke RM, O'Hickey SP, Walklet E, Bradley E, Mahoney B.Hum Vaccin Immunother. 2025 Dec;21(1):2561457. doi: 10.1080/21645515.2025.2561457. Epub 2025 Sep 16.PMID: 40955906

Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review.
Yao K, Feng H, Chen Y, Bao Y, Yan M, Li W, Wu B.Clin Drug Investig. 2025 Sep 17. doi: 10.1007/s40261-025-01477-0. Online ahead of print.PMID: 40960675

Comprehensive assessment of the impact of universal rotavirus vaccination program on the burden of diarrheal disease in children after 10 years of implementation in Argentina.
Degiuseppe JI.Vaccine. 2025 Sep 17;63:127681. doi: 10.1016/j.vaccine.2025.127681. Epub 2025 Aug 29.PMID: 40884908

Immunodominant structural proteins Gc and N drive T cell-mediated protection against La Crosse virus.
Alatrash R, Herrera BB.iScience. 2025 Aug 16;28(9):113378. doi: 10.1016/j.isci.2025.113378. eCollection 2025 Sep 19.PMID: 40970210

Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.

Gollub EL, Myszkowski N, Xi M, Boyraz G, Mendelsohn JB.Vaccine. 2025 Sep 17;63:127610. doi: 10.1016/j.vaccine.2025.127610. Epub 2025 Aug 18.PMID: 40829286

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.
Hodgson A, Haidara FC, Sow SO, Ansah PO, Ansah NA, Tapia MD, Bangre O, Enwere GC, Viviani S, Marchetti E, Montomoli E, Stanzani V, Tang Y, Plikaytis B, Parulekar V, Martellet L, Chaumont J, Makadi MF, Kulkarni PS, Carlone G, Borrow R, LaForce FM, Preziosi MP.Vaccine. 2025 Sep 17;64:127698. doi: 10.1016/j.vaccine.2025.127698. Online ahead of print.PMID: 40966979

Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine.
Groom HC, Kuntz JL, Varga AM, Smith N, Coto E, Cox SN, Babu TM, Briggs-Hagen M, Frivold C, Saydah S, Mularski RA, Boisvert C, Drummond M, Feldstein LR, Fortmann SP, MacMillan MP, McDonald D, Hollcroft M, Midgley CM, Plumb ID, Reich S, Schmidt MA, Yetz N, Grioni H, McCaffrey KM, Hatchie TL, Lo N, Lockwood C, Starita L, Englund JA, Weil AA, Carone M, Chu HY, Naleway AL.Vaccine. 2025 Sep 17;63:127618. doi: 10.1016/j.vaccine.2025.127618. Epub 2025 Aug 23.PMID: 40850295

Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells.
Zhou J, Liu Y, Xu W, Bhatta R, Han J, Baskaran D, Devmal S, Leal C, Wang H.Acta Biomater. 2025 Sep 15;204:234-245. doi: 10.1016/j.actbio.2025.08.005. Epub 2025 Aug 6.PMID: 40774368

Effects of telehealth during pregnancy on childhood vaccine attitudes and timeliness: A randomized controlled trial.
Aksucu G, Çağlar S.Vaccine. 2025 Sep 17;63:127678. doi: 10.1016/j.vaccine.2025.127678. Epub 2025 Aug 28.PMID: 40882266

GLP-1 Drugs in Heart Failure, beta-Blockers After MI, the Shingles Vaccine, and More From ESC 2025.
Abbasi J.JAMA. 2025 Sep 19. doi: 10.1001/jama.2025.15515. Online ahead of print.PMID: 40971173

Striped Skunk (Mephitis mephitis) Home Range and Oral Rabies Vaccine Bait Distribution in West Virginia, USA.
Johnson SR, Yang A, Pepin KM, Fischer JW, Walker NJ, Mills SA, VerCauteren KC, Gilbert AT, Chipman RB.J Wildl Dis. 2025 Sep 19. doi: 10.7589/JWD-D-24-00216. Online ahead of print.PMID: 40967627

Association Between COVID-19 Vaccination and Gastrointestinal Manifestations: A Cross-Sectional Study.
Massad M, Odeh M, Al-Ghsoon S, El-Mousa A, Hindiyeh H, Hindiyeh H, Shahin A, Sanwar J, Serhan HA, Nashwan AJ.Health Sci Rep. 2025 Sep 14;8(9):e71231. doi: 10.1002/hsr2.71231. eCollection 2025 Sep.PMID: 40959187

Short video platforms as sources of health information about HPV vaccine: A content and quality analysis.
Su L, Yao J, Ai X, Ren Y, Xu R, Wu X, Zhao S, Liu W, Song L, Du Z.Digit Health. 2025 Sep 15;11:20552076251379340. doi: 10.1177/20552076251379340. eCollection 2025 Jan-Dec.PMID: 40964602

Formulation, Characterization, and In Vivo Immunogenicity of Heat-Stabilized Dissolvable Microneedles Containing a Novel VLP Vaccine.

Leyba A, Francian A, Razjmoo M, Bierle A, Janardhana R, Jackson N, Chackerian B, Muttil P.Pharm Res. 2025 Sep 18. doi: 10.1007/s11095-025-03927-y. Online ahead of print.PMID: 40968316

Virological and immunological determinants of hepatitis E virus infection outcomes.
Wang X, Bian L, Ha EH, Wang L, O'Shaughnessy K, Zheng Y, Feng Z, Chen WB, Wu X.Curr Opin Virol. 2025 Sep 19;73:101491. doi: 10.1016/j.coviro.2025.101491. Online ahead of print.PMID: 40974759

Efficacy of a candidate vaccine against Leishmania infantum on naturally exposed dogs to sand flies.
Martorell S, Ligda P, Rai S, Alward L, Berish R, Weber A, Isaacson W, Millership J, King V, Pardali D, Theodorou K, Sotiraki S.Vaccine. 2025 Sep 17;63:127646. doi: 10.1016/j.vaccine.2025.127646. Epub 2025 Aug 23.PMID: 40850294

Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network.
Cheng KL, Yu WS, Wang YH, Ibarburu GH, Lee HL, Wei JC.J Clin Endocrinol Metab. 2025 Sep 16;110(10):e3366-e3375. doi: 10.1210/clinem/dgaf064.PMID: 39883558

Transmission dynamics and risk factors for pertussis during the 2023-2024 outbreak in Korea.
Kim SH, Lee H, Wi YM, Cho UJ, Lee SE, Ma SH.Vaccine. 2025 Sep 12;64:127726. doi: 10.1016/j.vaccine.2025.127726. Online ahead of print.PMID: 40945177

Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection.
Marking U, Bladh O, Aguilera K, Pongracz T, Havervall S, Greilert-Norin N, Blom K, Klingström J, Wang Y, Åberg M, Thålin C.EBioMedicine. 2025 Sep 16;120:105912. doi: 10.1016/j.ebiom.2025.105912. Online ahead of print.PMID: 40961508

Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.
Tota JE, Shing JZ, Roberts JN, Anderson EM, Saah AJ, Harari A, Franco EL, Kohn M, Kjær SK.Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70119. Online ahead of print.PMID: 40952771

Uptake rates of influenza vaccination in over 65s in Denmark: a comparison between Danish-born and migrant populations, 2015-21.
Deal A, Hayward SE, Kristensen KL, Seedat F, Petersen JH, Friedland JS, Valentiner-Branth P, Nørredam M, Hargreaves S.Eur J Public Health. 2025 Sep 15:ckaf148. doi: 10.1093/eurpub/ckaf148. Online ahead of print.PMID: 40971872

High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.
Lane A, Quach HQ, Ovsyannikova IG, Kennedy RB, Ross TM, Einav T.Vaccine. 2025 Sep 12:127677. doi: 10.1016/j.vaccine.2025.127677. Online ahead of print.PMID: 40946064

Protocol for genomic surveillance of Plasmodium falciparum antigens using amplicon-based PacBio long-read sequencing.
Plaza DF.STAR Protoc. 2025 Sep 15;6(4):104093. doi: 10.1016/j.xpro.2025.104093. Online ahead of print.PMID: 40956667

Does home COVID-19 testing bias COVID-19 vaccine effectiveness estimates?
Nowalk MP, Balasubramani GK, D'Agostino H, Zimmerman RK, Monto AS, Martin ET, Nguyen HQ, Gaglani M, Mamwala M, Tartof S, Lewin BJ, Wernli K, Wickersham B, Talbot HK, Grijalva CG, Chung JR, Flannery B; US Flu VE Network Investigators.Am J Prev Med. 2025 Sep 11:108096. doi: 10.1016/j.amepre.2025.108096. Online ahead of print.PMID: 40945668

Using reverse vaccinology to construct multi-epitope subunit vaccine candidates for Klebsiella pneumoniae.
Ballim T, Seele PP, Mpye KL, Khoza T.Hum Immunol. 2025 Sep 13;86(5):111568. doi: 10.1016/j.humimm.2025.111568. Online ahead of print.PMID: 40946484

Predicting the Trend of SARS-CoV-2 Mutation Frequencies Using Historical Data.
Zhou X, Yan Y, Hu K, Tang H, Wang Y, Wang L, Zhang C, Cao S.Bioinformatics. 2025 Sep 17:btaf508. doi: 10.1093/bioinformatics/btaf508. Online ahead of print.PMID: 40973044

Cross-comparison study of three ELISA methodologies to measure *Shigella Sonnei* O-antigen serum IgG.
Stickings P, Vipond C, Rigsby P, Micoli F, Rossi O, Mancini F, Conti V, Cohen D, Bialik A, Meron-Sudai S, Asato V, Clarkson KA, MacLennan CA, Kaminski RW.mSphere. 2025 Sep 15:e0035625. doi: 10.1128/msphere.00356-25. Online ahead of print.PMID: 40951974

Gene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model.
Hebert LS, Pickens W, Satterwhite E, Soto GB, Pflaum FM, Zhan M, Moody MA, Kain J, Kirchenbaum GA, Ferguson JA, Langel SN, Ross TM, Sautto GA, Uno N, Richardson RA, Georgiou G, Lavinder JJ, Ippolito GC, Seeger A.Vaccine. 2025 Sep 16;64:127725. doi: 10.1016/j.vaccine.2025.127725. Online ahead of print.PMID: 40961800

COVID-19 hoax belief endorsement and its implications for vaccine uptake: Investigating the role of perceived threat.
Morstead T, Loo N, Sin NL, DeLongis A.Vaccine. 2025 Sep 17;63:127630. doi: 10.1016/j.vaccine.2025.127630. Epub 2025 Aug 19.PMID: 40834548

COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
Jeong NY, Cho S, Lim E, Lee JR, Song JY, Park JS, Choi NK.Vaccine. 2025 Sep 17;63:127619. doi: 10.1016/j.vaccine.2025.127619. Epub 2025 Aug 14.PMID: 40818314

Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.
Mandolo J, Mulira L, Moyo M, Mvula M, Mtonga F, Henrion MYR, Wotcheni W, Cunliffe NA, Barnes KG, Jambo KC, Jere KC.PLoS Med. 2025 Sep 12;22(9):e1004734. doi: 10.1371/journal.pmed.1004734. eCollection 2025 Sep.PMID: 40938968

Corrigendum to "Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains" [Vaccine 59 (2025) 127270].
Hasan Z, Masood KI, Qaiser S, Kanji A, Mwendwa F, Alenquer M, Iqbal J, Ferreira F, Wassan Y, Balouch S, Hussain S, Begum K, Feroz K, Muhammad S, Sadiqa A, Akhtar M, Habib A, Ahmed SMA, Mian AA, Hussain R, Amorim MJ, Bhutta ZA.Vaccine. 2025 Sep 17;63:127686. doi: 10.1016/j.vaccine.2025.127686. Epub 2025 Sep 1.PMID: 40896891

Factors influencing HPV vaccine acceptance in immunosuppressed patient populations: a protocol for a systematic review.
Soares LMC, Carvalho AV, Azevedo da Silva CH, Maximo GM, Medeiros KS, de Souza DLB, Nogueira-Rodrigues A, Oliveira de Mendonça AE.BMJ Open. 2025 Sep 14;15(9):e094224. doi: 10.1136/bmjopen-2024-094224.PMID: 40953860

Development and External Validation of the FluScoreVax Risk Score for Influenza That Incorporates Vaccine Status.
Ebell MH, Chen Y, Luo F, Shen Y, Coenen S, Little P, Barrett B, Merenstein D, Ieven M.J Am Board Fam Med. 2025 Sep 15;38(3):401-410. doi: 10.3122/jabfm.2024.240366R1.PMID: 40789620

Deletion of the African swine fever virus E120R gene completely attenuates its virulence by enhancing host innate immunity and impairing virus release.
Ma B, Jiang Y, Li N, Wang F, Li Q, Yue H, Zhang Y, Hu R, Miao F.Emerg Microbes Infect. 2025 Dec;14(1):2555722. doi: 10.1080/22221751.2025.2555722. Epub 2025 Sep 20.PMID: 40899401

Ebola virus' hidden target: virus transmission to and infection of skin.
Richards PT, Fleck AM, Patel R, Fakhimi M, Bohan D, Geoghegan-Barek K, Honko AN, Stolte AE, Plescia CB, Messingham CO, Connell SJ, Crowe TP, Gourronc FA, Carrion R Jr, Griffiths A, Meyerholz DK, Klingelhutz AJ, Davey RA, Messingham KN, Maury W.J Virol. 2025 Sep 12:e0130025. doi: 10.1128/jvi.01300-25. Online ahead of print.PMID: 40938099

A Curve-Fitting Approach for Generating Long-Term Projections of COVID-19 Mortality.
Kafatos G, Seegan G, Behera B, Neasham D, Bradbury B, Accortt N.Disaster Med Public Health Prep. 2025 Sep 16;19:e262. doi: 10.1017/dmp.2025.10188.PMID: 40954983

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.
Sol O, Mermoud J, Hallikainen M, Kurl S, Rinne J, Dautzenberg P, Vijverberg EGB, Mummery C, Börjesson-Hanson A, Jonsson M, Ritchie C, Pennington C, Vukicevic M, Gollwitzer E, Fiorini E, Hickman DT, Hliva V, Gray J, Gerasymchuk V, Wagg J, Fournier N, Lê B, Kezic I, Steukers L, Triana-Baltzer G, Theunis C, Streffer J, Kosco-Vilbois M, Pfeifer A, Scheltens P.EBioMedicine. 2025 Sep 18;120:105940. doi: 10.1016/j.ebiom.2025.105940. Online ahead of print.PMID: 40972226

Humoral immunity to current variants of SARS-CoV-2 in exposed adults, September 2023 to September 2024.

Jeworowski LM, Mühlemann B, Walper F, Schmidt ML, Jansen J, Krumbholz A, Jones TC, Corman VM, Drosten C.mBio. 2025 Sep 12:e0161825. doi: 10.1128/mbio.01618-25. Online ahead of print.PMID: 40937853

Dietary supplementation of arachidonic acid promotes humoral immunity.
Feng S, Ma E, Na X, Wang Z, Tai W, Bao X, Wang M, Chang H, Wu B, Liu M, Li J, Shi H, Yang C, Xi M, Yang H, Li Y, Zhu Y, Wang P, Zhao L, Zhao A, Cheng G.EMBO Mol Med. 2025 Sep 12. doi: 10.1038/s44321-025-00310-7. Online ahead of print.PMID: 40940568

Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes.
Cuypers L, Dambre C, Desmet S.Vaccine. 2025 Sep 17;64:127763. doi: 10.1016/j.vaccine.2025.127763. Online ahead of print.PMID: 40966978

Oncolytic Hydrogel Enhances Immune Checkpoint Blockade by Generating In Situ Vaccine, Remodeling Tumor Physical and Metabolic Barriers.
Yang Z, Liu K, Li H, Li Y, Sun Q, Shang W, Wang M, Yang Y, Liu H, Yin D, Shen W.ACS Nano. 2025 Sep 16;19(36):32546-32568. doi: 10.1021/acsnano.5c09729. Epub 2025 Sep 8.PMID: 40919615

Documented vaccination as proof of immunity compared to serology in medical students.
Godoy P, Toledo D, Casas I, Colmenares K, Vilella A, Prat A, Mormeneo-Bayo S, Bartolomé R, Ibarz M, Domínguez A; Working Group.Hum Vaccin Immunother. 2025 Dec;21(1):2556584. doi: 10.1080/21645515.2025.2556584. Epub 2025 Sep 17.PMID: 40963305

Longitudinal dynamics of humoral immune responses following serial COVID-19 vaccinations and breakthrough infections in dialysis patients.
Tsai WC, Chu FY, Chiu YL, Wu HY, Yang JY, Pai MF, Hsu SP, Tung KT, Shu KH, Lin WY, Peng YS.Hum Vaccin Immunother. 2025 Dec;21(1):2561176. doi: 10.1080/21645515.2025.2561176. Epub 2025 Sep 15.PMID: 40955097

Disparities and temporal trends in pneumococcal vaccination uptake among older adults in the Israeli population: A population-based retrospective cohort study.
Turjeman A, Shochat T, Drozdinsky G, Leibovici L.Vaccine. 2025 Sep 15;64:127765. doi: 10.1016/j.vaccine.2025.127765. Online ahead of print.PMID: 40957306

Validation of a parent HPV vaccine misperceptions scale and its association with children's HPV vaccination status.
McDaniels-Davidson C, Parada H Jr, Martinez ME, Martinez LS, Nodora JN, Stack-Babich M, Keleman O, Miller EE, Felner JK, Strong D.Vaccine. 2025 Sep 17;63:127616. doi: 10.1016/j.vaccine.2025.127616. Epub 2025 Aug 24.PMID: 40854274

A mix of views: Perspectives on pregnant women's participation in maternal vaccine trials.
Nalubega P, Namugumya R, Kyohere M, Seeley J, Le Doare K, Ssali A.Vaccine. 2025 Sep 17;63:127627. doi: 10.1016/j.vaccine.2025.127627. Epub 2025 Aug 31.PMID: 40889445

Development of MenFive, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.
Alderson MR, Regan K, Martellet L, Hosken N, Kulkarni PS, Pisal SS, LaForce FM, Dhere RM.Hum Vaccin Immunother. 2025 Dec;21(1):2559506. doi: 10.1080/21645515.2025.2559506. Epub 2025 Sep 18.PMID: 40968077

Trends and inequalities in full immunization coverage among two-year-olds in Sierra Leone, 2008-2019.
Sesay U, Osborne A, Benya H, Bangura C, Ahinkorah BO.PLoS One. 2025 Sep 12;20(9):e0329572. doi: 10.1371/journal.pone.0329572. eCollection 2025.PMID: 40938935

Assessing COVID-19 Vaccination Uptake and Incident Infections Among Ethiopian Healthcare Workers, Addis Ababa-2022: Implications for Public Health Preparedness.
Hundie GB, Ashengo TA, Stender SC, Abraha M, Getachew A, Sirgu S, Muleta MB, Westercamp M, Ayalew F.Clin Infect Dis. 2025 Sep 16;81(2):248-254. doi: 10.1093/cid/ciaf341.PMID: 40728313

Role of universal and targeted recommendations for vaccines for sexually transmitted infections in the USA, China and Indonesia: a cross-sectional study.
Santana-Garces MA, Wagner AL, Harapan H, Lu Y.BMJ Public Health. 2025 Sep 14;3(2):e001897. doi: 10.1136/bmjph-2024-001897. eCollection 2025.PMID: 40959837

Sociodemographic factors influencing childhood vaccination in Albania: a cross-sectional study.
Qatipi L, Fico A, Toci E, Shtylla M, Biles M.Eur J Public Health. 2025 Sep 16:ckaf151. doi: 10.1093/eurpub/ckaf151. Online ahead of print.PMID: 40972005

Foot-and-mouth disease virus vaccine with VP1 G-H loop substitution of the Cathay strain broadens antigen spectrum.
Zha J, Zhang K, Zhang X, Sun P, Li D, Cao Y, Bai X, Ma X, Li K, Yuan H, Fu Y, Zhang J, Zhao Z, Wang J, Bao H, OuYang Y, Qi S, Liu Z, Lu Z, Li P.Appl Microbiol Biotechnol. 2025 Sep 11;109(1):199. doi: 10.1007/s00253-025-13561-8.PMID: 40932491

Thermosensitive Hydrogel In Situ Vaccine for Lymph Node Targeting and Enhanced Immunotherapy.
Zhao Z, Liu H, Li M, Zheng Y, Qi D, Chen C, Wang Z, Fu L, Han S, Yang X, Cao Z, Li X.Adv Healthc Mater. 2025 Sep 16:e02747. doi: 10.1002/adhm.202502747. Online ahead of print.PMID: 40958505

The mutual cyclical influence of internet information and vaccination intention on post-dissemination vaccination: A longitudinal study during the availability period of COVID-19 booster shots.
Inoue S, Fuji K.Vaccine. 2025 Sep 16;64:127741. doi: 10.1016/j.vaccine.2025.127741. Online ahead of print.PMID: 40961799

Association of parental education with adolescents' COVID-19 vaccine uptake: A nationwide register-based study in Finland.
Variskallio S, Moustgaard H, Remes H, Martikainen P.Vaccine. 2025 Sep 17;63:127615. doi: 10.1016/j.vaccine.2025.127615. Epub 2025 Aug 18.PMID: 40829287

Preparation time and usability assessment of commercially available freeze-dried respiratory syncytial virus vaccine presentations.

Moucka R, Chilson E, Conrad B, Weiser S, Moss S, Bruchsaler M.Expert Rev Vaccines. 2025 Sep 16. doi: 10.1080/14760584.2025.2559672. Online ahead of print.PMID: 40955438

The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats.
Moon SS, Richter-Roche M, Wang Y, Foytich KR, Bessey TK, Feriante C, McAllister DV, Luea E, Jiang B.Hum Vaccin Immunother. 2025 Dec;21(1):2555700. doi: 10.1080/21645515.2025.2555700. Epub 2025 Sep 11.PMID: 40936299

Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice.
Vasilev K, Puente-Massaguer E, Hoxie I, Bushfield K, Krammer F.Vaccine. 2025 Sep 17;63:127626. doi: 10.1016/j.vaccine.2025.127626. Epub 2025 Aug 27.PMID: 40876140

An Antigen-Free Nanovaccine-Enabled Holo-Immunotherapy for Establishing Robust Memory Immune Tolerance in Autoimmune Diseases.
Wang S, Wang Y, Li Y, Lai X, Hu M, Chen M, Li C, Liu X, Song Y, Deng Y.ACS Nano. 2025 Sep 13. doi: 10.1021/acsnano.5c09136. Online ahead of print.PMID: 40944643

Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.
Trines MM, Hoorn D, Hofstraat SRJ, Zwolsman RC, Anbergen T, Versteeg I, van van Elsas Y, Deckers J, Hendrikx MMA, Kleuskens T, Darwish YB, Ros GWB, Dijkstra SF, Priem B, Timmers M, Fransen PM, Pouderoijen MJ, de de Waal BFM, Meijer EW, Beldman TJ, Toner YC, Kluza E, Mulder WJM, Janssen HM, van der Meel R.Adv Mater. 2025 Sep 12:e04830. doi: 10.1002/adma.202504830. Online ahead of print.PMID: 40937965

The secret weapon to reduce multidrug-resistant Gram-negative infections: can vaccines help decrease MDR risk?
Peghin M, Grossi PA.Curr Opin Infect Dis. 2025 Sep 15. doi: 10.1097/QCO.0000000000001149. Online ahead of print.PMID: 40938132

Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea.
Cheong C, Choi WS, An JE, Cho J, Yoon YK, Yu SY.Vaccine. 2025 Sep 17;63:127648. doi: 10.1016/j.vaccine.2025.127648. Epub 2025 Aug 27.PMID: 40882264

3A and 2B proteins of SVA play chess game with host restriction factor DDX23 by apoptotic pathway.
Li J, Lin H, Zhou Y, Lei Z, Wang X, Bi R, Liu X, Wang J, Zhang H, Wang X, Liu J, Bo Z, Shen H, Yan J, Tong R, Xue Y, Zhuansun M, Zhou J, Suo X, Chang X, Yin Z, Sun P, Li L.J Virol. 2025 Sep 16:e0076125. doi: 10.1128/jvi.00761-25. Online ahead of print.PMID: 40956085

Efficacy of a glycoprotein G-deficient infectious laryngotracheitis virus vaccine delivered in the drinking-water.
Gopakumar G, Coppo MJ, Hartley CA, Underwood G, Diaz-Méndez A, Devlin JM.Avian Pathol. 2025 Sep 15:1-30. doi: 10.1080/03079457.2025.2559873. Online ahead of print.PMID: 40952354

Family spillover effects in cost-effectiveness analyses of vaccines.
Qian Y, Phillips M, Eiden AL, Carias C, Lavelle TA.Vaccine. 2025 Sep 19;64:127755. doi: 10.1016/j.vaccine.2025.127755. Online ahead of print.PMID: 40974734

Effects of multiple La Sota vaccinations on the atrophy of the lymphoid organs associated with velogenic Newcastle disease virus infection in pullets.
Omeke JN, Onyema I, Ikenna-Eze HN, Ugochukwu IC, Eze DC, Ezema WS, Okoye JOA.Acta Vet Hung. 2025 Jul 11;73(3):159-166. doi: 10.1556/004.2025.01143. Print 2025 Sep 15.PMID: 40643972

Production of human papillomavirus type 16 virus-like particles in Physcomitrella photobioreactors.
Niederau PA, Weilguny MC, Chamas S, Turney CE, Parsons J, Rodríguez-Franco M, Hoernstein SNW, Decker EL, Simonsen HT, Reski R.Plant Cell Rep. 2025 Sep 17;44(10):216. doi: 10.1007/s00299-025-03602-x.PMID: 40960656

Immunogenicity, security and protection against small ruminant lentivirus (SRLV) challenge in sheep, induced by intranasal immunization with a recombinant Sendai virus vector expressing SRLV gag-P25.
Gómez Á, Glaria I, Moncayola I, Echeverría I, Rodríguez-Largo A, de Blas I, Pérez E, Pérez M, Villanueva-Saz S, Lee B, de Diego A, de Miguel R, Luján L, Reina R.Vet Q. 2025 Dec;45(1):1-16. doi: 10.1080/01652176.2025.2556492. Epub 2025 Sep 17.PMID: 40959881

Influenza-Associated Hospitalizations During a High Severity Season - Influenza Hospitalization Surveillance Network, United States, 2024-25 Influenza Season.
O'Halloran A, Habeck JW, Gilmer M, Threlkel R, Chai SJ, Hall B, Armistead I, Alden NB, Meek J, Yousey-Hindes K, Openo KP, Witt LS, Monroe ML, Ryan PA, Leegwater L, Kim S, McMahon M, Lynfield R, Harbi K, Khalifa M, McCahon C, Barney G, Anderson BJ, Felsen CB, Tesini BL, Moran NE, Ingabire-Smith D, Sutton M, Hendrick MA, Schaffner W, Talbot HK, George A, Zahid H, Garg S, Bozio CH.MMWR Morb Mortal Wkly Rep. 2025 Sep 11;74(34):529-537. doi: 10.15585/mmwr.mm7434a1.PMID: 40934142

Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus.
Shaw CA, Stewart-Jones GBE, Jorquera P, Narayanan E, Elbashir S, Kaplonek P, Ma L, Hunter N, Hanahoe E, Ketova T, Mihai C, Mani S, Ong E, Presnyak V, Rabideau AE, Reid DW, Woods A, Carfi A.Vaccine. 2025 Sep 17;63:127589. doi: 10.1016/j.vaccine.2025.127589. Epub 2025 Aug 20.PMID: 40840264

Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.
Schiavone A, Edwards JC, Vigneswaran E, De Brito RCF, Hothi H, Frossard JP, Beechener ES, Calvert JG, Burkard CT, Balasch M, Seaton AV, Stevens M, Howard MK, Graham SP, Opriessnig T.Vaccine. 2025 Sep 19;64:127757. doi: 10.1016/j.vaccine.2025.127757. Online ahead of print.PMID: 40974733

Multi-attribute analysis of nanoparticle vaccine adjuvants by Electrical Asymmetrical Flow Field-flow Fractionation (EAF4) with light scattering detections.
Deng JZ, Song W, Lu T, Alkurdi E, Smith WJ, Mukherjee M, Zhuang P.J Chromatogr A. 2025 Sep 13;1758:466174. doi: 10.1016/j.chroma.2025.466174. Epub 2025 Jun 26.PMID: 40681416

SitoC7A-modified lipid nanoparticles for integrated mRNA delivery and targeted STING activation.

Qiao L, Fan N, Zhang Y, Chen Y, Qin S, Song X.J Control Release. 2025 Sep 15:114238. doi: 10.1016/j.jconrel.2025.114238. Online ahead of print.PMID: 40962123

Development and proof-of-concept evaluation for a low resource compatible Chikungunya virus diagnostic.
Balea R, Amarilla AA, Hobson-Peters J, Macdonald J, Suhrbier A, Kasimov VM, Watterson D, Pollak NM, McMillan DJ.PLoS Negl Trop Dis. 2025 Sep 12;19(9):e0012352. doi: 10.1371/journal.pntd.0012352. eCollection 2025 Sep.PMID: 40938967

Effect of maternal COVID-19 vaccination on mandibular molars development in albino rats offspring.
Dawoud LE, Hegazy EM, Mahmoud EF.Sci Rep. 2025 Sep 12;15(1):32453. doi: 10.1038/s41598-025-18115-6.PMID: 40940381

Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
Fu JYL, Syed Omar SF, Rajasuriar R, Kukreja A, Basri S, Kamarulzaman A, Tan CS, Said A, Su'ut L, Lim SK, Jalalonmuhali M, Bador MK, Sam IC, Chan YF; ASSeSS Consortia.Vaccine. 2025 Sep 17;63:127657. doi: 10.1016/j.vaccine.2025.127657. Epub 2025 Aug 27.PMID: 40876143

The influence of investor sentiment on the Chinese stock market amid COVID-19: An event study analysis.
Sun Y, Yang C.PLoS One. 2025 Sep 16;20(9):e0332216. doi: 10.1371/journal.pone.0332216. eCollection 2025.PMID: 40956842

The modified mRNA vaccine protects immunocompromised AG129 mice from lethal challenge and multi-tissue infection by Zika virus.
Yan Y, Wang J, Yang H, Yang Y, Yuan L, Tang C, Zhou Y, Huang Q, Yu W, Liang X, Lin D, Li Y, Du X, Yuan Y, Peng R, Xu J, Guo Z, Xie W, Quan W, Chen H, Zhou J, Lu S, Peng X.Emerg Microbes Infect. 2025 Dec;14(1):2556729. doi: 10.1080/22221751.2025.2556729. Epub 2025 Sep 18.PMID: 40899968

Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial.
Agnandji ST, Bok J, Alabi A, Kabwende AL, Mbouna A, Bie J, Moukiti E, Lalremruata A, Esen M, Kreidenweiss A, Kc N, Sim BKL, Richie TL, Preston Church LW, McCall MBB, Hoffman SL, Kremsner PG, Mordmüller B.Lancet Infect Dis. 2025 Sep 16:S1473-3099(25)00434-7. doi: 10.1016/S1473-3099(25)00434-7. Online ahead of print.PMID: 40972633

Microneedle & film-forming gel transdermal delivery strategy: A novel approach for vaccine delivery.
Xiong T, Han Y, Qi Z, Guo S, Hu X, Wang C, Li L, Ma T, Chen J, Li J, Han J, Wu H.Int J Pharm. 2025 Sep 15;682:125905. doi: 10.1016/j.ijpharm.2025.125905. Epub 2025 Jun 25.PMID: 40578458

Characterizing the FDA Adverse Event Reporting System (FAERS) as a Network to Improve Pattern Discovery.
Davis R, Dang O, De S, Ball R.Drug Saf. 2025 Sep 16. doi: 10.1007/s40264-025-01609-7. Online ahead of print.PMID: 40956485

Targeting Vaccine Information Framing to Recipients' Education: A Randomized Trial.

Dominici A, Dahlström LA.Health Econ. 2025 Sep 17. doi: 10.1002/hec.70036. Online ahead of print.PMID: 40958589

The Dynamic Impact of Community Social Vulnerability on COVID-19 Outcomes: A Census Tract-level Analysis of Fulton County, Georgia.
Doraivelu K, Williams S, Hazell M, Smith S, Chamberlain AT, Gandhi NR, Shah NS, Patel SA.Clin Infect Dis. 2025 Sep 16;81(2):231-238. doi: 10.1093/cid/ciaf177.PMID: 40176421

Bimetallic nanoadjuvants for cancer vaccines.
Luo J, Wang Y, Yu C, Yang Y.Trends Pharmacol Sci. 2025 Sep 18:S0165-6147(25)00183-X. doi: 10.1016/j.tips.2025.08.007. Online ahead of print.PMID: 40973570

Marburg Virus Disease in Rwanda, 2024 - Public Health and Clinical Responses.
Nsanzimana S, Remera E, Nkeshimana M, Westergaard RP, Firew T, Semakula M, Seruyange E, Neil KL, Kreuger MJ, Bekele A, Biramahire J, Bizimana A, Chirombo B, Diaz J, Dushimimana G, Fischer WA 2nd, Fletcher TE, Fowler R, Gatera MR, Giuliani R, Goldberg J, Hakorimana F, Hatchett R, Ingabire Z, Ingabire L, Ishimwe A, Isingizwe G, Jacquerioz F, Kayigi E, Kazindu S, Manirafasha A, Mills EJ, Mugabo H, Mukagatare I, Murayire J, Musanabaganwa C, Mushuru E, Mutesa L, Muvunyi CM, Muvunyi R, Mwiseneza L, Nahayo E, Ndayiragije V, Ndayisabye H, Ndayishimiye GS, Ngabonziza JCS, Niwemuhoza MG, Niyigaba N, Niyonshuti P, Niyonizeye MG, Nsekuye O, Ntakambirwa DK, Ntawuyirusha E, Ntihumbya JB, Nyirigira G, Rojek A, Rukundo A, Rwabihama JP, Rwamwejo F, Shumbusho G, Sibomana JP, Turatsinze D, Uwamahoro DL, Uwimana FX, Butera Y, Twagirumugabe T, Rwagasore E; Rwanda MVD Outbreak Response Team.N Engl J Med. 2025 Sep 11;393(10):983-993. doi: 10.1056/NEJMoa2415816.PMID: 40929633

FliC adjuvant augments protective efficacy of recombinant T2544 antigen against SalmonellaTyphiand Paratyphi A by increasing serum antibodies, intestinal secretory immunoglobulin A and T cell memory.
Chakraborty S, Dutta P, Pal A, Chakraborty S, Mitra S, Miyoshi SI, Das S.Vaccine. 2025 Sep 20;64:127767. doi: 10.1016/j.vaccine.2025.127767. Online ahead of print.PMID: 40976078

Vaccine uptake pre- and post-COVID-19 in American adults: a retrospective observational study using the Behavioral Risk Factor Surveillance System.
Beltran TA, Berry-Cabán CS, Rogers SM, Merrill BK.Korean J Fam Med. 2025 Sep 19. doi: 10.4082/kjfm.25.0098. Online ahead of print.PMID: 40968715

Risk Factors for Measles Outbreak in Pune City: A Case-Control Study.
Ajinsha AS, Parande MA, Bharati A, Jagdale GR, Tambe MP, Dixit J, Nanaware M, Borle PS, Salunke N, Sancheti PV, Salunke P, Jamadar D.Indian J Public Health. 2025 Sep 17. doi: 10.4103/ijph.ijph_240_24. Online ahead of print.PMID: 40964759

Perceptions About Influenza and COVID-19 Vaccines Among People With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Zou G, Jaar BG, Lash JP, Chen J, Charleston JB, Jittirat A, Patel D, Brown J, He J, Cornish-Zirker D, Rincon-Choles H, Appel LJ, Crews DC, Riekert KA, Dowdy DW, Matsushita K, Ishigami J; CRIC Study Investigators.Am J Kidney Dis. 2025 Sep 17:S0272-6386(25)01021-2. doi: 10.1053/j.ajkd.2025.07.008. Online ahead of print.PMID: 40972704

Impact of HPV vaccination on the incidence and clearance of HPV infections in sexually active young women.
Kassam P, Laurie C, El-Zein M, Tota JE, Tellier PP, Coutlée F, Burchell AN, Franco EL.Vaccine. 2025 Sep 17;63:127632. doi: 10.1016/j.vaccine.2025.127632. Epub 2025 Aug 23.PMID: 40850293

Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection.
Matthias KA, Connolly KL, Jerse AE, Kumova OK, Macintyre AN, Gray MC, Thomas KS, Criss AK, Zielke RA, Li L, Sikora AE, Ramirez-Bencomo F, Thistlethwaite A, Derrick JP, Lu WE, Bash MC.J Infect Dis. 2025 Sep 16:jiaf445. doi: 10.1093/infdis/jiaf445. Online ahead of print.PMID: 40971931

Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.
Schiavone A, Edwards JC, Vigneswaran E, De Brito RCF, Hothi H, Frossard JP, Beechener ES, Calvert JG, Burkard CT, Balasch M, Seaton AV, Stevens M, Howard MK, Graham SP, Opriessnig T.Vaccine. 2025 Sep 19;64:127757. doi: 10.1016/j.vaccine.2025.127757. Online ahead of print.PMID: 40974733

Changes in the Streptococcus pneumoniae population responsible for invasive disease of young children after the implementation of conjugated vaccines in the National Immunization Program in Poland.
Wróbel-Pawelczyk I, Gołębiewska A, Ronkiewicz P, Kiedrowska M, Błaszczyk K, Kuch A, Sadowy E, Hryniewicz W, Litt D, Groves N, Skoczyńska A.Vaccine. 2025 Sep 19;64:127759. doi: 10.1016/j.vaccine.2025.127759. Online ahead of print.PMID: 40974736

SARS-CoV-2 seropositivity amongst healthcare workers in South Africa during the Omicron wave: natural infection versus vaccination.
Hoffmann DJ, Meyer PWA, Worsley CM, van der Mescht MA, Visser A, Pillay TS.J Clin Pathol. 2025 Sep 18;78(10):717-722. doi: 10.1136/jcp-2024-209722.PMID: 39824540

GM-CSF-adjuvanted Newcastle disease virus-vectored bivalent vaccine elicits enhanced dual immunity against Newcastle disease and infectious bursal disease in chickens.
Wu Q, Liu J, Cao W, Li J, Li H, Jin Y, Li Z, Li X, Sun W, Bai L, Shen X, Guo X, Ren G.Vet Immunol Immunopathol. 2025 Sep 16;288:111002. doi: 10.1016/j.vetimm.2025.111002. Online ahead of print.PMID: 40972184

Barriers and enablers to childhood immunization in high zero-dose burden communities in Kano and Lagos states, Nigeria.
Bolarinwa OA, Salaudeen GA, Lar L, Alhaffar M, Abdelmagid N, McGowan CR, Adesoro O, Valentine P, Ahmed T, Clarke A, Makunja S, Akande TM.Vaccine. 2025 Sep 13;64:127754. doi: 10.1016/j.vaccine.2025.127754. Online ahead of print.PMID: 40946351

HPV Education and Its Impact on Vaccination Willingness and Recommendation Intentions Among Unvaccinated Japanese University Students: A Cross-Sectional Study.
Wakui N, Koakutsu Y, Watanabe M, Yokoyama Y, Okami A, Shirozu S, Okada K, Onuki Y, Machida Y.J Cancer Educ. 2025 Sep 18. doi: 10.1007/s13187-025-02733-9. Online ahead of print.PMID: 40968245

Limited nasal interferon production contributes to delayed respiratory virus clearance and suboptimal vaccine responses.

Sojati J, Parks OB, Eddens T, Lan J, Johnson M, Williams JV.JCI Insight. 2025 Sep 16:e182836. doi: 10.1172/jci.insight.182836. Online ahead of print.PMID: 40956633

Characterization of *Shigella* virulence factor intracellular spread A (IcsA, or VirG) functional epitopes against *S. flexneri* 2a and *S. sonnei* invasion and adherence.
Madhwal A, Vakamalla SSR, Li S, Zhang W.Appl Environ Microbiol. 2025 Sep 17;91(9):e0117525. doi: 10.1128/aem.01175-25. Epub 2025 Aug 22.PMID: 40844264

Single-round infectious rotaviruses with deletions of VP7 or VP4 genes, based on SA11 and WC3 strain backbones, and their potential use as viral vectors.
Kotaki T, Kanai Y, Onishi M, Sakai Y, Motooka D, Chen Z, Enoki Y, Komatsu S, Hirai K, Minami S, Kawagishi T, Ushijima H, Kobayashi T.PLoS Pathog. 2025 Sep 15;21(9):e1013484. doi: 10.1371/journal.ppat.1013484. eCollection 2025 Sep.PMID: 40953082

Comparative immunogenicity study of two different types of tuberculosis vaccines based on a heterologous boosting strategy.
Wang X, Wang R, Wang J, Zhang Z, Kong L, Xia L, Qi Z, Chen H.Arch Microbiol. 2025 Sep 15;207(10):262. doi: 10.1007/s00203-025-04463-4.PMID: 40952453

Design and in silico evaluation of a novel chimeric protein vaccine candidate against Salmonella Typhi.
Ajerloo MB, Hajizade A, Nazarian S, Khalili K.J Microbiol Methods. 2025 Sep 18:107268. doi: 10.1016/j.mimet.2025.107268. Online ahead of print.PMID: 40975437

Evaluation of immune responses to Tdap booster during pregnancy in women who received whole cell or acellular pertussis vaccines during childhood.
Hall JM, Caution KJ, Holt KJA, Gupta YA, Guo M, Mir UQ, Skoff TH, Hariri S, Pan X, Worly B, Dubey P.Emerg Microbes Infect. 2025 Dec;14(1):2547732. doi: 10.1080/22221751.2025.2547732. Epub 2025 Sep 15.PMID: 40811865

Understanding Hepatitis B Knowledge, Attitudes, and Stigma in the Korean Community in Australia.
Baek Y, Horwitz R, Brener L, Okeke S, Broady T, Treloar C, Cama E.J Racial Ethn Health Disparities. 2025 Sep 18. doi: 10.1007/s40615-025-02622-3. Online ahead of print.PMID: 40965828

Exploring Dolichos lablab compounds as potential inhibitors for fusion (F) protein of human metapneumovirus (HMPV): A systematic computational approach.
Hossain MM, Apu MJH, Aziz MFBA, Tanjil MTR, Das LC, Kar A, Evamoni FZ, Morshed MM.PLoS One. 2025 Sep 11;20(9):e0332170. doi: 10.1371/journal.pone.0332170. eCollection 2025.PMID: 40934244

Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
Ward JK, Youssef R, Peretti-Watel P.Vaccine. 2025 Sep 17;63:127668. doi: 10.1016/j.vaccine.2025.127668. Epub 2025 Aug 27.PMID: 40876136

A retrospective computational validation of a clinically evaluated recombinant envelope protein tetravalent dengue vaccine.

Reiné J, Tinnirello R, Cagigi A, Leow CY, Leow CH, Iannolo G, Douradinha B.Int J Biol Macromol. 2025 Sep 18:147688. doi: 10.1016/j.ijbiomac.2025.147688. Online ahead of print.PMID: 40975348

Community Engagement Strategy for Building Trust in Human Challenge Studies Using Participatory and Creative Methods: An Ethical Imperative.
Kunda-Ng'andu EM, Chirwa M, Muzazu S, Laban N, Chisenga C, Simuyandi M, Mwale S, Chilengi R, Sharma A.Bioethics. 2025 Sep 12. doi: 10.1111/bioe.70028. Online ahead of print.PMID: 40938292

A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.
Kang W, Wang F, Hao Z, Zhang Z, Su Q, Zhou H, Xu K.Vaccine. 2025 Sep 12;64:127743. doi: 10.1016/j.vaccine.2025.127743. Online ahead of print.PMID: 40945180

Prevalence and risk factors of viral hepatitis and HIV among people experiencing homelessness in Germany based on a nationwide study.
Heinrich F, Wong TLE, Graf W, Dost K, Brennecke A, Kowalski V, van Rüth V, Iwersen-Bergmann S, Hajek A, König HH, Renné T, Brehm TT, Pfefferle S, Schulze Zur Wiesch J, Dandri M, Aepfelbacher M, Püschel K, Ondruschka B, Lütgehetmann M, Stallbaum F.Sci Rep. 2025 Sep 17;15(1):32571. doi: 10.1038/s41598-025-18552-3.PMID: 40962833

The mRNA vaccine encoding Gc protein confers complete protection against severe fever with thrombocytopaenia syndrome virus.
Zhang X, Zhang X, Lu J, Yang P, Lu M, Tan S, Guo W, Hu X, Lin J, Shan C.Vaccine. 2025 Sep 17;63:127631. doi: 10.1016/j.vaccine.2025.127631. Epub 2025 Aug 21.PMID: 40845791

Advances in population-based interventions to control falciparum malaria.
Glossop SE, Peto TJ, Adhikari B.Trans R Soc Trop Med Hyg. 2025 Sep 18:traf088. doi: 10.1093/trstmh/traf088. Online ahead of print.PMID: 40973129

Florida plan to nix vaccine mandates raises alarm.
Cohen J.Science. 2025 Sep 11;389(6765):1075-1076. doi: 10.1126/science.aec1767. Epub 2025 Sep 11.PMID: 40934303

Modelling behavioural changes and vaccination in the transmission of respiratory viruses with co-infection.
Buonomo B, Penitente E.J Math Biol. 2025 Sep 16;91(4):41. doi: 10.1007/s00285-025-02280-3.PMID: 40956316

Advancing chikungunya vaccine equity: a Global Health imperative.
Taha AM, Sabet CJ, Nguyen D, Rodriguez-Morales AJ.Postgrad Med J. 2025 Sep 18;101(1200):931-932. doi: 10.1093/postmj/qgaf036.PMID: 40150992

Clade-Specific Influences of Glycans on the Interactions between HIV-1 Envelope and Broadly Neutralizing Antibodies.
Arandhara M, Kumar Y, Dixit NM, Maiti PK.J Chem Inf Model. 2025 Sep 16. doi: 10.1021/acs.jcim.5c01051. Online ahead of print.PMID: 40958474

Spermine-Functionalized Multiepitope Signaling Peptide Nanovaccine to Stimulate the Systemic Immunity against Pneumonia.
Ponbharathi A, Mehnath S, Sowndharya CK, Dharshini K, Ambigaibalan AC, Jeyaraj M.ACS Pharmacol Transl Sci. 2025 Aug 8;8(9):3182-3198. doi: 10.1021/acsptsci.5c00328. eCollection 2025 Sep 12.PMID: 40969898

Determinants of vaccination uptake among pregnant women in Kumasi: A multi-centre cross-sectional study.
Poku CA, Owusu GA, Gyamfuah P, Addae G, Dwumfour CK, Hagan D, Kumah CY, Lumor DA, Dzomeku V.PLoS One. 2025 Sep 16;20(9):e0332425. doi: 10.1371/journal.pone.0332425. eCollection 2025.PMID: 40956810

Effects of gain-and-loss framing HPV messages on attention and implicit attitudes: An event-related potential study.
Su F, Yang Y, Yu G.Acta Psychol (Amst). 2025 Sep 16;260:105570. doi: 10.1016/j.actpsy.2025.105570. Online ahead of print.PMID: 40961749

Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.
Scherm MJ, Hölzl R, González-Domínguez I, Hjorth R, Chiou SS, Maughan MF, Martik D, Krammer F, Puente-Massaguer E.Vaccine. 2025 Sep 18;64:127671. doi: 10.1016/j.vaccine.2025.127671. Online ahead of print.PMID: 40972238

Relationship dynamics and behavioral adaptations in the control of the 2022 mpox epidemic.
Hvid U, Simonsen L, Frisch M, Sneppen K.Proc Natl Acad Sci U S A. 2025 Sep 16;122(37):e2502861122. doi: 10.1073/pnas.2502861122. Epub 2025 Sep 10.PMID: 40928872

Draft genome and antibiotic resistance profile of a multidrug-resistant *K. pneumoniae*-ST152 strain KA017_S253 from a neonatal blood culture in Ghana.
Tetteh FKM, Egyir B, Boateng W, Owusu-Nyantakyi C, Danso JK, Haq K, Sampane-Donkor E, Duedu KO.Microbiol Resour Announc. 2025 Sep 11;14(9):e0058825. doi: 10.1128/mra.00588-25. Epub 2025 Aug 11.PMID: 40788146

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.
Pathirana J, Ramgopal M, Martin C, Lombaard JJ, Chahin C, Launay O, Ratanasuwan W, Greenberg D, Grijalva CG, Orenstein WA, Shenkerman A, Hall L, Fernsler D, Kim Y, Li J, Platt HL; STRIDE-7 Study Group.Lancet HIV. 2025 Sep 12:S2352-3018(25)00165-1. doi: 10.1016/S2352-3018(25)00165-1. Online ahead of print.PMID: 40953572

The resurgence of measles: Is adolescent vaccination the key??
Tyagi V, Saurabh K, Bhakhri BK, Singh DK, Rai R.Trop Doct. 2025 Sep 17:494755251376406. doi: 10.1177/00494755251376406. Online ahead of print.PMID: 40961259

Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537].

Kahusu CM, Peckeu-Abboud L, Goovaerts O, Matungulu E, Heyndrickx L, Ariën KK, Oostvogels S, Mubiala A, Milua S, Mbilizi IM, Shamamba S, Bayoka N, Ishara-Nshombo E, Tshimanga C, Nkuba A, Peeters M, Bazola B, Sabue J, Ngimba M, Mukanya N, Tshita P, Kinzungu C, Kasumba DM, Tshiani O, Mbala-Kingebeni P, Liesenborghs L, Mukadi-Bamuleka D, Mulangu S, Kavunga-Membo H, Adriaensen W.Vaccine. 2025 Sep 17;64:127719. doi: 10.1016/j.vaccine.2025.127719. Online ahead of print.PMID: 40966976

Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study.
Shi T, Hu D, Deng S, Qu G, Peng B, Zhang Y, Jin Y.Hum Vaccin Immunother. 2025 Dec;21(1):2562739. doi: 10.1080/21645515.2025.2562739. Epub 2025 Sep 19.PMID: 40971344

Characterization of humoral and cellular immunity induced by mRNA vaccines expressing norovirus VP1 proteins in mice and nonhuman primates.
Wei J, Bystol K, Alabanza L, Lim S, Greig J, Gopal P, Reyes Ballista JM, Galli JD, Warren C, Swartz A, David C, Jeong U, Gonzalez-Fernandez E, DeWitt LA, Go G, Lago A, Radcliffe S, May Fulton CD, Shen P, Fridman A, Gaspar J, Pirrone A, Wen Z, O'Donnell G, Austin L, McKenney D, Krosky P, Liu Y, Bett AJ, Zhang L.Mol Ther. 2025 Sep 12:S1525-0016(25)00751-8. doi: 10.1016/j.ymthe.2025.09.023. Online ahead of print.PMID: 40946165

An analytic approach considering two temporal mechanisms driving breakthrough viral infections after vaccination.
Brucker A, Hurst JH, O'Brien EC, Anderson D, Yarrington ME, Krishnan J, Goldstein BA.Vaccine. 2025 Sep 17;63:127638. doi: 10.1016/j.vaccine.2025.127638. Epub 2025 Aug 22.PMID: 40848677

A high-throughput multi-species platform using Biolayer Interferometry Immunosorbent Assay (BLI-ISA) as an alternative to indirect ELISA for vaccine development.
Lu T, Parvej MS, Whittier SK, Maiti S, Dietz ZK, Howlader DR, Zahan MN, Biswas S, Picking WD, Picking WL.J Immunol Methods. 2025 Sep 18;544:113980. doi: 10.1016/j.jim.2025.113980. Online ahead of print.PMID: 40975423

Gc glycoprotein trimer vaccine elicits robust neutralizing antibodies against severe fever with thrombocytopenia syndrome virus in mice.
Liu X, Li Q, Zhang H, Zhang M, Yang Y, Xiao H, He Q, Li H, Wang Y, Li Z.Int Immunopharmacol. 2025 Sep 11;165:115470. doi: 10.1016/j.intimp.2025.115470. Online ahead of print.PMID: 40939432

FliC adjuvant augments protective efficacy of recombinant T2544 antigen against SalmonellaTyphiand Paratyphi A by increasing serum antibodies, intestinal secretory immunoglobulin A and T cell memory.
Chakraborty S, Dutta P, Pal A, Chakraborty S, Mitra S, Miyoshi SI, Das S.Vaccine. 2025 Sep 20;64:127767. doi: 10.1016/j.vaccine.2025.127767. Online ahead of print.PMID: 40976078

Post TIA care in Ontario: A population-based cohort study on secondary prevention.
Fleet JL, Carter B, Kapral MK, Lam M, Frisbee S, Shariff SZ.J Neurol Sci. 2025 Sep 15;476:123603. doi: 10.1016/j.jns.2025.123603. Epub 2025 Jul 12.PMID: 40680348

Management of non-response to Hepatitis B re-vaccination.

Kroening HL, Giri P, Adisesh A.Occup Med (Lond). 2025 Sep 15:kqaf091. doi: 10.1093/occmed/kqaf091. Online ahead of print.PMID: 40971782

Comparative efficacy of a field-strain matched bivalent inactivated vaccine against contemporary newcastle disease and infectious bronchitis viruses in Egypt.
Azab AA, Samir M, Zakaria S, Maged H, Yehia N, Taha M, El-Sanousi AA, Khalil AA.Vet Immunol Immunopathol. 2025 Sep 16;288:111003. doi: 10.1016/j.vetimm.2025.111003. Online ahead of print.PMID: 40966821

Pneumococcal vaccination knowledge, attitudes, and practices among surveyed U.S. adults aged 19-64 years at increased risk for pneumococcal disease.
Ramachandran V, Tangney S, Gedlinske A, Askelson NM, Parker AM, Gidengil CA, Albert AP, Lindley MC, Kobayashi M, Scherer AM.Vaccine. 2025 Sep 15;64:127739. doi: 10.1016/j.vaccine.2025.127739. Online ahead of print.PMID: 40957308

Immunization acceptance after broad recommendation for RSV prophylaxis: Results from a cross-sectional study in Germany.
Wetzke M, Lange M, Beinhauer K, Röpe E, Borgmann J, Ritter S, Brodowski L, Müller F, Happle C.Vaccine. 2025 Sep 11;64:127716. doi: 10.1016/j.vaccine.2025.127716. Online ahead of print.PMID: 40939533

Investigating Interfacial Interactions between the Adjuvant and Antigens in Pneumococcal Conjugate Vaccine In Situ at the Molecular Level.
Wu Y, Gandhi Z, Rossi D, Guo W, Chen X, Gomez F, Lu T, Smith JP, Deng JZ, Chen Z.Anal Chem. 2025 Sep 11. doi: 10.1021/acs.analchem.5c03598. Online ahead of print.PMID: 40935135

Developing a Latin American Delphi consensus on vaccination for respiratory diseases in older adults.
Parodi JF, Runzer-Colmenares FM, Cano-Gutiérrez C, Dinamarca-Montecinos JL, La Torre PB, Boas PFV, Flores-Cohaila JA, Urrunaga-Pastor D, Gutiérrez-Robledo LM.Ann Geriatr Med Res. 2025 Sep 11. doi: 10.4235/agmr.25.0087. Online ahead of print.PMID: 40931721

Seroprevalence and determinants of SARS-CoV-2 anti-nucleocapsid IgG in a vaccinated Iranian adult population: A cross-sectional study, Summer 2023.
Yeganeh A, Kalantar E, Ghaffari A, Keramatinia A, Yeganeh F.Hum Vaccin Immunother. 2025 Dec;21(1):2560063. doi: 10.1080/21645515.2025.2560063. Epub 2025 Sep 17.PMID: 40958679

Evaluation of the effectiveness of the respiratory syncytial virus vaccine in children under 6 months of age in Cordoba, Argentina.
Scruzzi GF, Franchini CG, Giorgetti AC, Fonseca Ingüe L, Sarmiento DD, Belfiore SM, Willington AP, Canna F, Vittori ME, Nieva S, Klein GJ.Arch Argent Pediatr. 2025 Sep 18:e202510741. doi: 10.5546/aap.2025-10741.eng. Online ahead of print.PMID: 40956131

Vaccination against Hendra virus of previously unvaccinated mares and their foals demonstrates the effectiveness of the current prime and boost vaccination schedule for foals.
Carey KJ, Smith I, Hartley CA, Bailey KE, McIntosh K, Broder CC, Gilkerson JR.Vet Microbiol. 2025 Sep 15;310:110732. doi: 10.1016/j.vetmic.2025.110732. Online ahead of print.PMID: 40961579

Public Health in the Age of TikTok: A Content Analysis of Measles Narratives.
Basch CH, Denholtz C, Castillo RG, Jaime C.Int J Infect Dis. 2025 Sep 11:108055. doi: 10.1016/j.ijid.2025.108055. Online ahead of print.PMID: 40945903

Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
Pappas C, Brock N, Belser JA, Kieran TJ, Pulit-Penaloza JA, Sun X, Zeng H, Wang L, Zhou B, Tumpey TM, Maines TR.J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023-25. Online ahead of print.PMID: 40960295

Quantitative Cell Type Specific Immunopeptidome Analysis of Macrophage and Tumor Co-evolution Reveals Therapeutic MHC-I Peptides in Glioblastoma.
Cui Y, Phuong K, Abdelfattah NS, Temple HM, Maiorino L, Kim BJ, Dye J, Yu KKH, Spranger S, White FM.Cancer Res. 2025 Sep 18. doi: 10.1158/0008-5472.CAN-24-4674. Online ahead of print.PMID: 40966317

Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells.
Wang HH, Zaidi N.Cell. 2025 Sep 18;188(19):5121-5123. doi: 10.1016/j.cell.2025.08.025.PMID: 40972530

Comparative effectiveness of construal-level messaging in the COVID-19 Vaccine Injury Compensation Program in the Republic of Korea: a randomized controlled trial.
Moon J, Jeong SH, Choe YJ, Kang CR, Kim T, Kim D, Lee JK.Osong Public Health Res Perspect. 2025 Sep 12. doi: 10.24171/j.phrp.2024.0354. Online ahead of print.PMID: 40935805

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection.
Park H, Nakamura N, Miyamoto S, Sato Y, Kim KS, Kitagawa K, Kobashi Y, Tani Y, Shimazu Y, Zhao T, Nishikawa Y, Omata F, Kawashima M, Abe T, Saito Y, Nonaka S, Takita M, Yamamoto C, Morioka H, Kato K, Sagou K, Yagi T, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Shibata RY, Aihara K, Kodama T, Kamiyama A, Tamura T, Fukuhara T, Shibuya K, Suzuki T, Iwami S, Tsubokura M.Sci Transl Med. 2025 Sep 17;17(816):eadv4214. doi: 10.1126/scitranslmed.adv4214. Epub 2025 Sep 17.PMID: 40961221

Correction: Comparative evaluation of live attenuated and killed tachyzoites as vaccine candidates for toxoplasmosis.
Shanawany EEE, Abdel-Rahman EH, Nemr WA, Hassan SE, Hassan NMF, Desouky HM, Zalat R, Nofal AE, Shaapan RM, Younis SS.AMB Express. 2025 Sep 11;15(1):129. doi: 10.1186/s13568-025-01936-z.PMID: 40932523

Spatial disparities in zero-dose vaccination coverage for children aged 12-23 months in Ethiopia: A geographically weighted regression analysis.
Endehabtu BF, Alemu K, Mengiste SA, Zelalem M, Gullslett MK, Tilahun B.PLoS One. 2025 Sep 11;20(9):e0332162. doi: 10.1371/journal.pone.0332162. eCollection 2025.PMID: 40934201

A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.

Fan W, Zeng X, Chen Y, Yu Q, Zhang Z, Tian G, Liu C, Bao H, Qi X, Wu L, Zhang Y, Liu Y, Wang S, Cui H, Duan Y, Chen H, Gao Y.J Virol. 2025 Sep 11:e0114925. doi: 10.1128/jvi.01149-25. Online ahead of print.PMID: 40932249

Implementation of smartphone application for reporting adverse events following immunization by the treating doctors in tertiary care teaching hospitals in Chennai, India: Pilot and feasibility study.
Krishnamurthy VK, Ilangovan K, Viswanathan V, Suresh S, Chandrasekar R, Chandramohan R, Padmanabhan B, Manjunathaswamy A, Padmanabhan R, Subramaniam S, Dhanasekaran J, Ponnusamy A, Balaji N, Polpakkara D, Selvavinayagam TS, Dhalaria PM, Kumar P.Vaccine. 2025 Sep 17;63:127644. doi: 10.1016/j.vaccine.2025.127644. Epub 2025 Aug 21.PMID: 40845796

Boosting veterinary vaccine availability.
Loeb J.Vet Rec. 2025 Sep 20;197(6):220. doi: 10.1002/vetr.5977.PMID: 40970643

A new method for testing avian metapneumovirus vaccine efficacy: Evaluation of tracheal ciliary activity after a challenge.
Marzo E, Guirado E, Taberner E, Castanyer S, Teixidor I, Feu S.Vaccine. 2025 Sep 17;63:127641. doi: 10.1016/j.vaccine.2025.127641. Epub 2025 Aug 27.PMID: 40876141

Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
Okoli GN, Murphy C, Mak L, Cheng SMS, Peiris M, Cowling BJ.Vaccine. 2025 Sep 17;63:127687. doi: 10.1016/j.vaccine.2025.127687. Epub 2025 Sep 3.PMID: 40902334

One step closer to a pan-genotypic hepatitis C vaccine.
Gomez-Escobar E, Flores N, Shoukry NH.Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001530. Online ahead of print.PMID: 40961022

Determinants of severe COVID-19 in vaccinated adults: a study from southern Brazil (2021-2023).
Sorio GGL, da Silva Gregory V, Sganzerla D, Rodrigues Gonçalves M, Fernandes Dantas Filho F, da Silva Pitombeira Rigatto MH.Pathog Glob Health. 2025 Sep 14:1-8. doi: 10.1080/20477724.2025.2554138. Online ahead of print.PMID: 40946344

Influencing factors of influenza vaccination willingness among the elderly in Wuxi city: A study based on the Behavioral and Social Drivers (BeSD) framework and structural equation modeling.
Yang K, Jiang S, Jiang J.Hum Vaccin Immunother. 2025 Dec;21(1):2559508. doi: 10.1080/21645515.2025.2559508. Epub 2025 Sep 17.PMID: 40962719

Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle vaccine candidates in BALB/c mice.
Muthuraman KR, Boonyakida J, Matsuda M, Suzuki R, Kato T, Park EY.Vaccine. 2025 Sep 17;63:127670. doi: 10.1016/j.vaccine.2025.127670. Epub 2025 Aug 27.PMID: 40876139

Valuing combination vaccines: an incomplete picture and a pathway to a broader view.

Debellut F, Jit M, Portnoy A, Mvundura M, Giersing B, Hasso-Agopsowicz M, Hausdorff WP, Pecenka C.Vaccine. 2025 Sep 17;63:127675. doi: 10.1016/j.vaccine.2025.127675. Epub 2025 Aug 31.PMID: 40889446

A Trichinella spiralis serine protease mediates larva invasion of gut mucosa via inducing enterocyte apoptosis and damaging barrier integrity in mice.
Lu QQ, Zhang R, Zhang XZ, Wu JY, Cong PK, Long SR, Liu RD, Zhang X, Wang ZQ, Cui J.Int J Biol Macromol. 2025 Sep 11;328(Pt 2):147593. doi: 10.1016/j.ijbiomac.2025.147593. Online ahead of print.PMID: 40945834

Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network.
Soe P, Muller MP, Sadarangani M, Kellner JD, Vanderkooi OG, Naus M, Wong H, Isenor JE, Marty K, De Serres G, Valiquette L, McGeer A, Bettinger JA; Canadian Immunization Research Network.Hum Vaccin Immunother. 2025 Dec;21(1):2560172. doi: 10.1080/21645515.2025.2560172. Epub 2025 Sep 18.PMID: 40963477

Sequence variability of the K1 gene in Kaposi's sarcoma-associated herpesvirus and its role in pathogenesis.
Choi S, Song JT, Lee SH, Choi UY.Curr Opin Virol. 2025 Sep 17;73:101489. doi: 10.1016/j.coviro.2025.101489. Online ahead of print.PMID: 40967090

Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19.
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Lourenço KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H.Vaccine. 2025 Sep 19;64:127756. doi: 10.1016/j.vaccine.2025.127756. Online ahead of print.PMID: 40974737

Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong.
You D, Quan J, Bishai D, Lam WWT, Grépin KA, Chan L, Wu DD, Wong DKK, Wong WCW, Zhou J.Vaccine. 2025 Sep 17;63:127625. doi: 10.1016/j.vaccine.2025.127625. Epub 2025 Aug 22.PMID: 40848676

Severe Dengue Hemorrhagic Fever After TAK-003 Dengue Vaccination: A Case Report of a Potential Vaccine-Associated Adverse Reaction.
Rattanaumpawan P, Horthongkham N, Suwannakarn K, Athipanyasilp A, Jongwutiwes U.Int J Infect Dis. 2025 Sep 12:108062. doi: 10.1016/j.ijid.2025.108062. Online ahead of print.PMID: 40946778

A panel data analysis of the impact of government trust on support for universal and air travel vaccine mandates during the COVID-19 pandemic.
Nillasithanukroh S, Park CH, Richards R, Ghaleb A.Soc Sci Med. 2025 Sep 11;384:118586. doi: 10.1016/j.socscimed.2025.118586. Online ahead of print.PMID: 40946593

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.

Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV, Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS, Nistor GI, Dillman RO.Hum Vaccin Immunother. 2025 Dec;21(1):2556591. doi: 10.1080/21645515.2025.2556591. Epub 2025 Sep 12.PMID: 40938661

High coverage with delayed doses: Cross-sectional study of parental acceptance and uptake of varicella vaccination in children aged 4-12 years in Chaoyang District, Beijing.
Cao Y, Li X, Zhao Z, Li Z, Liu F, Liu P, Ma J, Shi Q, Zhang N, Jia B.Hum Vaccin Immunother. 2025 Dec;21(1):2558271. doi: 10.1080/21645515.2025.2558271. Epub 2025 Sep 15.PMID: 40952382

COVID-19 vaccinations in America: Don't forget long COVID and the post-acute sequelae.
Hotez PJ.Vaccine. 2025 Sep 17;63:127676. doi: 10.1016/j.vaccine.2025.127676. Epub 2025 Aug 27.PMID: 40876137

Post-vaccination sero-monitoring of bovine calves in Indian subcontinent: A review on progress towards brucellosis control.
Shome R, Konda PY, Gandu S, Skariah S, Muninarayanaswamy PKA, Maharana SM, Mohandoss N.Vet Immunol Immunopathol. 2025 Sep 12;288:110999. doi: 10.1016/j.vetimm.2025.110999. Online ahead of print.PMID: 40966822

Zn-coordinated lipid nanoparticles synergistically enhance spleen-targeting delivery and elicit $CD8^+$ T cell-mediated cancer immunotherapy.
Han Y, Zhang K, Xin N, Gao X, Ma G, An J, Li Y.J Colloid Interface Sci. 2025 Sep 14;702(Pt 2):139025. doi: 10.1016/j.jcis.2025.139025. Online ahead of print.PMID: 40961556

Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.
Odagiri T, Yoshino N, Sasaki Y, Ishikawa S, Muraki Y.Vaccine. 2025 Sep 15;64:127750. doi: 10.1016/j.vaccine.2025.127750. Online ahead of print.PMID: 40957307

Healthcare professionals' awareness of and barriers to shared-clinical-decision-making for HPV vaccination among adults 27-45 years.
Desai M, Sharma SV, Fokom Domgue J, Chido-Amajuoyi O, Yu R, Chan W, Darkoh C, Shete S.Hum Vaccin Immunother. 2025 Dec;21(1):2560061. doi: 10.1080/21645515.2025.2560061. Epub 2025 Sep 18.PMID: 40966492

SARS-CoV-2 convalescent plasma for the controlled clinical trial "COVIC-19": Experience from collection of very high-titer plasma from superimmunized individuals.
Hoffmann S, Seidel A, Ludwig C, Vieweg C, Müller R, Hofmann H, Jahrsdörfer B, Wuchter P, Klüter H, Schmidt M, Johnsen M, Burkhardt T, Appl T, Schrezenmeier E, Münch J, Tiberghien P, Schrezenmeier H, Körper S.Transfusion. 2025 Sep 12. doi: 10.1111/trf.18394. Online ahead of print.PMID: 40937925

The cumulative incidence and infection hospitalisation risk of SARS-CoV-2 by variant; a longitudinal study in England.
Gaughan C, Braunholtz D, Massie L, Khera T, Birrell PJ, De Angelis D, Blake J, Preece J, Pouwels K, Walker AS, Infection Survey Team TC.Am J Epidemiol. 2025 Sep 17:kwaf203. doi: 10.1093/aje/kwaf203. Online ahead of print.PMID: 40972591

Gut commensal Lactobacillus strain induces a balanced trained immunity phenotype to enhance vaccine efficacy through JAK-STAT-SOCS pathway.
Niu L, Li H, Guo J, Jia Z, Chang Q, Liu N, Zhang S, Ge J.Probiotics Antimicrob Proteins. 2025 Sep 18. doi: 10.1007/s12602-025-10769-y. Online ahead of print.PMID: 40965792

Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
Louth J, Holland A, Chum C, Morgan L, Tonge S, Linley E, Lucidarme J, Clark SA, Borrow R.Vaccine. 2025 Sep 17;63:127647. doi: 10.1016/j.vaccine.2025.127647. Epub 2025 Aug 23.PMID: 40850292

A Prospective Cohort Study of Hepatitis B Virus Vaccination in Pediatric Heart Transplant Recipients: Cellular and Humoral Immune Responses and the Role of Innate Immunity.
Lazaro-Martin B, Tarancon-Diez L, Camino Lopez M, Alonso R, Gil Villanueva N, Muñoz-Fernández MÁ, Hernanz-Lobo A, Navarro Gomez ML.Pediatr Infect Dis J. 2025 Sep 11. doi: 10.1097/INF.0000000000004958. Online ahead of print.PMID: 40928222

Seasonal influenza viruses show distinct adaptive dynamics during growth in chicken eggs.
Kistler K, Bedford T.Mol Biol Evol. 2025 Sep 17:msaf227. doi: 10.1093/molbev/msaf227. Online ahead of print.PMID: 40974095

Development of *in vitro* and *in vivo* neutralization assays for New World alphaviruses based on the VSV pseudovirus system.
Liu Y, Chen C, Liao B, Geng X, Huang W, Nie J.Emerg Microbes Infect. 2025 Dec;14(1):2555721. doi: 10.1080/22221751.2025.2555721. Epub 2025 Sep 16.PMID: 40890032

African swine fever virus pNP419L inhibits type I interferon signaling by blocking ISGF3-mediated transcriptional activation.
Chen Q, Liu L, Wu W, Li L, Yu Z, Liu Q, Wang D, Tan C, Chen H, Wang X.Int J Biol Macromol. 2025 Sep 15;328(Pt 2):147704. doi: 10.1016/j.ijbiomac.2025.147704. Online ahead of print.PMID: 40962095

Immunogenicity of Three-session Intradermal Rabies Post-exposure Prophylaxis in Indian Children and Adolescents.
Agarwal A, Rana S, Mathur SB, Manchanda V, Agarwal K, Singh M.Pediatr Infect Dis J. 2025 Sep 17. doi: 10.1097/INF.0000000000005004. Online ahead of print.PMID: 40966763

Bioencapsulation of Transgenic Nannochloropsis sp. Using Artemia as a Vaccine Delivery System to Zebrafish as a Fish Model Against Vibriosis.
Ismail NFN, Abidin AAZ, Yusoff FM, Karim MMA, Yasin ISM, Yusof ZNB.Mol Biotechnol. 2025 Sep 18. doi: 10.1007/s12033-025-01496-4. Online ahead of print.PMID: 40965591

Retrospective assessment of vaccination policy optimizations during an Omicron BA.2 epidemic in Hong Kong: A modelling study.
Young BR, Ho F, Lin Y, Lau EHY, Wu P, Cowling BJ, Tsang TK.J Infect Public Health. 2025 Sep 12;18(12):102972. doi: 10.1016/j.jiph.2025.102972. Online ahead of print.PMID: 40966820

Trust in Media, Trust in Science, Political Party, Big Five Personality Traits, and Vaccination Intention: A Cross-Sectional Study.
Johnson EK, Meadows C, Zhang Meadows CC.Health Sci Rep. 2025 Sep 17;8(9):e70957. doi: 10.1002/hsr2.70957. eCollection 2025 Sep.PMID: 40970103

HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent vaccine coverage.
Cosgrove S, Hider P, Anglemyer A, Walls T.Vaccine. 2025 Sep 17;63:127637. doi: 10.1016/j.vaccine.2025.127637. Epub 2025 Aug 27.PMID: 40876142

Assembly of the Mycobacterium tuberculosis type VII ESX-1 secretion system in Mycobacterium smegmatis identifies a new transcriptional activator of esx-1 genes and a novel TB vaccine.
Zriba S, Lim ZL, Snider M, Niroula N, Hardouin M, Chen JM.Microbiol Spectr. 2025 Sep 12:e0113125. doi: 10.1128/spectrum.01131-25. Online ahead of print.PMID: 40938095

Dynamics of cholera transmission in poultry farm: insights from a compartmental model and control strategies.
Malek A.Br Poult Sci. 2025 Sep 17:1-8. doi: 10.1080/00071668.2025.2556415. Online ahead of print.PMID: 40960429

Chitosan-coated PLGA nanoparticles as a delivery system for infectious bursal disease viral antigen in chickens.
Kumar V, Panickan S, Kumar A, Ramakrishnan S, Saxena S, Shrivastava S, Dandapat S.Avian Pathol. 2025 Sep 12:1-14. doi: 10.1080/03079457.2025.2547584. Online ahead of print.PMID: 40814829

Vaccination coverage by age 24 months among children born in 2020 and 2021 in China, during the COVID-19 pandemic: A study based on the national immunization information system.
Huang W, Xu M, Diao Z, Chen J, Lv H, Li J, Guang M, Liang H, Wang D, Zeng F, Liu D, Jing F, Liang X.Vaccine. 2025 Sep 12;64:127717. doi: 10.1016/j.vaccine.2025.127717. Online ahead of print.PMID: 40945181

Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
Barlow M, Flanagan S, Ghosh I, Carter J, Kemper A, Ko J, Bedford H, Noonan A, Sultan B, Gillyon-Powell M, Mandal S, Eisen S, Matthews PC.Vaccine. 2025 Sep 17;63:127639. doi: 10.1016/j.vaccine.2025.127639. Epub 2025 Aug 26.PMID: 40865309

Beyond Coverage: Policy Lessons From Socioeconomic Gaps in Paediatric Vaccine Access.
Trindade TS, Oliveira CC, Amaral MR, Costa N, Oliveira MA, Monteiro V, Costa M.Acta Paediatr. 2025 Sep 12. doi: 10.1111/apa.70299. Online ahead of print.PMID: 40937609

Streptococcus pneumoniae bacteremia: comparison of incidence, epidemiology, and clinical outcome in a pre- and post-COVID-19 period.
Bedini A, Di Trapani MD, Franceschi G, Zona S, Meschiari M, Soffritti A, Simion M, Franceschini E, Vocale C, Lazzarotto T, Sarti M, Mussini C.Eur J Clin Microbiol Infect Dis. 2025 Sep 20. doi: 10.1007/s10096-025-05267-6. Online ahead of print.PMID: 40974458

A New Saponin From Tridax procumbens L.: In Vitro and In Silico Studies Reveal Broad Spectrum of Bioactivities.
Ingole VV, Katade SR, Mhaske PC, Shaikh SB.Chem Biodivers. 2025 Sep 17:e01842. doi: 10.1002/cbdv.202501842. Online ahead of print.PMID: 40961457

Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial.
Haaland B, Dickson SP, Santana AF, Tanzi RE, Dubois B, Peters O, Grimmer T, Christensen J, Mallinckrodt C, Schneeberger A, Hendrix SB.J Alzheimers Dis. 2025 Sep 15:13872877251375985. doi: 10.1177/13872877251375985. Online ahead of print.PMID: 40953123

A feasibility study: Using mobile phone-based tools to collect community-level Behavioral and Social Drivers (BeSD) of vaccination data in Zambia.
Shragai T, Riley C, Bwalya M, Sikare E, Tembo R, Bibohere J, Kalangwa K, Mulenga WL, Simooya C, Aguma O, Matanda K, Liwewe MM, Abad N, Lam E, Winters A, Bonner KE.PLOS Glob Public Health. 2025 Sep 16;5(9):e0004839. doi: 10.1371/journal.pgph.0004839. eCollection 2025.PMID: 40956815

Enhancing Influenza Vaccination for Adults Aged 50-64Years: Addressing Moderate Vaccine Efficacy.
Davido B, Kharkhordine M.Clin Infect Dis. 2025 Sep 16;81(2):e40-e41. doi: 10.1093/cid/ciaf070.PMID: 39976116

Conjugation of TLR7/8 Adjuvants with Cholesteryl Pullulan for a Self-Assembled Nanogel Vaccine: Enhanced Immunostimulatory Activation with Reduced Systemic Inflammation.
Yazawa Y, Sawada SI, Sasaki Y, Akiyoshi K.ACS Appl Bio Mater. 2025 Sep 15;8(9):7899-7908. doi: 10.1021/acsabm.5c00866. Epub 2025 Aug 21.PMID: 40839856

Impact of a Free Influenza Vaccination Policy on Older Adults in Zhejiang, China: Cross-Sectional Survey of Vaccination Willingness and Determinants.
Zhao Y, Xu J, Zhang X, Xu Y, Yan X, Ren S, Wang L.JMIR Hum Factors. 2025 Sep 15;12:e73940. doi: 10.2196/73940.PMID: 40953309

Non-hematopoietic tryptophan metabolism is a driver of ineffective T cell responses during secondary pulmonary bacterial infection.
Roberts LM, Arakkal L, Wehrly T, Fonseka CP, Laskova P, Schwarz B, Bohrnsen E, Germain R, Bosio CM, Speranza E.J Immunol. 2025 Sep 16:vkaf197. doi: 10.1093/jimmun/vkaf197. Online ahead of print.PMID: 40972009

Isolation, propagation, and characterization of a G9P[4] human rotavirus strain 543765 in Iran.
Kachooei A, Aramideh-Khouy R, Hosseini-Tehrani M, Mir-Hosseinian M, Habib Z, Kazemi-Aghdam M, Jalivand S, Latifi T, Ataei-Pirkooh A, Shoja Z.Virology. 2025 Sep 17;612:110695. doi: 10.1016/j.virol.2025.110695. Online ahead of print.PMID: 40972453

Trace amounts of cobalt serve as an adjuvant for unglycosylated JEV-ED3 expressed in E. coli, inducing a potent virus-neutralizing immune response.
Islam MD, Kurosu T, Okawa M, Morikoshi N, Islam MM, Tsurui H, Kuroda Y.Vaccine. 2025 Sep 12;64:127742. doi: 10.1016/j.vaccine.2025.127742. Online ahead of print.PMID: 40945179

Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses.
Lloyd PC, Acharya G, Zhao H, Chen B, Beachler DC, Secora A, Djibo DA, Amend KL, Ambarsoomzadeh D, Clarke TC, Ng X, Parlett L, Thelus R, Wang X, McMahill-Walraven CN, Lyu R, Wilkinson M, Parambi R, Song J, Seeger JD, Yang G, Stone A, Ding N, Tarazi WW, Hu M, Chillarige Y, Anderson SA, Forshee RA.Vaccine. 2025 Sep 17;63:127614. doi: 10.1016/j.vaccine.2025.127614. Epub 2025 Aug 21.PMID: 40845790

Cost-effectiveness and public health impact of influenza vaccination strategies for Chinese patients with rheumatoid arthritis.
Xu K, Xu Z, Chen Y, Fan C, Fu C.Hum Vaccin Immunother. 2025 Dec;21(1):2563198. doi: 10.1080/21645515.2025.2563198. Epub 2025 Sep 19.PMID: 40971358

First Mpox emergency in Africa: Confronting the dual challenge of outbreak management and vaccine scarcity.
Gulumbe BH, Abdulrahim A, Abubakar MT.Trop Doct. 2025 Sep 18:494755251378823. doi: 10.1177/00494755251378823. Online ahead of print.PMID: 40966111

Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
Humphreys J, Blake A, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, Machado A, Brito A, Ljung R, Pihlstrom N, Mansiaux Y, Monge S, Bacci S, Nunes B; VEBIS-EHR working group.Vaccine. 2025 Sep 19;64:127752. doi: 10.1016/j.vaccine.2025.127752. Online ahead of print.PMID: 40974735

In Vitro and *Ex Vivo* Evidences that Pharmacological Induction of the Hypoxia Response Pathway Efficiently Restricts Measles and Nipah Virus Infections.
Canus L, Jacquemin C, Orch WE, Ogire E, Ferren M, Moissonnier E, Lalande A, Bourgeais A, Ducret G, Bouget J, Haftek Z, Jacolin F, Aublin-Gex A, Décimo D, Moroso M, Mely S, Rozières A, Faure M, Diaz O, Gerlier D, Si-Tahar M, Lotteau V, Perrin-Cocon L, Mathieu C, Vidalain PO.Emerg Microbes Infect. 2025 Sep 17:2563067. doi: 10.1080/22221751.2025.2563067. Online ahead of print.PMID: 40958637

Quality of Life Impact of Varicella on Children and Their Families in the UK: The QoLPoX Study.
Marlow R, Roderick M, Oliver J, Jordan Z, Rowbotham I, Jones S, Wilkins S, Thompson C, Whittaker L, Bethell D, Shackley F, Cathie K, Heath PT, Langlands J, Lopez-Bernal J, Amirthalingam G, Rodrigues F, Finn A; QoLPoX Research Group.Pediatr Infect Dis J. 2025 Sep 12. doi: 10.1097/INF.0000000000004967. Online ahead of print.PMID: 40970745

Randomized pragmatic trial of the comparative effectiveness of chicken egg-based inactivated, mammalian cell-culture-based inactivated, and recombinant protein quadrivalent seasonal influenza vaccines in United States Military Health System beneficiaries.
Colombo RE, Richard SA, Schmidt K, Schofield C, Ganesan A, Campbell W, Hrncir D, Lalani T, Mende K, Markelz AE, Berjohn CM, Housel L, Becher D, Zell ER, Ewing D, Sundaram AK, Modi JR, Saperstein A, Tilley DH Jr, Williams A, McClenathan B, Collins L, Spooner C, Seshadri S, Fries A, Maves R, Powers JH 3rd, O'Connell RJ, Pollett SD, Simons MP, Coles CL, Burgess TH; PAIVED Study Group.Clin Infect Dis. 2025 Sep 18:ciaf503. doi: 10.1093/cid/ciaf503. Online ahead of print.PMID: 40973113

mRNA-encoded mutant HPV16/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice.
Zhang Q, Cao B, Li L, Zhou Y, Ni C, Zhao Y, Xu D, Yu H, Jin L, Zhang Y, Qiao X, Zhang J, Liu S, Zhang X, Liu A, Han H, Ma X, Xu W.J Immunother Cancer. 2025 Sep 17;13(9):e012090. doi: 10.1136/jitc-2025-012090.PMID: 40967673

The UL24 gene affects duck plague virus replication, and its deletion attenuates virulence, enabling use as a vaccine.
Cao H, Ruan P, Chen H, Wang M, Yang L, Cheng A.Poult Sci. 2025 Sep 14;104(11):105848. doi: 10.1016/j.psj.2025.105848. Online ahead of print.PMID: 40974994

Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
Harit D, Sawant S, Spreng RL, Gurley S, Schechter A, Sharak A, Bae A, Creanga A, Kanekiyo M, Li Z, Sarzotti-Kelsoe M, Walter EB, Moody MA, Tomaras GD.Vaccine. 2025 Sep 19;64:127699. doi: 10.1016/j.vaccine.2025.127699. Online ahead of print.PMID: 40974739

Lipid A mimetic BECC438 potentiates durable and balanced antibody responses in an ovalbumin murine model of vaccination.
Harberts EM, Fields JK, Hunat JCS, Otteni DM, Gardner FM, Varisco DJ, Sundberg EJ, Snyder GA, Ernst RK.Immunohorizons. 2025 Sep 17;9(10):vlaf038. doi: 10.1093/immhor/vlaf038.PMID: 40972648

Brief report: Older adolescents and young adults may be at higher risk for changes to menstrual cycle length with COVID-19 vaccination.
Payne LA, Edelman A, Darney BG, Benhar E, Boniface ER.PLoS One. 2025 Sep 18;20(9):e0331346. doi: 10.1371/journal.pone.0331346. eCollection 2025.PMID: 40966228

Assessing the feasibility of partner-implemented digital payment systems for health workers: stakeholder perspectives from Uganda's yellow fever mass vaccination campaign - a qualitative study.
Ediau M, Ekirapa Kiracho E, Aweko J, Opio C, Ashaba MS, Waiswa P.BMJ Glob Health. 2025 Sep 18;10(Suppl 4):e017472. doi: 10.1136/bmjgh-2024-017472.PMID: 40973186

Does Medical Training of Local Health Department Executives Improve COVID-19 Vaccination Uptake and Case Growth?
Hou X, Jiao Y, Chen ZA, Fang X, Khan MM.J Public Health Manag Pract. 2025 Sep 18. doi: 10.1097/PHH.0000000000002208. Online ahead of print.PMID: 40971522

Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
Korves C, Kulldorff M, Balajee AS, Smith J, Zwain GM, Graham DJ, Whitaker H, Izurieta HS.Vaccine. 2025 Sep 17;63:127658. doi: 10.1016/j.vaccine.2025.127658. Epub 2025 Aug 27.PMID: 40876138

Estimating the Burden of Mild-to-Moderate Varicella-Related Infections by Medical Helpline Usage: A Time Series Analysis from 2015 to 2023 Among Children in Denmark.

Egeskov-Cavling AM, Johannesen CK, Rezahosseini O, Eiberg MF, Poulsen A, Folke F, Fischer TK.Infect Dis Ther. 2025 Sep 13. doi: 10.1007/s40121-025-01233-z. Online ahead of print.PMID: 40944874

The US Advisory Committee on Immunization Practices (ACIP): Trustworthy Travel Vaccine Guidance and Politics.
Chen LH, Barnett ED, Goad J, Schofield S, Shlim DR, Wilson ME.J Travel Med. 2025 Sep 15:taaf098. doi: 10.1093/jtm/taaf098. Online ahead of print.PMID: 40971795

Hotly anticipated US vaccine meeting ends with confusion - and a few decisions.
Lenharo M, Ledford H.Nature. 2025 Sep 20. doi: 10.1038/d41586-025-03054-z. Online ahead of print.PMID: 40973756

Enhancing the virulence of G2a subtype PEDV by chimeric expression of G2c subtype S gene.
Pan S, Zou J, Mou C, Wang Z, Liu H, Fu L, Chen Z.Vet Microbiol. 2025 Sep 17;310:110728. doi: 10.1016/j.vetmic.2025.110728. Online ahead of print.PMID: 40976147

Reimagining vaccine confidence in the digital age.
Yang YT.BMJ. 2025 Sep 19;390:r1955. doi: 10.1136/bmj.r1955.PMID: 40973442

INFLUENZA VACCINATION FOR PREVENTION OF DEATH AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF STROKE: A SUBANALYSIS OF THE VIP-ACS TRIAL.
Fonseca HA, Sampaio Silva G, Monfardini F, Nicolau JC, Rizzo LV, Berwanger O.Int J Stroke. 2025 Sep 19:17474930251383626. doi: 10.1177/17474930251383626. Online ahead of print.PMID: 40973981

The Chitosan Nanoparticle-based Adjuvant CH-100 Orchestrates Multifaceted Innate Immune Activation via STING-Dependent and -Independent Pathways.
Nagai E, Ori D, Kano N, Ikegawa M, Kobiyama K, Ishii KJ, Kawasaki T, Kawai T.Int Immunol. 2025 Sep 15:dxaf054. doi: 10.1093/intimm/dxaf054. Online ahead of print.PMID: 40973173

Domain-Specific Impacts of Spike Protein Mutations on Infectivity and Antibody Escape in SARS-CoV-2 Omicron BA.1.
Kim TH, Bae S, Myoung J.J Microbiol Biotechnol. 2025 Sep 16;35:e2507040. doi: 10.4014/jmb.2507.07040.PMID: 40967903

Correction to: Pneumococci remain the main cause of complicated pediatric pneumonia in the post-pandemic era despite extensive pneumococcal vaccine use.
Gomes-Silva J, Pinho MD, Friaes A, Ramirez M, Melo-Cristino J, Silva-Costa C; Portuguese Group for the Study of Streptococcal Infections; Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society.Pneumonia (Nathan). 2025 Sep 15;17(1):25. doi: 10.1186/s41479-025-00179-7.PMID: 40954506

Precision Targeting of Myeloid Cells via Peptide Dendrimer-Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies.
Billing LJ, Martin L, Henser-Brownhill T, Samangouei P, Leach A, Knight P, Apostolidou M, Ladak A, Nagel B, Kwok A.Adv Sci (Weinh). 2025 Sep 19:e14417. doi: 10.1002/advs.202514417. Online ahead of print.PMID: 40971720

The relationship between state vaccination exemption policies and MMR vaccination trends in the U.S.
Saiyed S, Dong E, Gardner LM.Vaccine. 2025 Sep 20;64:127773. doi: 10.1016/j.vaccine.2025.127773. Online ahead of print.PMID: 40976077

Prosthetic Joint Infection Caused by Streptococcus pneumoniae Serotype 15F: A Rare Manifestation of an Emerging Non-Vaccine Serotype.
Saijo M, Constantine S, Wakai T, Sakuma A, Ando S, Takayanagi S.Intern Med. 2025 Sep 18. doi: 10.2169/internalmedicine.6099-25. Online ahead of print.PMID: 40967803

A safe start for PfSPZ Vaccine, but efficacy in children remains elusive.
Aderinto N, Oyedele TJ.Lancet Infect Dis. 2025 Sep 16:S1473-3099(25)00478-5. doi: 10.1016/S1473-3099(25)00478-5. Online ahead of print.PMID: 40972631

The 1904 Rio De Janeiro vaccine revolt: Resistance to compulsory smallpox vaccination.
Esparza J, Damaso CR.Vaccine. 2025 Sep 19;64:127774. doi: 10.1016/j.vaccine.2025.127774. Online ahead of print.PMID: 40974738

Computing the inducibility of broadly neutralizing antibodies under a context-dependent model of affinity maturation: applications to sequential vaccine design.
Mathews J, Van Itallie E, Li Y, Wiehe K, Schmidler SC.J Immunol. 2025 Sep 13:vkaf234. doi: 10.1093/jimmun/vkaf234. Online ahead of print.PMID: 40971634

Complete genome sequence of Baby Chick Ranikhet Disease Vaccine (BCRDV) strain in Bangladesh.
Parveen N, Karim MR, Happy SS, Begum T, Hossen A, Uddin AA, Ahmed T, Jahan S, Kamal MM, Samad MA.Microbiol Resour Announc. 2025 Sep 17:e0068125. doi: 10.1128/mra.00681-25. Online ahead of print.PMID: 40960370

Epidemiological analysis and detection of a 27a-like porcine parvovirus strain with pathogenicity in pregnant sows in Japan.
Sato T, Hayashi S, Sugiura K.J Vet Med Sci. 2025 Sep 18. doi: 10.1292/jvms.25-0291. Online ahead of print.PMID: 40967781

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([01.09.2025 TO 22.09.2025]) *as the publication date 89 records.*

1.WO/2025/179633VACCINE FOR INDUCING IMMUNOLOGICAL TOLERANCE, PREPARATION METHOD THEREFOR, AND THE USE THEREOF

WO - 04.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2024/081161Solicitante WUXI BOSTON BIOPHARMACEUTICAL CO., LTD.Inventor/a LIU, Jinsheng

The present invention relates to a vaccine for inducing immunological tolerance, a preparation method therefor, and the use thereof, and belongs to the technical field of biological medicines. The provided vaccine for inducing immunological tolerance comprises a

polymer carrier, and an antigen and immunomodulator which are loaded on the polymer carrier. The vaccine for inducing immunological tolerance comprises a nano vaccine and/or a micron vaccine, the particle size of the nano vaccine being 150-1000 nm and the particle size of the micron vaccine being 1μm-5μm. The surface potential of the vaccine for inducing immunological tolerance is -3mV to -150mV. The nano vaccine can more rapidly and efficiently penetrate into lymph nodes by itself and activate the immune system, and the micron vaccine is first phagocytosed by an antigen-presenting cell at an injection site and then enters the lymph nodes by means of homing effects and thus slowly acts, and therefore the long-term effect and the short-term effect cooperate to better exert the functions. The nano vaccine or micron vaccine which is prepared by using PEMA as an emulsifier and carries more negative electric charges can release the antigen rapidly and thus takes effect quickly, and the nano vaccine or micron vaccine which is prepared by using PVA as an emulsifier and carries less negative electric charges releases the antigen slowly, and thus has long-lasting effects, and therefore using the vaccines which act rapidly and act slowly in combination can exert functions in both short term and long term.

2.202502760 50VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE

US - 04.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18262975Solicitante BAYER ANIMAL HEALTH GMBHInventor/a Thomas ILG

The present invention relates to a vaccine composition for breaking self-tolerance against a self-protein of a host, in particular for breaking self-tolerance against endogenous cytokines in an animal host. The vaccine composition of the invention contains a polyprotein, a DNA encoding for the polyprotein and/or an RNA encoding for the polyprotein and one or more immunostimulatory oligonucleotides. The polyprotein comprises at least two self-protein segments of the host and one or more T-cell epitopes of non-host origin in between and/or adjacent to the at least two self-protein segments.

The present invention further concerns the use of the vaccine composition for the prevention and/or treatment of diseases including the prevention and/or treatment of a pruritic condition and/or an allergic condition. In another aspect, the present invention provides a method for detecting the presence of autoantibodies against self-proteins that can be generated with the vaccine composition of the invention.

3.WO/2025/179362FISH VACCINE, USE THEREOF AND METHOD OF PREPARATION

WO - 04.09.2025

Clasificación Internacional A61K 39/02Nº de solicitud PCT/BR2025/050080Solicitante FARMACORE BIOTECNOLOGIA LTDAInventor/a LOPES SILVA, Celio

The present invention relates to the development of a microencapsulated vaccine containing inactivated Streptococcus agalactiae, together with the adjuvants beta glucan and mineral oil, to be administered orally to fish together with feed in pelletised form or coated with the vaccine. In addition, the invention relates to the use of this vaccine to immunise fish, more specifically Nile tilapia (Oreochromis niloticus) to activate both innate and adaptive (humoral and cellular) intestinal mucosal immunity and protect tilapia against streptococcosis. Such a vaccine can be applied in intensive fishing production systems, with the aim of reducing fish mortality, reducing the use of antimicrobials and not causing environmental damage, being easy to administer and control, reducing fish handling, and being suitable for immunising large numbers of animals at the same time without stress and at low cost.

4.WO/2025/183490MUCOSAL VACCINE COMPOSITION AND USE THEREOF

WO - 04.09.2025

Clasificación Internacional A61K 9/00Nº de solicitud PCT/KR2025/002790Solicitante SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventor/a YEOM, Su Cheong

The present invention relates to a vaccine composition for mucosal immunity and use thereof. It has been identified that the vaccine composition of the present invention is in the form of a 2D patch and effectively induces nasal mucosal immunity despite nasal mucociliary clearance (MCC). Thus, the vaccine composition provided in the present invention can be variously utilized for mucosal immunity in which various antigenic substances are used.

5.WO/2025/183539PORCINE CIRCOVIRUS TYPE 2 INFECTION-PREVENTING VACCINE COMPOSITION FOR INTRADERMAL INJECTION

WO - 04.09.2025

Clasificación Internacional A61K 39/39Nº de solicitud PCT/KR2025/099498Solicitante INNOVAC INC.Inventor/a HAHN, Tae-Wook

The present invention relates to a porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection. The porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection, according to the present invention, has been verified to be safe through clinical evaluation, and has been confirmed to induce a higher level of a neutralizing antibody titer compared to an intramuscular injection group. This means that the porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection, according to the present invention, effectively protects against porcine circovirus which is recently prevalent, and thus may be utilized in various ways in the fields of porcine circovirus infection prevention and pig farming.

6.WO/2025/184664MULTI-ANTIGEN HERPES SIMPLEX VACCINE

WO - 04.09.2025

Clasificación Internacional A61K 39/245Nº de solicitud PCT/US2025/018209Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor/a BENMOHAMED, Lbachir

Herpes simplex virus (HSV) is a significant concern for the global health community due to its morbidity and often-asymptomatic nature. Infected individuals may develop conditions such as ocular disease or genital herpes as characteristic manifestations of the infection. The complexity of HSV's infectious mechanisms has led to adaptations in existing treatment options, but despite these advancements, no definitive or highly effective vaccine has yet been found. Several promising vaccine candidates have been developed using recombinant technology, genetic engineering, and advanced methods. Over the past decade, vaccine development has increasingly favored viral vector-based vaccines, which often elicit a stronger immune response than other approved vaccines that may require boosters. The protective efficacy of five recombinant adenovirus-based therapeutic vaccines is described herein, focusing on their impact on the frequency and function of DRG- and VM-resident CD4+ and CD8+ T cells and their effect on the frequency and severity of recurrent genital herpes.

7.WO/2025/180206IMMUNOENHANCING RNA MOLECULE, AND COMPOSITION, VACCINE AND KIT THEREOF

WO - 04.09.2025

Clasificación Internacional C12N 15/62Nº de solicitud PCT/CN2025/076748Solicitante UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINAInventor/a WANG, Yucai

The present invention relates to the technical field of biology, and provides an immunoenhancing RNA molecule, and a composition, vaccine and kit thereof. The present invention provides an RNA molecule, wherein a coding region of the RNA molecule comprises an HSP structural region, an SIG structural region and an AN structural region; and the HSP structural region encodes an HSP protein family or variants, fragments or derivatives thereof. The HSP protein family comprises HSP70 and family proteins in full-length, truncated, or mutated forms, which enhance antigen uptake, activation levels, and antigen presentation, thereby improving antigen-specific immune responses from multiple angles. In addition, the present invention provides a composition, vaccine and kit comprising the RNA molecule, for use in preventing and treating a variety of diseases, such as cancers, infectious diseases, autoimmune diseases, allergies, or graft versus host disease.

8.WO/2025/179940RSV NANOPARTICLE VACCINE AND PREPARATION METHOD THEREFOR

WO - 04.09.2025

Clasificación Internacional C07K 14/135Nº de solicitud PCT/CN2024/129834Solicitante UNIVERSALVAX BIOTECHNOLOGIES (TAIZHOU) CO., LTD.Inventor/a LI, Jianping

The present invention relates to the technical field of biomedicine. Specifically provided are a respiratory syncytial virus (RSV) Pre-F recombinant protein nanoparticle vaccine and a preparation method therefor. By performing amino acid mutation on an RSV Pre-F protein, and performing fusion expression on the mutated Pre-F protein and ferritin particles in eukaryotic cells, PreF-Ferritin fusion

protein nanoparticles, in which eight Pre-F protein trimers are densely displayed on the surface of each ferritin particle, are obtained. By stabilizing and exposing antigen epitopes required to be displayed and disrupting or masking unrequired antigen epitopes, the PreF-Ferritin fusion protein nanoparticles effectively improve the immunogenicity and the production stability of the antigen. Experiments show that: when the PreF-Ferritin fusion protein is injected into mice, high-titer protective sera can be acquired, and the mice sera can yield relatively high neutralizing titers against RSV.

9.20250276055VISCO-ELASTIC SOLID FORMULATION FOR ORAL DELIVERY OF A BIOLOGICALLY ACTIVE AGENT

US - 04.09.2025

Clasificación Internacional A61K 39/145Nº de solicitud 19199276Solicitante US BIOLOGIC, INCInventor/a Jolieke Gerdy Van Oosterwijk

The presently disclosed subject matter relates a formulation for oral delivery of biologically active agent. In one embodiment, single dose formulation for oral delivery of biologically active agent includes a vaccine antigen expression system and a visco-elastic solid carrier configured to microencapsulate the vaccine antigen expression system. The vaccine antigen expression system is a bacterial antigen expression vehicle expressing one or more recombinant viral protein antigens, wherein the bacterial antigen expression vehicle is *Bacillus subtilis*.

10.20250277192RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED NA

US - 04.09.2025

Clasificación Internacional C12N 7/00Nº de solicitud 19213713Solicitante The University of TokyoInventor/a Yoshihiro Kawaoka

Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.

11.20250276054AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONS

US - 04.09.2025

Clasificación Internacional A61K 39/145Nº de solicitud 19070329Solicitante Novavax, Inc.Inventor/a Gale SMITH

An influenza vaccine nanoparticle includes a recombinant avian influenza hemagglutinin (HA) glycoprotein, where the HA glycoprotein is derived from Type A influenza, subtype A (H5N1) and a Matrix-M adjuvant. The HA glycoprotein has a hydrophobic C-terminus associated with a component of the Matrix-M adjuvant, the component of the Matrix-M being a Matrix-A particle or a Matrix-C particle. In another embodiment, the invention is directed to a vaccine composition having a recombinant glycoprotein antigen with a C-terminus, and a Matrix-M adjuvant. The C-terminus of the glycoprotein antigen is hydrophobic and is associated with a component of the Matrix-M adjuvant.

12.4608455SELBSTANORDNENDE NANOPARTIKEL

EP - 03.09.2025

Clasificación Internacional A61K 47/69Nº de solicitud 23809898Solicitante BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INCInventor/a LYNN GEOFFREY MARTIN

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker,[ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

13.WO/2025/184665SENESCENCE VACCINE

WO - 04.09.2025

Clasificación Internacional A61K 35/14Nº de solicitud PCT/US2025/018210Solicitante IMMORTA BIO, INC.Inventor/a ICHIM, Thomas E.

Methods, and compositions of matter useful for enhancing activity of endogenous and/or exogenous regenerative cells by selectively eliminating senescent cells through induction of immunity against said senescent cells or components thereof. Fusion of autologous patient cells made senescent, autologous antigen presenting cells and utilized as a vaccine. Autologous fibroblasts can be made senescent by genotoxic stress and fused with dendritic cells. Said dendritic cells may be generated from circulating monocytes, CD34 cells or autologous iPSC cells.

14.4608373NANOPARTIKEL, IMPFSTOFFZUSAMMENSETZUNGEN, VERFAHREN, VERWENDUNGEN UND VERFAHREN ZUR VERABREICHUNG DAVON

EP - 03.09.2025

Clasificación Internacional A61K 9/00Nº de solicitud 23804769Solicitante CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN CONICETInventor/a AZZARONI OMAR

The present disclosure is directed to adjuvant nanoparticles for vaccines comprising a molar TPP/PAH ratio of 0.01/0.6, a diameter from 80nm to 526nm, a diameter polydispersity from 0.04 to 0.25, and a surface Z potential from +70mV to -20mV. The charge and size of the nanoparticles will depend on the molar ratio, concentration, or quantity of TPP and PAH compounds, the initial pH of the procedure, and the medium in which the procedure is carried out. Additionally, vaccine compositions formulated with different immunogens are disclosed, in which the nanoparticles encapsulate the antigens, target them to immune sites of interest, and activate the immune system; and preparation methods thereof.

15.4608442IMPFSTOFF AUF NUKLEINSÄUREBASIS

EP - 03.09.2025

Clasificación Internacional A61K 39/215Nº de solicitud 23805158Solicitante GLAXOSMITHKLINE BIOLOGICALS SAInventor/a PETSCH BENJAMIN

The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.

16.202502760 49EGFR VACCINE CASSETTES

US - 04.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud 19036888Solicitante Gritstone Bio, Inc.Inventor/a Karin Jooss

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of EGFR neoepitope-encoding sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

17.4608820HETEROCYCLISCHE VERBINDUNGEN ZUR STING-AKTIVIERUNG

EP - 03.09.2025

Clasificación Internacional C07D 401/14Nº de solicitud 23798139Solicitante BOEHRINGER INGELHEIM INTInventor/a GRAHAM KEITH ANDREW NEWTON

The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of formula (I), as well as the use of these compounds or the pharmaceutical compositions as a medicament, e.g., for treating canine or feline cancer, or as vaccine adjuvants.

18.WO/2025/184598STABLE AND IMMUNOGENIC CMV VACCINE

WO - 04.09.2025

Clasificación Internacional C07K 14/045Nº de solicitud PCT/US2025/017978Solicitante CITY OF HOPEInventor/a DIAMOND, Don J.

Reconstituted synthetic Modified Vaccina Ankara (rsMVA) vectors, compositions thereof, and vaccines comprising the same; and methods of eliciting an immune response and/or preventing, treating, or ameliorating CMV infection in a subject in need thereof using the rsMVA vectors, compositions, and vaccines described herein.

19.202502759 20METHOD OF SAFE ADMINISTRATION OF PHOSPHORYLATED TAU PEPTIDE VACCINE

US - 04.09.2025

Clasificación Internacional A61K 9/1271Nº de solicitud 19216215Solicitante AC Immune SAInventor/a Andrea Pfeifer

Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.

20.202502760 39METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)

US - 04.09.2025

Clasificación Internacional A61K 38/19Nº de solicitud 19084026Solicitante ALBERT EINSTEIN COLLEGE OF MEDICINEInventor/a Betsy Herold

Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions.

21.322193VACCINE

IL - 01.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud 322193Solicitante ASTRAZENECA ABInventor/a

22.WO/2025/181488CG-DINUCLEOTIDE DEPLETED SELF-AMPLIFYING RNA MOLECULE

WO - 04.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/GB2025/050400Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITEDInventor/a SHATTOCK, Robin

The invention relates to self-amplifying RNA (saRNA) molecules, and to saRNA molecules comprising a reduced or depleted CpG nucleic acid sequence. The invention extends to saRNA replicons and to nucleic acids and expression vectors encoding such saRNA constructs, and to methods for improving saRNA-mediated gene expression. The invention also extends to the use of such saRNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such saRNA constructs, and methods and uses thereof.

23.4608439?KLEBSIELLA PNEUMONIAE ?IMPFSTOFF

EP - 03.09.2025

Clasificación Internacional A61K 39/108Nº de solicitud 23798353Solicitante IDORSIA PHARMACEUTICALS LTDInventor/a BROECKER FELIX

The present invention relates to novel oligosaccharide-carrier protein conjugates of Formula (I), and their use as pharmaceuticals, in particular as vaccines. The invention also concerns related aspects including oligosaccharide intermediates of Formulae (II) and (III), as well as processes for the preparation of the conjugates. Furthermore, the invention relates to pharmaceutical compositions comprising the oligosaccharide-carrier protein conjugates, as well as the use of the oligosaccharide-carrier protein conjugates of Formula (IV) in biological assays.

24.2025220796RABIES VIRUS VACCINE

AU - 04.09.2025

Clasificación Internacional Nº de solicitud 2025220796Solicitante Intervet International B.VInventor/a TARPEY, Ian

25.4610659SÄUGETIER-MHC-PEPTIDANZEIGE ALS EPITOPAUSWAHLWERKZEUG FÜR IMPFSTOFFDESIGN

EP - 03.09.2025

Clasificación Internacional G01N 33/68Nº de solicitud 25167878Solicitante ETH ZUERICHInventor/a KISIELOW JAN

The present invention relates to a method for identifying candidate peptides presented by the major histocompatibility complex (MHC) for in vivo and/or in vitro interventions including vaccination, induction of immunological tolerance, blocking of TCRs and MHC-mediated toxin delivery, for immunogenicity testing and other in vitro T-cell reactivity tests.

26.WO/2025/184356VACCINES AND COMPOSITIONS AGAINST GAMMA HERPESVIRUSES

WO - 04.09.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/017607Solicitante HDT BIO CORP.Inventor/a ERASMUS, Jesse

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using these compositions as a vaccine for treatment of a gamma herpesvirus or a cancer are also provided.

27.20250277234RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF

US - 04.09.2025

Clasificación Internacional C12N 15/86Nº de solicitud 18551261Solicitante GENEMATRIX, INC.Inventor/a Soo Ok KIM

The present invention is a chimeric adenovirus vector in which the knob domain of the end of the fiber protein of human adenovirus type 5 is replaced with the knob gene of chimpanzee adenovirus serotype 6 and/or in addition the hexon protein of human adenovirus type 5 is replaced with hypervariable regions 1-7 of human adenovirus serotype 28. The present invention not only provides the optimal adenovirus vector in the development of treatments or vaccines for various diseases, but also when the chimeric adenovirus vector produced in the present invention is infected with a host cell for production, it can contribute to improved productivity by exhibiting superior cell infection ability compared to the recombinant HAdV-5 vector-based vaccine.

28.322488MULTICISTRONIC VACCINE AND METHODS FOR PRODUCING AND USING THE SAME

IL - 01.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud 322488Solicitante OCUGEN, INC.Inventor/a UPADHYAY, Arun, Kumar

29.322502RSV F VACCINE FORMULATIONS

IL - 01.09.2025

Clasificación Internacional A61K 39/00Nº de solicitud 322502Solicitante NOVAVAX, INC.Inventor/a TIAN, Jing-Hui

30.WO/2025/184052INTERLEUKIN 2 AND INTERLEUKIN 12 FUSION PROTEINS AND METHODS OF USING

WO - 04.09.2025

Clasificación Internacional A61K 39/285Nº de solicitud PCT/US2025/017120Solicitante ALLEGHENY SINGER RESEARCH INSTITUTEInventor/a BARTLETT, David L.

Provided herein is a recombinant oncolytic virus comprising an oncolytic virus genome comprising a nucleic acid encoding an IL-2/IL-12 fusion protein. The fusion protein may be membrane-anchored. Also provided are cells expressing the recombinant oncolytic virus

as well as method of using the recombinant oncolytic virus and cells described herein, for example for the treatment of cancer. In a preferred embodiment, the oncolytic virus is a vaccinia virus.

31.4608812LIPIDE AUF VITAMINBASIS UND LIPIDNANOPARTIKEL DAMIT

EP - 03.09.2025

Clasificación Internacional C07D 311/04Nº de solicitud 23883807Solicitante ADVANCED RNA VACCINE ARV TECH INCInventor/a XU JIANGSHENG

Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

32.20250277007CWP2 PROTEIN AS AN EFFECTIVE VACCINE AGAINST CLOSTRIDIOIDES DIFFICILE INFECTION

US - 04.09.2025

Clasificación Internacional C07K 14/33Nº de solicitud 19066479Solicitante UNIVERSITY OF SOUTH FLORIDAInventor/a Xingmin Sun

The present disclosure relates to methods and compositions to treat or prevent *Clostridioides difficile* infection or recurrence.

33.WO/2025/180455A CIRCULAR RNA VACCINE AGAINST HERPES ZOSTER VIRUS AND THE USE THEREOF

WO - 04.09.2025

Clasificación Internacional C12N 15/38Nº de solicitud PCT/CN2025/079615Solicitante THERORNA INC.Inventor/a GAO, Lu

Provided are modified varicella-zoster virus (VZV) gE polypeptide, a circular RNA encoding the modified VZV gE polypeptide, a linear RNA encoding the modified VZV gE polypeptide and the use thereof for inducing an antigen specific immune response in a subject, or preventing or treating VZV infection.

34.20250277005METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE

US - 04.09.2025

Clasificación Internacional C07K 14/28Nº de solicitud 19213316Solicitante UNIVERSITY OF KANSASInventor/a Wendy L. PICKING

Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

35.20250276028COMPOSITION FOR REDUCING SIZE OR VOLUME OF TARGET TISSUE OR KIT INCLUDING SAME

US - 04.09.2025

Clasificación Internacional A61K 35/76Nº de solicitud 18858857Solicitante SK BIOSCIENCE CO., LTD.Inventor/a Eun-som KIM

The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

36.4608819HETEROCYCLISCHE VERBINDUNGEN ZUR STING-AKTIVIERUNG

EP - 03.09.2025

Clasificación Internacional C07D 401/14Nº de solicitud 23797749Solicitante BOEHRINGER INGELHEIM INTInventor/a GRAHAM KEITH ANDREW NEWTON

The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of formula (I), as well as the use of these compounds or the pharmaceutical compositions as a medicament, e.g., for treating canine or feline cancer, or as vaccine adjuvants.

37.4608851REKOMBINANTES AKTIVIERUNGS-ASSOZIIERTES SEKRETIERTES PROTEIN

EP - 03.09.2025

Clasificación Internacional C07K 14/435Nº de solicitud 23798735Solicitante UNIV GENTInventor/a GELDHOF PETER

The present invention relates to a recombinant activation-associated secreted protein (ASP) or fragment thereof, said ASP or fragment comprising an N-glycan comprising a core α1,3-fucose and/or a core α1,6-fucose (Fuc). The invention further relates to a pharmaceutical composition comprising such a recombinant ASP or fragment thereof. Additionally, the invention relates to the recombinant ASP or fragment thereof for use as a human or veterinary medicine, in particular as a vaccine, more in particular for use against parasitic nematode infections.

38.321887RECOMBINANT MODIFIED SARNA (VRP) FOR CANCER VACCINE

IL - 01.09.2025

Clasificación Internacional A61K 31/7105Nº de solicitud 321887Solicitante Bavarian Nordic A/SInventor/a

39.20250281606CANNABIDIOL FOR AUGMENTING VACCINE MEDIATED IMMUNITY AND PROPHYLAXIS OF COVID-19

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/39Nº DE SOLICITUD 18266655SOLICITANTE SHREEMA MERCHANTINVENTOR/A SHREEMA MERCHANT

THE PRESENT INVENTION RELATES TO A PHARMACEUTICAL COMPOSITION COMPRISING THERAPEUTICALLY EFFECTIVE AMOUNT OF CANNABIDIOL FOR ADMINISTRATION WITH A COVID-19 VACCINE TO A MAMMAL/HUMAN TO SUSTAIN AND/OR ENHANCE EFFECT OF VACCINE. FURTHER THE INVENTION RELATES TO METHODS TO SUSTAIN AND/OR ENHANCE EFFECT OF A COVID-19 VACCINE IN A MAMMAL/HUMAN BY ADMINISTERING TO SUCH A MAMMAL/HUMAN A PHARMACEUTICAL COMPOSITION COMPRISING A THERAPEUTICALLY EFFECTIVE AMOUNT OF CANNABIDIOL WITH A COVID-19 VACCINE.

ADMINISTRATION OF CANNABIDIOL WITH VACCINE CAN BE OF FOLLOWING TYPES: I) BEFORE ADMINISTERING COVID-19 VACCINE; OR II) ALONG WITH COVID-19 VACCINE; OR III) AFTER ADMINISTERING COVID-19 VACCINE; OR IV) ANY COMBINATION OF I, II AND III INCLUDING BEFORE, ALONG WITH AND AFTER ADMINISTERING COVID-19 VACCINE.

40.WO/2025/189415RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANT JN.1, BA.2.86, AND XBB LINEAGES, COMBINATION DRUG AND USE

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 14/165Nº DE SOLICITUD PCT/CN2024/081625SOLICITANTE WESTVAC BIOPHARMA CO., LTD.INVENTOR/A WEI, XIAWEI

THE PRESENT INVENTION RELATES TO A RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANT JN.1, BA.2.86, AND XBB LINEAGES, A COMBINATION DRUG, AND A USE. TO ADDRESS SIGNIFICANT IMMUNE ESCAPE AND IMMUNE IMPRINTING PHENOMENA OBSERVED WITH OMICRON JN.1, BA.2.86 AND XBB LINEAGE SUBVARIANTS FOLLOWING PRIOR VACCINATION OR VIRUS INFECTION, AN XBB.1.5 RECOMBINANT PROTEIN VACCINE IS PROVIDED. THIS VACCINE ELICITS POTENT HUMORAL AND CELLULAR IMMUNE RESPONSES AGAINST

CURRENTLY CIRCULATING JN.1, BA.2.86, AND XBB LINEAGE VARIANTS. COMPARED WITH HOMOLOGOUS VACCINATION, HETEROLOGOUS VACCINATION WITH THIS VACCINE FOLLOWING ADMINISTRATION OF AN INACTIVATED OR MRNA-BASED VACCINE ACHIEVES SUPERIOR IMMUNE RESPONSES. MOREOVER, THE VACCINE INDUCES EFFECTIVE PROTECTIVE IMMUNITY AGAINST LIVE OMICRON EG.5.1 VIRUS ATTACK IN VIVO. THEREFORE, THE MONOVALENT XBB.1.5 VACCINE HAS CLINICAL USE VALUE.

41.WO/2025/189658RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANTS JN.1, BA.2.86, AND XBB LINEAGES, DRUG FOR COMBINED USE, AND USE

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/215Nº DE SOLICITUD PCT/CN2024/109998SOLICITANTE WESTVAC BIOPHARMA CO., LTD.INVENTOR/A WEI, XIAWEI

THE PRESENT INVENTION RELATES TO A RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANTS JN.1, BA.2.86, AND XBB LINEAGES, A DRUG FOR COMBINED USE, AND USE. TO SOLVE THE PROBLEM THAT OMICRON JN.1, BA.2.86, AND XBB LINEAGE SUBVARIANTS EXHIBIT SIGNIFICANT IMMUNE ESCAPE AND BLOTTING IMMUNITY AFTER PREVIOUS VACCINATION AND VIRAL INFECTION, AN XBB.1.5 RECOMBINANT PROTEIN VACCINE IS PROVIDED. THE VACCINE, WHEN ADMINISTERED EITHER INTRAMUSCULARLY OR INTRANASALLY, INDUCES STRONG HUMORAL, CELLULAR, AND MUCOSAL IMMUNE RESPONSES AGAINST JN.1, BA.2.86, AND XBB LINEAGE VARIANTS. COMPARED WITH HOMOLOGOUS VACCINATION, AFTER INACTIVATED OR MRNA VACCINES ARE APPLIED, THE VACCINE IS USED FOR HETEROLOGOUS VACCINATION TO OBTAIN A BETTER IMMUNE RESPONSE. MOREOVER, THE VACCINE INDUCES EFFECTIVE PROTECTIVE IMMUNITY IN VIVO AGAINST OMICRON EG.5.1 LIVE VIRUS ATTACKS. THUS, THE XBB.1.5 VACCINE HAS CLINICAL EFFICACY.

42.20250288660SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES

US - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/145Nº DE SOLICITUD 18964885SOLICITANTE SEQIRUS UK LIMITEDINVENTOR/A DEREK O'HAGAN

INFLUENZA VACCINES ARE ADMINISTERED USING SOLID BIODEGRADABLE MICRONEEDLES. THE MICRONEEDLES ARE FABRICATED FROM THE INFLUENZA VACCINE IN COMBINATION WITH SOLID EXCIPIENT(S) AND, AFTER PENETRATING THE SKIN, THEY DISSOLVE IN SITU AND RELEASE THE VACCINE TO THE IMMUNE SYSTEM. THE INFLUENZA VACCINE IS (I) A PURIFIED INFLUENZA VIRUS SURFACE ANTIGEN VACCINE, RATHER THAN A LIVE VACCINE OR A WHOLE-VIRUS OR SPLIT INACTIVATED VACCINE (II) AN INFLUENZA VACCINE PREPARED FROM VIRUSES GROWN IN CELL CULTURE, NOT EGGS, (III) A MONOVALENT INFLUENZA VACCINE E.G. FOR IMMUNISING AGAINST A PANDEMIC STRAIN, (IV) A BIVALENT VACCINE, (V) A TETRAVALENT OR >4-VALENT VACCINE, (VI) A MERCURY-FREE VACCINE, OR (VII) A GELATIN-FREE VACCINE.

43.20250281604MRNA VACCINE FOR PORCINE DELTACORONAVIRUS, PREPARATION METHOD AND APPLICATION THEREOF

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/225Nº DE SOLICITUD 19073006SOLICITANTE JIANGSU ACADEMY OF AGRICULTURAL SCIENCESINVENTOR/A BIN LI

AN MRNA VACCINE ENCAPSULATED WITH LIPID NANOPARTICLES FOR PDCOV, A PREPARATION METHOD AND AN APPLICATION THEREOF ARE PROVIDED, AND THE MRNA VACCINE FOR PDCOV INCLUDES AT LEAST ONE OF SEQUENCES AS DESCRIBED IN SEQ ID NO: 1-2; THE LIPID NANOPARTICLE-ENCAPSULATED MRNA VACCINES INCLUDES THE MRNA VACCINE, AND LIPIDS FOR ENCAPSULATING THE MRNA VACCINE, AND THE LIPIDS ARE FORMED BY MIXING IONIZABLE LIPOSOME, DISTEAROYL PHOSPHATIDYLCHOLINE, CHOLESTEROL AND PEG LIPOSOME.

44.4615494NIEDRIGDOSIERTE IMPFSTOFFZUSAMMENSETZUNGEN

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/00Nº DE SOLICITUD 23889719SOLICITANTE CENTIVAX INCINVENTOR/A GLANVILLE JACOB

THE PRESENT DISCLOSURE PROVIDES A VACCINE COMPOSITION COMPRISING SIX OR MORE HOMOLOGOUS DISTINCT ANTIGEN COMPONENTS. ANY TWO OF THE SIX OR MORE HOMOLOGOUS DISTINCT ANTIGEN COMPONENTS MAY SHARE LESS THAN 98% OR 95% SEQUENCE IDENTITY. THE HOMOLOGOUS DISTINCT ANTIGEN COMPONENTS MAY COMPRISE PROTEINS. AN AMOUNT OF A PROTEIN IN A DOSE OF SAID HUMAN ADULT VACCINE COMPOSITION MAY BE ABOUT 600 NANOGRAMS (NG) TO ABOUT 3 MICROGRAMS (µG). THE HOMOLOGOUS DISTINCT ANTIGEN COMPONENTS MAY COMPRISE A PLURALITY OF RNA. AN AMOUNT OF AN RNA OF SAID PLURALITY OF RNA IN A DOSE OF SAID VACCINE COMPOSITION MAY BE ABOUT 1 NG TO ABOUT 5 µG PER DOSE. THE HOMOLOGOUS DISTINCT ANTIGEN COMPONENTS MAY COMPRISE A PLURALITY OF PROTEINS DISPLAYED ON HETEROLOGOUS VIRAL-LIKE PARTICLES (VLPS). AN AMOUNT OF A PROTEIN DISPLAYED ON A HETEROLOGOUS VLP OF THE PLURALITY OF PROTEINS DISPLAYED ON HETEROLOGOUS VLPS IN A DOSE OF THE VACCINE COMPOSITION MAY BE ABOUT 1 NG TO ABOUT 5 µG PER DOSE.

45.WO/2025/190157CIRCULAR RNA VACCINE FOR TREATING CANINE MELANOMA

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/00Nº DE SOLICITUD PCT/CN2025/081177SOLICITANTE SHANGHAI SHENRAY UNITED BIOMEDICAL CO., LTD.INVENTOR/A LIU, CHUNXI

A CIRCULAR RNA VACCINE FOR TREATING CANINE MELANOMA. THE CIRCULAR RNA VACCINE CONTAINS A CIRCULAR RNA MOLECULE ENCODING AN OPTIMIZED CANINE TYROSINASE, AND THE OPTIMIZED CANINE TYROSINASE COMPRISES CANINE TYROSINASE OR A HOMOLOGOUS SEQUENCE THEREOF, A LINKER ARM, AND AN ENHANCER SEQUENCE OR A HOMOLOGOUS SEQUENCE THEREOF. THE IMMUNOGENICITY OF THE CANINE TYROSINASE IS ENHANCED BY MEANS OF OPTIMIZATION, THEREBY STIMULATING THE IMMUNE SYSTEM TO RECOGNIZE THE CANINE TYROSINASE. IN ADDITION, THE CIRCULAR RNA VACCINE OF THE CANINE TYROSINASE IS PREPARED BY MEANS OF USING A CIRCULAR RNA TECHNIQUE AND AN

LNP DELIVERY TECHNIQUE. THE OPTIMIZED CANINE TYROSINASE IS HIGHLY EXPRESSED IN VIVO, AND THUS THE IMMUNE SYSTEM IS ACTIVATED TO HAVE A THERAPEUTIC EFFECT ON CANINE MELANOMA.

46.WO/2025/185599MRNA TUMOR VACCINE ENCODING MEMBRANE-BOUND IL-12 CYTOKINE ADJUVANT, AND USE THEREOF

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/00Nº DE SOLICITUD PCT/CN2025/080420SOLICITANTE TSINGHUA UNIVERSITYINVENTOR/A FU, YANGXIN

THE PRESENT INVENTION RELATES TO AN MRNA TUMOR VACCINE ENCODING A MEMBRANE-BOUND IL-12 CYTOKINE ADJUVANT, AND THE USE THEREOF. BY MEANS OF THE MRNA TUMOR VACCINE, THE TOXICITY OF IL-12 IS REDUCED AND THE THERAPEUTIC EFFECT OF THE MRNA TUMOR VACCINE IS IMPROVED. THE MRNA CONTAINS THREE PARTS: A SEQUENCE (IL12) ENCODING IL-12, A SEQUENCE (MD) ENCODING A MEMBRANE DOMAIN, AND A SEQUENCE (AG) ENCODING A TUMOR ANTIGEN.

47.WO/2025/191546CHIMERIC VIRUS-LIKE PARTICLE VACCINE AGAINST ROTAVIRUS

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD PCT/IB2025/054774SOLICITANTE PASTEUR INSTITUTE OF IRANINVENTOR/A SHOJA, ZABIHOLLAH

THE PRESENT DISCLOSURE RELATES TO A RECOMBINANT CHIMERIC VIRUS-LIKE PARTICLE (CVLP) VACCINE COMPOSITION AGAINST ROTAVIRUS INFECTION. THE VACCINE COMPRISES A VIRUS-LIKE PARTICLE FRAGMENT INCLUDING A HEPATITIS B CORE (HBC) PROTEIN FUNCTIONING AS AN ADJUVANT, INTO WHICH A HETEROLOGOUS IMMUNOGENIC DOMAIN DERIVED FROM THE ROTAVIRUS VPS* PROTEIN IS INSERTED WITHIN THE MAJOR IMMUNODOMINANT REGION (MIR) OF HBC. THE CONSTRUCT IS ENCODED BY SEQ ID NO. 1, AND EXPRESSED IN A PROKARYOTIC SYSTEM. THE CVLPVPS* VACCINE COMPOSITION OF THE PRESENT DISCLOSURE OFFERS A NON-REPLICATING, PROTEIN-BASED ALTERNATIVE TO LIVE ATTENUATED VACCINES, AND THE PLATFORM MAY HELP ADDRESS CHALLENGES RELATED TO SAFETY, STRAIN SPECIFICITY, AND ANTIGEN DELIVERY.

48.4615498GENTECHNISCH HERGESTELLTER MRNA-IMPFSTOFF GEGEN VARICELLA ZOSTER VIRUSSCHINDELN

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/25Nº DE SOLICITUD 23889645SOLICITANTE VERNAGEN LLCINVENTOR/A KIM BAEK

PROVIDED HEREIN ARE A SHINGLES VACCINE COMPOSITION INCLUDING A MESSENGER RIBONUCLEIC ACID (MRNA) INCLUDING AN OPEN READING FRAME (ORF) ENCODING VARICELLA ZOSTER VIRUS (VZV) GLYCOPROTEIN E (GE)(WHICH IS SOLUBLE VZV GE OR FULL-LENGTH VZV

GE) AND A COMPOSITION FOR INDUCING IMMUNE RESPONSE AGAINST SHINGLES INCLUDING THE SHINGLES VACCINE COMPOSITION.

49.20250281599COMPOSITION COMPRISING ENGINEERED PLANT-DERIVED EXTRACELLULAR VESICLES AND USE THEREOF AS A VACCINE

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/215Nº DE SOLICITUD 18261572SOLICITANTE EVOBIOTECH S.R.L.INVENTOR/A GIOVANNI CAMUSSI

A METHOD FOR TREATMENT OR PROPHYLAXIS OF A DISEASE IN A SUBJECT INVOLVING ADMINISTERING TO THE SUBJECT A VACCINE COMPOSITION INCLUDING NON-IMMUNOMODULATING, ENGINEERED, PLANT-DERIVED EXTRACELLULAR VESICLES (EVS), IS PROVIDED. THE EVS ARE LOADED WITH AN EXOGENOUS NUCLEIC ACID MOLECULE ENCODING A PROTEIN ANTIGEN. THE DISEASE IS AN INFECTIOUS DISEASE OR CANCER. A METHOD FOR THE PREPARATION OF THE VACCINE COMPOSITION, WHICH MAKES USE OF ONE OR MORE POLYCATIONIC SUBSTANCES AND ONE OR MORE SUGAR MOLECULES IS ALSO PROVIDED.

50.4615496VP4-BASIERTER DREIWERTIGER PSEUDOVIRUS-NANOPARTIKELIMPFSTOFF FÜR ROTAVIRUS UND VERFAHREN ZUR VERWENDUNG DAVON

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD 23822171SOLICITANTE CHILDRENS HOSPITAL MED CTINVENTOR/A TAN MING

DISCLOSED HEREIN ARE VACCINE COMPOSITIONS, IN PARTICULAR, POLYVALENT ICOSAHEDRAL COMPOSITIONS FOR PRESENTATION OF A ROTAVIRUS ANTIGEN. THE DISCLOSED COMPOSITIONS MAY CONTAIN AN S PARTICLE MADE UP OF RECOMBINANT FUSION PROTEINS THAT FURTHER COMPRISE A ROTAVIRUS ANTIGEN. THE RECOMBINANT FUSION PROTEINS MAY INCLUDE A NOROVIRUS (NOV) S DOMAIN PROTEIN, A LINKER PROTEIN DOMAIN OPERATIVELY CONNECTED TO THE NOROVIRUS S DOMAIN PROTEIN, AND A ROTAVIRUS ANTIGEN PROTEIN DOMAIN. THE DISCLOSED PARTICLES AND COMPOSITIONS MAY BE USED AS A VACCINE COMPOSITION FOR REDUCING THE LIKELIHOOD OF BECOMING INFECTED WITH ROTAVIRUS, DIMINISHING THE SEVERITY OF A ROTAVIRUS INFECTION, REDUCING THE DURATION OF TIME OF A ROTAVIRUS INFECTION, OR OTHERWISE IMPROVING AN IMMUNE RESPONSE FOLLOWING CONTACT WITH ROTAVIRUS IN AN INDIVIDUAL.

51.20250281597A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/145Nº DE SOLICITUD 18702577SOLICITANTE INTERVET INC.INVENTOR/A BASAV HANGALAPURA NAGARAJ

THE PRESENT INVENTION PERTAINS TO THE USE OF A VACCINE BASED ON AN ALPHAVIRUS RNA REPLICON PARTICLE (ARP) VECTOR ENCODING AN ANTIGEN OF AN IAV-S FOR THE PASSIVE VACCINATION OF PIGLETS AGAINST A PATHOGENIC INFECTION WITH SWINE INFLUENZA VIRUS.

52.WO/2025/190709VACCINE AGAINST MOSQUITO EXTRACELLULAR VESICLES FOR PROTECTING AGAINST FLAVIVIRUSES

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 35/56Nº DE SOLICITUD PCT/EP2025/055697SOLICITANTE INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENTINVENTOR/A POMPON, JULIEN FRANCIS

THE PRESENT INVENTION RELATES TO AN ISOLATED MOSQUITO EXTRACELLULAR VESICLE FOR USE AS AN IMMUNOGENIC AGENT IN THE PREVENTION OF AT LEAST ONE VECTOR-BORNE DISEASE. THE PRESENT INVENTION ALSO RELATES TO A VACCINE COMPOSITION COMPRISING AT LEAST ONE MOSQUITO EXTRACELLULAR VESICLE. THE PRESENT INVENTION FURTHER RELATES TO THE USE OF A MOSQUITO EXTRACELLULAR VESICLE IN IDENTIFYING AT LEAST ONE IMMUNOGENIC PEPTIDE CAPABLE OF REDUCING, IN A VERTEBRATE, THE TRANSMISSION OF A VECTOR-BORNE DISEASE WHEN THE VERTEBRATE IS BITTEN BY THE VECTOR, AND TO A METHOD FOR IDENTIFYING AT LEAST ONE IMMUNOGENIC PEPTIDE CAPABLE OF BLOCKING, IN A VERTEBRATE, THE TRANSMISSION OF A VECTOR-BORNE DISEASE WHEN THE VERTEBRATE IS BITTEN BY THE VECTOR, THE METHOD COMPRISING A STEP OF IDENTIFYING IN VITRO AT LEAST ONE TARGET ANTIBODY PRESENT IN AN ANIMAL SERUM SAMPLE IMMUNISED AGAINST MOSQUITO EXTRACELLULAR VESICLES.

53.20250281593NUCLEOSIDE-MODIFIED MRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD 19053665SOLICITANTE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAINVENTOR/A DREW WEISSMAN

THE PRESENT INVENTION RELATES TO COMPOSITIONS AND METHODS FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE AGAINST HEPATITIS C VIRUS (HCV) IN A SUBJECT. IN SOME EMBODIMENTS, THE PRESENT INVENTION PROVIDES A COMPOSITION COMPRISING A NUCLEOSIDEMODIFIED NUCLEIC ACID MOLECULE ENCODING A HCV ANTIGEN, ADJUVANT, OR A COMBINATION THEREOF. FOR EXAMPLE, IN SOME EMBODIMENTS, THE COMPOSITION COMPRISES A VACCINE COMPRISING A NUCLEOSIDE-MODIFIED NUCLEIC ACID MOLECULE ENCODING A HCV ANTIGEN, ADJUVANT, OR A COMBINATION THEREOF.

54.WO/2025/188781AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONS

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD PCT/US2025/018378SOLICITANTE NOVAVAX, INC.INVENTOR/A SMITH, GALE

AN INFLUENZA VACCINE NANOPARTICLE INCLUDES A RECOMBINANT AVIAN INFLUENZA HEMAGGLUTININ (HA) GLYCOPROTEIN, WHERE THE HA GLYCOPROTEIN IS DERIVED FROM TYPE A INFLUENZA, SUBTYPE A(H5N1) AND A MATRIX-M ADJUVANT. THE HA GLYCOPROTEIN HAS A HYDROPHOBIC C-TERMINUS ASSOCIATED WITH A COMPONENT OF THE MATRIX-M ADJUVANT, THE COMPONENT OF THE MATRIX-M BEING A MATRIX-A PARTICLE OR A MATRIX-C PARTICLE. IN

ANOTHER EMBODIMENT, THE INVENTION IS DIRECTED TO A VACCINE COMPOSITION HAVING A RECOMBINANT GLYCOPROTEIN ANTIGEN WITH A C-TERMINUS, AND A MATRIX-M ADJUVANT. THE C-TERMINUS OF THE GLYCOPROTEIN ANTIGEN IS HYDROPHOBIC AND IS ASSOCIATED WITH A COMPONENT OF THE MATRIX-M ADJUVANT.

55.WO/2025/189435METHOD FOR USING MULTI-EPITOPE ANTIGEN TO CONSTRUCT RNA VACCINE FOR FIPV

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL C12N 15/50Nº DE SOLICITUD PCT/CN2024/081756SOLICITANTE BEIJING SYNGENTECH CO., LTD.INVENTOR/A LIU, QIANG

PROVIDED IS A METHOD FOR USING A MULTI-EPITOPE ANTIGEN TO CONSTRUCT AN RNA VACCINE FOR FELINE INFECTIOUS PERITONITIS VIRUS (FIPV). THE METHOD RELATES TO AN ISOLATED NUCLEIC ACID MOLECULE. THE NUCLEIC ACID MOLECULE COMPRISES: AT LEAST ONE OF A FIRST NUCLEIC ACID FRAGMENT, A SECOND NUCLEIC ACID FRAGMENT, A THIRD NUCLEIC ACID FRAGMENT, A FOURTH NUCLEIC ACID FRAGMENT AND A FIFTH NUCLEIC ACID FRAGMENT, WHEREIN THE FIRST NUCLEIC ACID FRAGMENT IS DERIVED FROM THE N-TERMINAL DOMAIN (NTD) OF THE N PROTEIN OF THE FIPV STRAIN QS, THE SECOND NUCLEIC ACID FRAGMENT IS DERIVED FROM THE C-TERMINAL DOMAIN (CTD) OF THE N PROTEIN FROM THE FIPV STRAIN QS, THE THIRD NUCLEIC ACID FRAGMENT ENCODES THE NSP12 PROTEIN OF THE FIPV STRAIN QS, THE FOURTH NUCLEIC ACID FRAGMENT IS DERIVED FROM THE EPITOPE HR2_4 OF THE S PROTEIN OF THE FIPV STRAIN 79-1146, THE FIFTH NUCLEIC ACID FRAGMENT IS DERIVED FROM THE EPITOPE HR2_11 OF THE S PROTEIN OF THE FIPV STRAIN 79-1146, AND THE NUCLEIC ACID MOLECULE IS RNA.

56.WO/2025/191265MALARIA VACCINE

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/015Nº DE SOLICITUD PCT/GB2025/050503SOLICITANTE OXFORD UNIVERSITY INNOVATION LIMITEDINVENTOR/A HILL, ADRIAN VIVIAN SINTON

THE PRESENT INVENTION RELATES TO FUSION POLYPEPTIDES AND PARTICLES, PARTICULARLY VIRUS-LIKE PARTICLES (VLPS), COMPRISING SELECTED REPEAT UNITS DERIVED FROM THE REPEATING REGIONS OF TYPE I AND TYPE II CIRCUMSPOROZOITE PROTEINS (CSPS) OF PLASMODIUM VIVAX (PV), TOGETHER WITH AN AMINO ACID SEQUENCE DERIVED FROM THE HEPATITIS B VIRUS SURFACE ANTIGEN. THE INVENTION ALSO RELATES TO NUCLEOTIDE SEQUENCES CODING FOR SUCH FUSION POLYPEPTIDES, VECTORS AND PLASMIDS COMPRISING SUCH NUCLEOTIDE SEQUENCES, AND HOST CELLS COMPRISING SUCH VECTORS AND PLASMIDS. THE INVENTION ADDITIONALLY RELATES TO COMPOSITIONS, PARTICULARLY VACCINE COMPOSITIONS, COMPRISING THE FUSION POLYPEPTIDES OR VLPS FOR USE IN THE PREVENTION OF MALARIA.

57.WO/2025/189436METHOD FOR CONSTRUCTING CIRCULAR RNA POLYTOPE VACCINE FOR FELINE INFECTIOUS PERITONITIS VIRUS (FIPV)

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL C12N 15/50Nº DE SOLICITUD PCT/CN2024/081758SOLICITANTE BEIJING SYNGENTECH CO., LTD.INVENTOR/A LIU, QIANG

PROVIDED IS A METHOD FOR CONSTRUCTING A CIRCULAR RNA POLYTOPE VACCINE FOR FELINE INFECTIOUS PERITONITIS VIRUS (FIPV), WHICH COMPRISES: PROVIDING AN ISOLATED NUCLEIC ACID MOLECULE. THE NUCLEIC ACID MOLECULE COMPRISES: AT LEAST ONE OF A FIRST NUCLEIC ACID FRAGMENT, A SECOND NUCLEIC ACID FRAGMENT, A THIRD NUCLEIC ACID FRAGMENT, A FOURTH NUCLEIC ACID FRAGMENT AND A FIFTH NUCLEIC ACID FRAGMENT; THE FIRST NUCLEIC ACID FRAGMENT IS DERIVED FROM THE N TERMINUS (NTD) OF THE N PROTEIN OF A FELINE INFECTIOUS PERITONITIS VIRUS QS STRAIN; THE SECOND NUCLEIC ACID FRAGMENT IS DERIVED FROM THE C TERMINUS (CTD) OF THE N PROTEIN OF THE FELINE INFECTIOUS PERITONITIS VIRUS QS STRAIN; THE THIRD NUCLEIC ACID FRAGMENT ENCODES NSP12 PROTEIN OF THE FELINE INFECTIOUS PERITONITIS VIRUS QS STRAIN; THE FOURTH NUCLEIC ACID FRAGMENT IS DERIVED FROM THE EPITOPE HR2_4 OF THE S PROTEIN OF THE FELINE INFECTIOUS PERITONITIS VIRUS 79-1146 STRAIN; AND THE FIFTH NUCLEIC ACID FRAGMENT IS DERIVED FROM THE EPITOPE HR2_11 OF THE S PROTEIN OF THE FELINE INFECTIOUS PERITONITIS VIRUS 79-1146 STRAIN. THE NUCLEIC ACID MOLECULE IS A CIRCULAR RNA.

58.WO/2025/193857IMPROVED RSV VACCINE COMPOSITIONS & METHODS

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/155Nº DE SOLICITUD PCT/US2025/019611SOLICITANTE CALDER BIOSCIENCES INC.INVENTOR/A GIDWANI, SONAL

THE PRESENT INVENTION PROVIDES MUTANT RSV F MOLECULES THAT CAN BE, OR ARE, STABILIZED IN THE PRE-FUSION CONFORMATION (PREF) BY THE INTRODUCTION OF ONE OR MORE DITYROSINE (DT) CROSSLINKS. THE PRESENT INVENTION ALSO PROVIDES METHODS OF MAKING SUCH MUTANT RSV F MOLECULES, VACCINE COMPOSITIONS COMPRISING SUCH MUTANT RSV F MOLECULES, AND METHODS OF USE OF SUCH MUTANT RSV F MOLECULES, FOR EXAMPLE IN VACCINATION METHODS TO PROTECT SUBJECTS AGAINST RSV INFECTION.

59.20250282832CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 14/005Nº DE SOLICITUD 18553324SOLICITANTE IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA.INVENTOR/A RÚBENS PRINCE DOS SANTOS ALVES

A CHIMERIC NUCLEOTIDE SEQUENCE THAT CORRESPONDS TO AN ENCODED FUSION PROTEIN COMPRISING A POLYEPITOPE RESULTING FROM SELECTING AND JUXTAPOSING MULTIPLE EPITOPES FROM A CORONAVIRUS PROTEIN TO INDUCE AN IMMUNE RESPONSE IN MAMMALS. IN ONE EMBODIMENT, SAID FUSION PROTEIN COMPRISES: A) A FIRST PEPTIDE CONSISTING OF EPITOPES FOUND IN THE AMINO ACID SEQUENCE OF REPLICASE POLYPROTEIN 1AB (PR1AB); B) A FIRST SPACER; C) A MODIFIED FORM OF HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) GLYCOPROTEIN D (GD). IN ONE EMBODIMENT, THE REPLICASE POLYPROTEIN IS DEFINED BY SEQ ID NO: 96 FLANKED BY A GD FRAGMENT COMPRISING THE AMINO ACID SEQUENCE DEFINED BY SEQ ID NO: 98 IN THE N-TERMINAL PORTION AND ANOTHER GD FRAGMENT COMPRISING THE AMINO ACID SEQUENCE DEFINED BY SEQ ID NO: 100 IN THE C-TERMINAL REGION. USE OF THE FUSION PROTEIN HAS SURPRISING RESULTS IN INDUCING CELLULAR AND HUMORAL IMMUNE RESPONSES AGAINST CORONAVIRUS, SARS-COV-2, AND RELATED VIRUSES.

60.WO/2025/188244GENETIC SIGNATURES FOR PREDICTING VACCINE RESPONSE AND USES THEREOF

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C12Q 1/6827Nº DE SOLICITUD PCT/SG2025/050151SOLICITANTE AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHINVENTOR/A CHEN, HSIU-YI

THIS DISCLOSURE CONCERNS INSERTION/DELETION (INDEL) GENE SIGNATURES AND NON-GENETIC FACTORS THAT MAY BE USED TO PREDICT VACCINE RESPONSE, AND METHODS OF USE THEREOF.

61.4615500LYOPHILISIERTER UND STABILISIERTER ATTENUIERTER LEBENDIMPFSTOFF GEGEN TULARÄMIE

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/39Nº DE SOLICITUD 23889606SOLICITANTE SOUTHWEST RES INSTINVENTOR/A CARSON KENNETH H

A LYOPHILIZED STABILIZED FORMULATION CONTAINING A LIVE ATTENUATED VACCINE STRAIN AGAINST TULAREMIA.

62.WO/2025/188693BICYCLIC TLR7 AGONISTS AND USES THEREOF

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07D 487/04Nº DE SOLICITUD PCT/US2025/018253SOLICITANTE BRISTOL-MYERS SQUIBB COMPANYINVENTOR/A POUDEL, YAM BAHADUR

COMPOUNDS ACCORDING TO FORMULA (I) ARE USEFUL AS AGONISTS OF TOLL-LIKE RECEPTOR 7 (TLR7). SUCH COMPOUNDS CAN BE USED ALONE OR AS PART OF AN ANTIBODY-DRUG CONJUGATE IN CANCER TREATMENT, FOR EXAMPLE IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT. SUCH COMPOUNDS MAY ALSO BE USED AS VACCINE ADJUVANTS.

63.WO/2025/188872E. COLI CFAE TIP PROTEIN EXHIBITS ANTI-INFLAMMATORY PROPERTIES FOR THE TREATMENT OF AUTOIMMUNITY

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/108Nº DE SOLICITUD PCT/US2025/018538SOLICITANTE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDINVENTOR/A FANGER, GARY

ORIGINALLY CONCEIVED AS A DIARRHEAL VACCINE FOR HUMANS, COLONIZATION FACTOR ANTIGEN I (CFA/I) FROM ENTEROTOXIGENIC E. COLI(ETEC) WAS FOUND TO BE POTENTLY EFFECTIVE FOR SUPPRESSING MULTIPLE SCLEROSIS, ARTHRITIS, TYPE 1 DIABETES, AND SJS IN ANIMAL MODELS. CFAE IS A TIP PROTEIN OF CFA/I FIMBRIAE AND MEDIATES BINDING TO INTESTINAL EPITHELIUM. IN THIS DISCLOSURE, IT IS DEMONSTRATED THAT ONLY CFAE SUBUNIT IS REQUIRED IN LIEU OF THE INTACT CFA/I FIMBRIAE FOR ANTI-INFLAMMATORY ACTIVITY. BASED ON THE EVIDENCE PROVIDED HERE SHOWING THAT CFAE, EXPRESSED BY LACTOCOCCUS LACTIS (LL- CFAE), IS ABLE TO DAMPEN AUTOIMMUNITY, THIS DISCLOSURE PROVIDES CFAE-EXPRESSING PROBIOTIC STRAIN AS A POTENTIAL ANTI-INFLAMMATORY/AUTOIMMUNE THERAPEUTIC. ALSO, COMPOSITION AND USE METHOD OF LL-CFAE ARE ALSO SUGGESTED.

64.WO/2025/186359SINGLE DOMAIN ACTIVATION-ASSOCIATED SECRETED PROTEIN AND USES THEREOF

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 14/435Nº DE SOLICITUD PCT/EP2025/056073SOLICITANTE ACADEMISCH ZIEKENHUIS LEIDEN (PUBLIEKRECHTELIJK RECHTSPERSOON)INVENTOR/A GELDHOF, PETER

THE PRESENT INVENTION RELATES TO A SINGLE DOMAIN ACTIVATION-ASSOCIATED SECRETED PROTEIN (ASP) OR FRAGMENT THEREOF. THE INVENTION FURTHER RELATES TO A COMPOSITION COMPRISING SAID ASP OR FRAGMENT THEREOF AND THE USE AS A VETERINARY MEDICINE, IN PARTICULAR AS A VACCINE; MORE IN PARTICULAR FOR USE AGAINST PARASITIC NEMATODE INFECTION BY COOPERIA.

65.WO/2025/189138PEPTIDE LIGANDS FOR AFFINITY CAPTURE OF NUCLEIC ACIDS

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 9/00Nº DE SOLICITUD PCT/US2025/018994SOLICITANTE RENSSELAER POLYTECHNIC INSTITUTEINVENTOR/A KARANDE, PANKAJ

AN AFFINITY MEMBRANE SEPARATOR IS PROVIDED THAT INCLUDES A SEPARATION SUBSTRATE WITH A PLURALITY OF PEPTIDE LIGANDS POSITIONED THEREON. THE PEPTIDE LIGANDS PREFERENTIALLY BIND TO ONE OF A NUCLEIC ACID PRODUCT AND A WASTE NUCLEIC ACID PRODUCT, E.G., PRODUCED BY A MRNA SYNTHESIS BIOREACTOR. THE PEPTIDE LIGANDS INCLUDE FEWER THAN 20 RESIDUES AND AT LEAST ONE DEFINED SECONDARY STRUCTURE, AND HAVE A GLOBAL CHARGE GREATER THAN ABOUT 1 AND AT LEAST ONE LYSINE, ARGININE,

OR GLUTAMINE RESIDUE IN ORDER TO PREFERENTIALLY BIND DS-RNA RELATIVE TO SS-RNA, OR A GLOBAL CHARGE LESS THAN ABOUT 0 AND AT LEAST ONE SERINE OR ASPARAGINE RESIDUE IN ORDER TO PREFERENTIALLY BIND SS-RNA RELATIVE TO DS-RNA. PEPTIDE LIGANDS CAN ADVANTAGEOUSLY BIND TO DS-RNA BYPRODUCTS FROM THE PRODUCTION OF SS-RNA VACCINES, E.G., AGAINST SARS-COV-2, WHILE ALLOWING THE SS-RNA VACCINES THEMSELVES TO PASS THROUGH THE SEPARATOR, PROVIDING AN EFFICIENT SYSTEM FOR PRODUCTION OF PURIFIED SS-RNA VACCINE PRODUCTS.

66.4616863IMPFSTOFF GEGEN EXTRAZELLULÄRE MÜCKENVESIKEL ZUM SCHUTZ GEGEN FLAVIVIRUS

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 35/56Nº DE SOLICITUD 24305370SOLICITANTE INSTITUT DE RECH POUR LE DEVELOPPEMENTINVENTOR/A POMPON JULIEN FRANCIS

LA PRÉSENTE INVENTION SE RAPPORTE À UNE VÉSICULE EXTRACELLULAIRE ISOLÉE DE MOUSTIQUE POUR SON UTILISATION COMME AGENT IMMUNOGÈNE DANS LA PRÉVENTION D'AU MOINS UNE MALADIE À TRANSMISSION VECTORIELLE.LA PRÉSENTE INVENTION SE RAPPORTE ÉGALEMENT À UNE COMPOSITION VACCINALE COMPRENANT AU MOINS UNE VÉSICULE EXTRACELLULAIRE DE MOUSTIQUE.LA PRÉSENTE INVENTION SE RAPPORTE EN OUTRE À UNE UTILISATION D'UNE VÉSICULE EXTRACELLULAIRE DE MOUSTIQUE POUR IDENTIFIER AU MOINS UN PEPTIDE IMMUNOGÈNE CAPABLES DE RÉDUIRE, CHEZ UN VERTÉBRÉ LA TRANSMISSION D'UNE MALADIE À TRANSMISSION VECTORIELLE LORS D'UNE PIQÛRE DU VERTÉBRÉ PAR LE VECTEUR, AINSI QU'À UN PROCÉDÉ D'IDENTIFICATION D'AU MOINS UN PEPTIDE IMMUNOGÈNE CAPABLE DE BLOQUER, CHEZ UN VERTÉBRÉ, LA TRANSMISSION D'UNE MALADIE À TRANSMISSION VECTORIELLE LORS D'UNE PIQÛRE DU VERTÉBRÉ PAR LE VECTEUR, COMPRENANT UNE ÉTAPE D'IDENTIFICATION IN VITRO D'AU MOINS UNE CIBLE D'ANTICORPS PRÉSENTS DANS UN ÉCHANTILLON DE SÉRUM D'ANIMAL IMMUNISÉ CONTRE DES VÉSICULES EXTRACELLULAIRES DE MOUSTIQUE.

67.4615470PEPTIDE UND KOMBINATIONEN AUS PEPTIDEN ZUR VERWENDUNG IN DER IMMUNTHERAPIE GEGEN AKUTE MYELOISCHE LEUKÄMIE (AML) UND ANDERE HÄMATOLOGISCHE NEOPLASMEN

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 35/00Nº DE SOLICITUD 23802277SOLICITANTE UNIV TUEBINGEN MEDIZINISCHE FAKULTAETINVENTOR/A WALZ JULIANE

THE PRESENT INVENTION RELATES TO PEPTIDES, PROTEINS, NUCLEIC ACIDS AND CELLS FOR USE IN IMMUNOTHERAPEUTIC METHODS. IN PARTICULAR, THE PRESENT INVENTION RELATES TO THE IMMUNOTHERAPY OF CANCER, IN PARTICULAR OF HEMATOLOGICAL NEOPLASMS, SUCH AS ACUTE MYELOID LEUKEMIA (AML). THE PRESENT INVENTION FURTHERMORE RELATES TO TUMOR-ASSOCIATED T-CELL PEPTIDE EPITOPES THAT CAN FOR EXAMPLE SERVE AS ACTIVE PHARMACEUTICAL INGREDIENTS OF VACCINE COMPOSITIONS THAT STIMULATE ANTI-TUMOR IMMUNE RESPONSES, OR TO STIMULATE T CELLS EX VIVO AND TRANSFER INTO PATIENTS. PEPTIDES BOUND TO MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC), OR

PEPTIDES AS SUCH, CAN ALSO BE TARGETS OF ANTIBODIES, SOLUBLE T-CELL RECEPTORS, AND OTHER BINDING MOLECULES.

68.3564257MUTANTE FRAGMENTER AF OSPA OG FREMGANGSMÅDER OG ANVENDELSER RELATERET DERTIL

DK - 15.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 14/20Nº DE SOLICITUD 19177679SOLICITANTE VALNEVA AUSTRIA GMBHINVENTOR/A LUNDBERG, URBAN

THE PRESENT INVENTION RELATES TO COMPOSITIONS USEFUL IN THE PREVENTION AND TREATMENT OF A BORRELIA INFECTION. PARTICULARLY, THE PRESENT INVENTION RELATES TO AN IMMUNOGENIC POLYPEPTIDE COMPRISING A HYBRID C-TERMINAL FRAGMENT OF AN OUTER SURFACE PROTEIN A (OSPA), A NUCLEIC ACID CODING THE SAME, A HOST CELL COMPRISING THE NUCLEIC ACID, A METHOD FOR PRODUCING THE POLYPEPTIDE, A PHARMACEUTICAL COMPOSITION COMPRISING THE POLYPEPTIDE OR NUCLEIC ACID, PARTICULARLY FOR USE AS A MEDICAMENT OR VACCINE OR FOR USE IN A METHOD OF TREATING OR PREVENTING A BORRELIA INFECTION.

69.WO/2025/189043ORAL VACCINE COMPOSITIONS AND RELATED METHODS

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C12N 15/73Nº DE SOLICITUD PCT/US2025/018803SOLICITANTE SALVITUS, INC.INVENTOR/A SOLO, KIRK

PROVIDED HEREIN ARE RECOMBINANT PHAGE, PROBIOTIC VACCINES AND THERAPEUTICS COMPRISING RECOMBINANT PHAGE; AND RELATED METHODS OF USING SAME.

70.4615491VERBESSERTER IMPFSTOFF

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/00Nº DE SOLICITUD 23801763SOLICITANTE ONCODNAINVENTOR/A VAN HUFFEL CHRISTOPHE

A SYNTHETIC DNA MOLECULE COMPRISING ONE SEGMENT ENCODING A TUMOR NEOANTIGEN OR AN EPITOPE FROM AN INFECTIOUS AGENT UNDER THE CONTROL OF A PROMOTER FOR THE TRANSCRIPTION INTO A CORRESPONDING RNA MOLECULE AND A SEGMENT FOR THE TRANSLATION OF THE SAID TRANSLATED RNA MOLECULE INTO A PEPTIDE.

71.4615495GRUPPE-A-STREPTOCOCCUS-IMPFSTOFFANTIGEN

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/09Nº DE SOLICITUD 23802289SOLICITANTE UNIV BRUXELLESINVENTOR/A SMEESTERS PIERRE LADISLAS EDITH MARIE ROBERT

THE INVENTION PROVIDES IMMUNOGENIC PEPTIDES, POLYPEPTIDES, AND COMPOSITIONS BASED ON GROUP A STREPTOCOCCUS (GAS) ENN PROTEIN, AND THEIR USE IN THE THERAPY, PARTICULARLY PROPHYLAXIS, OF GAS INFECTIONS.

72.20250290111ANCESTRAL PROTEIN SEQUENCES AND PRODUCTION THEREOF

US - 18.09.2025

CLASIFICACIÓN INTERNACIONAL C12P 21/02Nº DE SOLICITUD 18862233SOLICITANTE PER-OLOF SYRÉNINVENTOR/A KAREN SCHRIEVER

A PROTEIN, SUCH AS AN ANTIGENIC PROTEIN, IS PRODUCED BY DETERMINING AN AMINO ACID SEQUENCE OF AN ANCESTRAL VERSION OF A GIVEN PROTEIN IN AN ANCESTRAL SEQUENCE RECONSTRUCTION METHOD BASED ON A PLURALITY OF HOMOLOGOUS AMINO ACID SEQUENCES OF THE GIVEN PROTEIN. A DOMAIN OF THE AMINO ACID SEQUENCE OF THE ANCESTRAL VERSION OF THE GIVEN PROTEIN IS REPLACED WITH A CORRESPONDING DOMAIN DERIVED FROM AN AMINO ACID SEQUENCE OF THE GIVEN PROTEIN OR A HOMOLOGOUS VERSION THEREOF. THE PROTEIN THEREBY COMPRISES THE AMINO ACID SEQUENCE OBTAINED BY REPLACING THE DOMAIN OF THE AMINO ACID SEQUENCE OF THE ANCESTRAL VERSION OF THE GIVEN PROTEIN WITH THE CORRESPONDING DOMAIN DERIVED FROM THE AMINO ACID SEQUENCE OF THE GIVEN PROTEIN OR THE HOMOLOGOUS VERSION THEREOF. THE PROTEIN IS SUITABLE AS ANTIGEN, AS VACCINE CANDIDATE AND/OR FOR STRUCTURAL STUDIES.

73.20250290095TRANS-REPLICATING RNA

US - 18.09.2025

CLASIFICACIÓN INTERNACIONAL C12N 15/86Nº DE SOLICITUD 19216945SOLICITANTE BIONTECH SEINVENTOR/A TIM BEISSERT

THE PRESENT INVENTION GENERALLY RELATES TO SYSTEMS AND METHODS SUITABLE FOR HIGH-LEVEL PROTEIN PRODUCTION. WHILE ONE OR MORE ELEMENTS OF THE PRESENT INVENTION ARE DERIVED FROM AN ALPHAVIRUS, THE PRESENT INVENTION DOES NOT REQUIRE PROPAGATION OF VIRUS PARTICLES. IN PARTICULAR, A SYSTEM COMPRISING TWO SEPARATE RNA MOLECULES IS FORESEEN, EACH COMPRISING A NUCLEOTIDE SEQUENCE DERIVED FROM AN ALPHAVIRUS: ONE RNA MOLECULE COMPRISES A RNA CONSTRUCT FOR EXPRESSING ALPHAVIRUS REPLICASE, AND ONE RNA MOLECULE COMPRISES A RNA REPLICON THAT CAN BE REPLICATED BY THE REPLICASE IN TRANS. THE RNA CONSTRUCT FOR EXPRESSING ALPHAVIRUS REPLICASE COMPRISES A 5'-CAP. IT WAS SURPRISINGLY FOUND THAT THE 5'-CAP IS SUITABLE FOR EFFICIENTLY DRIVING EXPRESSION OF A TRANSGENE FROM THE REPLICON IN TRANS. THE SYSTEM OF THE PRESENT INVENTION ENABLES EXPRESSION OF A PROTEIN OF INTEREST IN A CELL OR ORGANISM, BUT IS NOT ASSOCIATED WITH UNDESIRED VIRUS-PARTICLE FORMATION. THEREFORE, THE PRESENT INVENTION IS SUITABLE FOR EFFICIENTLY AND SAFELY PRODUCING A PROTEIN OF INTEREST, E.G. A THERAPEUTIC PROTEIN OR AN ANTIGENIC PROTEIN, SUCH AS A VACCINE, IN A TARGET ORGANISM. RESPECTIVE METHODS OF PROTEIN PRODUCTION IN VITRO AND IN VIVO AS WELL AS MEDICAL USES ARE PROVIDED

HEREIN. THE PRESENT INVENTION ALSO PROVIDES DNA ENCODING THE RNA MOLECULES OF THE INVENTION, AND CELLS COMPRISING THE RNA MOLECULES OF THE INVENTION.

74.4615499IMPFSTOFF ZUR BEHANDLUNG VON ALLERGIEN

EP - 17.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/35Nº DE SOLICITUD 22964694SOLICITANTE WORG PHARMACEUTICALS ZHEJIANG CO LTDINVENTOR/A KARAULOV ALEXANDER

A PEPTIDE CONSISTING OF 20 TO 30 AMINO ACID RESIDUES DERIVED FROM AMINO ACID POSITION 120 TO 171 OF MATURE ALLERGEN FEL D 4 IS PROVIDED AS WELL AS FUSION PROTEINS COMPRISING SAID PEPTIDE.

75.2025903955FLAVIVIRUS VACCINE COMPOSITIONS AND RELATED METHODS

AU - 11.09.2025

CLASIFICACIÓN INTERNACIONAL Nº DE SOLICITUD 2025903955SOLICITANTE VAXMED PTY LTDINVENTOR/A GIVEN, NOT

76.20250282786TRICYCLIC TLR7 AGONISTS AND USES THEREOF

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07D 487/04Nº DE SOLICITUD 19069365SOLICITANTE BRISTOL-MYERS SQUIBB COMPANYINVENTOR/A YAM BAHADUR POUDEL

COMPOUNDS ACCORDING TO FORMULA (I) ARE USEFUL AS AGONISTS OF TOLL-LIKE RECEPTOR 7 (TLR7).

SUCH COMPOUNDS CAN BE USED IN CANCER TREATMENT, ESPECIALLY IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT, OR AS A VACCINE ADJUVANT.

77.WO/2025/189239EIMERIA VACCINE

WO - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/012Nº DE SOLICITUD PCT/AU2025/050229SOLICITANTE EIMERIA PTY LTDINVENTOR/A VRBA, VLADIMIR

THE PRESENT DISCLOSURE RELATES TO METHODS AND COMPOSITIONS FOR THE PRODUCTION OF A STERILIZED FORMULATION OF VIABLE OOCYSTS FROM PROTOZOA, SUCH AS EIMERIA BY UTILIZING PEROXYCARBOXYLIC ACID TO INDUCE SPORULATION AND STERILIZATION. THE PRESENT DISCLOSURE ALSO RELATES TO COMPOSITIONS COMPRISING THE OOCYSTS AND USE OF THESE COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF INFECTIONS.

78.20250282776BICYCLIC TLR7 AGONISTS AND USES THEREOF

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07D 471/04Nº DE SOLICITUD 19069357SOLICITANTE BRISTOL-MYERS SQUIBB COMPANYINVENTOR/A YAM BAHADUR POUDEL

COMPOUNDS ACCORDING TO FORMULA (I) ARE USEFUL AS AGONISTS OF TOLL-LIKE RECEPTOR 7 (TLR7).

SUCH COMPOUNDS CAN BE USED ALONE OR AS PART OF AN ANTIBODY-DRUG CONJUGATE IN CANCER TREATMENT, FOR EXAMPLE IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT. SUCH COMPOUNDS MAY ALSO BE USED AS VACCINE ADJUVANTS.

79.WO/2025/189196SYSTEMS AND METHODS FOR PRE-FILLED MODULAR MULTI-STAGE PRODUCT DELIVERY

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61J 1/20Nº DE SOLICITUD PCT/US2025/019225SOLICITANTE KOSKA FAMILY LIMITEDINVENTOR/A WALKER, JAY S.

A PRE-FILLED, SINGLE-DOSE, MODULAR MULTI-STAGE MEDICAL AGENT DELIVERY SYSTEM ASSEMBLED AND CONFIGURED TO ALLOW DELIVERY OF A SINGLE DOSE OF A COMBINED THERAPEUTIC AGENT (E.G., VACCINE, DRUG, MEDICAMENT, ETC.) FROM A BLOW-FILL-SEAL (BFS) VIAL TO A PATIENT. THE DELIVERY ASSEMBLY GENERALLY INCLUDES A MODULAR DESIGN CONSISTING OF SEPARATELY CONSTRUCTED COMPONENTS COOPERATIVELY ARRANGED AND COUPLED TO ONE ANOTHER, SUCH AS TO FACILITATE DELIVERY OF A RECONSTITUTED LYOPHILIZED AGENT TO A PATIENT.

80.20250281591STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/085Nº DE SOLICITUD 18551830SOLICITANTE JANSSEN PHARMACEUTICALS, INC.INVENTOR/A BRIAN MORROW

THE PRESENT DISCLOSURE RELATES TO IMMUNOGENIC COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE IN A SUBJECT FOR THE TREATMENT AND/OR PREVENTION OF A STAPHYLOCOCCUS AUREUS INFECTION. THE IMMUNOGENIC COMPOSITIONS DISCLOSED HEREIN COMPRISE A S. AUREUS PROTEIN A (SPA) POLYPEPTIDE AND A S. AUREUS LEUKOCIDIN A (LUKA) AND/OR LEUKOCIDIN B (LUKB) VARIANT POLYPEPTIDE. THE PRESENT DISCLOSURE FURTHER RELATES TO METHODS OF GENERATING AN IMMUNE RESPONSE AGAINST S. AUREUS IN A SUBJECT THAT INVOLVE ADMINISTERING THE DISCLOSED IMMUNOGENIC COMPOSITIONS.

81.20250281582TREATMENT OF PRURITUS IN HORSES

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/00Nº DE SOLICITUD 18927510SOLICITANTE UNIVERSITÄT ZÜRICHINVENTOR/A ANTONIA FETTELSCHOSS

THE PRESENT INVENTION RELATES TO COMPOSITIONS, IMMUNOGENIC OR VACCINE COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF A CONDITION OR DISORDER SELECTED FROM A PRURITIC CONDITION OR AN ALLERGIC CONDITION, OF EQUINE MAMMALS, PREFERABLY OF HORSES. FURTHERMORE, THE INVENTION PROVIDES METHODS FOR PREVENTING OR TREATING PRURITUS, PREFERABLY PRURITUS ASSOCIATED WITH A PRURITIC CONDITION OR AN ALLERGIC CONDITION SUCH AS ALLERGIC DERMATITIS, OF EQUINE MAMMALS, PREFERABLY OF HORSES.

82.20250282838MULTI-EPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07K 14/47Nº DE SOLICITUD 19064783SOLICITANTE OTHAIR PROTHENA LIMITEDINVENTOR/A ROBIN BARBOUR

THE DISCLOSURE PROVIDES PEPTIDE COMPOSITIONS AND IMMUNOTHERAPY COMPOSITIONS COMPRISING AN AMYLOID-BETA (AB) PEPTIDE AND A TAU PEPTIDE. THE DISCLOSURE ALSO PROVIDES METHODS OF TREATING OR EFFECTING PROPHYLAXIS OF ALZHEIMER'S DISEASE OR OTHER DISEASES WITH BETA-AMYLOID DEPOSITION IN A SUBJECT, INCLUDING METHODS OF CLEARING DEPOSITS, INHIBITING OR REDUCING AGGREGATION OF AB AND/OR TAU, BLOCKING THE UPTAKE BY NEURONS, CLEARING AMYLOID, AND INHIBITING PROPAGATION OF TAU SEEDS IN A SUBJECT HAVING OR AT RISK OF DEVELOPING ALZHEIMER'S DISEASE OR OTHER DISEASES CONTAINING TAU AND/OR AMYLOID-BETA ACCUMULATIONS. THE METHODS INCLUDE ADMINISTERING TO SUCH PATIENTS THE COMPOSITIONS COMPRISING AN AMYLOID-BETA (AB) PEPTIDE AND A TAU PEPTIDE.

83.WO/2025/185290DRUG FOR TREATING HPV INFECTION-RELATED DISEASES

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD PCT/CN2024/139920SOLICITANTE NEW WISH BIOTECHNOLOGY WUXI CO., LTDINVENTOR/A QI, HAILONG

PROVIDED ARE AN ANTIGEN COMBINATION, A FUSION PROTEIN, AND A CODING NUCLEIC ACID. THE MATERIALS ARE USED FOR PREPARING A SELF-REPLICATING RNA VACCINE FOR TREATING PERSISTENT CERVICAL HPV INFECTION AND INDUCED INTRAEPITHELIAL NEOPLASIA AND CERVICAL CANCER, WHICH CAN EXTEND THE INDICATION TO INCLUDE LONG-TERM HPV-INFECTED INDIVIDUALS. THEREFORE, VIRUS-INFECTED CELLS CAN BE ELIMINATED TO TREAT LONG-TERM INFECTION, AND PRECANCEROUS LESIONS AND CERVICAL CANCER CAN ALSO BE TREATED MORE EFFECTIVELY.

84.20250281600NOVEL COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/215Nº DE SOLICITUD 18277921SOLICITANTE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMANINVENTOR/A NIRAJ HARISH TOLIA

NEW COMPOSITIONS OF MATTER, SUITABLE AS VACCINE CANDIDATES, WERE DERIVED FROM TARGET ANTIGENS USING A NOVEL COMPUTATIONAL DESIGN PIPELINE AND IN VITRO SCREENING. THE NEW COMPOSITIONS OF MATTER INCLUDE NEW PROTEIN SEQUENCES DERIVED FROM THE RECEPTOR BINDING DOMAIN (RBD) OF A CORONAVIRUS SPIKE PROTEIN. THE PRESENT DISCLOSURE PROVIDES IMMUNOLOGICAL COMPOSITIONS AND METHODS RELATED TO THE DESIGN, PRODUCTION, AND ADMINISTRATION OF SUCH COMPOSITIONS.

85.20250281424SMALL MOLECULE ANTAGONISTS OF PF4

US - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 31/122Nº DE SOLICITUD 18247216SOLICITANTE YUHANG ZHOUINVENTOR/A BRUCE SACHAIS

THE PRESENT APPLICATION PROVIDES A COMPOUND OF FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, WHEREIN Y, R1, R2, R3 AND R4 ARE DESCRIBED HEREIN. THE METHODS OF USING THESE COMPOUNDS TO INHIBIT TETRAMERIZATION OF PF4 AND TO TREAT THE ASSOCIATED DISEASES AND CONDITIONS, SUCH AS HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS (HITT) AND VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT), METHODS OF MAKING THESE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS ARE ALSO DISCLOSED.

86.20250290927PEPTIDES AND PEPTIDE MICROARRAYS FOR DETECTION AND DIFFERENTIATION OF ANTIBODY RESPONSES TO EBOLA VIRUS

US - 18.09.2025

CLASIFICACIÓN INTERNACIONAL G01N 33/569Nº DE SOLICITUD 19220639SOLICITANTE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKINVENTOR/A NISCHAY MISHRA

PEPTIDES, PLATFORMS AND METHODS FOR DETECTING ANTIBODY RESPONSES TO FILOVIRUS INFECTIONS, DETECTING ANTIBODY RESPONSES TO EBOV INFECTION, AND DETECTING ANTIBODY RESPONSES TO VACCINATION BY EBOV VESICULAR STOMATITIS VIRUS-BASED VACCINE.

87.WO/2025/186660MUTATED SPIKE PROTEINS AS VACCINES AGAINST SARS-COV-2

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 39/12Nº DE SOLICITUD PCT/IB2025/052041SOLICITANTE FONDAZIONE TOSCANA LIFE SCIENCESINVENTOR/A RAPPUOLI, RINO

THE PRESENT INVENTION RELATES TO SECOND-GENERATION VACCINE AGAINST COVID-19 TO ABROGATE OR DIMINISH THE BINDING OF THE SARS-COV-2 SPIKE (S) PROTEIN, OR PART OF IT, TO THE HUMAN ANGIOTENSIN-CONVERTING ENZYME 2 (HACE2). SUCH VACCINES PRESENT SEVERAL ADVANTAGES AS TO AVOID PATHWAYS OF IMMUNE DYSREGULATION ACTIVATED FOLLOWING S PROTEIN/HACE2 INTERACTION WHILE MAINTAINING THE ABILITY TO ELICIT A STRONG AND ROBUST ANTIBODY NEUTRALIZATION RESPONSE TO SARS-COV-2. THE INVENTION RELATES ALSO TO THE USE OF THE S PROTEIN FOR THERAPEUTIC USES AND FOR VACCINES IN THE PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION OR CONDITIONS OR DISORDERS RESULTING FROM SUCH INFECTION.

88.20250288526SOLID DOSE FORMULATIONS FOR NEEDLE-FREE DELIVERY

US - 18.09.2025

CLASIFICACIÓN INTERNACIONAL A61K 9/20Nº DE SOLICITUD 19221880SOLICITANTE AVAXZIPEN LIMITEDINVENTOR/A DAVID ANDREW GRANT

THE PRESENT DISCLOSURE RELATES TO SOLID DOSE FORMULATIONS FOR NEEDLE-FREE DELIVERY COMPRISING 0.01 TO 60 (W/W) OF ONE OR MORE THERAPEUTIC AGENT AND/OR PROPHYLACTIC AGENT; AND 40.0% TO 99.99% (W/W) OF DEXTRAN. THE INVENTION FURTHER CONCERNS METHODS OF PRODUCING A SOLID DOSE FORMULATION TABLET AND APPLICATION ITS PARTICULAR MEDICAL USES, IN PARTICULAR AS A VACCINE.

89.WO/2025/188694TRICYCLIC TLR7 AGONISTS AND USES THEREOF

WO - 11.09.2025

CLASIFICACIÓN INTERNACIONAL C07D 487/04Nº DE SOLICITUD PCT/US2025/018254SOLICITANTE BRISTOL-MYERS SQUIBB COMPANYINVENTOR/A POUDEL, YAM BAHADUR

COMPOUNDS ACCORDING TO FORMULA (I) ARE USEFUL AS AGONISTS OF TOLL-LIKE RECEPTOR 7 (TLR7). SUCH COMPOUNDS CAN BE USED IN CANCER TREATMENT, ESPECIALLY IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT, OR AS A VACCINE ADJUVANT.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20250901"<=20250922 23 records*

Document ID	Title	Inventor	Applicant Name
US 20250270656 A1	METHODS AND SYSTEMS FOR DEVELOPING PERSONALIZED VACCINE BY IDENTIFICATION AND PRIORITIZATION OF MUTATION-DERIVED NEOANTIGENS	Velculescu; Victor et al.	Personal Genome Diagnostics Inc.

US 20250269009 A1	VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION	HOU; Baidong	RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD,INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
US 20250270298 A1	MULTIVALENT ANTI-CAMPYLOBACTER ANTIBODIES AND VACCINE	Kumar; Arvind et al.	BiomEdit, LLC
US 20250268997 A1	A Subunit Cryptococcus Vaccine	Levitz; Stuart et al.	University of Massachusetts
US 20250269004 A1	ENTEROCOCCUS FAECALIS VACCINE AND USES THEREOF	Fairman; Jeffery C. et al.	Vaxcyte, Inc.,University of Florida Research Foundation, Inc.
US 20250269003 A1	NANO-ENHANCED VACCINE	Kester; Mark et al.	University of Virginia Patent Foundation
US 20250269006 A1	METHODS FOR PREDICTING EFFICACY OF A MODIFIED LIVE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) VACCINE	Hammer; Mark et al.	ELANCO US INC.
US 20250269002 A1	CTA VACCINE CASSETTES	Jooss; Karin et al.	Gritstone Bio, Inc.
US 12397048 B2	Bunyavirales vaccine	Petsch; Benjamin et al.	CureVac SE
US 12397050 B2	Universal mammalian influenza vaccine	Verhoeven; David et al.	Iowa State University Research Foundation, Inc.
US 12397052 B2	Microcapsule-based vaccine	Ma; Guanghui et al.	INSTITUTE OF PROCESS ENGINEERING, CHINESE ACADEMY OF SCIENCES
US 12396833 B2	Vaccine spray equipment	Tan; Zhijian et al.	FOSHAN STANDARD BIO-TECH CO., LTD.
US 12397051 B2	Vaccine for use against coronavirus and variants thereof	Nag; Kakon et al.	Globe Biotech Limited
US 20250262291 A1	MICROPARTICLES FROM STREPTOCOCCUS PNEUMONIAE AS VACCINE ANTIGENS	Henriques Normark; Birgitta et al.	ZalVac AB
US 20250262287 A1	ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM	ROBERTS; James et al.	Lumen Bioscience, Inc.

US 20250263448 A1	VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS	MORAES; Trevor et al.	ENGINEERED ANTIGENS INC.
US 20250262294 A1	VACCINE	Iqbal; Munir et al.	THE PIRBRIGHT INSTITUTE
US 20250262292 A1	VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS	MORAES; Trevor et al.	ENGINEERED ANTIGENS INC.
US 12390514 B2	Cancer vaccine	Maianti; Juan Pablo et al.	President and Fellows of Harvard College
US 12390516 B2	Vaccines against tick-borne diseases	Ganta; Roman R.	Kansas State University Research Foundation
US 12391736 B2	Off-the-shelf cancer vaccines	Plasterk; Ronald Hans Anton	CureVac Netherlands B.V.
US 12390521 B2	Canine distemper vaccines and methods of treatment using the same	Reeder; Sophia et al.	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
US 12390523 B2	Coronavirus vaccine	Rauch; Susanne et al.	CureVac SE
US 20250288660 A1	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	O'HAGAN; Derek et al.	Seqirus UK Limited
US 20250288522 A1	LIPID NANOPARTICLE mRNA VACCINES	BAUMHOF; Patrick et al.	CureVac SE,Acuitas Therapeutics Inc.
US 20250288661 A1	AVIAN INFLUENZA VIRUS VACCINES	Young; Alan John	VST LLC dba Medgene
US 12415836 B2	Anti-dengue vaccines and antibodies	Screaton; Gavin et al.	OXFORD UNIVERSITY INNOVATION LIMITED,UNIVERSITÉ PARIS-SACLAY
US 12414987 B2	Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof	Kong; Wei et al.	CHANGCHUN BCHT BIOTECHNOLOGY CO.,JILIN UNIVERSITY
US 20250282888 A1	ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS	KIPPS; Thomas James et al.	The Regents of the University of California

US 20250281593 A1	Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus	Weissman; Drew et al.	The Trustees of the University of Pennsylvania,The Johns Hopkins University,Vanderbilt University
US 20250281599 A1	COMPOSITION COMPRISING ENGINEERED PLANT-DERIVED EXTRACELLULAR VESICLES AND USE THEREOF AS A VACCINE	CAMUSSI; Giovanni et al.	EVOBIOTECH S.R.L.
US 20250282831 A1	NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES	ALLEGRETTI; Marcello et al.	Dompe' Farmaceutici SPA
US 20250281597 A1	A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION	Nagaraj; Basav Hangalapura et al.	Intervet Inc.
US 20250282838 A1	Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease	BARBOUR; Robin et al.	OTHAIR PROTHENA LIMITED
US 20250281606 A1	CANNABIDIOL FOR AUGMENTING VACCINE MEDIATED IMMUNITY AND PROPHYLAXIS OF COVID-19	MERCHANT; Shreema	MERCHANT; Shreema,PATEL; Manit,AKSEERA PHARMA CORP.
US 20250282832 A1	CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS	ALVES; Rúbens Prince Dos Santos et al.	IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA.
US 20250281591 A1	STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS	MORROW; Brian et al.	JANSSEN PHARMACEUTICALS, INC.,NEW YORK UNIVERSITY
US 20250281604 A1	mRNA vaccine for porcine Deltacoronavirus, preparation method and application thereof	LI; Bin et al.	Jiangsu Academy of Agricultural Sciences
US 12410409 B2	Influenza viruses with mutant PB2 gene segment as live attenuated vaccines	Kawaoka; Yoshihiro et al.	Wisconsin Alumni Research Foundation (WARF)
US 12409213 B2	Live attenuated oral vaccine against shigellosis and typhoid fever	Wu; Yun et al.	Sanaria Inc.
US 12409218 B2	Influenza vaccine	Ciaramella; Giuseppe	ModernaTX, Inc.
US 12409215 B2	Vaccine compositions	Rademacher; Laurens et al.	Emergex Vaccines Holding Limited
US 12409220 B2	Conjugate polypeptides and vaccines for inducing immune responses	Hartigan-O'Connor; Dennis J.	The Regents of The University of California

US 12409135 B2	Neoepitope vaccine delivery vehicle and methods of making the same	Liu; Philip T. et al.	ImmunityBio, Inc.
US 20250277005 A1	METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE	PICKING; Wendy L. et al.	UNIVERSITY OF KANSAS
US 20250275920 A1	Method of Safe Administration of Phosphorylated TAU Peptide Vaccine	Pfeifer; Andrea et al.	AC Immune SA,Janssen Pharmaceuticals, Inc.
US 20250276050 A1	VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE	ILG; Thomas et al.	BAYER ANIMAL HEALTH GMBH
US 20250276049 A1	EGFR VACCINE CASSETTES	Jooss; Karin et al.	Gritstone Bio, Inc.
US 20250277007 A1	CWP2 PROTEIN AS AN EFFECTIVE VACCINE AGAINST CLOSTRIDIOIDES DIFFICILE INFECTION	Sun; Xingmin et al.	UNIVERSITY OF SOUTH FLORIDA
US 20250276053 A1	ROTAVIRUS VACCINES	Young; Alan John	VST LLC dba MEDGENE
US 12403336 B2	Betacorona virus mRNA vaccines	Ciaramella; Giuseppe et al.	ModernaTX, Inc.
US 12403186 B2	Allogeneic tumor cell vaccine	Borriello; Frank	ALLOPLEX BIOTHERAPEUTICS, INC.
US 12403187 B2	Bacterial vaccine	Sørum; Henning	BELLEVACC AS
US 12404533 B2	Bioconjugate vaccines' synthesis in prokaryotic cell lysates	Jewett; Michael Christopher et al.	Northwestern University,Cornell University
US 12404306 B2	Human papillomavirus vaccines and uses of the same	Brough; Douglas E. et al.	Precigen, Inc.
US 12403190 B2	Coronavirus vaccine and methods of use thereof	Gill; Davinder	Gill; Davinder

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma*

absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES